WO2023129976A1

WO2023129976A1 - Salt and solid forms of ketanserin

Info

Publication number: WO2023129976A1
Application number: PCT/US2022/082488
Authority: WO
Inventors: Matthew Duncton; Samuel CLARK; Grace Jung; Gary Goodson
Original assignee: Terran Biosciences Inc
Current assignee: Terran Biosciences Inc
Priority date: 2021-12-29
Filing date: 2022-12-28
Publication date: 2023-07-06
Anticipated expiration: 2024-06-29

Abstract

The disclosure relates to forms of ketanserin, including solid forms of ketanserin free base, salts of ketanserin and solid forms thereof, including crystalline forms of the compound and salts thereof, as well as polymorphs of the solid forms.

Description

SALT AND SOLID FORMS OF KETANSERIN

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to and the benefit of U.S. Provisional Application Nos. 63/294,581, filed on December 29, 2021, 63/294,746, filed on December 29, 2021, 63/306,927, filed on February 4, 2022, 63/326,771, filed on April 1, 2022, 63/357,622, filed on June 30, 2022, and 63/412,306, filed on September 30, 2022, all of which are incorporated by reference herein in their entirety for all purposes.

FIELD

The present disclosure relates to forms of ketanserin, including solid forms of ketanserin free base, salts of ketanserin and solid forms thereof, including crystalline forms of the compound and salts thereof, as well as polymorphs of the solid forms.

BACKGROUND

Ketanserin is a selective 5-HT2 serotonin receptor antagonist with weak adrenergic receptor blocking properties. Ketanserin also blocks 5-HT receptors on platelets, antagonizing platelet aggregation promoted by serotonin.

SUMMARY

Disclosed herein are forms of ketanserin, including solid forms of ketanserin free form, salts of ketanserin and solid forms thereof, including crystalline forms of the compound and salts thereof, as well as polymorphs of the solid forms.

Also disclosed are methods for making the salt and solid forms and methods for using the salt and solid forms of ketanserin. In some embodiments, the solid form of ketanserin is a form of the free base form of the compound, such as polymorph of the free base form of the compound. In other embodiments, the solid form of ketanserin is a salt, and may be a polymorph of the salt.

Also disclosed herein are methods for using the forms of ketanserin, such as a method for using form of ketanserin as a 5-HT2 serotonin receptor modulator, including, without limitation the use of ketanserin as a monotherapy or in combination with another agent, such as psychedelic agent.

The foregoing and other objects, features, and advantages of the invention will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 provides an XRPD pattern of free base form Pattern A of ketanserin.

Figure 2 provides an XRPD pattern of free base form Pattern B.

Figure 3 provides an XRPD pattern of ketanserin hydrochloride Pattern A.

Figure 4 provides an XRPD pattern of ketanserin sulfate Pattern A.

Figure 5 provides an XRPD pattern of ketanserin fumarate Pattern A.

Figure 6 provides an XRPD pattern of ketanserin fumarate Pattern B.

Figure 7 provides an XRPD pattern of ketanserin citrate Pattern A.

Figure 8 provides an XRPD pattern of ketanserin maleate Pattern A.

Figure 9 provides an XRPD pattern of ketanserin p-tosylate Pattern A.

Figure 10 provides an XRPD pattern of ketanserin esylate Pattern A.

Figure 11 provides an XRPD pattern of ketanserin esylate Pattern B.

Figure 12 provides an XRPD pattern of ketanserin esylate Pattern C.

Figure 13 provides an XRPD pattern of ketanserin mesylate Pattern A.

Figure 14 provides an XRPD pattern of ketanserin mesylate Pattern B.

Figure 15 provides an XRPD pattern of ketanserin besylate Pattern A.

Figure 16 provides an XRPD pattern of ketanserin besylate Pattern B.

Figure 17 provides an XRPD pattern of ketanserin hydrochloride Pattern B.

Figure 18 provides an XRPD pattern of ketanserin L-tartrate Pattern A.

Figure 19 provides an XRPD pattern of ketanserin L-malate Pattern A.

Figure 20 provides an XRPD pattern of ketanserin succinate Pattern A.

Figure 21 provides an XRPD pattern of ketanserin succinate Pattern B.

Figure 22 provides an XRPD pattern of ketanserin succinate Pattern C.

Figure 23 provides an XRPD pattern of ketanserin succinate Pattern D.

Figure 24 provides an XRPD pattern of ketanserin succinate Pattern E. Figure 25 provides an XRPD pattern of ketanserin succinate Pattern F.

Figure 26 provides an XRPD pattern of ketanserin succinate Pattern G.

Figure 27 provides an XRPD pattern of ketanserin succinate Pattern H.

Figure 28 provides an XRPD pattern of ketanserin L-tartrate Group 4.

Figure 29 provides an XRPD pattern of ketanserin L-tartrate Pattern C.

Figure 30 provides an XRPD pattern of ketanserin L-tartrate Group 3.

Figure 31 provides an XRPD pattern of ketanserin L-tartrate Pattern E.

Figure 32 provides an XRPD pattern of ketanserin L-tartrate Pattern F.

Figure 33 provides an XRPD pattern of ketanserin L-tartrate Pattern G.

Figure 34 provides an XRPD pattern of ketanserin L-tartrate Pattern H.

Figure 35 provides an XRPD pattern of ketanserin L-tartrate Group 1.

Figure 36 provides an XRPD pattern of ketanserin L-tartrate Pattern I.

Figure 37 provides an XRPD pattern of ketanserin L-tartrate Pattern J.

Figure 38 provides an XRPD pattern of ketanserin L-tartrate Group 2.

Figure 39 provides an XRPD pattern of ketanserin L-tartrate of Group 5.

Figure 40 provides an XRPD pattern of ketanserin L-tartrate Pattern L.

Figure 41 provides an XRPD pattern of ketanserin L-tartrate Pattern M.

Figure 42 provides an XRPD pattern of ketanserin L-tartrate Pattern N.

Figure 43 provides an XRPD pattern of ketanserin L-tartrate Pattern O.

Figure 44 provides an XRPD pattern of ketanserin free base form Pattern A.

Figure 45 provides an XRPD pattern of ketanserin free base form Pattern B.

Figure 46 provides an XRPD pattern of ketanserin free base form Pattern C.

Figure 47 provides an XRPD pattern of ketanserin malate Pattern B.

Figure 48 provides an XRPD pattern of ketanserin malate Pattern C*.

Figure 49 provides an XRPD pattern of ketanserin malate Pattern D.

Figure 50 provides an XRPD pattern of ketanserin malate Pattern E.

Figure 51 provides a DSC thermogram of ketanserin maleate Pattern B.

Figure 52 provides a proton NMR spectrum of ketanserin maleate Pattern B.

Figure 53 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern P.

Figure 54 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern R.

Figure 55 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern S. Figure 56 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern B. Figure 57 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern K. Figure 58 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern D.

Figure 59 provides an XRPD diffractogram of crystalline ketanserin- L-tartrate having Pattern Q. Figure 60 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern T. Figure 61 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern A. Figure 62 provides an XRPD diffractogram of crystalline ketanserin L-tartrate in the form of Group 1.

Figure 63 provides an XRPD diffractogram of crystalline ketanserin of free base form Pattern A.

Figure 64 provides an XRPD diffractogram of crystalline ketanserin of free base form Pattern D.

Figure 65 provides an XRPD diffractogram of ketanserin L-malate Pattern A.

Figure 66 provides an XRPD diffractogram of ketanserin L-malate Pattern C.

Figure 67 illustrates the effect of ketanserin on average cumulative head twitches induced by LSD.

Figure 68 provides a bar chart of head twitches occurring before and after control or antagonist administration (left bar in each pair is LSD/vehicle control and right is LSD/ketanserin).

Figure 69 illustrates the effect of ketanserin on average cumulative head twitches induced by psilocybin.

Figure 70 provides a bar chart of head twitches occurring before and after control or antagonist administration (left bar in each pair is psilocybin/vehicle control and right is psilocybin/ketanserin).

Figure 71 illustrates functional whole-brain network partition. Modified and reprinted from Ji et al., NeuroImage (2019).

Figure 72 illustrates dense Global Brain Connectivity (GBC) maps showing the difference in GBC (AGBC) for the ketanserin (Ket) + LSD-treated subjects vs placebo (Pla) + Pla contrast at the early time point (75 -minute) after treatment.

Figure 73 illustrates dense GBC maps showing the difference in GBC (AGBC) for the placebo + LSD-treated subjects vs placebo + placebo contrast at the early time point (75-minute) after treatment. Figure 74 illustrates dense GBC maps showing the difference in GBC (AGBC) for the ketanserin + LSD-treated subjects vs placebo + placebo contrast at the late time point (300-minute) after treatment.

Figure 75 illustrates dense GBC maps showing the difference in GBC (AGBC) for the placebo + LSD-treated subjects vs placebo + placebo contrast at the late time point (300-minute) after treatment.

Figure 76 illustrates a collection of panels showing early session time point (75-minute) results and late session time point (300-minute) results for the difference in Functional Connectivity (AFC) between the test conditions. The left of each row indicates the test conditions and the top of each column indicates the time points. Positive and negative contrasts are rendered, respectively, in red and blue hues. Nodes along the edges indicate (cortical and subcortical) parcels of the CAP-NP parcellation.

Figure 77 illustrates related effects of Ket+LSD and Pla+LSD on parcels’ GBC values. Panels show 2d-histograms across parcels, indicating how pretreatment+treatment effects for Ket+LSD and Pla+LSD (relative to the placebo+placebo condition) were related. At the early time point (left panel; 75 minutes), the bulk of the distribution scattered around 0 effects, but some parcels with strong effects (bottom right) led to a net negative correlation. At the late time point (right panel; 300 minutes), a strong positive correlation was observed. Table 181 also shows correlations between GBC changes in parcels induced by Pla+LSD and Ket+LSD (relative to Pla+Pla).

Figure 78 illustrates related effects of Ket+LSD and Pla+LSD on parcels’ Functional Connectivity (FC) values. Panels show 2d-histograms across connections between parcels, indicating how pretreatment+treatment effects for Ket+LSD and Pla+LSD (relative to the placebo+placebo condition) are related. At the early time point (left panel; 75 minutes), effects between the two conditions were weakly correlated, whereas at the late time point (right panel; 300 minutes) a strong positive correlation was observed. Table 182 also shows correlations between FC changes in parcels induced by Pla+LSD and Ket+LSD (relative to Pla+Pla).

Figure 79 illustrates AGBC confidence intervals for the early time point. Confidence intervals were calculated assuming a t-distribution. The CAP-NP network to which a parcel belongs is indicated by labels on the row. Additionally, a confidence interval was plotted in a desaturated (light) shade of grayscale if the FDR-BH corrected p-value is > 0.05. Top row indicates Pla+LSD vs Pla+Pla. Middle row indicates Ket+LSD vs Pla+Pla. Bottom row indicates Pla+LSD vs Ket+LSD.

Figure 80 illustrates AGBC confidence intervals for the late time point. Confidence intervals were calculated assuming a t-distribution. The CAP-NP network to which a parcel belongs is indicated by labels on the row. Additionally, a confidence interval was plotted in a desaturated (light) shade of grayscale if the FDR-BH corrected p-value is > 0.05. Top row indicates Pla+LSD vs Pla+Pla. Middle row indicates Ket+LSD vs Pla+Pla. Bottom row indicates Pla+LSD vs Ket+LSD.

Figure 81 illustrates network FC contrasts. For each pair of networks, all connection contrasts (i.e. AFC values) between these two networks were averaged resulting in a network x network FC contrast matrix. Networks are defined in the CAP-NP atlas. The contrasts shown here are average contrasts for a given network pair (left column of panels: 75 minutes after treatment; right column of panels: 300 minutes after treatment).

Figure 82 illustrates the time course of subjective drug effects for the labeled subject groups. Five Dimension Altered States of Consciousness Questionnaire short version scores were assessed at 180, 250, and 360 minutes after second drug administration for the means across scales, and the scale scores for Pla, LSD, and Ket+LSD conditions. Scores are expressed as percent of the scale maximum. Data are expressed as means +/- the standard error of the mean (SEM). Abbreviations indicate Blissful State: BS, Changed Meaning of Percepts: CMP, Disembodiment: D, Elementary Imagery: El, Spiritual Experience: SE. N-=23. The first graph indicates the mean across scales. The second and third graphs indicates that the subjective LSD effects were still intense and high above placebo at 360 minutes. The fourth graph indicates that at no time point is there a significant presentation of self-reported altered states of consciousness in the Ket+LSD test subject group compared with the other graphs. This figure is reprinted from eLife Preller 2018. (Preller et al. eLife. 2018 Oct 25;7:e35082. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor, PMID: 30355445).

Figure 83 illustrates chord plot showing the difference in connectivity (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 84 illustrates chord plot for Pla+LSD vs Pla+Pla contrast for the 75 minute time point. This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 85 illustrates chord plot for Ket+LSD vs Pla+Pla contrast for the 75 minute time point. This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 86 illustrates chord plot for Pla+LSD vs Ket+LSD contrast for the 75 minute time point. This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 87 illustrates chord plot for Pla+LSD vs Pla+Pla contrast for the 300 minute time point. This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 88 illustrates chord plot for Ket+LSD vs Pla+Pla contrast for the 300 minute time point. This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 89 illustrates chord plot for Pla+LSD vs Ket+LSD contrast for the 300 minute time point. This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 90 illustrates contrasts for Visual 1 network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Visual 1 network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)). Figure 91 illustrates contrasts for Visual2 network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Visual2 network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 92 illustrates contrasts for Somatomotor network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Somatomotor network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 93 illustrates contrasts for Cingulo-Opercular network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Cingulo-Opercular network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 94 illustrates contrasts for Dorsal-Attention network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Dorsal-Attention network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 95 illustrates contrasts for Language network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Language network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 96 illustrates contrasts for Frontoparietal network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Frontoparietal network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 97 illustrates contrasts for Auditory network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Auditory network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 98 illustrates contrasts for Default network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Default network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 99 illustrates contrasts for Posterior-Multimodal network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Posterior-Multimodal network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 100 illustrates contrasts for Ventral-Multimodal (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Ventral-Multimodal network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)). Figure 101 illustrates contrasts for Orbito- Affective network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m. Visualizes the difference in connectivity (AFC) specifically for connections with the Orbito-Affective network. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).

Figure 102 illustrates AGBCz contrast maps at 75min. Left: Placebo+LSD Vs Ket+LSD AGBCz contrast map at 75 minutes. Right: The same AGBCz contrast map but thresholded such that only the bottom and top 10% of parcels are visualized. The most positive contrasts are shown in parcels of the visual network, and the most negative contrasts are shown in parcels of the cingulo-opercular network

Figure 103 illustrates Placebo+LSD vs Ket+LSD seed connectivity maps averaged across all parcels of the Visual (left) and Cingulo-Opercular (right) networks at 75 minutes. Seed connectivity contrasts averaged across parcels of the visual networks were strongly positive with superior temporal regions, whereas seed connectivity contrasts averaged across parcels of the cingulo-opercular network were strongly positive with visual regions and strongly negative with regions of the anterior cingulate cortex.

Figure 104 illustrates AGBCz contrast maps for Pla+LSD vs Ket+LSD at 300min Left: AGBCz contrast map at 300 minutes. Right: The same AGBCz contrast map but thresholded such that only the bottom and top 10% of parcels are visualized. The Pla+LSD vs Ket+LSD contrast for the AGBCz metric shows strong positive contrasts in parcels of the visual network and strong negative contrasts in parcels of the cingulo-opercular network.

Figure 105 illustrates seed connectivity maps for Placebo+LSD vs Ket+LSD averaged across all parcels of the Visual (left) and Cingulo-Opercular networks (right) at 300 minutes. Seed connectivity contrast maps averaged across parcels of the visual networks are weak overall, whereas seed connectivity contrasts maps averaged across parcels of the cingulo-opercular network show strong positive contrasts with visual networks and superior temporal regions. Figure 106 illustrates AGBCz contrast map at different timepoints for Ket+LSD vs Pla+Pla. Top: AGBCz contrast map at 75 minutes (left) 300 minutes (middle), and 300 minutes vs 75 minutes (right). Bottom: The same AGBCz contrast maps but thresholded such that only the bottom and top 10% of parcels are visualized. For the changes that occurred for the Ket+LSD vs Pla+Pla contrast between the 75 min and the 300 min time point (right), the strongest positive changes appear in visual networks, whereas the strongest negative changes occur in the cingulo- opercular network

Figure 107 illustrates seed connectivity maps for Ket+LSD vs Pla+Pla averaged across all parcels of the Visual (left) and Cingulo-Opercular (right) networks between 75 minute and 300 minute timepoints. Seed connectivity contrasts averaged across parcels of visual networks were strongly positive with somatomotor and superior temporal regions (left). Seed connectivity contrasts averaged across parcels of the cingulo-opercular network were strongly positive with visual regions and strongly negative with somatomotor and anterior cingulate regions (right). Figure 108 illustrates the pattern of changes between the 300 min and 75 min time point for Ket+LSD vs Pla+Pla contrast and the Pla+LSD vs Ket+LSD contrast at 75min for AFC (left) and for AGBCz (right). The Pla+LSD vs Ket+LSD contrast, here at 75 min, is an approximation for the neural effect that Ket blocks. The changes between the 75 min and 300 min time points for the Ket+LSD vs Pla+Pla contrast resemble this pattern, both at the level of AFC (left) and AGBCz (right).

Figure 109 illustrates alignment of gene expression maps with contrast maps. The histogram of Pearson correlations between 16088 gene expression maps from the Allen Human Brain Atlas and the AGBCz contrast maps shown in grey. Top left: Pla+LSD vs Pla+Pla at 75min. Top right: Pla+LSD vs Pla+Pla at 300min. Bottom left: Ket+LSD vs Pla+Pla at 75min Bottom right: Ket+LSD vs Pla+Pla at 300min. The Pearson correlation of the 5HT2A gene expression map with the contrast maps is highlighted in blue. The alignment of the 5HT2A expression map is opposite for the Ket+LSD vs Pla+Pla condition at the 75 min time point compared to the other shown conditions and time points.

FIG. 110 depicts the XRPD pattern of ketanserin L-tartrate Pattern A. FIG. Ill depicts the XRPD pattern of ketanserin L-malate Pattern A. FIG. 112 depicts the XRPD pattern of ketanserin succinate Pattern A. FIG. 113 depicts the XRPD pattern of ketanserin succinate Pattern A. FIG. 114 depicts the XRPD pattern of ketanserin L-tartrate Group 3.

FIG. 115 depicts the XRPD pattern of ketanserin succinate Pattern C.

FIG. 116 depicts the XRPD pattern of ketanserin free base form Pattern A.

FIG. 117 depicts the ’H-NMR of ketanserin besylate Pattern A.

FIG. 118 depicts the ’H-NMR of ketanserin besylate Pattern B.

FIG. 119 depicts the ^XH-NMR of ketanserin citrate Pattern A.

FIG. 120 depicts the DSC curve of ketanserin citrate Pattern A.

FIG. 121 depicts the ’H-NMR of ketanserin esylate Pattern A.

FIG. 122 depicts the ’H-NMR of ketanserin esylate Pattern B.

FIG. 123 depicts the ’H-NMR of ketanserin esylate Pattern C.

FIG. 124 depicts the ’H-NMR of ketanserin fumarate Pattern A.

FIG. 125 depicts the DSC curve of ketanserin fumarate Pattern A.

FIG. 126 depicts the ’H-NMR of ketanserin fumarate Pattern B.

FIG. 127 depicts the DSC curve of ketanserin fumarate Pattern B.

FIG. 128 depicts the ^XH-NMR of ketanserin hydrochloride Pattern A.

FIG. 129 depicts the DSC curve of ketanserin hydrochloride Pattern A.

FIG. 130 depicts the TGA curve of ketanserin hydrochloride Pattern A.

FIG. 131 depicts the ’H-NMR of ketanserin maleate Pattern A.

FIG. 132 depicts the DSC curve of ketanserin maleate Pattern A.

FIG. 133 depicts the TGA curve of ketanserin maleate Pattern A.

FIG. 134 depicts the ’H-NMR of ketanserin mesylate Pattern A.

FIG. 135 depicts the ’H-NMR of ketanserin mesylate Pattern B.

FIG. 136 depicts the ’H-NMR of ketanserin sulfate Pattern A.

FIG. 137 depicts the DSC curve of ketanserin sulfate Pattern A.

FIG. 138 depicts the TGA curve of ketanserin sulfate Pattern A.

FIG. 139 depicts the ’H-NMR of ketanserin p-tosylate Pattern A.

FIG. 140 depicts the DSC curve of ketanserin p-tosylate Pattern A.

FIG. 141 depicts the ^XH-NMR of ketanserin free base form Pattern A.

FIG. 142 depicts the DSC curve of ketanserin free base form Pattern A.

FIG. 143 depicts the TGA curve of ketanserin free base form Pattern A.

FIG. 144 depicts the ^XH-NMR of ketanserin free base form Pattern B. FIG. 145 depicts the DSC curve of ketanserin free base form Pattern B.

FIG. 146 depicts the TGA curve of ketanserin free base form Pattern B.

FIG. 147 depicts the 'H-NMR of ketanserin free base form Pattern C.

FIG. 148 depicts the DSC curve of ketanserin free base form Pattern C.

FIG. 149 depicts the TGA curve of ketanserin free base form Pattern C.

FIG. 150 depicts the 'H-NMR of ketanserin free base form Pattern D.

FIG. 151 depicts the DSC curve of ketanserin free base form Pattern D.

FIG. 152 depicts the TGA curve of ketanserin free base form Pattern D.

FIG. 153 depicts the IR spectrum of ketanserin free base form Pattern A.

FIG. 154 depicts the IR spectrum of ketanserin L-tartrate Pattern A.

FIG. 155 depicts the IR spectrum of ketanserin L-malate Pattern A.

FIG. 156 depicts the IR spectrum of ketanserin succinate Pattern A.

FIG. 157 depicts the DVS pattern of ketanserin free base form Pattern A.

FIG. 158 depicts the DVS pattern of ketanserin L-tartrate Pattern A.

FIG. 159 depicts the DVS pattern of ketanserin L-malate Pattern A.

FIG. 160 depicts the DVS pattern of ketanserin succinate Pattern A.

FIG. 161 depicts the XRPD overlay of a variable temperature (VT) XRPD experiment using succinate Pattern F as starting material.

FIG. 162 depicts the XRPD overlay of a variable temperature (VT) XRPD experiment using L- T artrate pattern A as starting material. Pattern F.

FIG. 163 XRPD overlay of samples obtained from ketanserin L-tartrate Variable Humidity XRPD (VH-XRPD) experiments.

FIG. 164 XRPD overlay of samples obtained from ketanserin L-tartrate VH-XRPD experiments.

FIG. 165 XRPD overlay of samples obtained from ketanserin L-tartrate VH-XRPD experiments.

FIG. 166 depicts the 'H-NMR of ketanserin L-malate Pattern A.

FIG. 167 depicts the DSC curve of ketanserin L-malate Pattern A.

FIG. 168 depicts the TGA curve of ketanserin L-malate Pattern A.

FIG. 169 depicts the TGA curve of ketanserin L-malate Pattern B.

FIG. 170 depicts the 'H-NMR of ketanserin L-malate Pattern C*. FIG. 171 depicts the 'H-NMR of ketanserin L-malate Pattern D.

FIG. 172 depicts the DSC curve of ketanserin L-malate Pattern D.

FIG. 173 depicts the TGA curve of ketanserin L-malate Pattern D.

FIG. 174 depicts the 'H-NMR of ketanserin L-malate Pattern E.

FIG. 175 depicts the DSC curve of ketanserin L-malate Pattern E.

FIG. 176 depicts the TGA curve of ketanserin L-malate Pattern E.

FIG. 177 depicts the 'H-NMR of ketanserin succinate Pattern A.

FIG. 178 depicts the DSC curve of ketanserin succinate Pattern A.

FIG. 179 depicts the TGA curve of ketanserin succinate Pattern A.

FIG. 180 depicts the 'H-NMR of ketanserin succinate Pattern B.

FIG. 181 depicts the DSC curve of ketanserin succinate Pattern B.

FIG. 182 depicts the TGA curve of ketanserin succinate Pattern B.

FIG. 183 depicts the 'H-NMR of ketanserin succinate Pattern C.

FIG. 184 depicts the DSC curve of ketanserin succinate Pattern C.

FIG. 185 depicts the TGA curve of ketanserin succinate Pattern C.

FIG. 186 depicts the 'H-NMR of ketanserin succinate Pattern D.

FIG. 187 depicts the DSC curve of ketanserin succinate Pattern D.

FIG. 188 depicts the TGA curve of ketanserin succinate Pattern D.

FIG. 189 depicts the 'H-NMR of ketanserin succinate Pattern E.

FIG. 190 depicts the DSC curve of ketanserin succinate Pattern E.

FIG. 191 depicts the TGA curve of ketanserin succinate Pattern E.

FIG. 192 depicts the 'H-NMR of ketanserin succinate Pattern F.

FIG. 193 depicts the DSC curve of ketanserin succinate Pattern F.

FIG. 194 depicts the TGA curve of ketanserin succinate Pattern F.

FIG. 195 depicts the 'H-NMR of ketanserin succinate Pattern G.

FIG. 196 depicts the 'H-NMR of ketanserin succinate Pattern H.

FIG. 197 depicts the DSC curve of ketanserin succinate Pattern H.

FIG. 198 depicts the TGA curve of ketanserin succinate Pattern H.

FIG. 199 depicts the 'H-NMR of ketanserin L-tartrate Pattern A.

FIG. 200 depicts the DSC curve of ketanserin L-tartrate Pattern A.

FIG. 201 depicts the TGA curve of ketanserin L-tartrate Pattern A. FIG. 202 depicts the 'H-NMR of ketanserin L-tartrate Pattern B.

FIG. 203 depicts the DSC curve of ketanserin L-tartrate Pattern B.

FIG. 204 depicts the TGA curve of ketanserin L-tartrate Pattern B.

FIG. 205 depicts the 'H-NMR of ketanserin L-tartrate Pattern C.

FIG. 206 depicts the DSC curve of ketanserin L-tartrate Pattern C.

FIG. 207 depicts the TGA curve of ketanserin L-tartrate Pattern C.

FIG. 208 depicts the 'H-NMR of ketanserin L-tartrate Pattern D.

FIG. 209 depicts the 'H-NMR of ketanserin L-tartrate Pattern E.

FIG. 210 depicts the 'H-NMR of ketanserin L-tartrate Pattern F.

FIG. 211 depicts the 'H-NMR of ketanserin L-tartrate Pattern G.

FIG. 212 depicts the 'H-NMR of ketanserin L-tartrate Pattern H.

FIG. 213 depicts the DSC curve of ketanserin L-tartrate Pattern H.

FIG. 214 depicts the TGA curve of ketanserin L-tartrate Pattern H.

FIG. 215 depicts the 'H-NMR of ketanserin L-tartrate Pattern I.

FIG. 216 depicts the DSC curve of ketanserin L-tartrate Pattern I.

FIG. 217 depicts the TGA curve of ketanserin L-tartrate Pattern I.

FIG. 218 depicts the 'H-NMR of ketanserin L-tartrate Pattern J.

FIG. 219 depicts the DSC curve of ketanserin L-tartrate Pattern J.

FIG. 220 depicts the TGA curve of ketanserin L-tartrate Pattern J.

FIG. 221 depicts the 'H-NMR of ketanserin L-tartrate Pattern K.

FIG. 222 depicts the DSC curve of ketanserin L-tartrate Pattern K.

FIG. 223 depicts the TGA curve of ketanserin L-tartrate Pattern K.

FIG. 224 depicts the 'H-NMR of ketanserin L-tartrate Pattern L.

FIG. 225 depicts the DSC curve of ketanserin L-tartrate Pattern L.

FIG. 226 depicts the TGA curve of ketanserin L-tartrate Pattern L.

FIG. 227 depicts the 'H-NMR of ketanserin L-tartrate Pattern M.

FIG. 228 depicts the DSC curve of ketanserin L-tartrate Pattern M.

FIG. 229 depicts the TGA curve of ketanserin L-tartrate Pattern M.

FIG. 230 depicts the 'H-NMR of ketanserin L-tartrate Pattern N.

FIG. 231 depicts the DSC curve of ketanserin L-tartrate Pattern N.

FIG. 232 depicts the TGA curve of ketanserin L-tartrate Pattern N. FIG. 233 depicts the 'H-NMR of ketanserin L-tartrate Pattern O.

FIG. 234 depicts the DSC curve of ketanserin L-tartrate Pattern O.

FIG. 235 depicts the TGA curve of ketanserin L-tartrate Pattern O.

FIG. 236 depicts the 'H-NMR of ketanserin L-tartrate Pattern P.

FIG. 237 depicts the 'H-NMR of ketanserin L-tartrate Pattern Q.

FIG. 238 depicts the DSC curve of ketanserin L-tartrate Pattern Q.

FIG. 239 depicts the TGA curve of ketanserin L-tartrate Pattern Q.

FIG. 240 depicts the 'H-NMR of ketanserin L-tartrate Pattern R.

FIG. 241 depicts the DSC curve of ketanserin L-tartrate Pattern R.

FIG. 242 depicts the TGA curve of ketanserin L-tartrate Pattern R.

FIG. 243 depicts the 'H-NMR of ketanserin L-tartrate Pattern S.

FIG. 244 depicts the DSC curve of ketanserin L-tartrate Pattern S.

FIG. 245 depicts the TGA curve of ketanserin L-tartrate Pattern S.

FIG. 246 depicts the 'H-NMR of ketanserin L-tartrate Group 1.

FIG. 247 depicts the DSC curve of ketanserin L-tartrate Group 1.

FIG. 248 depicts the TGA curve of ketanserin L-tartrate Group 1.

FIG. 249 depicts the 'H-NMR of ketanserin L-tartrate Group 2.

FIG. 250 depicts the DSC curve of ketanserin L-tartrate Group 2.

FIG. 251 depicts the TGA curve of ketanserin L-tartrate Group 2.

FIG. 252 depicts the 'H-NMR of ketanserin L-tartrate Group 3.

FIG. 253 depicts the DSC curve of ketanserin L-tartrate Group 3.

FIG. 254 depicts the TGA curve of ketanserin L-tartrate Group 3.

FIG. 255 depicts the 'H-NMR of ketanserin L-tartrate Group 4.

FIG. 256 depicts the DSC curve of ketanserin L-tartrate Group 4.

FIG. 257 depicts the TGA curve of ketanserin L-tartrate Group 4.

FIG. 258 depicts the 'H-NMR of ketanserin L-tartrate Group 5.

FIG. 259 depicts the DSC curve of ketanserin L-tartrate Group 5.

FIG. 260 depicts the TGA curve of ketanserin L-tartrate Group 5.

FIG. 261 depicts the XRPD pattern of ketanserin maleate Pattern B.

FIG. 262 depicts the XRPD pattern of ketanserin sulfate Pattern B.

FIG. 263 depicts the 'H-NMR of ketanserin sulfate Pattern B. FIG. 264 depicts the DSC curve of ketanserin sulfate Pattern B. FIG. 265 depicts the TGA curve of ketanserin sulfate Pattern B. FIG. 266 depicts the ^XH-NMR of ketanserin L-malate Pattern B. FIG. 267 depicts the DSC curve of ketanserin L-malate Pattern B.

DETAILED DESCRIPTION

The compound ketanserin was discovered and developed by Janssen in the 1980s. See, for example Vandenberk et al. U.S. Pat. No. 4,335,127. However, until now, the scope of the compounds salt and solid state forms had not been explored. Surprisingly the present inventors have discovered novel solid forms and salts of ketanserin that have superior properties to known forms. Accordingly, disclosed herein are novel forms of ketanserin, including solid forms of ketanserin free form, salts of ketanserin and solid forms thereof, including crystalline forms of the compound and salts thereof, as well as polymorphs of the solid forms.

Also disclosed are methods for making the salt and solid forms and methods for using the salt and solid forms of ketanserin. In some embodiments, the solid form of ketanserin is a form of the free base form of the compound, such as polymorph of the free base form of the compound. In other embodiments, the solid form of ketanserin is a salt, and may be a polymorph of the salt. The salt may be formed from an acid selected from hydrochloric acid, fumaric acid, galactaric (mucic) acid, naphthalene- 1,5-disulfonic acid, citric acid, sulfuric acid, ^/-glucuronic acid, ethane- 1,2-disulfonic acid, lactobionic acid,/?-toluenesulfonic acid, D-glucoheptonic acid, thiocyanic acid, (-)-Z-pyroglutamic acid, methanesulfonic acid, /.-malic acid, dodecylsulfuric acid, hippuric acid, naphthalene-2-sulfonic acid, //-gluconic acid, benzenesulfonic acid, D,L- lactic acid, oxalic acid, oleic acid, glycerophosphoric acid, succinic acid, ethanesulfonic acid 2- hydroxy, glutaric acid, Z-aspartic acid, cinnamic acid, maleic acid, adipic acid, phosphoric acid, sebacic acid, ethanesulfonic acid, (+)-camphoric acid, glutamic acid, acetic acid, xinafoic acid, or a combination thereof. In any embodiments, a stoichiometric ratio of acid to ketanserin is from about 0.4 to about 2.2, such as from about 0.5 to about 2, or from about 0.5, 1 or 2.

In any embodiments, the solid form may be a crystalline solid, a hydrate, or a combination thereof. The crystalline solid may be substantially a single form, such as a polymorph form. And the polymorph may be selected to have one or more desired properties, particularly improved properties, such as physical properties, chemical properties, pharmacokinetic properties, or a combination thereof. The one or more desired properties may comprise melting point, glass transition temperature, flowability, thermal stability, mechanical stability, shelf life, stability against polymorphic transition, hygroscopic properties, solubility in water and/or organic solvents, reactivity, compatibility with excipients and/or delivery vehicles, bioavailability, absorption, distribution, metabolism, excretion, toxicity including cytotoxicity, dissolution rate, half-life, or a combination thereof.

Also disclosed herein are embodiments, of a pharmaceutical composition, comprising a salt and/or a solid form of ketanserin, and a pharmaceutically acceptable excipient.

A method for administering salts and solid forms of ketanserin also is disclosed herein. In some embodiments, the method comprises administering to a subject an effective amount of a solid form of ketanserin, or a pharmaceutical composition thereof. In some embodiments, the subject is suffering from a neurological disease or a psychiatric disorder, or both, such as a neurodegenerative disorder. The neurological disorder or psychiatric disorder, or both, may comprise depression, addiction, anxiety, or a post-traumatic stress disorder, and/or the neurological disorder or psychiatric disorder, or both, may comprise treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder. In some embodiments, the neurological disorder or psychiatric disorder, or both, comprises stroke, traumatic brain injury, or a combination thereof.

The method may comprise further comprising administering an effective amount of an psychedelic agent to the subject.

In any embodiments, administering the solid form of the compound comprises oral, parenteral, or topical administration. In certain embodiments, oral administration is used, but in other particular embodiments, administration is by injection, inhalation, intraocular, intravaginal, intrarectal or transdermal routes.

I. Definitions

The following explanations of terms and methods are provided to better describe the present disclosure and to guide those of ordinary skill in the art in the practice of the present disclosure. The singular forms “a,” “an,” and “the” refer to one or more than one, unless the context clearly dictates otherwise. The term “or” refers to a single element of stated alternative elements or a combination of two or more elements, unless the context clearly indicates otherwise. As used herein, “comprises” means “includes.” Thus, “comprising A or B,” means “including A, B, or A and B,” without excluding additional elements. All references, including patents and patent applications cited herein, are incorporated by reference in their entirety, unless otherwise specified.

Unless otherwise indicated, all numbers expressing quantities of components, molecular weights, percentages, temperatures, times, and so forth, as used in the specification or claims, are to be understood as being modified by the term “about.” Accordingly, unless otherwise indicated, implicitly or explicitly, the numerical parameters set forth are approximations that may depend on the desired properties sought and/or limits of detection under standard test conditions/methods. When directly and explicitly distinguishing embodiments from discussed prior art, the embodiment numbers are not approximates unless the word “about” is expressly recited.

Unless explained otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting.

“Administering” refers to any suitable mode of administration, including, oral administration, administration as a suppository, topical contact, parenteral, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, intrathecal administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to the subject.

“Ketanserin” refers to the compound:

which is marketed under the trade name “Sufrexal” and has CAS number 74050-98-9.

“Subject” refers to an animal, such as a mammal, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In certain embodiments, the subject is a human subject.

“Therapeutically effective amount” or “therapeutically sufficient amount” or “effective or sufficient amount” refers to a dose that produces therapeutic effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). In sensitized cells, the therapeutically effective dose can often be lower than the conventional therapeutically effective dose for non-sensitized cells.

“Neuronal plasticity” refers to the ability of the brain to change its structure and/or function continuously throughout a subject’s life. Examples of the changes to the brain include, but are not limited to, the ability to adapt or respond to internal and/or external stimuli, such as due to an injury, and the ability to produce new neurites, dendritic spines, and synapses.

“Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post- traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.

“Combination therapy” refers to a method of treating a disease or disorder, wherein two or more different pharmaceutical agents are administered in overlapping regimens so that the subject is simultaneously exposed to both agents. For example, the compounds of the invention can be used in combination with other pharmaceutically active compounds. The compounds of the invention can be administered simultaneously (as a single preparation or separate preparation) or sequentially to the other drug therapy. In general, a combination therapy envisions administration of two or more drugs during a single cycle or course of therapy.

As used herein, the term “modified release” relates to formulations that have a different release profile than a standard formulation. As used in the context of a coating, “modified release” coating encompasses coatings that delay release, sustain release, extend release, prevent release, minimize release and/or otherwise prolong the release of a drug relative to formulations lacking such coatings which release a drug relatively quickly (i.e., “immediate release” compositions). The term “modified release” encompasses “sustained release,” “extended release,” “delayed release,” including “delayed immediate release” and the like. The term “modified release” is used in an overlapping fashion with “controlled release” or “delayed release”. The term “modified-release” or “delayed release” dosage composition refers broadly to a dosage form showing one or more modified-release properties, as described herein.

“Neurotrophic factors” refers to a family of soluble peptides or proteins which support the survival, growth, and differentiation of developing and mature neurons.

“Modulate” or “modulating” or “modulation” refers to an increase or decrease in the amount, quality, or effect of a particular activity, function or molecule. By way of illustration and not limitation, agonists, partial agonists, antagonists, and allosteric modulators (e.g., a positive allosteric modulator) of a G protein-coupled receptor (e.g., 5HT2A) are modulators of the receptor.

“Agonism” refers to the activation of a receptor or enzyme by a modulator, or agonist, to produce a biological response.

“Agonist” refers to a modulator that binds to a receptor or enzyme and activates the receptor to produce a biological response. By way of example only, “5HT2A agonist” can be used to refer to a compound that exhibits an ECso with respect to 5HT2A activity of no more than about 100 mM. In some embodiments, the term “agonist” includes full agonists or partial agonists. “Full agonist” refers to a modulator that binds to and activates a receptor with the maximum response that an agonist can elicit at the receptor. “Partial agonist” refers to a modulator that binds to and activates a given receptor, but has partial efficacy, that is, less than the maximal response, at the receptor relative to a full agonist.

“Positive allosteric modulator” refers to a modulator that binds to a site distinct from the orthosteric binding site and enhances or amplifies the effect of an agonist.

“Antagonism” refers to the inactivation of a receptor or enzyme by a modulator, or antagonist. Antagonism of a receptor, for example, is when a molecule binds to the receptor and does not allow activity to occur. “Antagonist” or “neutral antagonist” refers to a modulator that binds to a receptor or enzyme and blocks a biological response. An antagonist has no activity in the absence of an agonist or inverse agonist but can block the activity of either, causing no change in the biological response.

“Composition” refers to a product comprising the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation.

“Pharmaceutically acceptable excipient” refers to a substance that aids the administration of an active agent to and absorption by a subject. Pharmaceutical excipients useful in the present invention include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.

IL Compounds

Disclosed herein are salts and solid forms of ketanserin that are useful to treat various disorders, such as brain disorders. Also disclosed are methods for making the salts and solid forms of ketanserin and method of administering the salts and solid forms of the compound

Ketanserin.

In some embodiments, a solid form of the compound is a crystalline form of ketanserin. In some embodiments, the solid form of ketanserin is a polymorph of ketanserin, such as a polymorph of the free base compound or a polymorph of the salt. In some embodiments, the solid form of the compound is a salt of the compound. In some embodiments, the solid form of the compound is a crystalline salt form of the compound, such as an acid addition salt form.

Salts In some embodiments, the solid form of ketanserin comprises a salt of ketanserin.

Suitable salts include pharmaceutically acceptable salts of ketanserin. In some embodiments, the solid form of ketanserin is not, and does not include, ketanserin tartrate.

In some embodiments, the salt of ketanserin may be formed from a suitable pharmaceutically acceptable acid, including, without limitation, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, benzene sulfonic acid, isethionic acid, methanesulfonic acid, ethanesulfonic acid, -toluenesulfonic acid, salicylic acid, xinafoic acid and the like. Additional information concerning pharmaceutically acceptable salts can be found in, for example, S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977; 66: 1-19 which is incorporated herein by reference.

In some embodiments, the salt may be formed using an acid from Table 1. Table 1

But in certain embodiments, hydrochloric acid is not used.

The acid salts of ketanserin disclosed herein can have any suitable stoichiometric ratio of acid to ketanserin. In one embodiment, the molar ratio of acid to ketanserin is from about 0.4 to about 2.2, such as forms wherein the salt has a stoichiometric ratio of acid to ketanserin of from about 0.5 to about 2, such as about 0.5, about 1 or about 2.

III. Solid forms

Embodiments of ketanserin of the present disclosure are in a solid form. The solid form may be a crystalline form or an amorphous form. In some embodiments, the solid form is a crystalline form, such as a polymorph. In some embodiments, the solid form of ketanserin is a free base form of ketanserin. In some embodiments, the solid form of ketanserin is a salt. And in certain embodiments, the solid form is a crystalline salt form of the compound. A person of ordinary skill in the art understands that solid forms of ketanserin, such as crystalline forms including salt and non-salt crystalline forms of ketanserin, may exist in more than one crystal form. Such different forms are referred to as polymorphs. In some embodiments, the disclosed compounds are particular polymorphs of ketanserin or a ketanserin salt.

In some embodiments, the solid form of ketanserin disclosed herein is selected to be a crystalline form, such as a particular polymorph of a crystalline form of ketanserin that provides one or more desired properties. In one embodiment, the crystalline form offers advantages over the amorphous form of the molecule. In another embodiment, the disclosed polymorph offers improved properties as compared to another polymorph of ketanserin. The ketanserin may be a salt or free base compound. The one or more desired properties may include, but are not limited to, physical properties, including but not limited to, melting point, glass transition temperature, flowability, and/or stability, such as thermal stability, mechanical stability, shelf life, stability against polymorphic transition, etc.; chemical properties, such as, but not limited to, hygroscopic properties, solubility in water and/or organic solvents, reactivity, compatibility with excipients and/or delivery vehicles; and/or pharmacokinetic properties, such as, but not limited to, bioavailability, absorption, distribution, metabolism, excretion, toxicity including cytotoxicity, dissolution rate, and/or half-life.

The desired polymorph may be produced by techniques known to persons of ordinary skill in the art. Such techniques include, but are not limited to, crystallization in particular solvents and/or at particular temperatures, supersaturation, using a precipitation agent, such as a salt, glycol, alcohol, etc., co-crystallization, lyophilization, spray drying, freeze drying, and/or complexing with an inert agent.

Techniques to identify a particular solid form of ketanserin are known to persons of ordinary skill in the art, and include, but are not limited to, X-ray crystallography, X-ray diffraction, electron crystallography, powder diffraction, including X-ray, neutron, or electron diffraction, X-ray fiber diffraction, small-angle X-ray scattering, and/or melting point.

Solid forms of free base form Pattern A

In some embodiments, the present disclosure provides solid forms of free base form Pattern A, e.g., crystalline forms of free base form Pattern A. In some embodiments, the free base form Pattern A XRPD profile is substantially similar to that shown in any one of FIGs. 1, 44, 63, or 116. In some embodiments, the free base form Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 141. In some embodiments, the free base form Pattern A TGA profile is substantially similar to that shown in FIG. 143. In some embodiments, the free base form Pattern A DSC profile is substantially similar to that shown in FIG. 142.

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by an XRPD signal at 9.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29 and 21.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, and 14.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °29, and 14.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, and 4.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °29, 14.2 °29, and 4.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, and 20.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °29, 14.2 °20, 4.7 °20, and 20.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, and 27.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, and 27.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, and 26.8 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, and 26.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, and 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, and 17.5 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, 17.5 °20, and 18.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, 17.5 °20, and 18.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, 17.5 °20, 18.8 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, 17.5 °20, 18.8 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 2 is a numerical representation of selected XRPD signals shown in at least Figure 1.

In some embodiments, the crystalline free base form Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 2. Table 2 Peak list of free base form Pattern A

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by an XRPD signal at 21.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29 and 20.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, and 27.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °29, and 27.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, and 18.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °29, 27.7 °29, and 18.9 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °29, 27.7 °29, 18.9 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, and 26.9 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °29, 27.7 °20, 18.9 °20, 17.5 °20, and 26.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, and 10.7 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, and 19.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, and 19.7 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, and 16.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, and 16.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, 16.4 °29, and 9.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, 16.4 °20, and 9.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 3 is a numerical representation of selected XRPD signals shown in at least Figure 63.

In some embodiments, the crystalline free base form Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, or ten XRPD signals selected from those set forth in Table 3.

Table 3 Peak list of free base form Pattern A

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by an XRPD signal at 9.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29 and 20.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, and 14.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °29, and 14.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, 14.1 °29, and 4.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °29, 14.1 °29, and 4.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, 14.1 °29, 4.7 °29, and 20.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °29, 14.1 °29, 4.7 °29, and 20.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, 14.1 °29, 4.7 °29, 20.1 °29, and 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °29, 14.1 °20, 4.7 °20, 20.1 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, and 19.7 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, and 19.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, and 27.6 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, and 27.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, and 18.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, and 18.8 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, 18.8 °29, and 10.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, 18.8 °20, and 10.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, Table 4 is a numerical representation of selected XRPD signals shown in at least Figure 44.

In some embodiments, the crystalline free base form Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 4.

Table 4 Peak list of free base form Pattern A

Solid forms of free base form Pattern B In some embodiments, the present disclosure provides solid forms of free base form

Pattern B, e.g., crystalline forms of free base form Pattern B. In some embodiments, the free base form Pattern B XRPD profile is substantially similar to that shown in FIGs. 2 or 45. In some embodiments, the free base form Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 144. In some embodiments, the free base form Pattern B TGA profile is substantially similar to that shown in FIG. 146. In some embodiments, the free base form Pattern B DSC profile is substantially similar to that shown in FIG. 145. In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by an XRPD signal at 16.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29 and 26.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °29, and 27.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, and 16.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °29, 27.0 °20, and 16.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °29, 27.0 °20, 16.2 °20, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, and 22.2 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, and 22.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, and 21.7 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, and 21.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, and 22.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, and 22.3 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, 22.3 °20, and 13.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, 22.3 °20, and 13.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, 22.3 °20, 13.5 °20, and 13.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, 22.3 °20, 13.5 °20, and 13.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 5 is a numerical representation of selected XRPD signals shown in at least Figure 2. In some embodiments, the crystalline free base form Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, or eighteen XRPD signals selected from those set forth in Table 5. Table 5 Peak list of free base form Pattern B

Solid forms of free base form Pattern C

In some embodiments, the present disclosure provides solid forms of free base form Pattern C, e.g., crystalline forms of free base form Pattern C. In some embodiments, the free base form Pattern C XRPD profile is substantially similar to that shown in FIG. 46. In some embodiments, the free base form Pattern C 1H NMR spectrum is substantially similar to that shown in FIG. 147. In some embodiments, the free base form Pattern C TGA profile is substantially similar to that shown in FIG. 149. In some embodiments, the free base form Pattern C DSC profile is substantially similar to that shown in FIG. 148.

In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by an XRPD signal at 14.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29 and 22.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, and 7.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °29, and 7.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, and 9.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °29, 7.4 °29, and 9.5 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, and 11.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °29, 7.4 °29, 9.5 °20, and 11.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, and 3.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °29, 7.4 °20, 9.5 °20, 11.1 °20, and 3.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, and 14.2 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, and 14.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, 14.2 °20, and 18.6 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, 14.2 °20, and 18.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, 14.2 °20, 18.6 °20, and 21.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, 14.2 °20, 18.6 °20, and 21.0 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, Table 6 is a numerical representation of selected XRPD signals shown in at least Figure 46.

In some embodiments, the crystalline free base form Pattern C is characterized by one, two, three, four, five, six, seven, eight, or nine XRPD signals selected from those set forth in Table 6. Table 6 Peak list of free base form Pattern C

Solid forms of free base form Pattern D

In some embodiments, the present disclosure provides solid forms of free base form Pattern D, e.g., crystalline forms of free base form Pattern D. In some embodiments, the free base form Pattern D XRPD profile is substantially similar to that shown in FIG. 64. In some embodiments, the free base form Pattern D 1H NMR spectrum is substantially similar to that shown in FIG. 150. In some embodiments, the free base form Pattern D TGA profile is substantially similar to that shown in FIG. 152. In some embodiments, the free base form Pattern D DSC profile is substantially similar to that shown in FIG. 151.

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by an XRPD signal at 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29 and 16.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °29, and 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, and 18.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °29, 17.5 °29, and 18.9 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, and 10.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °29, 17.5 °29, 18.9 °20, and 10.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, and 24.3 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °29, 17.5 °20, 18.9 °20, 10.4 °20, and 24.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, and 17.1 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, and 17.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, and 3.5 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, and 3.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, 3.5 °20, and 4.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, 3.5 °20, and 4.0 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, 3.5 °20, 4.0 °29, and 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, 3.5 °20, 4.0 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 7 is a numerical representation of selected XRPD signals shown in at least Figure 64.

In some embodiments, the crystalline free base form Pattern D is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, or eighteen XRPD signals selected from those set forth in Table 7.

Table 7 Peak list of free base form Pattern D

Solid forms of ketanserin hydrochloride Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin hydrochloride Pattern A, e.g., crystalline forms of ketanserin hydrochloride Pattern A. In some embodiments, the ketanserin hydrochloride Pattern A XRPD profile is substantially similar to that shown in FIG. 3. In some embodiments, the ketanserin hydrochloride Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 128. In some embodiments, the ketanserin hydrochloride Pattern A TGA profile is substantially similar to that shown in FIG. 130. In some embodiments, the ketanserin hydrochloride Pattern A DSC profile is substantially similar to that shown in FIG. 129.

In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by an XRPD signal at 15.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °29 and 18.3 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.5 °29, 18.3 °29, and 24.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °29, 18.3 °20, and 24.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °29, 18.3 °29, 24.6 °29, and 10.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °29, 18.3 °29, 24.6 °29, 10.7 °29, and 25.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, and 25.2 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °29, 18.3 °29, 24.6 °29, 10.7 °29, 25.2 °29, and 22.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, and 22.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20, and 14.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20, and 14.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20,

14.1 °29, and 5.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20, 14.1 °20, and 5.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

14.1 °20, 5.3 °20, and 28.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °29, 18.3 °29, 24.6 °29, 10.7 °29,

25.2 °20, 22.9 °20, 14.1 °20, 5.3 °20, and 28.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

14.1 °20, 5.3 °20, 28.5 °20, and 16.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °29, 18.3 °29, 24.6 °29, 10.7 °29,

25.2 °20, 22.9 °20, 14.1 °20, 5.3 °20, 28.5 °20, and 16.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, Table 8 is a numerical representation of selected XRPD signals shown in at least Figure 3.

In some embodiments, the crystalline ketanserin hydrochloride Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty XRPD signals selected from those set forth in Table 8.

Table 8 Peak list of ketanserin hydrochloride Pattern A

Solid forms of ketanserin hydrochloride Pattern B In some embodiments, the present disclosure provides solid forms of ketanserin hydrochloride Pattern B, e.g., crystalline forms of ketanserin hydrochloride Pattern B. In some embodiments, the ketanserin hydrochloride Pattern B XRPD profile is substantially similar to that shown in FIG. 17.

In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by an XRPD signal at 25.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29 and 14.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 25.6 °29, 14.8 °29, and 26.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, and 26.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °29, 14.8 °29, 26.8 °29, and 7.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, and 7.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29, and 13.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29, and 13.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29, 13.5 °29, and 22.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, and 22.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20, and 14.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20, and

14.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20,

14.5 °20, and 29.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29,

13.5 °20, 22.3 °20, 14.5 °20, and 29.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

14.5 °20, 29.8 °20, and 13.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29,

13.5 °20, 22.3 °20, 14.5 °20, 29.8 °20, and 13.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20, 14.5 °20, 29.8 °20, 13.8 °20, and 17.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29, 13.5 °20, 22.3 °20, 14.5 °20, 29.8 °20, 13.8 °20, and 17.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20;

Cu Kai radiation).

In some embodiments, Table 9 is a numerical representation of selected XRPD signals shown in at least Figure 17.

In some embodiments, the crystalline ketanserin hydrochloride Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or twenty-one XRPD signals selected from those set forth in Table 9.

Table 9 Peak list of ketanserin hydrochloride Pattern B

Solid forms of ke tanserin sulfate Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin sulfate Pattern A, e.g., crystalline forms of ketanserin sulfate Pattern A. In some embodiments, the ketanserin sulfate Pattern A XRPD profile is substantially similar to that shown in FIG. 4. In some embodiments, the ketanserin sulfate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 136. In some embodiments, the ketanserin sulfate Pattern A TGA profile is substantially similar to that shown in FIG. 138. In some embodiments, the ketanserin sulfate Pattern A DSC profile is substantially similar to that shown in FIG. 137.

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by an XRPD signal at 23.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29 and 22.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, and 8.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29, 22.5 °29, and 8.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, and 16.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °20, 22.5 °20, 8.9 °20, and 16.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, and 25.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °20, 22.5 °20, 8.9 °20, 16.5 °20, and 25.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, and 13.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °20, 22.5 °20, 8.9 °20, 16.5 °20, 25.0 °20, and 13.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, and 21.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °20, 22.5 °20, 8.9 °20, 16.5 °20, 25.0 °20, 13.9 °20, and 21.1 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °20, and 14.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, and 14.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, 14.9 °29, and 17.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, 14.9 °29, and 17.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, 14.9 °29, 17.4 °29, and 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, 14.9 °29, 17.4 °29, and 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, Table 10 is a numerical representation of selected XRPD signals shown in at least Figure 4.

In some embodiments, the crystalline ketanserin sulfate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty-five, twenty-six, or twenty-seven XRPD signals selected from those set forth in Table 10.

Table 10 Peak list of ketanserin sulfate Pattern A

Solid forms ofketanserin sulfate Pattern B

In some embodiments, the present disclosure provides solid forms of ketanserin sulfate Pattern B, e.g., crystalline forms of ketanserin sulfate Pattern B. In some embodiments, the ketanserin sulfate Pattern B XRPD profile is substantially similar to that shown in FIG. 262. In some embodiments, the ketanserin sulfate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 263. In some embodiments, the ketanserin sulfate Pattern B TGA profile is substantially similar to that shown in FIG. 265. In some embodiments, the ketanserin sulfate Pattern B DSC profile is substantially similar to that shown in FIG. 264.

In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by an XRPD signal at 5.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °20 and 18.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 5.9 °20, 18.9 °20, and 22.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, and 22.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, and 7.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °20, 18.9 °29, 22.2 °29, and 7.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, and 18.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, 22.2 °20, 7.5 °20, and 18.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, and 14.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °20, 18.9 °20, 22.2 °20, 7.5 °20, 18.7 °20, and 14.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °29, and

24.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °20, 18.9 °20, 22.2 °20, 7.5 °20, 18.7 °20, 14.3 °20, and 24.3 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °29,

24.3 °20, and 20.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °20, 24.3 °20, and 20.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

24.3 °20, 20.6 °20, and 18.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °20, 24.3 °20, 20.6 °20, and 18.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

24.3 °20, 20.6 °20, 18.2 °20, and 16.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °20, 24.3 °20, 20.6 °20, 18.2 °20, and 16.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the crystalline ketanserin sulfate Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty- two, thirty-three, thirty-four, or thirty-five XRPD signals selected from those set forth in Table 10 A.

Table 10A Peak list of ketanserin sulfate Pattern B

Solid forms ofketanserin fumarate Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin fumarate Pattern A, e.g., crystalline forms of ketanserin fumarate Pattern A. In some embodiments, the ketanserin fumarate Pattern A XRPD profile is substantially similar to that shown in FIG. 5. In some embodiments, the ketanserin fumarate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 124. In some embodiments, the ketanserin fumarate Pattern A DSC profile is substantially similar to that shown in FIG. 125. In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by an XRPD signal at 24.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29 and 9.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, and 23.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °29, and 23.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, and 27.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °20, 23.1 °20, and 27.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, and 8.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °20, 9.7 °20, 23.1 °20, 27.1 °20, and 8.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, and 26.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °20, 9.7 °20, 23.1 °20, 27.1 °20, 8.1 °20, and 26.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, and 21.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °20, 9.7 °20, 23.1 °20, 27.1 °20, 8.1 °20, 26.0 °20, and 21.0 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, and 16.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, and 16.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, 16.2 °29, and 23.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, 16.2 °29, and 23.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, 16.2 °29, 23.5 °29, and 17.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, 16.2 °29, 23.5 °29, and 17.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, Table 11 is a numerical representation of selected XRPD signals shown in at least Figure 5.

In some embodiments, the crystalline ketanserin fumarate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, or eighteen XRPD signals selected from those set forth in Table 11.

Table 11 Peak list of ketanserin fumarate Pattern A

Solid forms ofketanserin fumarate Pattern B

In some embodiments, the present disclosure provides solid forms of ketanserin fumarate Pattern B, e.g., crystalline forms of ketanserin fumarate Pattern B. In some embodiments, the ketanserin fumarate Pattern B XRPD profile is substantially similar to that shown in FIG. 6. In some embodiments, the ketanserin fumarate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 126. In some embodiments, the ketanserin fumarate Pattern B DSC profile is substantially similar to that shown in FIG. 127.

In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by an XRPD signal at 15.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °29 and 9.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °29, 9.6 °29, and 23.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °29, 9.6 °29, and 23.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 9.6 °29, 23.1 °29, and 3.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °20, 9.6 °20, 23.1 °20, and 3.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 9.6 °29, 23.1 °29, 3.8 °29, and 19.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °20, 9.6 °20, 23.1 °20, 3.8 °20, and 19.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 9.6 °29, 23.1 °29, 3.8 °29, 19.1 °29, and 11.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °20, 9.6 °20, 23.1 °20, 3.8 °20, 19.1 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, Table 12 is a numerical representation of selected XRPD signals shown in at least Figure 6. In some embodiments, the crystalline ketanserin fumarate Pattern B is characterized by one, two, three, four, five, or six XRPD signals selected from those set forth in Table 12.

Table 12 Peak list of ketanserin fumarate Pattern B

Solid forms of ketanserin citrate Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin citrate Pattern A, e.g., crystalline forms of ketanserin citrate Pattern A. In some embodiments, the ketanserin citrate Pattern A XRPD profile is substantially similar to that shown in FIG. 7. In some embodiments, the ketanserin citrate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 119. In some embodiments, the ketanserin citrate Pattern A DSC profile is substantially similar to that shown in FIG. 120.

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by an XRPD signal at 14.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29 and 19.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 14.1 °29, 19.8 °29, and 3.5 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29, 19.8 °29, and 3.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °29, 19.8 °29, 3.5 °29, and 13.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29, 19.8 °29, 3.5 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, and 7.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29, 19.8 °29, 3.5 °20, 13.3 °20, and 7.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, and 22.7 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, and 21.0 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, and 21.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, and 20.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, and 20.7 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, 20.7 °29, and 10.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, 20.7 °20, and 10.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, 20.7 °20, 10.1 °20, and 15.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, 20.7 °20, 10.1 °20, and 15.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 13 is a numerical representation of selected XRPD signals shown in at least Figure 7.

In some embodiments, the crystalline ketanserin citrate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 13.

Table 13 Peak list of ketanserin citrate Pattern A

Solid forms of ke tanserin maleate Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin maleate Pattern A, e.g., crystalline forms of ketanserin maleate Pattern A. In some embodiments, the ketanserin maleate Pattern A XRPD profile is substantially similar to that shown in FIG. 8. In some embodiments, the ketanserin maleate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 131. In some embodiments, the ketanserin maleate Pattern A TGA profile is substantially similar to that shown in FIG. 133. In some embodiments, the ketanserin maleate Pattern A DSC profile is substantially similar to that shown in FIG. 132.

In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by an XRPD signal at 11.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °29 and 26.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 11.2 °29, 26.1 °29, and 24.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °29, 26.1 °29, and 24.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °29, 26.1 °29, 24.3 °29, and 24.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °29, 26.1 °20, 24.3 °20, and 24.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °29, 26.1 °29, 24.3 °29, 24.7 °29, and 25.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, and 25.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °29, 26.1 °29, 24.3 °29, 24.7 °29, 25.7 °29, and 27.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, and 27.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, and 15.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, and 15.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °29, and 9.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °20, and 9.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °20, 9.1 °20, and 16.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °20, 9.1 °20, and 16.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °20, 9.1 °20, 16.6 °20, and 22.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °29, 26.1 °29, 24.3 °29, 24.7 °29, 25.7 °20, 27.7 °20, 15.7 °20, 9.1 °20, 16.6 °20, and 22.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 14 is a numerical representation of selected XRPD signals shown in at least Figure 8.

In some embodiments, the crystalline ketanserin maleate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or seventeen XRPD signals selected from those set forth in Table 14.

Table 14 Peak list of ketanserin maleate Pattern A

Solid forms ofketanserin maleate Pattern B

In some embodiments, the present disclosure provides solid forms of ketanserin maleate Pattern B, e.g., crystalline forms of ketanserin maleate Pattern B. In some embodiments, the ketanserin maleate Pattern B XRPD profile is substantially similar to that shown in FIG. 261. In some embodiments, the ketanserin maleate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 52. In some embodiments, the ketanserin maleate Pattern B DSC profile is substantially similar to that shown in FIG. 51.

In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by an XRPD signal at 18.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29 and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, and 6.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °29, and 6.0 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, and 17.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °20, 6.0 °20, and 17.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, and 26.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at

18.1 °20, 8.8 °20, 6.0 °20, 17.6 °20, and 26.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, and 16.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °20, 8.8 °20, 6.0 °20, 17.6 °20, 26.9 °20, and 16.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29, and

17.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °20, 8.8 °20, 6.0 °20, 17.6 °20, 26.9 °20, 16.6 °20, and 17.2 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29,

17.2 °29, and 13.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29, 17.2 °29, and 13.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29,

17.2 °29, 13.8 °29, and 23.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29, 17.2 °29, 13.8 °29, and 23.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

17.2 °29, 13.8 °29, 23.5 °29, and 21.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29, 17.2 °29, 13.8 °29, 23.5 °29, and 21.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the crystalline ketanserin maleate Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or seventeen XRPD signals selected from those set forth in Table 14 A.

Table 14A Peak list of ketanserin maleate Pattern B

Solid forms of ke tanserin p-tosylate Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin p- tosylate Pattern A, e.g., crystalline forms of ketanserin p-tosylate Pattern A. In some embodiments, the ketanserin p-tosylate Pattern A XRPD profile is substantially similar to that shown in FIG. 9. In some embodiments, the ketanserin p-tosylate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 139. In some embodiments, the ketanserin p-tosylate Pattern A DSC profile is substantially similar to that shown in FIG. 140. In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by an XRPD signal at 21.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °29 and 3.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, and 23.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °29, 3.3 °29, and 23.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, and 21.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin p- tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °20, 3.3 °20, 23.2 °20, and 21.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, and 10.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °20, 3.3 °20, 23.2 °20, 21.1 °20, and 10.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, and 8.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °20, 3.3 °20, 23.2 °20, 21.1 °20, 10.0 °20, and 8.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, 8.6 °29, and 23.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °20, 3.3 °20, 23.2 °20, 21.1 °20, 10.0 °20, 8.6 °20, and 23.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, 8.6 °29, 23.0 °20, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p- tosylate Pattern A characterized by XRPD signals at 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °20, 8.6 °20, 23.0 °20, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, 8.6 °29, 23.0 °20, 27.0 °20, and 17.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p- tosylate Pattern A characterized by XRPD signals at 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °20, 8.6 °20, 23.0 °20, 27.0 °20, and 17.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, 8.6 °29, 23.0 °20, 27.0 °20, 17.9 °20, and 21.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p- tosylate Pattern A characterized by XRPD signals at 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °20, 8.6 °20, 23.0 °20, 27.0 °20, 17.9 °20, and 21.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 15 is a numerical representation of selected XRPD signals shown in at least Figure 9.

In some embodiments, the crystalline ketanserin p-tosylate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, or thirty XRPD signals selected from those set forth in Table 15. Table 15 Peak list of ketanserin p-tosylate Pattern A

Solid forms ofketanserin esylate Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin esylate Pattern A, e.g., crystalline forms of ketanserin esylate Pattern A. In some embodiments, the ketanserin esylate Pattern A XRPD profile is substantially similar to that shown in FIG. 10. In some embodiments, the ketanserin esylate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 121.

In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by an XRPD signal at 20.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29 and 10.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, and 22.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29, 10.4 °29, and 22.0 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °29, 10.4 °29, 22.0 °29, and 26.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29, 10.4 °29, 22.0 °20, and 26.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, and 14.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29, 10.4 °20, 22.0 °20, 26.0 °20, and 14.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, and 20.3 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, and 20.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, and 26.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, and 26.9 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, and 24.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, and 24.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, 24.9 °29, and 13.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, 24.9 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, 24.9 °20, 13.3 °20, and 22.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29, 10.4 °29, 22.0 °29, 26.0 °29, 14.6 °29, 20.3 °20, 26.9 °20, 24.9 °20, 13.3 °20, and 22.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 16 is a numerical representation of selected XRPD signals shown in at least Figure 10. In some embodiments, the crystalline ketanserin esylate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, or ten XRPD signals selected from those set forth in Table 16.

Table 16 Peak list of ketanserin esylate Pattern A

Solid forms of ketanserin esylate Pattern B

In some embodiments, the present disclosure provides solid forms of ketanserin esylate Pattern B, e.g., crystalline forms of ketanserin esylate Pattern B. In some embodiments, the ketanserin esylate Pattern B XRPD profile is substantially similar to that shown in FIG. 11. In some embodiments, the ketanserin esylate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 122.

In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by an XRPD signal at 21.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °29 and 22.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 21.8 °20, 22.1 °20, and 10.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °29, 22.1 °29, and 10.9 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 22.1 °29, 10.9 °29, and 24.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °29, 22.1 °29, 10.9 °20, and 24.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °20, 22.1 °20, 10.9 °20, 24.9 °20, and 26.5 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °20, 22.1 °20, 10.9 °20, 24.9 °20, and 26.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °20, 22.1 °20, 10.9 °20, 24.9 °20, 26.5 °20, and 27.1 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °29, 22.1 °29, 10.9 °29, 24.9 °29, 26.5 °29, and 27.1 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 17 is a numerical representation of selected XRPD signals shown in at least Figure 11.

In some embodiments, the crystalline ketanserin esylate Pattern B is characterized by one, two, three, four, five, or six XRPD signals selected from those set forth in Table 17.

Table 17 Peak list of ketanserin esylate Pattern B

Solid forms of ketanserin esylate Pattern C

In some embodiments, the present disclosure provides solid forms of ketanserin esylate Pattern C, e.g., crystalline forms of ketanserin esylate Pattern C. In some embodiments, the ketanserin esylate Pattern C XRPD profile is substantially similar to that shown in FIG. 12. In some embodiments, the ketanserin esylate Pattern C 1H NMR spectrum is substantially similar to that shown in FIG. 123.

In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by an XRPD signal at 10.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20 and 5.3 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 10.5 °29, 5.3 °29, and 8.8 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °29, 5.3 °29, and 8.8 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °29, 5.3 °29, 8.8 °29, and 22.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °29, 5.3 °29, 8.8 °29, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, and 23.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °29, 5.3 °29, 8.8 °29, 22.7 °29, and 23.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, and 14.2 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °29, 5.3 °29, 8.8 °20, 22.7 °20, 23.8 °20, and 14.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, and 19.8 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, and 19.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, and 15.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, and 15.5 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, 15.5 °29, and 28.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, 15.5 °20, and 28.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, 15.5 °20, 28.6 °20, and 7.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, 15.5 °20, 28.6 °20, and 7.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 18 is a numerical representation of selected XRPD signals shown in at least Figure 12.

In some embodiments, the crystalline ketanserin esylate Pattern C is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 18. Table 18 Peak list of ketanserin esylate Pattern C

Solid forms of ketanserin mesylate Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin mesylate Pattern A, e.g., crystalline forms of ketanserin mesylate Pattern A. In some embodiments, the ketanserin mesylate Pattern A XRPD profile is substantially similar to that shown in FIG. 13. In some embodiments, the ketanserin mesylate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 134.

In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by an XRPD signal at 24.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °29 and 23.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, and 27.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °29, 23.1 °29, and 27.6 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °29, 23.1 °29, 27.6 °29, and 22.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °29, 23.1 °20, 27.6 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °29, 23.1 °29, 27.6 °29, 22.7 °29, and 17.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, and 17.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °29, 23.1 °29, 27.6 °29, 22.7 °29, 17.8 °29, and 11.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, and 11.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, and 14.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, and 14.9 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20,

14.9 °29, and 20.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, 14.9 °20, and 20.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

14.9 °20, 20.3 °20, and 29.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, 14.9 °20, 20.3 °20, and 29.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

14.9 °20, 20.3 °20, 29.6 °20, and 15.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °29, 23.1 °29, 27.6 °29, 22.7 °29, 17.8 °20, 11.4 °20, 14.9 °20, 20.3 °20, 29.6 °20, and 15.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 19 is a numerical representation of selected XRPD signals shown in at least Figure 13. In some embodiments, the crystalline ketanserin mesylate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 19. Table 19 Peak list of ketanserin mesylate Pattern A

Solid forms of ketanserin mesylate Pattern B

In some embodiments, the present disclosure provides solid forms of ketanserin mesylate Pattern B, e.g., crystalline forms of ketanserin mesylate Pattern B. In some embodiments, the ketanserin mesylate Pattern B XRPD profile is substantially similar to that shown in FIG. 14. In some embodiments, the ketanserin mesylate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 135. In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by an XRPD signal at 23.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °29 and 27.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 23.1 °29, 27.6 °29, and 23.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °29, 27.6 °29, and 23.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °29, 27.6 °29, 23.9 °29, and 14.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °29, 27.6 °29, 23.9 °29, 14.8 °29, and 23.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, and 23.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °29, 27.6 °29, 23.9 °29, 14.8 °29, 23.6 °29, and 17.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, and 17.7 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, and 15.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, and

15.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20,

15.8 °20, and 18.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, 15.8 °20, and 18.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

15.8 °20, 18.9 °20, and 15.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, 15.8 °20, 18.9 °20, and 15.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

15.8 °20, 18.9 °20, 15.5 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °29, 27.6 °29, 23.9 °29, 14.8 °29, 23.6 °20, 17.7 °20, 15.8 °20, 18.9 °20, 15.5 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, Table 20 is a numerical representation of selected XRPD signals shown in at least Figure 14.

In some embodiments, the crystalline ketanserin mesylate Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, or twenty-two XRPD signals selected from those set forth in Table 20.

Table 20 Peak list of ketanserin mesylate Pattern B

Solid forms ofketanserin besylate Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin besylate Pattern A, e.g., crystalline forms of ketanserin besylate Pattern A. In some embodiments, the ketanserin besylate Pattern A XRPD profile is substantially similar to that shown in FIG. 15. In some embodiments, the ketanserin besylate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 117.

In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by an XRPD signal at 9.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °29 and 4.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, and 24.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °29, 4.8 °29, and 24.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, 24.1 °29, and 17.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form ofketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °29, 4.8 °29, 24.1 °29, and 17.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, 24.1 °29, 17.2 °29, and 22.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at

9.6 °20, 4.8 °20, 24.1 °20, 17.2 °20, and 22.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, 24.1 °29, 17.2 °29, 22.6 °29, and 21.0 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °20, 4.8 °20, 24.1 °20, 17.2 °20, 22.6 °20, and 21.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, 24.1 °29, 17.2 °29, 22.6 °29, 21.0 °29, and

20.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °20, 4.8 °20, 24.1 °20, 17.2 °20, 22.6 °20, 21.0 °20, and 20.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, Table 21 is a numerical representation of selected XRPD signals shown in at least Figure 15.

In some embodiments, the crystalline ketanserin besylate Pattern A is characterized by one, two, three, four, five, six, or seven XRPD signals selected from those set forth in Table 21.

Table 21 Peak list of ketanserin besylate Pattern A

Solid forms ofketanserin besylate Pattern B

In some embodiments, the present disclosure provides solid forms of ketanserin besylate Pattern B, e.g., crystalline forms of ketanserin besylate Pattern B. In some embodiments, the ketanserin besylate Pattern B XRPD profile is substantially similar to that shown in FIG. 16. In some embodiments, the ketanserin besylate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 118.

In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by an XRPD signal at 21.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °29 and 9.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, and 3.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °29, 9.9 °29, and 3.3 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 9.9 °29, 3.3 °29, and 15.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °29, 9.9 °20, 3.3 °20, and 15.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 9.9 °29, 3.3 °29, 15.4 °29, and 23.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °20, 9.9 °29, 3.3 °20, 15.4 °29, and 23.3 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 9.9 °29, 3.3 °29, 15.4 °29, 23.3 °29, and 6.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, and 6.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 9.9 °29, 3.3 °29, 15.4 °29, 23.3 °29, 6.7 °29, and 13.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, and 13.3 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, 13.3 °29, and 4.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, 13.3 °29, and 4.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, 13.3 °29, 4.9 °29, and 20.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °29, 9.9 °29, 3.3 °29, 15.4 °29, 23.3 °29, 6.7 °29, 13.3 °29, 4.9 °20, and 20.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, Table 22 is a numerical representation of selected XRPD signals shown in at least Figure 16.

In some embodiments, the crystalline ketanserin besylate Pattern B is characterized by one, two, three, four, five, six, seven, eight, or nine XRPD signals selected from those set forth in Table 22.

Table 22 Peak list of ketanserin besylate Pattern B

Solid forms of ketanserin succinate Pattern A In some embodiments, the present disclosure provides solid forms of ketanserin succinate

Pattern A, e.g., crystalline forms of ketanserin succinate Pattern A. In some embodiments, the ketanserin succinate Pattern A XRPD profile is substantially similar to that shown in any one of FIGs. 20, 112, or 113. In some embodiments, the ketanserin succinate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 177. In some embodiments, the ketanserin succinate Pattern A TGA profile is substantially similar to that shown in FIG. 179. In some embodiments, the ketanserin succinate Pattern A DSC profile is substantially similar to that shown in FIG. 178. In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by an XRPD signal at 15.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29 and 19.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, and 11.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, and 23.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 11.5 °20, and 23.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, and 9.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, and 9.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, and 24.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, 9.8 °20, and 24.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °29, and 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, 9.8 °20, 24.6 °20, and

21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °29,

21.5 °20, and 20.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °20, 21.5 °20, and 20.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

21.5 °20, 20.8 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °20, 21.5 °20, 20.8 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

21.5 °20, 20.8 °20, 25.3 °20, and 3.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °20, 24.6 °20, 21.5 °20, 20.8 °20, 25.3 °20, and 3.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, Table 23 is a numerical representation of selected XRPD signals shown in at least Figure 20.

In some embodiments, the crystalline ketanserin succinate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, or eleven XRPD signals selected from those set forth in Table 23.

Table 23 Peak list of ketanserin succinate Pattern A

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by an XRPD signal at 15.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29 and 19.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, and 9.8 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, and 9.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 9.8 °29, and 24.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °20, 9.8 °20, and 24.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, and 11.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at

15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, 11.5 °29, and 23.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, and 23.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, 11.5 °29, 23.0 °29, and

25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, and 25.3 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °29, and 20.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °20, and 20.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °20, 20.8 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, 11.5 °29, 23.0 °20, 25.3 °20, 20.8 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °20, 20.8 °20, 21.5 °20, and 18.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, 11.5 °29, 23.0 °20, 25.3 °20, 20.8 °20, 21.5 °20, and 18.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the crystalline ketanserin succinate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen XRPD signals selected from those set forth in Table 24.

Table 24 Peak list of ketanserin succinate Pattern A

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29 and 23.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 23.0 °29, and 11.5 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 23.0 °29, 11.5 °29, and 19.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 23.0 °20, 11.5 °20, and 19.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 23.0 °29, 11.5 °29, 19.4 °29, and 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 23.0 °29, 11.5 °29, 19.4 °29, 21.5 °29, and 9.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, and 9.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 23.0 °29, 11.5 °29, 19.4 °29, 21.5 °29, 9.8 °29, and 21.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, and 21.7 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °29, and 25.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, and 25.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, 25.0 °20, and 15.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 23.0 °29, 11.5 °29, 19.4 °29, 21.5 °29, 9.8 °20, 21.7 °20, 25.0 °20, and 15.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, 25.0 °20, 15.0 °20, and 24.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, 25.0 °20, 15.0 °20, and 24.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the crystalline ketanserin succinate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve XRPD signals selected from those set forth in Table 25.

Table 25 Peak list of ketanserin succinate Pattern A

Solid forms ofketanserin succinate Pattern B

In some embodiments, the present disclosure provides solid forms of ketanserin succinate Pattern B, e.g., crystalline forms of ketanserin succinate Pattern B. In some embodiments, the ketanserin succinate Pattern B XRPD profile is substantially similar to that shown in FIG. 21. In some embodiments, the ketanserin succinate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 180. In some embodiments, the ketanserin succinate Pattern B TGA profile is substantially similar to that shown in FIG. 182. In some embodiments, the ketanserin succinate Pattern B DSC profile is substantially similar to that shown in FIG. 181.

In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by an XRPD signal at 26.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °29 and 20.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 26.2 °20, 20.0 °20, and 27.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °29, 20.0 °29, and 27.5 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, and 22.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, and 22.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, and 18.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, and 18.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, and 25.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, 18.2 °20, and 25.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °29, and 31.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, 18.2 °20, 25.7 °20, and 31.5 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °29, 31.5 °29, and 8.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, 18.2 °20, 25.7 °20, 31.5 °20, and 8.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °29, 31.5 °20, 8.7 °20, and 20.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °20, 31.5 °20, 8.7 °20, and 20.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °29, 31.5 °20, 8.7 °20, 20.4 °20, and 16.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °20, 25.7 °20, 31.5 °20, 8.7 °20, 20.4 °20, and 16.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 26 is a numerical representation of selected XRPD signals shown in at least Figure 21.

In some embodiments, the crystalline ketanserin succinate Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, or twenty-two XRPD signals selected from those set forth in Table 26.

Table 26 Peak list of ketanserin succinate Pattern B

Solid forms ofketanserin succinate Pattern C

In some embodiments, the present disclosure provides solid forms of ketanserin succinate Pattern C, e.g., crystalline forms of ketanserin succinate Pattern C. In some embodiments, the ketanserin succinate Pattern C XRPD profile is substantially similar to that shown in FIGs. 22 or 115. In some embodiments, the ketanserin succinate Pattern C 1H NMR spectrum is substantially similar to that shown in FIG. 183. In some embodiments, the ketanserin succinate Pattern C TGA profile is substantially similar to that shown in FIG. 185. In some embodiments, the ketanserin succinate Pattern C DSC profile is substantially similar to that shown in FIG. 184.

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by an XRPD signal at 19.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29 and 26.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, and 15.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 26.4 °29, and 15.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, and 25.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 26.4 °20, 15.1 °20, and 25.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, and 9.9 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at

19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, and 9.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, and 15.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, 9.9 °20, and 15.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °29, and

15.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, 9.9 °20, 15.0 °20, and 15.9 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °29, 15.9 °29, and 22.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, 9.9 °20, 15.0 °20, 15.9 °20, and 22.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °29, 15.9 °20, 22.4 °20, and 18.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °20, 15.9 °20, 22.4 °20, and 18.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °29, 15.9 °20, 22.4 °20, 18.1 °20, and 16.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °20, 15.9 °20, 22.4 °20, 18.1 °20, and 16.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the crystalline ketanserin succinate Pattern C is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty XRPD signals selected from those set forth in Table 27.

Table 27 Peak list of ketanserin succinate Pattern C

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by an XRPD signal at 19.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29 and 9.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, and 25.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 9.9 °29, and 25.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, and 26.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 9.9 °20, 25.0 °20, and 26.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, and 10.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 9.9 °20, 25.0 °20, 26.4 °20, and 10.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, and 15.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 9.9 °20, 25.0 °20, 26.4 °20, 10.1 °20, and 15.2 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, and 27.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 9.9 °20, 25.0 °20, 26.4 °20, 10.1 °20, 15.2 °20, and 27.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °20, 27.9 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °29, 13.3 °29, and 16.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °29, 13.3 °29, and 16.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °29, 13.3 °29, 16.3 °29, and 24.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °29, 13.3 °29, 16.3 °29, and 24.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, Table 27A is a numerical representation of selected XRPD signals shown in at least Figure 22.

In some embodiments, the crystalline ketanserin succinate Pattern C is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty-five, or twenty-six XRPD signals selected from those set forth in Table 27A.

Table 27A Peak list of ketanserin succinate Pattern C

Solid forms ofketanserin succinate Pattern D

In some embodiments, the present disclosure provides solid forms of ketanserin succinate Pattern D, e.g., crystalline forms of ketanserin succinate Pattern D. In some embodiments, the ketanserin succinate Pattern D XRPD profile is substantially similar to that shown in FIG. 23. In some embodiments, the ketanserin succinate Pattern D 1H NMR spectrum is substantially similar to that shown in FIG. 186. In some embodiments, the ketanserin succinate Pattern D TGA profile is substantially similar to that shown in FIG. 188. In some embodiments, the ketanserin succinate Pattern D DSC profile is substantially similar to that shown in FIG. 187. In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by an XRPD signal at 5.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °29 and 26.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, and 27.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °29, 26.7 °29, and 27.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, and 9.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, and 9.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, and 21.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, and 21.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, and 10.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, 21.7 °20, and 10.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, 10.9 °29, and

14.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, 21.7 °20, 10.9 °20, and 14.7 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, 10.9 °29,

14.7 °29, and 8.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, 21.7 °20, 10.9 °20, 14.7 °20, and 8.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

14.7 °20, 8.7 °20, and 4.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, 10.9 °20, 14.7 °20, 8.7 °20, and 4.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

14.7 °20, 8.7 °20, 4.4 °20, and 16.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °20, 10.9 °20, 14.7 °20, 8.7 °20, 4.4 °20, and 16.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, Table 28 is a numerical representation of selected XRPD signals shown in at least Figure 23.

In some embodiments, the crystalline ketanserin succinate Pattern D is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty -five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, or thirty-one XRPD signals selected from those set forth in Table 28.

Table 28 Peak list of ketanserin succinate Pattern D

Solid forms ofketanserin succinate Pattern E

In some embodiments, the present disclosure provides solid forms of ketanserin succinate Pattern E, e.g., crystalline forms of ketanserin succinate Pattern E. In some embodiments, the ketanserin succinate Pattern E XRPD profile is substantially similar to that shown in FIG. 24. In some embodiments, the ketanserin succinate Pattern E 1H NMR spectrum is substantially similar to that shown in FIG. 189. In some embodiments, the ketanserin succinate Pattern E TGA profile is substantially similar to that shown in FIG. 191. In some embodiments, the ketanserin succinate Pattern E DSC profile is substantially similar to that shown in FIG. 190. In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by an XRPD signal at 14.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29 and 21.0 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, and 4.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29, 21.0 °29, and 4.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, and 22.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °20, 21.0 °20, 4.7 °20, and 22.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, and 11.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °20, 21.0 °20, 4.7 °20, 22.3 °20, and 11.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, and 7.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °20, 21.0 °20, 4.7 °20, 22.3 °20, 11.1 °20, and 7.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °20, 21.0 °20, 4.7 °20, 22.3 °20, 11.1 °20, 7.4 °20, and 8.8 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °20, 4.7 °20, 22.3 °20, 11.1 °20, 7.4 °20, 8.8 °29, and 9.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, and 9.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, 9.4 °29, and 21.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, 9.4 °29, and 21.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, 9.4 °29, 21.3 °29, and 4.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, 9.4 °29, 21.3 °29, and 4.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, Table 29 is a numerical representation of selected XRPD signals shown in at least Figure 24.

In some embodiments, the crystalline ketanserin succinate Pattern E is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or twenty-one XRPD signals selected from those set forth in Table 29.

Table 29 Peak list of ketanserin succinate Pattern E

Solid forms ofketanserin succinate Pattern F

In some embodiments, the present disclosure provides solid forms of ketanserin succinate Pattern F, e.g., crystalline forms of ketanserin succinate Pattern F. In some embodiments, the ketanserin succinate Pattern F XRPD profile is substantially similar to that shown in FIG. 25. In some embodiments, the ketanserin succinate Pattern F 1H NMR spectrum is substantially similar to that shown in FIG. 192. In some embodiments, the ketanserin succinate Pattern F TGA profile is substantially similar to that shown in FIG. 194. In some embodiments, the ketanserin succinate Pattern F DSC profile is substantially similar to that shown in FIG. 193. In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by an XRPD signal at 26.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °29 and 26.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, and 14.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °29, 26.5 °29, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, and 23.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, and 23.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, and 12.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, and 12.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, and 16.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, 12.1 °20, and 16.9 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, 16.9 °29, and 4.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, 12.1 °20, 16.9 °20, and 4.5 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, 16.9 °29,

4.5 °29, and 16.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, 12.1 °20, 16.9 °20, 4.5 °20, and 16.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

4.5 °20, 16.6 °20, and 25.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, 16.9 °20, 4.5 °20, 16.6 °20, and 25.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

4.5 °20, 16.6 °20, 25.0 °20, and 10.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °20, 16.9 °20, 4.5 °20, 16.6 °20, 25.0 °20, and 10.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, Table 30 is a numerical representation of selected XRPD signals shown in at least Figure 25.

In some embodiments, the crystalline ketanserin succinate Pattern F is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty -five, twenty-six, twenty-seven, twenty-eight, or twenty-nine XRPD signals selected from those set forth in Table 30.

Table 30 Peak list of ketanserin succinate Pattern F

Solid forms ofketanserin succinate Pattern G

In some embodiments, the present disclosure provides solid forms of ketanserin succinate Pattern G, e.g., crystalline forms of ketanserin succinate Pattern G. In some embodiments, the ketanserin succinate Pattern G XRPD profile is substantially similar to that shown in FIG. 26. In some embodiments, the ketanserin succinate Pattern G 1H NMR spectrum is substantially similar to that shown in FIG. 195.

In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by an XRPD signal at 21.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °29 and 21.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, and 11.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °29, 21.8 °29, and 11.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, and 5.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, and 5.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, and 10.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, and 10.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, and 20.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, and 20.2 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, 20.2 °29, and 27.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, 20.2 °20, and 27.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, 20.2 °29, 27.7 °20, and 26.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, 20.2 °20, 27.7 °20, and 26.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, 20.2 °29, 27.7 °20, 26.9 °20, and 18.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, 20.2 °20, 27.7 °20, 26.9 °20, and 18.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, 20.2 °29, 27.7 °20, 26.9 °20, 18.9 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °20, 20.2 °20, 27.7 °20, 26.9 °20, 18.9 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 31 is a numerical representation of selected XRPD signals shown in at least Figure 26.

In some embodiments, the crystalline ketanserin succinate Pattern G is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 31.

Table 31 Peak list of ketanserin succinate Pattern G

Solid forms ofketanserin succinate Pattern H

In some embodiments, the present disclosure provides solid forms of ketanserin succinate Pattern H, e.g., crystalline forms of ketanserin succinate Pattern H. In some embodiments, the ketanserin succinate Pattern H XRPD profile is substantially similar to that shown in FIG. 27. In some embodiments, the ketanserin succinate Pattern H 1H NMR spectrum is substantially similar to that shown in FIG. 196. In some embodiments, the ketanserin succinate Pattern H TGA profile is substantially similar to that shown in FIG. 198. In some embodiments, the ketanserin succinate Pattern H DSC profile is substantially similar to that shown in FIG. 197. In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by an XRPD signal at 24.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °29 and 23.1 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three XRPD signals selected from the group consisting of 24.9 °29, 23.1 °29, and 27.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °29, 23.1 °29, and 27.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °29, 23.1 °29, 27.1 °29, and 9.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, and 9.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °29, 23.1 °29, 27.1 °29, 9.7 °29, and 25.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, and 25.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °29, 23.1 °29, 27.1 °29, 9.7 °29, 25.9 °29, and 10.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, and 10.8 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, and 13.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, and 13.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20,

13.2 °20, and 17.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, 13.2 °20, and 17.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20,

13.2 °20, 17.7 °20, and 20.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, 13.2 °20, 17.7 °20, and 20.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

13.2 °20, 17.7 °20, 20.8 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °29, 23.1 °29, 27.1 °29, 9.7 °29, 25.9 °20, 10.8 °20, 13.2 °20, 17.7 °20, 20.8 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 32 is a numerical representation of selected XRPD signals shown in at least Figure 27.

In some embodiments, the crystalline ketanserin succinate Pattern H is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 32.

Table 32 Peak list of ketanserin succinate Pattern H

Solid forms of ke tanserin L-tartrate Pattern A

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern A, e.g., crystalline forms of ketanserin L-tartrate Pattern A. In some embodiments, the ketanserin L-tartrate Pattern A XRPD profile is substantially similar to that shown in any one of FIGs. 18, 61, or 110. In some embodiments, the ketanserin L-tartrate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 199. In some embodiments, the ketanserin L-tartrate Pattern A TGA profile is substantially similar to that shown in FIG. 201. In some embodiments, the ketanserin L-tartrate Pattern A DSC profile is substantially similar to that shown in FIG. 200.

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by an XRPD signal at 21.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29 and 13.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, and 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 13.9 °20, and 15.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, and 21.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, and 21.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, 21.7 °29, and 25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, 21.7 °29, 25.3 °29, and 16.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, and 16.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, 21.7 °29, 25.3 °29, 16.6 °29, and 15.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, and

15.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20,

15.1 °20, and 12.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, 15.1 °20, and 12.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

15.1 °20, 12.6 °20, and 20.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, 15.1 °20, 12.6 °20, and 20.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

15.1 °20, 12.6 °20, 20.9 °20, and 7.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L- tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, 15.1 °20, 12.6 °20, 20.9 °20, and 7.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 33 is a numerical representation of selected XRPD signals shown in at least Figure 18.

In some embodiments, the crystalline ketanserin L-tartrate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty XRPD signals selected from those set forth in Table 33. Table 33 Peak list of ketanserin L-tartrate Pattern A

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by an XRPD signal at 21.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29 and 13.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, and 25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 13.9 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, and 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, and 15.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, and 16.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, and 16.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °29, and 15.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, and 15.1 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °29, 15.1 °29, and 12.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, and

12.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °29, 15.1 °29,

12.7 °20, and 21.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, 12.7 °20, and 21.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

12.7 °20, 21.0 °20, and 22.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, 12.7 °20, 21.0 °20, and 22.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

12.7 °20, 21.0 °20, 22.3 °20, and 18.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L- tartrate Pattern A characterized by XRPD signals at 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °20, 15.1 °20, 12.7 °20, 21.0 °20, 22.3 °20, and 18.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the crystalline ketanserin L-tartrate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty XRPD signals selected from those set forth in Table 34. Table 34 Peak list of ketanserin L-tartrate Pattern A

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29 and 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 15.6 °29, and 14.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, and 12.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 15.6 °20, 14.8 °20, and 12.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, and 20.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, and 20.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, and 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, 17.5 °29, and 25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, 17.5 °20, and 25.3 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, 17.5 °29,

25.3 °29, and 7.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, 17.5 °20, 25.3 °20, and 7.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

25.3 °20, 7.8 °20, and 21.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, 17.5 °20, 25.3 °20, 7.8 °20, and 21.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

25.3 °20, 7.8 °20, 21.1 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L- tartrate Pattern A characterized by XRPD signals at 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °20, 17.5 °20, 25.3 °20, 7.8 °20, 21.1 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 35 is a numerical representation of selected XRPD signals shown in at least Figure 61.

In some embodiments, the crystalline ketanserin L-tartrate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 35. Table 35 Peak list of ketanserin L-tartrate Pattern A

Solid forms of ketanserin L-tartrate Pattern B

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern B, e.g., crystalline forms of ketanserin L-tartrate Pattern B. In some embodiments, the ketanserin L-tartrate Pattern B XRPD profile is substantially similar to that shown in FIG. 56. In some embodiments, the ketanserin L-tartrate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 202. In some embodiments, the ketanserin L-tartrate Pattern B TGA profile is substantially similar to that shown in FIG. 204. In some embodiments, the ketanserin L-tartrate Pattern B DSC profile is substantially similar to that shown in FIG. 203.

In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by an XRPD signal at 10.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by XRPD signals at 10.8 °29 and 21.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 10.8 °20, 21.6 °20, and 14.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by XRPD signals at 10.8 °29, 21.6 °29, and 14.7 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °29, 21.6 °29, 14.7 °29, and 20.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by XRPD signals at 10.8 °20, 21.6 °20, 14.7 °20, and 20.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °29, 21.6 °29, 14.7 °29, 20.1 °29, and 17.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by XRPD signals at 10.8 °20, 21.6 °20, 14.7 °20, 20.1 °20, and 17.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °29, 21.6 °29, 14.7 °29, 20.1 °29, 17.8 °29, and 32.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by XRPD signals at 10.8 °20, 21.6 °20, 14.7 °20, 20.1 °20, 17.8 °20, and 32.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 21.6 °20, 14.7 °20, 20.1 °20, 17.8 °20, 32.6 °20, and 16.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by XRPD signals at 10.8 °20, 21.6 °20, 14.7 °20, 20.1 °20, 17.8 °20, 32.6 °20, and 16.9 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 21.6 °20, 14.7 °20, 20.1 °20, 17.8 °20, 32.6 °20,

16.9 °29, and 25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by XRPD signals at 10.8 °20, 21.6 °20, 14.7 °20, 20.1 °20, 17.8 °20, 32.6 °20, 16.9 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

16.9 °20, 25.3 °20, and 19.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L-tartrate Pattern B characterized by XRPD signals at 10.8 °29, 21.6 °29, 14.7 °29, 20.1 °29, 17.8 °29, 32.6 °20, 16.9 °20, 25.3 °20, and 19.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

16.9 °20, 25.3 °20, 19.8 °20, and 20.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern B is crystalline ketanserin L- tartrate Pattern B characterized by XRPD signals at 10.8 °29, 21.6 °29, 14.7 °29, 20.1 °29, 17.8 °20, 32.6 °20, 16.9 °20, 25.3 °20, 19.8 °20, and 20.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 36 is a numerical representation of selected XRPD signals shown in at least Figure 56. In some embodiments, the crystalline ketanserin L-tartrate Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen XRPD signals selected from those set forth in Table 36. Table 36 Peak list of ketanserin L-tartrate Pattern B

Solid forms of ketanserin L-tartrate Pattern C

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern C, e.g., crystalline forms of ketanserin L-tartrate Pattern C. In some embodiments, the ketanserin L-tartrate Pattern C XRPD profile is substantially similar to that shown in FIG. 29. In some embodiments, the ketanserin L-tartrate Pattern C 1H NMR spectrum is substantially similar to that shown in FIG. 205. In some embodiments, the ketanserin L-tartrate Pattern C TGA profile is substantially similar to that shown in FIG. 207. In some embodiments, the ketanserin L-tartrate Pattern C DSC profile is substantially similar to that shown in FIG. 206. In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L- tartrate Pattern C characterized by an XRPD signal at 13.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by XRPD signals at 13.2 °29 and 11.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 13.2 °20, 11.7 °20, and 25.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by XRPD signals at 13.2 °29, 11.7 °29, and 25.4 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °29, 11.7 °29, 25.4 °29, and 18.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by XRPD signals at 13.2 °29, 11.7 °20, 25.4 °20, and 18.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °29, 11.7 °29, 25.4 °29, 18.8 °29, and 27.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by XRPD signals at 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °29, 11.7 °29, 25.4 °29, 18.8 °29, 27.0 °29, and 17.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by XRPD signals at 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, 27.0 °20, and 17.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, 27.0 °20, 17.6 °20, and 26.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by XRPD signals at 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, 27.0 °20, 17.6 °20, and 26.6 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, 27.0 °20, 17.6 °20,

26.6 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by XRPD signals at 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, 27.0 °20, 17.6 °20, 26.6 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

26.6 °20, 8.8 °20, and 14.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L-tartrate Pattern C characterized by XRPD signals at 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, 27.0 °20, 17.6 °20, 26.6 °20, 8.8 °20, and 14.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

26.6 °20, 8.8 °20, 14.6 °20, and 24.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern C is crystalline ketanserin L- tartrate Pattern C characterized by XRPD signals at 13.2 °29, 11.7 °29, 25.4 °29, 18.8 °29, 27.0 °20, 17.6 °20, 26.6 °20, 8.8 °20, 14.6 °20, and 24.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, Table 37 is a numerical representation of selected XRPD signals shown in at least Figure 29.

In some embodiments, the crystalline ketanserin L-tartrate Pattern C is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, or eighteen XRPD signals selected from those set forth in Table 37.

Table 37 Peak list of ketanserin L-tartrate Pattern C

Solid forms of ketanserin L-tartrate Pattern D In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate

Pattern D, e.g., crystalline forms of ketanserin L-tartrate Pattern D. In some embodiments, the ketanserin L-tartrate Pattern D XRPD profile is substantially similar to that shown in FIG. 58. In some embodiments, the ketanserin L-tartrate Pattern D 1H NMR spectrum is substantially similar to that shown in FIG. 208.

In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by an XRPD signal at 21.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by XRPD signals at 21.0 °29 and 9.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 21.0 °20, 9.5 °20, and 14.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by XRPD signals at 21.0 °29, 9.5 °29, and 14.2 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 9.5 °29, 14.2 °29, and 10.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by XRPD signals at 21.0 °29, 9.5 °20, 14.2 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 9.5 °29, 14.2 °29, 10.7 °29, and 27.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by XRPD signals at 21.0 °20, 9.5 °20, 14.2 °20, 10.7 °20, and 27.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 9.5 °29, 14.2 °29, 10.7 °29, 27.7 °29, and 4.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by XRPD signals at 21.0 °20, 9.5 °20, 14.2 °20, 10.7 °20, 27.7 °20, and 4.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 9.5 °29, 14.2 °29, 10.7 °29, 27.7 °29, 4.7 °29, and 26.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by XRPD signals at 21.0 °20, 9.5 °20, 14.2 °20, 10.7 °20, 27.7 °20, 4.7 °20, and 26.9 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 9.5 °20, 14.2 °20, 10.7 °20, 27.7 °20, 4.7 °20, 26.9 °29, and 20.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern D is crystalline ketanserin L-tartrate Pattern D characterized by XRPD signals at 21.0 °20, 9.5 °20, 14.2 °20, 10.7 °20, 27.7 °20, 4.7 °20, 26.9 °20, and 20.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 38 is a numerical representation of selected XRPD signals shown in at least Figure 58.

In some embodiments, the crystalline ketanserin L-tartrate Pattern D is characterized by one, two, three, four, five, six, seven, or eight XRPD signals selected from those set forth in Table 38.

Table 38 Peak list of ketanserin L-tartrate Pattern D

Solid forms of ke tanserin L-tartrate Pattern E

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern E, e.g., crystalline forms of ketanserin L-tartrate Pattern E. In some embodiments, the ketanserin L-tartrate Pattern E XRPD profile is substantially similar to that shown in FIG. 31. In some embodiments, the ketanserin L-tartrate Pattern E 1H NMR spectrum is substantially similar to that shown in FIG. 209.

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L- tartrate Pattern E characterized by an XRPD signal at 6.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by XRPD signals at 6.2 °29 and 17.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by two or more, or three XRPD signals selected from the group consisting of 6.2 °20, 17.1 °20, and 24.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by XRPD signals at 6.2 °29, 17.1 °29, and 24.3 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °29, 17.1 °29, 24.3 °29, and 11.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by XRPD signals at 6.2 °29, 17.1 °20, 24.3 °20, and 11.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °29, 17.1 °29, 24.3 °29, 11.8 °29, and 22.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by XRPD signals at 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, and 22.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °29, 17.1 °29, 24.3 °29, 11.8 °29, 22.8 °29, and 19.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by XRPD signals at 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, 22.8 °20, and 19.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °29, 17.1 °29, 24.3 °29, 11.8 °29, 22.8 °29, 19.0 °29, and 14.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by XRPD signals at 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, 22.8 °20, 19.0 °20, and 14.5 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, 22.8 °20, 19.0 °20, 14.5 °29, and 25.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by XRPD signals at 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, 22.8 °20, 19.0 °20, 14.5 °20, and 25.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, 22.8 °20, 19.0 °20, 14.5 °20, 25.6 °20, and 12.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by XRPD signals at 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, 22.8 °20, 19.0 °20, 14.5 °20, 25.6 °20, and 12.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, 22.8 °20, 19.0 °20, 14.5 °20, 25.6 °20, 12.3 °20, and 24.7 °20 (±0.2 °20; ±0.1 °20; or ±O.O °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern E is crystalline ketanserin L-tartrate Pattern E characterized by XRPD signals at 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, 22.8 °20, 19.0 °20, 14.5 °20, 25.6 °20, 12.3 °20, and 24.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, Table 39 is a numerical representation of selected XRPD signals shown in at least Figure 31.

In some embodiments, the crystalline ketanserin L-tartrate Pattern E is characterized by one, two, three, four, five, six, seven, eight, nine, or ten XRPD signals selected from those set forth in Table 39.

Table 39 Peak list of ketanserin L-tartrate Pattern E

Solid forms of ketanserin L-tartrate Pattern F In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern F, e.g., crystalline forms of ketanserin L-tartrate Pattern F. In some embodiments, the ketanserin L-tartrate Pattern F XRPD profile is substantially similar to that shown in FIG. 32. In some embodiments, the ketanserin L-tartrate Pattern F 1H NMR spectrum is substantially similar to that shown in FIG. 210.

In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by an XRPD signal at 21.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by XRPD signals at 21.7 °29 and 15.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by two or more, or three XRPD signals selected from the group consisting of 21.7 °20, 15.5 °20, and 16.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by XRPD signals at 21.7 °29, 15.5 °29, and 16.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 15.5 °29, 16.8 °29, and 12.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by XRPD signals at 21.7 °20, 15.5 °20, 16.8 °20, and 12.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 15.5 °29, 16.8 °29, 12.5 °29, and 14.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by XRPD signals at 21.7 °20, 15.5 °20, 16.8 °20, 12.5 °20, and 14.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 15.5 °29, 16.8 °29, 12.5 °29, 14.0 °29, and 7.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by XRPD signals at 21.7 °20, 15.5 °20, 16.8 °20, 12.5 °20, 14.0 °20, and 7.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 15.5 °29, 16.8 °29, 12.5 °29, 14.0 °29, 7.7 °29, and 16.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by XRPD signals at 21.7 °20, 15.5 °20, 16.8 °20, 12.5 °20, 14.0 °20, 7.7 °20, and 16.5 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 15.5 °20, 16.8 °20, 12.5 °20, 14.0 °20, 7.7 °20, 16.5 °29, and 14.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by XRPD signals at 21.7 °20, 15.5 °20, 16.8 °20, 12.5 °20, 14.0 °20, 7.7 °20, 16.5 °20, and 14.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 15.5 °20, 16.8 °20, 12.5 °20, 14.0 °20, 7.7 °20, 16.5 °20, 14.9 °20, and 20.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by XRPD signals at 21.7 °29, 15.5 °29, 16.8 °29, 12.5 °29, 14.0 °29, 7.7 °20, 16.5 °20, 14.9 °20, and 20.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 15.5 °20, 16.8 °20, 12.5 °20, 14.0 °20, 7.7 °20, 16.5 °20, 14.9 °20, 20.9 °20, and 17.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern F is crystalline ketanserin L-tartrate Pattern F characterized by XRPD signals at 21.7 °29, 15.5 °29, 16.8 °29, 12.5 °29, 14.0 °29, 7.7 °20, 16.5 °20, 14.9 °20, 20.9 °20, and 17.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, Table 40 is a numerical representation of selected XRPD signals shown in at least Figure 32.

In some embodiments, the crystalline ketanserin L-tartrate Pattern F is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty -four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty -nine, thirty, thirty-one, thirty -two, thirty-three, or thirty-four XRPD signals selected from those set forth in Table 40.

Table 40 Peak list of ketanserin L-tartrate Pattern F

Solid forms ofketanserin L-tar irate Pattern G

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern G, e.g., crystalline forms of ketanserin L-tartrate Pattern G. In some embodiments, the ketanserin L-tartrate Pattern G XRPD profile is substantially similar to that shown in FIG. 33. In some embodiments, the ketanserin L-tartrate Pattern G 1H NMR spectrum is substantially similar to that shown in FIG. 211.

In some embodiments, the solid form ofketanserin L-tartrate Pattern G is crystalline ketanserin L- tartrate Pattern G characterized by an XRPD signal at 6.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by XRPD signals at 6.4 °29 and 17.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by two or more, or three XRPD signals selected from the group consisting of 6.4 °20, 17.4 °20, and 14.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by XRPD signals at 6.4 °29, 17.4 °29, and 14.7 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °29, 17.4 °29, 14.7 °29, and 18.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by XRPD signals at 6.4 °29,

17.4 °20, 14.7 °20, and 18.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °29, 17.4 °29, 14.7 °29, 18.5 °29, and 12.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by XRPD signals at

6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, and 12.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °29, 17.4 °29, 14.7 °29, 18.5 °29, 12.1 °29, and 24.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by XRPD signals at 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, and 24.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °29, 17.4 °29, 14.7 °29, 18.5 °29, 12.1 °29, 24.9 °29, and 25.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by XRPD signals at 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, 24.9 °20, and 25.8 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, 24.9 °20, 25.8 °29, and 16.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by XRPD signals at 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, 24.9 °20, 25.8 °20, and 16.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, 24.9 °20, 25.8 °20, 16.2 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by XRPD signals at 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, 24.9 °20, 25.8 °20, 16.2 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, 24.9 °20, 25.8 °20, 16.2 °20, 22.7 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern G is crystalline ketanserin L-tartrate Pattern G characterized by XRPD signals at 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, 24.9 °20, 25.8 °20, 16.2 °20, 22.7 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 41 is a numerical representation of selected XRPD signals shown in at least Figure 33.

In some embodiments, the crystalline ketanserin L-tartrate Pattern G is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, or twenty- four XRPD signals selected from those set forth in Table 41.

Table 41 Peak list of ketanserin L-tartrate Pattern G

Solid forms of ke tanserin L-tartrate Pattern H

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern H, e.g., crystalline forms of ketanserin L-tartrate Pattern H. In some embodiments, the ketanserin L-tartrate Pattern H XRPD profile is substantially similar to that shown in FIG. 34. In some embodiments, the ketanserin L-tartrate Pattern H 1H NMR spectrum is substantially similar to that shown in FIG. 212. In some embodiments, the ketanserin L-tartrate Pattern H TGA profile is substantially similar to that shown in FIG. 214. In some embodiments, the ketanserin L-tartrate Pattern H DSC profile is substantially similar to that shown in FIG. 213.

In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by an XRPD signal at 21.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by XRPD signals at 21.6 °29 and 14.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °29, 14.9 °29, and 7.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by XRPD signals at 21.6 °29, 14.9 °29, and 7.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 14.9 °29, 7.4 °29, and 3.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by XRPD signals at 21.6 °29, 14.9 °29, 7.4 °29, and 3.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 14.9 °29, 7.4 °29, 3.7 °29, and 13.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by XRPD signals at 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, and 13.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 14.9 °29, 7.4 °29, 3.7 °29, 13.0 °29, and 18.3 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by XRPD signals at 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, 13.0 °20, and 18.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 14.9 °29, 7.4 °29, 3.7 °29, 13.0 °29, 18.3 °29, and

16.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by XRPD signals at 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, 13.0 °20, 18.3 °20, and 16.7 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, 13.0 °20, 18.3 °20, 16.7 °29, and 20.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by XRPD signals at 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, 13.0 °20, 18.3 °20, 16.7 °20, and 20.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, 13.0 °20, 18.3 °20, 16.7 °20, 20.9 °20, and 22.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by XRPD signals at 21.6 °29, 14.9 °29, 7.4 °29, 3.7 °29, 13.0 °29, 18.3 °20, 16.7 °20, 20.9 °20, and 22.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, 13.0 °20, 18.3 °20, 16.7 °20, 20.9 °20, 22.4 °20, and 25.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern H is crystalline ketanserin L-tartrate Pattern H characterized by XRPD signals at 21.6 °29, 14.9 °29, 7.4 °29, 3.7 °29, 13.0 °29, 18.3 °20, 16.7 °20, 20.9 °20, 22.4 °20, and 25.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 42 is a numerical representation of selected XRPD signals shown in at least Figure 34. In some embodiments, the crystalline ketanserin L-tartrate Pattern H is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or seventeen XRPD signals selected from those set forth in Table 42.

Table 42 Peak list of ketanserin L-tartrate Pattern H

Solid forms of ketanserin L-tartrate Pattern I

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern I, e.g., crystalline forms of ketanserin L-tartrate Pattern I. In some embodiments, the ketanserin L-tartrate Pattern I XRPD profile is substantially similar to that shown in FIG. 36. In some embodiments, the ketanserin L-tartrate Pattern I 1H NMR spectrum is substantially similar to that shown in FIG. 215. In some embodiments, the ketanserin L-tartrate Pattern I TGA profile is substantially similar to that shown in FIG. 217. In some embodiments, the ketanserin L-tartrate Pattern I DSC profile is substantially similar to that shown in FIG. 216.

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by an XRPD signal at 15.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by XRPD signals at 15.8 °29 and 26.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by two or more, or three XRPD signals selected from the group consisting of 15.8 °29, 26.4 °29, and 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by XRPD signals at 15.8 °29, 26.4 °29, and 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °29, 26.4 °29, 17.5 °29, and 27.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by XRPD signals at 15.8 °29, 26.4 °29, 17.5 °29, and 27.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °29, 26.4 °29, 17.5 °29, 27.6 °29, and 16.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by XRPD signals at 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, and 16.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °29, 26.4 °29, 17.5 °29, 27.6 °29, 16.3 °29, and 5.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by XRPD signals at 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, 16.3 °20, and 5.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °29, 26.4 °29, 17.5 °29, 27.6 °29, 16.3 °29, 5.4 °29, and 12.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by XRPD signals at 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, 16.3 °20, 5.4 °20, and 12.2 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, 16.3 °20, 5.4 °20, 12.2 °29, and 24.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by XRPD signals at 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, 16.3 °20, 5.4 °20, 12.2 °20, and 24.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, 16.3 °20, 5.4 °20, 12.2 °20, 24.0 °20, and 26.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by XRPD signals at 15.8 °29, 26.4 °29, 17.5 °29, 27.6 °29, 16.3 °29, 5.4 °20, 12.2 °20, 24.0 °20, and 26.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, 16.3 °20, 5.4 °20, 12.2 °20, 24.0 °20, 26.6 °20, and 18.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern I is crystalline ketanserin L-tartrate Pattern I characterized by XRPD signals at 15.8 °29, 26.4 °29, 17.5 °29, 27.6 °29, 16.3 °29, 5.4 °20, 12.2 °20, 24.0 °20, 26.6 °20, and 18.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, Table 43 is a numerical representation of selected XRPD signals shown in at least Figure 36.

In some embodiments, the crystalline ketanserin L-tartrate Pattern I is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty -four, twenty-five, or twenty-six XRPD signals selected from those set forth in Table 43.

Table 43 Peak list of ketanserin L-tartrate Pattern I

Solid forms of ke tanserin L-tartrate Pattern J

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern J, e.g., crystalline forms of ketanserin L-tartrate Pattern J. In some embodiments, the ketanserin L-tartrate Pattern J XRPD profile is substantially similar to that shown in FIG. 37. In some embodiments, the ketanserin L-tartrate Pattern J 1H NMR spectrum is substantially similar to that shown in FIG. 218. In some embodiments, the ketanserin L-tartrate Pattern J TGA profile is substantially similar to that shown in FIG. 220. In some embodiments, the ketanserin L-tartrate Pattern J DSC profile is substantially similar to that shown in FIG. 219. In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by an XRPD signal at 15.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by XRPD signals at 15.5 °29 and 21.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by two or more, or three XRPD signals selected from the group consisting of 15.5 °20, 21.8 °20, and 23.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by XRPD signals at 15.5 °29, 21.8 °29, and 23.3 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °29, 21.8 °29, 23.3 °29, and 15.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by XRPD signals at 15.5 °29, 21.8 °20, 23.3 °20, and 15.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °29, 21.8 °29, 23.3 °29, 15.2 °29, and 26.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by XRPD signals at 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, and 26.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °29, 21.8 °29, 23.3 °29, 15.2 °29, 26.2 °29, and 16.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by XRPD signals at 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, 26.2 °20, and 16.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, 26.2 °20, 16.6 °20, and 5.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by XRPD signals at 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, 26.2 °20, 16.6 °20, and 5.8 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, 26.2 °20, 16.6 °20,

5.8 °29, and 17.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by XRPD signals at 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, 26.2 °20, 16.6 °20, 5.8 °20, and 17.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

5.8 °20, 17.1 °20, and 19.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L-tartrate Pattern J characterized by XRPD signals at 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, 26.2 °20, 16.6 °20, 5.8 °20, 17.1 °20, and 19.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

5.8 °20, 17.1 °20, 19.2 °20, and 13.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern J is crystalline ketanserin L- tartrate Pattern J characterized by XRPD signals at 15.5 °29, 21.8 °29, 23.3 °29, 15.2 °29, 26.2 °20, 16.6 °20, 5.8 °20, 17.1 °20, 19.2 °20, and 13.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 44 is a numerical representation of selected XRPD signals shown in at least Figure 37.

In some embodiments, the crystalline ketanserin L-tartrate Pattern J is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve XRPD signals selected from those set forth in Table 44. Table 44 Peak list of ketanserin L-tartrate Pattern J

Solid forms of ketanserin L-tartrate Pattern K

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern K, e.g., crystalline forms of ketanserin L-tartrate Pattern K. In some embodiments, the ketanserin L-tartrate Pattern K XRPD profile is substantially similar to that shown in FIG. 57. In some embodiments, the ketanserin L-tartrate Pattern K 1H NMR spectrum is substantially similar to that shown in FIG. 221. In some embodiments, the ketanserin L-tartrate Pattern K TGA profile is substantially similar to that shown in FIG. 223. In some embodiments, the ketanserin L-tartrate Pattern K DSC profile is substantially similar to that shown in FIG. 222.

In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by an XRPD signal at 4.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by XRPD signals at 4.9 °29 and 9.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by two or more, or three XRPD signals selected from the group consisting of 4.9 °29, 9.8 °29, and 19.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by XRPD signals at 4.9 °29, 9.8 °29, and 19.6 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °29, 9.8 °29, 19.6 °29, and 16.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by XRPD signals at 4.9 °29,

9.8 °20, 19.6 °20, and 16.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °29, 9.8 °29, 19.6 °29, 16.3 °29, and 14.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by XRPD signals at

4.9 °20, 9.8 °20, 19.6 °20, 16.3 °20, and 14.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °29, 9.8 °29, 19.6 °29, 16.3 °29, 14.7 °29, and 24.2 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by XRPD signals at 4.9 °20, 9.8 °20, 19.6 °20, 16.3 °20, 14.7 °20, and 24.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °29, 9.8 °29, 19.6 °29, 16.3 °29, 14.7 °29, 24.2 °29, and 19.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern K is crystalline ketanserin L-tartrate Pattern K characterized by XRPD signals at 4.9 °20, 9.8 °20, 19.6 °20, 16.3 °20, 14.7 °20, 24.2 °20, and 19.0 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, Table 45 is a numerical representation of selected XRPD signals shown in at least Figure 57.

In some embodiments, the crystalline ketanserin L-tartrate Pattern K is characterized by one, two, three, four, five, six, or seven XRPD signals selected from those set forth in Table 45.

Table 45 Peak list of ketanserin L-tartrate Pattern K

Solid forms of ketanserin L-tartrate Pattern L

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern L, e.g., crystalline forms of ketanserin L-tartrate Pattern L. In some embodiments, the ketanserin L-tartrate Pattern L XRPD profile is substantially similar to that shown in FIG. 40. In some embodiments, the ketanserin L-tartrate Pattern L 1H NMR spectrum is substantially similar to that shown in FIG. 224. In some embodiments, the ketanserin L-tartrate Pattern L TGA profile is substantially similar to that shown in FIG. 226. In some embodiments, the ketanserin L-tartrate Pattern L DSC profile is substantially similar to that shown in FIG. 225.

In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by an XRPD signal at 11.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by XRPD signals at 11.7 °29 and 13.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by two or more, or three XRPD signals selected from the group consisting of 11.7 °20, 13.2 °20, and 18.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by XRPD signals at 11.7 °29, 13.2 °29, and 18.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °29, 13.2 °29, 18.8 °29, and 25.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by XRPD signals at 11.7 °20, 13.2 °20, 18.8 °20, and 25.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °29, 13.2 °29, 18.8 °29, 25.5 °29, and 27.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by XRPD signals at 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °29, 13.2 °29, 18.8 °29, 25.5 °29, 27.0 °29, and 17.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by XRPD signals at 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, 27.0 °20, and 17.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, 27.0 °20, 17.6 °20, and 14.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by XRPD signals at 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, 27.0 °20, 17.6 °20, and 14.6 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, 27.0 °20, 17.6 °20,

14.6 °29, and 25.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by XRPD signals at 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, 27.0 °20, 17.6 °20, 14.6 °20, and 25.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

14.6 °20, 25.6 °20, and 19.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L-tartrate Pattern L characterized by XRPD signals at 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, 27.0 °20, 17.6 °20, 14.6 °20, 25.6 °20, and 19.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

14.6 °20, 25.6 °20, 19.7 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern L is crystalline ketanserin L- tartrate Pattern L characterized by XRPD signals at 11.7 °29, 13.2 °29, 18.8 °29, 25.5 °29, 27.0 °20, 17.6 °20, 14.6 °20, 25.6 °20, 19.7 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 46 is a numerical representation of selected XRPD signals shown in at least Figure 40. In some embodiments, the crystalline ketanserin L-tartrate Pattern L is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 46. Table 46 Peak list of ketanserin L-tartrate Pattern L

Solid forms of ketanserin L-tartrate Pattern M

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern M, e.g., crystalline forms of ketanserin L-tartrate Pattern M. In some embodiments, the ketanserin L-tartrate Pattern M XRPD profile is substantially similar to that shown in FIG. 41. In some embodiments, the ketanserin L-tartrate Pattern M 1H NMR spectrum is substantially similar to that shown in FIG. 227. In some embodiments, the ketanserin L-tartrate Pattern M TGA profile is substantially similar to that shown in FIG. 229. In some embodiments, the ketanserin L-tartrate Pattern M DSC profile is substantially similar to that shown in FIG. 228.

In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by an XRPD signal at 19.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by XRPD signals at 19.9 °29 and 20.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by two or more, or three XRPD signals selected from the group consisting of 19.9 °20, 20.5 °20, and 10.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by XRPD signals at 19.9 °29, 20.5 °29, and 10.0 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.9 °29, 20.5 °29, 10.0 °29, and 29.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by XRPD signals at 19.9 °29, 20.5 °20, 10.0 °20, and 29.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.9 °29, 20.5 °29, 10.0 °29, 29.4 °29, and 10.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by XRPD signals at 19.9 °20, 20.5 °20, 10.0 °20, 29.4 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.9 °29, 20.5 °29, 10.0 °29, 29.4 °29, 10.7 °29, and 25.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by XRPD signals at 19.9 °20, 20.5 °20, 10.0 °20, 29.4 °20, 10.7 °20, and 25.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.9 °20, 20.5 °20, 10.0 °20, 29.4 °20, 10.7 °20, 25.2 °20, and 22.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by XRPD signals at 19.9 °20, 20.5 °20, 10.0 °20, 29.4 °20, 10.7 °20, 25.2 °20, and 22.3 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.9 °20, 20.5 °20, 10.0 °20, 29.4 °20, 10.7 °20, 25.2 °20,

22.3 °29, and 15.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by XRPD signals at 19.9 °20, 20.5 °20, 10.0 °20, 29.4 °20, 10.7 °20, 25.2 °20, 22.3 °20, and 15.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

22.3 °20, 15.7 °20, and 22.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L-tartrate Pattern M characterized by XRPD signals at 19.9 °29, 20.5 °29, 10.0 °29, 29.4 °29, 10.7 °29, 25.2 °20, 22.3 °20, 15.7 °20, and 22.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

22.3 °20, 15.7 °20, 22.9 °20, and 30.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern M is crystalline ketanserin L- tartrate Pattern M characterized by XRPD signals at 19.9 °29, 20.5 °29, 10.0 °29, 29.4 °29, 10.7 °20, 25.2 °20, 22.3 °20, 15.7 °20, 22.9 °20, and 30.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 47 is a numerical representation of selected XRPD signals shown in at least Figure 41. In some embodiments, the crystalline ketanserin L-tartrate Pattern M is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve XRPD signals selected from those set forth in Table 47.

Table 47 Peak list of ketanserin L-tartrate Pattern M

Solid forms of ketanserin L-tartrate Pattern N

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern N, e.g., crystalline forms of ketanserin L-tartrate Pattern N. In some embodiments, the ketanserin L-tartrate Pattern N XRPD profile is substantially similar to that shown in FIG. 42. In some embodiments, the ketanserin L-tartrate Pattern N 1H NMR spectrum is substantially similar to that shown in FIG. 230. In some embodiments, the ketanserin L-tartrate Pattern N TGA profile is substantially similar to that shown in FIG. 232. In some embodiments, the ketanserin L-tartrate Pattern N DSC profile is substantially similar to that shown in FIG. 231.

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by an XRPD signal at 16.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by XRPD signals at 16.9 °29 and 23.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by two or more, or three XRPD signals selected from the group consisting of 16.9 °20, 23.6 °20, and 15.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by XRPD signals at 16.9 °29, 23.6 °29, and 15.2 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °29, 23.6 °29, 15.2 °29, and 17.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by XRPD signals at 16.9 °20, 23.6 °20, 15.2 °20, and 17.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °29, 23.6 °29, 15.2 °29, 17.9 °29, and 8.9 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by XRPD signals at 16.9 °29, 23.6 °29, 15.2 °20, 17.9 °20, and 8.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °29, 23.6 °29, 15.2 °29, 17.9 °29, 8.9 °29, and 18.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by XRPD signals at 16.9 °20, 23.6 °20, 15.2 °20, 17.9 °20, 8.9 °20, and 18.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °29, 23.6 °29, 15.2 °29, 17.9 °29, 8.9 °29, 18.5 °29, and 20.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by XRPD signals at 16.9 °20, 23.6 °20, 15.2 °20, 17.9 °20, 8.9 °20, 18.5 °20, and 20.4 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °20, 23.6 °20, 15.2 °20, 17.9 °20, 8.9 °20, 18.5 °20, 20.4 °29, and 3.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by XRPD signals at 16.9 °20, 23.6 °20, 15.2 °20, 17.9 °20, 8.9 °20, 18.5 °20, 20.4 °20, and 3.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °20, 23.6 °20, 15.2 °20, 17.9 °20, 8.9 °20, 18.5 °20, 20.4 °20, 3.7 °20, and 7.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by XRPD signals at 16.9 °29, 23.6 °29, 15.2 °29, 17.9 °29, 8.9 °29, 18.5 °20, 20.4 °20, 3.7 °20, and 7.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °20, 23.6 °20, 15.2 °20, 17.9 °20, 8.9 °20, 18.5 °20, 20.4 °20, 3.7 °20, 7.6 °20, and 9.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern N is crystalline ketanserin L-tartrate Pattern N characterized by XRPD signals at 16.9 °29, 23.6 °29, 15.2 °29, 17.9 °29, 8.9 °29, 18.5 °20, 20.4 °20, 3.7 °20, 7.6 °20, and 9.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, Table 48 is a numerical representation of selected XRPD signals shown in at least Figure 42.

In some embodiments, the crystalline ketanserin L-tartrate Pattern N is characterized by one, two, three, four, five, six, seven, eight, nine, or ten XRPD signals selected from those set forth in Table 48.

Table 48 Peak list of ketanserin L-tartrate Pattern N

Solid forms of ketanserin L-tartrate Pattern O In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate

Pattern O, e.g., crystalline forms of ketanserin L-tartrate Pattern O. In some embodiments, the ketanserin L-tartrate Pattern O XRPD profile is substantially similar to that shown in FIG. 43. In some embodiments, the ketanserin L-tartrate Pattern O 1H NMR spectrum is substantially similar to that shown in FIG. 233. In some embodiments, the ketanserin L-tartrate Pattern O TGA profile is substantially similar to that shown in FIG. 235. In some embodiments, the ketanserin L-tartrate Pattern O DSC profile is substantially similar to that shown in FIG. 234.

In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by an XRPD signal at 18.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by XRPD signals at 18.6 °29 and 9.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by two or more, or three XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, and 11.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by XRPD signals at 18.6 °29, 9.9 °29, and 11.6 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, 11.6 °29, and 5.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by XRPD signals at 18.6 °29, 9.9 °20, 11.6 °20, and 5.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, 11.6 °29, 5.0 °29, and 13.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by XRPD signals at 18.6 °20, 9.9 °20, 11.6 °20, 5.0 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, 11.6 °29, 5.0 °29, 13.3 °29, and 25.4 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by XRPD signals at 18.6 °20, 9.9 °20, 11.6 °20, 5.0 °20, 13.3 °20, and 25.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, 11.6 °29, 5.0 °29, 13.3 °29, 25.4 °29, and 26.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by XRPD signals at 18.6 °20, 9.9 °20, 11.6 °20, 5.0 °20, 13.3 °20, 25.4 °20, and 26.9 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, 11.6 °29, 5.0 °29, 13.3 °29, 25.4 °29, 26.9 °29, and 14.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by XRPD signals at 18.6 °20, 9.9 °20, 11.6 °20, 5.0 °20, 13.3 °20, 25.4 °20, 26.9 °20, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, 11.6 °29, 5.0 °29, 13.3 °29, 25.4 °29, 26.9 °20, 14.8 °20, and 17.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by XRPD signals at 18.6 °29, 9.9 °29, 11.6 °29, 5.0 °29, 13.3 °29, 25.4 °20, 26.9 °20, 14.8 °20, and 17.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, 11.6 °29, 5.0 °29, 13.3 °29, 25.4 °29, 26.9 °20, 14.8 °20, 17.6 °20, and 29.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern O is crystalline ketanserin L-tartrate Pattern O characterized by XRPD signals at 18.6 °29, 9.9 °29, 11.6 °29, 5.0 °29, 13.3 °29, 25.4 °20, 26.9 °20, 14.8 °20, 17.6 °20, and 29.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 49 is a numerical representation of selected XRPD signals shown in at least Figure 43.

In some embodiments, the crystalline ketanserin L-tartrate Pattern O is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve XRPD signals selected from those set forth in Table 49. Table 49 Peak list of ketanserin L-tartrate Pattern O

Solid forms of ketanserin L-tartrate Pattern P In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate

Pattern P, e.g., crystalline forms of ketanserin L-tartrate Pattern P. In some embodiments, the ketanserin L-tartrate Pattern P XRPD profile is substantially similar to that shown in FIG. 53. In some embodiments, the ketanserin L-tartrate Pattern P 1H NMR spectrum is substantially similar to that shown in FIG. 236. In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by an XRPD signal at 13.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by XRPD signals at 13.3 °29 and 16.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by two or more, or three XRPD signals selected from the group consisting of 13.3 °20, 16.6 °20, and 18.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by XRPD signals at 13.3 °29, 16.6 °29, and 18.5 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.3 °29, 16.6 °29, 18.5 °29, and 26.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by XRPD signals at 13.3 °20, 16.6 °20, 18.5 °20, and 26.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.3 °29, 16.6 °29, 18.5 °29, 26.9 °29, and 25.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by XRPD signals at 13.3 °20, 16.6 °20, 18.5 °20, 26.9 °20, and 25.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.3 °29, 16.6 °29, 18.5 °29, 26.9 °29, 25.1 °29, and 15.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by XRPD signals at 13.3 °20, 16.6 °20, 18.5 °20, 26.9 °20, 25.1 °20, and 15.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.3 °29, 16.6 °29, 18.5 °29, 26.9 °29, 25.1 °29, 15.9 °29, and 20.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by XRPD signals at 13.3 °20, 16.6 °20, 18.5 °20, 26.9 °20, 25.1 °20, 15.9 °20, and 20.6 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.3 °29, 16.6 °29, 18.5 °29, 26.9 °29, 25.1 °29, 15.9 °29,

20.6 °29, and 18.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by XRPD signals at 13.3 °20, 16.6 °20, 18.5 °20, 26.9 °20, 25.1 °20, 15.9 °20, 20.6 °20, and 18.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.3 °29, 16.6 °29, 18.5 °29, 26.9 °29, 25.1 °29, 15.9 °29,

20.6 °20, 18.2 °20, and 14.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L-tartrate Pattern P characterized by XRPD signals at 13.3 °29, 16.6 °29, 18.5 °29, 26.9 °29, 25.1 °29, 15.9 °20, 20.6 °20, 18.2 °20, and 14.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

20.6 °20, 18.2 °20, 14.1 °20, and 23.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern P is crystalline ketanserin L- tartrate Pattern P characterized by XRPD signals at 13.3 °29, 16.6 °29, 18.5 °29, 26.9 °29, 25.1 °20, 15.9 °20, 20.6 °20, 18.2 °20, 14.1 °20, and 23.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 50 is a numerical representation of selected XRPD signals shown in at least Figure 53.

In some embodiments, the crystalline ketanserin L-tartrate Pattern P is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty -four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, or thirty-five XRPD signals selected from those set forth in Table 50. Table 50 Peak list of ketanserin L-tartrate Pattern P

Solid forms ofketanserin L-tar irate Pattern Q

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern Q, e.g., crystalline forms of ketanserin L-tartrate Pattern Q. In some embodiments, the ketanserin L-tartrate Pattern Q XRPD profile is substantially similar to that shown in FIG. 59. In some embodiments, the ketanserin L-tartrate Pattern Q 1H NMR spectrum is substantially similar to that shown in FIG. 237. In some embodiments, the ketanserin L-tartrate Pattern Q TGA profile is substantially similar to that shown in FIG. 239. In some embodiments, the ketanserin L-tartrate Pattern Q DSC profile is substantially similar to that shown in FIG. 238.

In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by an XRPD signal at 15.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by XRPD signals at 15.3 °29 and 14.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °29, 14.2 °29, and 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by XRPD signals at 15.3 °29, 14.2 °29, and 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 14.2 °29, 21.5 °29, and 26.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by XRPD signals at 15.3 °20, 14.2 °20, 21.5 °20, and 26.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 14.2 °29, 21.5 °29, 26.0 °29, and 23.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by XRPD signals at 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, and 23.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 14.2 °29, 21.5 °29, 26.0 °29, 23.9 °29, and 12.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by XRPD signals at 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, and 12.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, and 17.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by XRPD signals at 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, and 17.8 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, 17.8 °29, and 14.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by XRPD signals at 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, 17.8 °20, and 14.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, 17.8 °20, 14.5 °20, and 18.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by XRPD signals at 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, 17.8 °20, 14.5 °20, and 18.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, 17.8 °20, 14.5 °20, 18.1 °20, and 9.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern Q is crystalline ketanserin L- tartrate Pattern Q characterized by XRPD signals at 15.3 °29, 14.2 °29, 21.5 °29, 26.0 °29, 23.9 °20, 12.0 °20, 17.8 °20, 14.5 °20, 18.1 °20, and 9.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 51 is a numerical representation of selected XRPD signals shown in at least Figure 59.

In some embodiments, the crystalline ketanserin L-tartrate Pattern Q is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, or nineteen XRPD signals selected from those set forth in Table 51.

Table 51 Peak list of ketanserin L-tartrate Pattern Q

Solid forms of ke tanserin L-tartrate Pattern R

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern R, e.g., crystalline forms of ketanserin L-tartrate Pattern R. In some embodiments, the ketanserin L-tartrate Pattern R XRPD profile is substantially similar to that shown in FIG. 54. In some embodiments, the ketanserin L-tartrate Pattern R 1H NMR spectrum is substantially similar to that shown in FIG. 240. In some embodiments, the ketanserin L-tartrate Pattern R TGA profile is substantially similar to that shown in FIG. 242. In some embodiments, the ketanserin L-tartrate Pattern R DSC profile is substantially similar to that shown in FIG. 241. In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by an XRPD signal at 13.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by XRPD signals at 13.2 °29 and 25.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by two or more, or three XRPD signals selected from the group consisting of 13.2 °20, 25.4 °20, and 26.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by XRPD signals at 13.2 °29, 25.4 °29, and 26.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °29, 25.4 °29, 26.8 °29, and 14.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by XRPD signals at 13.2 °20, 25.4 °20, 26.8 °20, and 14.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °29, 25.4 °29, 26.8 °29, 14.5 °29, and 11.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by XRPD signals at 13.2 °20, 25.4 °20, 26.8 °20, 14.5 °20, and 11.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °29, 25.4 °29, 26.8 °29, 14.5 °29, 11.0 °29, and 11.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by XRPD signals at 13.2 °20, 25.4 °20, 26.8 °20, 14.5 °20, 11.0 °20, and 11.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °29, 25.4 °29, 26.8 °29, 14.5 °29, 11.0 °29, 11.2 °29, and 18.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by XRPD signals at 13.2 °20, 25.4 °20, 26.8 °20, 14.5 °20, 11.0 °20, 11.2 °20, and 18.6 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °29, 25.4 °29, 26.8 °29, 14.5 °29, 11.0 °29, 11.2 °29,

18.6 °29, and 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by XRPD signals at 13.2 °20, 25.4 °20, 26.8 °20, 14.5 °20, 11.0 °20, 11.2 °20, 18.6 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

18.6 °20, 17.5 °20, and 26.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L-tartrate Pattern R characterized by XRPD signals at 13.2 °20, 25.4 °20, 26.8 °20, 14.5 °20, 11.0 °20, 11.2 °20, 18.6 °20, 17.5 °20, and 26.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

18.6 °20, 17.5 °20, 26.3 °20, and 5.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern R is crystalline ketanserin L- tartrate Pattern R characterized by XRPD signals at 13.2 °29, 25.4 °29, 26.8 °29, 14.5 °29, 11.0 °20, 11.2 °20, 18.6 °20, 17.5 °20, 26.3 °20, and 5.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 52 is a numerical representation of selected XRPD signals shown in at least Figure 54.

In some embodiments, the crystalline ketanserin L-tartrate Pattern R is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen XRPD signals selected from those set forth in Table 52. Table 52 Peak list of ketanserin L-tartrate Pattern R

Solid forms of ketanserin L-tartrate Pattern S

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern S, e.g., crystalline forms of ketanserin L-tartrate Pattern S. In some embodiments, the ketanserin L-tartrate Pattern S XRPD profile is substantially similar to that shown in FIG. 55. In some embodiments, the ketanserin L-tartrate Pattern S 1H NMR spectrum is substantially similar to that shown in FIG. 243. In some embodiments, the ketanserin L-tartrate Pattern S TGA profile is substantially similar to that shown in FIG. 245. In some embodiments, the ketanserin L-tartrate Pattern S DSC profile is substantially similar to that shown in FIG. 244.

In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by an XRPD signal at 6.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by XRPD signals at 6.3 °29 and 18.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by two or more, or three XRPD signals selected from the group consisting of 6.3 °29, 18.5 °29, and 11.6 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by XRPD signals at 6.3 °29, 18.5 °29, and 11.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °29, 18.5 °29, 11.6 °29, and 13.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by XRPD signals at 6.3 °20, 18.5 °29, 11.6 °29, and 13.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °29, 18.5 °29, 11.6 °29, 13.2 °29, and 11.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by XRPD signals at 6.3 °29, 18.5 °29, 11.6 °20, 13.2 °20, and 11.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °29, 18.5 °29, 11.6 °29, 13.2 °29, 11.9 °29, and 17.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by XRPD signals at 6.3 °20, 18.5 °20, 11.6 °29, 13.2 °29, 11.9 °29, and 17.3 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °29, 18.5 °29, 11.6 °29, 13.2 °29, 11.9 °29, 17.3 °29, and 14.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by XRPD signals at 6.3 °20, 18.5 °20, 11.6 °20, 13.2 °20, 11.9 °20, 17.3 °20, and 14.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °29, 18.5 °29, 11.6 °29, 13.2 °29, 11.9 °29, 17.3 °29, 14.6 °29, and 16.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by XRPD signals at 6.3 °20, 18.5 °20, 11.6 °20, 13.2 °20, 11.9 °20, 17.3 °20, 14.6 °20, and 16.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °29, 18.5 °29, 11.6 °29, 13.2 °29, 11.9 °29, 17.3 °29, 14.6 °20, 16.2 °20, and 19.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by XRPD signals at 6.3 °20, 18.5 °20, 11.6 °20, 13.2 °20, 11.9 °20, 17.3 °20, 14.6 °20, 16.2 °20, and 19.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °29, 18.5 °29, 11.6 °29, 13.2 °29, 11.9 °29, 17.3 °29, 14.6 °20, 16.2 °20, 19.0 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern S is crystalline ketanserin L-tartrate Pattern S characterized by XRPD signals at 6.3 °20, 18.5 °20, 11.6 °20, 13.2 °20, 11.9 °20, 17.3 °20, 14.6 °20, 16.2 °20, 19.0 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 53 is a numerical representation of selected XRPD signals shown in at least Figure 55.

In some embodiments, the crystalline ketanserin L-tartrate Pattern S is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, or twenty- four XRPD signals selected from those set forth in Table 53.

Table 53 Peak list of ketanserin L-tartrate Pattern S

Solid forms ofketanserin L-tar irate Pattern T

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Pattern T, e.g., crystalline forms of ketanserin L-tartrate Pattern T. In some embodiments, the ketanserin L-tartrate Pattern T XRPD profile is substantially similar to that shown in FIG. 60.

In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by an XRPD signal at 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by XRPD signals at 21.5 °29 and 21.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by two or more, or three XRPD signals selected from the group consisting of 21.5 °20, 21.4 °20, and 15.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by XRPD signals at 21.5 °29, 21.4 °29, and 15.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.5 °29, 21.4 °29, 15.8 °29, and 15.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by XRPD signals at 21.5 °29,

21.4 °20, 15.8 °20, and 15.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.5 °29, 21.4 °29, 15.8 °29, 15.0 °29, and 15.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by XRPD signals at

21.5 °20, 21.4 °20, 15.8 °20, 15.0 °20, and 15.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.5 °29, 21.4 °29, 15.8 °29, 15.0 °29, 15.5 °29, and 17.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by XRPD signals at 21.5 °20, 21.4 °20, 15.8 °20, 15.0 °20, 15.5 °20, and 17.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.5 °29, 21.4 °29, 15.8 °29, 15.0 °29, 15.5 °29, 17.4 °29, and 17.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by XRPD signals at 21.5 °20, 21.4 °20, 15.8 °20, 15.0 °20, 15.5 °20, 17.4 °20, and 17.1 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.5 °29, 21.4 °29, 15.8 °29, 15.0 °29, 15.5 °29, 17.4 °29,

17.1 °29, and 14.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by XRPD signals at 21.5 °20, 21.4 °20, 15.8 °20, 15.0 °20, 15.5 °20, 17.4 °20, 17.1 °20, and 14.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

17.1 °20, 14.5 °20, and 12.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L-tartrate Pattern T characterized by XRPD signals at 21.5 °20, 21.4 °20, 15.8 °20, 15.0 °20, 15.5 °20, 17.4 °20, 17.1 °20, 14.5 °20, and 12.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

17.1 °20, 14.5 °20, 12.6 °20, and 14.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Pattern T is crystalline ketanserin L- tartrate Pattern T characterized by XRPD signals at 21.5 °29, 21.4 °29, 15.8 °29, 15.0 °29, 15.5 °29, 17.4 °29, 17.1 °29, 14.5 °29, 12.6 °29, and 14.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, Table 54 is a numerical representation of selected XRPD signals shown in at least Figure 60.

In some embodiments, the crystalline ketanserin L-tartrate Pattern T is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, or twenty-three XRPD signals selected from those set forth in Table 54.

Table 54 Peak list of ketanserin L-tartrate Pattern T

Solid forms of ke tanserin L-tar irate Group 1

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Group 1, e.g., crystalline forms of ketanserin L-tartrate Group 1. In some embodiments, the ketanserin L-tartrate Group 1 XRPD profile is substantially similar to that shown in FIGs. 35 or 62. In some embodiments, the ketanserin L-tartrate Group 1 1H NMR spectrum is substantially similar to that shown in FIG. 246. In some embodiments, the ketanserin L-tartrate Group 1 TGA profile is substantially similar to that shown in FIG. 248. In some embodiments, the ketanserin L- tartrate Group 1 DSC profile is substantially similar to that shown in FIG. 247.

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by an XRPD signal at 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 15.6 °29 and 21.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three XRPD signals selected from the group consisting of 15.6 °29, 21.8 °29, and 23.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 15.6 °29, 21.8 °29, and 23.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °29, 21.8 °29, 23.3 °29, and 15.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 15.6 °29, 21.8 °20, 23.3 °20, and 15.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °29, 21.8 °29, 23.3 °29, 15.1 °29, and 17.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at

15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, and 17.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °29, 21.8 °29, 23.3 °29, 15.1 °29, 17.2 °29, and 26.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, and 26.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, 26.3 °20, and 16.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, 26.3 °20, and 16.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, 26.3 °20,

16.6 °29, and 5.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, 26.3 °20, 16.6 °20, and 5.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, 26.3 °20, 16.6 °20, 5.8 °20, and 26.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, 26.3 °20, 16.6 °20, 5.8 °20, and 26.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, 26.3 °20, 16.6 °20, 5.8 °20, 26.0 °20, and 27.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L- tartrate Group 1 characterized by XRPD signals at 15.6 °29, 21.8 °29, 23.3 °29, 15.1 °29, 17.2 °29, 26.3 °20, 16.6 °20, 5.8 °20, 26.0 °20, and 27.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 55 is a numerical representation of selected XRPD signals shown in at least Figure 62.

In some embodiments, the crystalline ketanserin L-tartrate Group 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve XRPD signals selected from those set forth in Table 55.

Table 55 Peak list of ketanserin L-tartrate Group 1

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by an XRPD signal at 21.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 21.9 °29 and 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three XRPD signals selected from the group consisting of 21.9 °29, 15.6 °29, and 23.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 21.9 °29, 15.6 °29, and 23.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °29, 15.6 °29, 23.3 °29, and 26.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 21.9 °29, 15.6 °29, 23.3 °29, and 26.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °29, 15.6 °29, 23.3 °29, 26.4 °29, and 17.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 21.9 °29, 15.6 °29, 23.3 °29, 26.4 °29, and 17.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °29, 15.6 °29, 23.3 °29, 26.4 °29, 17.2 °29, and 5.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, and 5.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °29, 15.6 °29, 23.3 °29, 26.4 °29, 17.2 °29, 5.9 °29, and 26.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, 5.9 °20, and 26.0 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, 5.9 °20, 26.0 °29, and 27.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, 5.9 °20, 26.0 °20, and 27.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, 5.9 °20, 26.0 °20, 27.6 °20, and 23.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, 5.9 °20, 26.0 °20, 27.6 °20, and 23.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, 5.9 °20, 26.0 °20, 27.6 °20, 23.0 °20, and 15.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 1 is crystalline ketanserin L-tartrate Group 1 characterized by XRPD signals at 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, 5.9 °20, 26.0 °20, 27.6 °20, 23.0 °20, and 15.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, Table 55A is a numerical representation of selected XRPD signals shown in at least Figure 35.

In some embodiments, the crystalline ketanserin L-tartrate Group 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen XRPD signals selected from those set forth in Table 55A.

Table 55 A Peak list of ketanserin L-tartrate salt Group 1

Solid forms of ketanserin L-tartrate Group 2 In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Group 2, e.g., crystalline forms of ketanserin L-tartrate Group 2. In some embodiments, the ketanserin L-tartrate Group 2 XRPD profile is substantially similar to that shown in FIG. 38. In some embodiments, the ketanserin L-tartrate Group 2 1H NMR spectrum is substantially similar to that shown in FIG. 249. In some embodiments, the ketanserin L-tartrate Group 2 TGA profile is substantially similar to that shown in FIG. 251. In some embodiments, the ketanserin L-tartrate Group 2 DSC profile is substantially similar to that shown in FIG. 250.

In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by an XRPD signal at 19.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by XRPD signals at 19.8 °20 and 15.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by two or more, or three XRPD signals selected from the group consisting of 19.8 °20, 15.3 °20, and 25.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by XRPD signals at 19.8 °29, 15.3 °29, and 25.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 15.3 °29, 25.2 °29, and 22.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by XRPD signals at 19.8 °20, 15.3 °29, 25.2 °29, and 22.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 15.3 °29, 25.2 °29, 22.1 °29, and 9.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by XRPD signals at 19.8 °29, 15.3 °29, 25.2 °20, 22.1 °20, and 9.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 15.3 °29, 25.2 °29, 22.1 °29, 9.9 °29, and 18.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by XRPD signals at 19.8 °20, 15.3 °20, 25.2 °20, 22.1 °20, 9.9 °20, and 18.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 15.3 °29, 25.2 °29, 22.1 °29, 9.9 °29, 18.2 °29, and 21.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by XRPD signals at 19.8 °20, 15.3 °20, 25.2 °20, 22.1 °20, 9.9 °20, 18.2 °20, and 21.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °20, 15.3 °20, 25.2 °20, 22.1 °20, 9.9 °20, 18.2 °20, 21.6 °29, and 29.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by XRPD signals at 19.8 °20, 15.3 °20, 25.2 °20, 22.1 °20, 9.9 °20, 18.2 °20, 21.6 °20, and 29.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °20, 15.3 °20, 25.2 °20, 22.1 °20, 9.9 °20, 18.2 °20, 21.6 °20, 29.4 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by XRPD signals at 19.8 °20, 15.3 °20, 25.2 °20, 22.1 °20, 9.9 °20, 18.2 °20, 21.6 °20, 29.4 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °20, 15.3 °20, 25.2 °20, 22.1 °20, 9.9 °20, 18.2 °20, 21.6 °20, 29.4 °20, 17.0 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 2 is crystalline ketanserin L-tartrate Group 2 characterized by XRPD signals at 19.8 °20, 15.3 °20, 25.2 °20, 22.1 °20, 9.9 °20, 18.2 °20, 21.6 °20, 29.4 °20, 17.0 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, Table 56 is a numerical representation of selected XRPD signals shown in at least Figure 38.

In some embodiments, the crystalline ketanserin L-tartrate Group 2 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 56.

Table 56 Peak list of ketanserin L-tartrate Group 2

Solid forms of ketanserin L-tartrate Group 3

In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Group 3, e.g., crystalline forms of ketanserin L-tartrate Group 3. In some embodiments, the ketanserin L-tartrate Group 3 XRPD profile is substantially similar to that shown in FIGs. 30 or 114. In some embodiments, the ketanserin L-tartrate Group 3 1H NMR spectrum is substantially similar to that shown in FIG. 252. In some embodiments, the ketanserin L-tartrate Group 3 TGA profile is substantially similar to that shown in FIG. 254. In some embodiments, the ketanserin L- tartrate Group 3 DSC profile is substantially similar to that shown in FIG. 253.

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by an XRPD signal at 24.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.2 °29 and 4.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three XRPD signals selected from the group consisting of 24.2 °20, 4.6 °20, and 25.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.2 °29, 4.6 °29, and 25.6 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °29, 4.6 °29, 25.6 °29, and 25.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.2 °20, 4.6 °20, 25.6 °20, and 25.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °29, 4.6 °29, 25.6 °29, 25.8 °29, and 9.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, and 9.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °29, 4.6 °29, 25.6 °29, 25.8 °29, 9.2 °29, and 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, and 15.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °29, 4.6 °29, 25.6 °29, 25.8 °29, 9.2 °29, 15.6 °29, and 15.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, 15.6 °20, and 15.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, 15.6 °20, 15.5 °29, and 16.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, 15.6 °20, 15.5 °20, and 16.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, 15.6 °20, 15.5 °20, 16.9 °20, and 14.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, 15.6 °20, 15.5 °20, 16.9 °20, and 14.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, 15.6 °20, 15.5 °20, 16.9 °20, 14.4 °20, and 18.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, 15.6 °20, 15.5 °20, 16.9 °20, 14.4 °20, and 18.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the crystalline ketanserin L-tartrate Group 3 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen XRPD signals selected from those set forth in Table 57.

Table 57 Peak list of ketanserin L-tartrate Group 3

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by an XRPD signal at 24.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.3 °29 and 25.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three XRPD signals selected from the group consisting of 24.3 °20, 25.7 °20, and 15.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.3 °29, 25.7 °29, and 15.4 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.3 °29, 25.7 °29, 15.4 °29, and 16.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.3 °20, 25.7 °20, 15.4 °20, and 16.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.3 °29, 25.7 °29, 15.4 °29, 16.9 °29, and 14.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.3 °20, 25.7 °20, 15.4 °20, 16.9 °20, and 14.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.3 °29, 25.7 °29, 15.4 °29, 16.9 °29, 14.5 °29, and 26.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.3 °20, 25.7 °20, 15.4 °20, 16.9 °20, 14.5 °20, and 26.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.3 °29, 25.7 °29, 15.4 °29, 16.9 °29, 14.5 °29, 26.3 °29, and 20.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.3 °20, 25.7 °20, 15.4 °20, 16.9 °20, 14.5 °20, 26.3 °20, and 20.3 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.3 °29, 25.7 °29, 15.4 °29, 16.9 °29, 14.5 °29, 26.3 °29,

20.3 °29, and 9.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.3 °20, 25.7 °20, 15.4 °20, 16.9 °20, 14.5 °20, 26.3 °20, 20.3 °20, and 9.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

20.3 °20, 9.7 °20, and 4.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.3 °20, 25.7 °20, 15.4 °20, 16.9 °20, 14.5 °20, 26.3 °20, 20.3 °20, 9.7 °20, and 4.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

20.3 °20, 9.7 °20, 4.7 °20, and 9.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 3 is crystalline ketanserin L-tartrate Group 3 characterized by XRPD signals at 24.3 °20, 25.7 °20, 15.4 °20, 16.9 °20, 14.5 °20, 26.3 °20, 20.3 °20, 9.7 °20, 4.7 °20, and 9.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 58 is a numerical representation of selected XRPD signals shown in at least Figure 30.

In some embodiments, the crystalline ketanserin L-tartrate Group 3 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve XRPD signals selected from those set forth in Table 58. Table 58 Peak list of ketanserin L-tartrate Group 3

Solid forms of ketanserin L-tartrate Group 4 In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate

Group 4, e.g., crystalline forms of ketanserin L-tartrate Group 4. In some embodiments, the ketanserin L-tartrate Group 4 XRPD profile is substantially similar to that shown in FIG. 28. In some embodiments, the ketanserin L-tartrate Group 4 1H NMR spectrum is substantially similar to that shown in FIG. 255. In some embodiments, the ketanserin L-tartrate Group 4 TGA profile is substantially similar to that shown in FIG. 257. In some embodiments, the ketanserin L-tartrate Group 4 DSC profile is substantially similar to that shown in FIG. 256.

In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by an XRPD signal at 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by XRPD signals at 15.6 °29 and 22.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by two or more, or three XRPD signals selected from the group consisting of 15.6 °20, 22.2 °20, and 19.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by XRPD signals at 15.6 °29, 22.2 °29, and 19.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °29, 22.2 °29, 19.8 °29, and 20.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by XRPD signals at 15.6 °20, 22.2 °20, 19.8 °20, and 20.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °29, 22.2 °29, 19.8 °29, 20.6 °29, and 25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by XRPD signals at 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °29, 22.2 °29, 19.8 °29, 20.6 °29, 25.3 °29, and 21.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by XRPD signals at 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, and 21.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, 21.9 °20, and 17.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by XRPD signals at 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, 21.9 °20, and 17.0 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, 21.9 °20, 17.0 °29, and 10.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by XRPD signals at 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, 21.9 °20, 17.0 °20, and 10.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, 21.9 °20, 17.0 °20, 10.0 °20, and 6.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by XRPD signals at 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, 21.9 °20, 17.0 °20, 10.0 °20, and 6.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, 21.9 °20, 17.0 °20, 10.0 °20, 6.2 °20, and 29.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 4 is crystalline ketanserin L- tartrate Group 4 characterized by XRPD signals at 15.6 °29, 22.2 °29, 19.8 °29, 20.6 °29, 25.3 °29, 21.9 °20, 17.0 °20, 10.0 °20, 6.2 °20, and 29.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 59 is a numerical representation of selected XRPD signals shown in at least Figure 28.

In some embodiments, the crystalline ketanserin L-tartrate Group 4 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, or twenty-five XRPD signals selected from those set forth in Table 59. Table 59 Peak list of ketanserin L-tartrate Group 4

Solid forms of ketanserin L-tartrate Group 5 In some embodiments, the present disclosure provides solid forms of ketanserin L-tartrate Group 5, e.g., crystalline forms of ketanserin L-tartrate Group 5. In some embodiments, the ketanserin L-tartrate Group 5 XRPD profile is substantially similar to that shown in FIG. 39. In some embodiments, the ketanserin L-tartrate Group 5 1H NMR spectrum is substantially similar to that shown in FIG. 258. In some embodiments, the ketanserin L-tartrate Group 5 TGA profile is substantially similar to that shown in FIG. 260. In some embodiments, the ketanserin L-tartrate Group 5 DSC profile is substantially similar to that shown in FIG. 259.

In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by an XRPD signal at 10.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by XRPD signals at 10.1 °20 and 18.9 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by two or more, or three XRPD signals selected from the group consisting of 10.1 °20, 18.9 °20, and 15.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by XRPD signals at 10.1 °29, 18.9 °29, and 15.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.1 °29, 18.9 °29, 15.1 °29, and 13.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by XRPD signals at 10.1 °29, 18.9 °29, 15.1 °29, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.1 °29, 18.9 °29, 15.1 °29, 13.3 °29, and 18.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by XRPD signals at 10.1 °20, 18.9 °20, 15.1 °20, 13.3 °20, and 18.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.1 °29, 18.9 °29, 15.1 °29, 13.3 °29, 18.4 °29, and 16.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by XRPD signals at 10.1 °20, 18.9 °20, 15.1 °20, 13.3 °20, 18.4 °20, and 16.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.1 °29, 18.9 °29, 15.1 °29, 13.3 °29, 18.4 °29, 16.7 °29, and 26.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by XRPD signals at 10.1 °20, 18.9 °20, 15.1 °20, 13.3 °20, 18.4 °20, 16.7 °20, and

26.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.1 °29, 18.9 °29, 15.1 °29, 13.3 °29, 18.4 °29, 16.7 °29,

26.4 °20, and 14.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by XRPD signals at 10.1 °20, 18.9 °20, 15.1 °20, 13.3 °20, 18.4 °20, 16.7 °20, 26.4 °20, and 14.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

26.4 °20, 14.3 °20, and 23.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by XRPD signals at 10.1 °20, 18.9 °20, 15.1 °20, 13.3 °20, 18.4 °20, 16.7 °20, 26.4 °20, 14.3 °20, and 23.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L-tartrate Group 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.1 °29, 18.9 °29, 15.1 °29, 13.3 °29, 18.4 °29, 16.7 °29, 26.4 °29, 14.3 °29, 23.7 °29, and 20.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-tartrate Group 5 is crystalline ketanserin L- tartrate Group 5 characterized by XRPD signals at 10.1 °29, 18.9 °29, 15.1 °29, 13.3 °29, 18.4 °29, 16.7 °29, 26.4 °29, 14.3 °29, 23.7 °29, and 20.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, Table 60 is a numerical representation of selected XRPD signals shown in at least Figure 39.

In some embodiments, the crystalline ketanserin L-tartrate Group 5 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, or eleven XRPD signals selected from those set forth in Table 60. Table 60 Peak list of ketanserin L-tartrate Group 5

Solid forms of ketanserin L-malate Pattern A In some embodiments, the present disclosure provides solid forms of ketanserin L-malate Pattern A, e.g., crystalline forms of ketanserin L-malate Pattern A. In some embodiments, the ketanserin L-malate Pattern A XRPD profile is substantially similar to that shown in any one of FIGs. 19, 65, or 111. In some embodiments, the ketanserin L-malate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 166. In some embodiments, the ketanserin L-malate Pattern A TGA profile is substantially similar to that shown in FIG. 168. In some embodiments, the ketanserin L-malate Pattern A DSC profile is substantially similar to that shown in FIG. 167.

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by an XRPD signal at 16.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29 and 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 16.1 °29, 17.5 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29, 17.5 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.5 °29, 8.8 °29, and 18.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29, 17.5 °29, 8.8 °29, and 18.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.5 °29, 8.8 °29, 18.8 °29, and 24.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °20, 17.5 °20, 8.8 °20, 18.8 °20, and 24.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.5 °29, 8.8 °29, 18.8 °29, 24.2 °29, and 10.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °20, 17.5 °20, 8.8 °20, 18.8 °20, 24.2 °20, and 10.4 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.5 °29, 8.8 °29, 18.8 °29, 24.2 °29, 10.4 °29, and 16.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °20, 17.5 °20, 8.8 °20, 18.8 °20, 24.2 °20, 10.4 °20, and

16.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.5 °29, 8.8 °29, 18.8 °29, 24.2 °29, 10.4 °29,

16.3 °20, and 26.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29, 17.5 °29, 8.8 °29, 18.8 °29, 24.2 °29, 10.4 °20, 16.3 °20, and 26.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

16.3 °20, 26.4 °20, and 23.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29, 17.5 °29, 8.8 °29, 18.8 °29, 24.2 °29, 10.4 °20, 16.3 °20, 26.4 °20, and 23.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.5 °29, 8.8 °29, 18.8 °29, 24.2 °29, 10.4 °29, 16.3 °29, 26.4 °29, 23.4 °29, and 20.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L- malate Pattern A characterized by XRPD signals at 16.1 °29, 17.5 °29, 8.8 °29, 18.8 °29, 24.2 °29, 10.4 °29, 16.3 °29, 26.4 °29, 23.4 °29, and 20.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, Table 61 is a numerical representation of selected XRPD signals shown in at least Figure 19.

In some embodiments, the crystalline ketanserin L-malate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve XRPD signals selected from those set forth in Table 61. Table 61 Peak list of ketanserin L-malate Pattern A

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29 and 17.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29, 17.6 °29, and 8.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.6 °29, 8.8 °29, and 18.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29, 17.6 °20, 8.8 °20, and 18.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.6 °29, 8.8 °29, 18.9 °29, and 24.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, and 24.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.6 °29, 8.8 °29, 18.9 °29, 24.2 °29, and 26.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, and 26.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °29, 17.6 °29, 8.8 °29, 18.9 °29, 24.2 °29, 26.5 °29, and 10.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, 26.5 °20, and 10.4 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, 26.5 °20, 10.4 °29, and 20.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, 26.5 °20, 10.4 °20, and 20.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, 26.5 °20, 10.4 °20, 20.2 °20, and 23.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29, 17.6 °29, 8.8 °29, 18.9 °29, 24.2 °29, 26.5 °20, 10.4 °20, 20.2 °20, and 23.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, 26.5 °20, 10.4 °20, 20.2 °20, 23.5 °20, and 20.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 16.1 °29, 17.6 °29, 8.8 °29, 18.9 °29, 24.2 °29, 26.5 °20, 10.4 °20, 20.2 °20, 23.5 °20, and 20.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the crystalline ketanserin L-malate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, or eleven XRPD signals selected from those set forth in Table 62. Table 62 Peak list of ketanserin L-malate Pattern A

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by an XRPD signal at 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 17.5 °29 and 16.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 17.5 °29, 16.0 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 17.5 °29, 16.0 °29, and 8.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °29, 16.0 °29, 8.8 °29, and 20.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 17.5 °29, 16.0 °20, 8.8 °20, and 20.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °29, 16.0 °29, 8.8 °29, 20.7 °29, and 26.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, and 26.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °29, 16.0 °29, 8.8 °29, 20.7 °29, 26.4 °29, and 18.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, and 18.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °29, 16.0 °29, 8.8 °29, 20.7 °29, 26.4 °29, 18.8 °29, and 23.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, 18.8 °20, and 23.4 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, 18.8 °20, 23.4 °29, and 20.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, 18.8 °20, 23.4 °20, and 20.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, 18.8 °20, 23.4 °20, 20.1 °20, and 18.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 17.5 °29, 16.0 °29, 8.8 °29, 20.7 °29, 26.4 °29, 18.8 °20, 23.4 °20, 20.1 °20, and 18.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, 18.8 °20, 23.4 °20, 20.1 °20, 18.3 °20, and 24.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern A is crystalline ketanserin L-malate Pattern A characterized by XRPD signals at 17.5 °29, 16.0 °29, 8.8 °29, 20.7 °29, 26.4 °29, 18.8 °20, 23.4 °20, 20.1 °20, 18.3 °20, and 24.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, Table 63 is a numerical representation of selected XRPD signals shown in at least Figure 65.

In some embodiments, the crystalline ketanserin L-malate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 63.

Table 63 Peak list of ketanserin L-malate Pattern A

Solid forms ofketanserin L-malate Pattern B

In some embodiments, the present disclosure provides solid forms of ketanserin L-malate Pattern B, e.g., crystalline forms of ketanserin L-malate Pattern B. In some embodiments, the ketanserin L-malate Pattern B XRPD profile is substantially similar to that shown in FIG. 47. In some embodiments, the ketanserin L-malate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 266 In some embodiments, the ketanserin L-malate Pattern B TGA profile is substantially similar to that shown in FIG. 169. In some embodiments, the ketanserin L-malate Pattern B DSC profile is substantially similar to that shown in FIG. 267. In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by an XRPD signal at 18.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by XRPD signals at 18.0 °20 and 21.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 18.0 °20, 21.2 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by XRPD signals at 18.0 °29, 21.2 °29, and 8.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.0 °29, 21.2 °29, 8.8 °29, and 4.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by XRPD signals at 18.0 °29, 21.2 °20, 8.8 °20, and 4.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.0 °29, 21.2 °29, 8.8 °29, 4.0 °29, and 24.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by XRPD signals at 18.0 °20, 21.2 °20, 8.8 °20, 4.0 °20, and 24.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.0 °29, 21.2 °29, 8.8 °29, 4.0 °29, 24.4 °29, and 14.5 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by XRPD signals at 18.0 °20, 21.2 °20, 8.8 °20, 4.0 °20, 24.4 °20, and 14.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.0 °29, 21.2 °29, 8.8 °29, 4.0 °29, 24.4 °29, 14.5 °29, and 11.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern B is crystalline ketanserin L-malate Pattern B characterized by XRPD signals at 18.0 °20, 21.2 °20, 8.8 °20, 4.0 °20, 24.4 °20, 14.5 °20, and 11.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, Table 64 is a numerical representation of selected XRPD signals shown in at least Figure 47.

In some embodiments, the crystalline ketanserin L-malate Pattern B is characterized by one, two, three, four, five, six, or seven XRPD signals selected from those set forth in Table 64.

Table 64 Peak list of ketanserin L-malate Pattern B

Solid forms of ketanserin L-malate Pattern C

In some embodiments, the present disclosure provides solid forms of ketanserin L-malate Pattern C, e.g., crystalline forms of ketanserin L-malate Pattern C. In some embodiments, the ketanserin L-malate Pattern C XRPD profile is substantially similar to that shown in FIG. 66.

In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by an XRPD signal at 20.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by XRPD signals at 20.9 °20 and 27.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 20.9 °20, 27.5 °20, and 16.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by XRPD signals at 20.9 °29, 27.5 °29, and 16.8 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °29, 27.5 °29, 16.8 °29, and 20.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by XRPD signals at 20.9 °29,

27.5 °20, 16.8 °20, and 20.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °29, 27.5 °29, 16.8 °29, 20.1 °29, and 9.4 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by XRPD signals at 20.9 °20, 27.5 °20, 16.8 °20, 20.1 °20, and 9.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °29, 27.5 °29, 16.8 °29, 20.1 °29, 9.4 °29, and 3.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by XRPD signals at 20.9 °20, 27.5 °20, 16.8 °20, 20.1 °20, 9.4 °20, and 3.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °29, 27.5 °29, 16.8 °29, 20.1 °29, 9.4 °29, 3.4 °29, and

10.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern C is crystalline ketanserin L-malate Pattern C characterized by XRPD signals at 20.9 °20, 27.5 °20, 16.8 °20, 20.1 °20, 9.4 °20, 3.4 °20, and 10.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, Table 65 is a numerical representation of selected XRPD signals shown in at least Figure 66. In some embodiments, the crystalline ketanserin L-malate Pattern C is characterized by one, two, three, four, five, six, or seven XRPD signals selected from those set forth in Table 65.

Table 65 Peak list of ketanserin L-malate Pattern C

Solid forms of ketanserin L-malate Pattern C*

In some embodiments, the present disclosure provides solid forms of ketanserin L-malate Pattern C*, e.g., crystalline forms of ketanserin L-malate Pattern C*. In some embodiments, the ketanserin L-malate Pattern C* XRPD profile is substantially similar to that shown in FIG. 48. In some embodiments, the ketanserin L-malate Pattern C* 1HNMR spectrum is substantially similar to that shown in FIG. 170.

In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by an XRPD signal at 17.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by XRPD signals at 17.2 °29 and 22.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by two or more, or three XRPD signals selected from the group consisting of 17.2 °20, 22.6 °20, and 3.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by XRPD signals at 17.2 °29, 22.6 °29, and 3.4 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.2 °29, 22.6 °29, 3.4 °29, and 26.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by XRPD signals at 17.2 °20, 22.6 °20, 3.4 °20, and 26.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.2 °29, 22.6 °29, 3.4 °29, 26.2 °29, and 21.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by XRPD signals at 17.2 °20, 22.6 °20, 3.4 °20, 26.2 °20, and 21.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.2 °29, 22.6 °29, 3.4 °29, 26.2 °29, 21.3 °29, and 18.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by XRPD signals at 17.2 °20, 22.6 °20, 3.4 °20, 26.2 °20, 21.3 °20, and 18.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.2 °29, 22.6 °29, 3.4 °29, 26.2 °29, 21.3 °29, 18.5 °29, and 9.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern C* is crystalline ketanserin L-malate Pattern C* characterized by XRPD signals at 17.2 °20, 22.6 °20, 3.4 °20, 26.2 °20, 21.3 °20, 18.5 °20, and 9.0 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, Table 66 is a numerical representation of selected XRPD signals shown in at least Figure 48. In some embodiments, the crystalline ketanserin L-malate Pattern C* is characterized by one, two, three, four, five, six, or seven XRPD signals selected from those set forth in Table 66.

Table 66 Peak list of ketanserin L-malate Pattern C*

Solid forms of ketanserin L-malate Pattern D

In some embodiments, the present disclosure provides solid forms of ketanserin L-malate Pattern D, e.g., crystalline forms of ketanserin L-malate Pattern D. In some embodiments, the ketanserin L-malate Pattern D XRPD profile is substantially similar to that shown in FIG. 49. In some embodiments, the ketanserin L-malate Pattern D 1H NMR spectrum is substantially similar to that shown in FIG. 171. In some embodiments, the ketanserin L-malate Pattern D TGA profile is substantially similar to that shown in FIG. 173. In some embodiments, the ketanserin L-malate Pattern D DSC profile is substantially similar to that shown in FIG. 172.

In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by an XRPD signal at 9.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by XRPD signals at 9.4 °29 and 24.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 9.4 °29, 24.4 °29, and 16.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by XRPD signals at 9.4 °29, 24.4 °29, and 16.5 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 24.4 °29, 16.5 °29, and 18.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by XRPD signals at 9.4 °29,

24.4 °20, 16.5 °20, and 18.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 24.4 °29, 16.5 °29, 18.9 °29, and 15.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L- malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by XRPD signals at

9.4 °20, 24.4 °20, 16.5 °20, 18.9 °20, and 15.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 24.4 °29, 16.5 °29, 18.9 °29, 15.5 °29, and 14.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by XRPD signals at 9.4 °20, 24.4 °20, 16.5 °20, 18.9 °20, 15.5 °20, and 14.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 24.4 °29, 16.5 °29, 18.9 °29, 15.5 °29, 14.7 °29, and 19.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by XRPD signals at 9.4 °20, 24.4 °20, 16.5 °20, 18.9 °20, 15.5 °20, 14.7 °20, and 19.1 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 24.4 °29, 16.5 °29, 18.9 °29, 15.5 °29, 14.7 °29, 19.1 °29, and 26.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by XRPD signals at 9.4 °29, 24.4 °29, 16.5 °29, 18.9 °29, 15.5 °29, 14.7 °29, 19.1 °29, and 26.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 24.4 °29, 16.5 °29, 18.9 °29, 15.5 °29, 14.7 °29, 19.1 °29, 26.8 °29, and 22.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by XRPD signals at 9.4 °29, 24.4 °29, 16.5 °29, 18.9 °29, 15.5 °29, 14.7 °29, 19.1 °29, 26.8 °29, and 22.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 24.4 °29, 16.5 °29, 18.9 °29, 15.5 °29, 14.7 °29, 19.1 °29, 26.8 °29, 22.7 °29, and 17.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern D is crystalline ketanserin L-malate Pattern D characterized by XRPD signals at 9.4 °29, 24.4 °29, 16.5 °29, 18.9 °29, 15.5 °29, 14.7 °29, 19.1 °29, 26.8 °29, 22.7 °29, and 17.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, Table 67 is a numerical representation of selected XRPD signals shown in at least Figure 49.

In some embodiments, the crystalline ketanserin L-malate Pattern D is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty -four, or twenty-five XRPD signals selected from those set forth in Table 67.

Table 67 Peak list of ketanserin L-malate Pattern D

Solid forms ofketanserin L-malate Pattern E

In some embodiments, the present disclosure provides solid forms of ketanserin L-malate

Pattern E, e.g., crystalline forms of ketanserin L-malate Pattern E. In some embodiments, the ketanserin L-malate Pattern E XRPD profile is substantially similar to that shown in FIG. 50. In some embodiments, the ketanserin L-malate Pattern E 1H NMR spectrum is substantially similar to that shown in FIG. 174. In some embodiments, the ketanserin L-malate Pattern E TGA profile is substantially similar to that shown in FIG. 176. In some embodiments, the ketanserin L-malate Pattern E DSC profile is substantially similar to that shown in FIG. 175.

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by an XRPD signal at 10.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by XRPD signals at 10.8 °20 and 10.2 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by two or more, or three XRPD signals selected from the group consisting of 10.8 °20, 10.2 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by XRPD signals at 10.8 °29, 10.2 °29, and 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °29, 10.2 °29, 21.5 °29, and 20.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by XRPD signals at 10.8 °29, 10.2 °29, 21.5 °29, and 20.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °29, 10.2 °29, 21.5 °29, 20.3 °29, and 14.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by XRPD signals at 10.8 °29, 10.2 °29, 21.5 °20, 20.3 °20, and 14.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °29, 10.2 °29, 21.5 °29, 20.3 °29, 14.9 °29, and 5.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by XRPD signals at 10.8 °20, 10.2 °20, 21.5 °20, 20.3 °20, 14.9 °20, and 5.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °29, 10.2 °29, 21.5 °29, 20.3 °29, 14.9 °29, 5.4 °29, and 24.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by XRPD signals at 10.8 °20, 10.2 °20, 21.5 °20, 20.3 °20, 14.9 °20, 5.4 °20, and 24.0 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 10.2 °20, 21.5 °20, 20.3 °20, 14.9 °20, 5.4 °20, 24.0 °29, and 30.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by XRPD signals at 10.8 °20, 10.2 °20, 21.5 °20, 20.3 °20, 14.9 °20, 5.4 °20, 24.0 °20, and 30.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 10.2 °20, 21.5 °20, 20.3 °20, 14.9 °20, 5.4 °20, 24.0 °20, 30.3 °20, and 30.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation). In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by XRPD signals at 10.8 °29, 10.2 °29, 21.5 °29, 20.3 °29, 14.9 °29, 5.4 °20, 24.0 °20, 30.3 °20, and 30.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 10.2 °20, 21.5 °20, 20.3 °20, 14.9 °20, 5.4 °20, 24.0 °20, 30.3 °20, 30.9 °20, and 33.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). In some embodiments, the solid form of ketanserin L-malate Pattern E is crystalline ketanserin L-malate Pattern E characterized by XRPD signals at 10.8 °29, 10.2 °29, 21.5 °29, 20.3 °29, 14.9 °29, 5.4 °20, 24.0 °20, 30.3 °20, 30.9 °20, and 33.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

In some embodiments, Table 68 is a numerical representation of selected XRPD signals shown in at least Figure 50. In some embodiments, the crystalline ketanserin L-malate Pattern E is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, or twenty- four XRPD signals selected from those set forth in Table 68. Table 68 Peak list of ketanserin L-malate Pattern E

IV. Pharmaceutical Compositions and Formulations

In some embodiments, the present disclosure provides a pharmaceutical composition comprising one or more of the solid forms of ketanserin, illustrated above, and a pharmaceutically acceptable excipient. Such compositions are suitable for administration to a subject, such as a human subject.

The presently disclosed pharmaceutical compositions can be prepared in a wide variety of oral, parenteral and topical dosage forms. Oral preparations include tablets, pills, powder, capsules, lozenges, cachets, slurries, suspensions, etc., suitable for ingestion by the patient. The compositions of the present disclosure can also be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compositions described herein can be administered by inhalation, for example, intranasally. Additionally, the compositions of the present disclosure can be administered transdermally. The compositions of this disclosure can also be administered by intraocular, intravaginal, and intrarectal routes including suppositories, insufflation, powders and aerosol formulations (for examples of steroid inhalants, see Rohatagi, J. Clin. Pharmacol. 35: 1187-1193, 1995; Tjwa, Ann. Allergy Asthma Immunol. 75: 107-111, 1995). Accordingly, the present disclosure also provides pharmaceutical compositions including a pharmaceutically acceptable carrier or excipient and the solid form of ketanserin of the present disclosure.

For preparing pharmaceutical compositions from the compounds disclosed herein, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, e.g., the latest edition of Remington's Pharmaceutical Sciences, Mack Publishing Co, Easton PA ("Remington's").

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5% to 70% or 10% to 70% of the compounds of the present disclosure.

Suitable solid excipients include, but are not limited to, magnesium carbonate; magnesium stearate; talc; pectin; dextrin; starch; tragacanth; a low melting wax; cocoa butter; carbohydrates; sugars including, but not limited to, lactose, sucrose, mannitol, or sorbitol, starch from com, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethylcellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins including, but not limited to, gelatin and collagen.

If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the compounds of the present disclosure are dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include suspensions, for example, water or water/propylene glycol suspensions.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension can also contain one or more preservatives such as ethyl or //-propyl //-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin. Formulations can be adjusted for osmolarity.

Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include suspensions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

Oil suspensions can be formulated by suspending the compound of the present invention in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these. The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose. These formulations can be preserved by the addition of an antioxidant such as ascorbic acid. As an example of an injectable oil vehicle, see Minto, J. Pharmacol. Exp. Ther. 281 :93-102, 1997. The pharmaceutical formulations of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a demulcent, a preservative, or a coloring agent.

The compositions of the present disclosure can also be delivered as microspheres for slow release in the body. For example, microspheres can be formulated for administration via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997). Both transdermal and intradermal routes afford constant delivery for weeks or months.

In some embodiments, the pharmaceutical compositions of the present disclosure can be formulated for parenteral administration, such as intravenous (IV) administration or administration into a body cavity or lumen of an organ. The formulations for administration will commonly comprise a solution or suspension of the compositions of the present disclosure dissolved or suspended in a pharmaceutically acceptable carrier. Among the acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride. In addition, sterile fixed oils can conventionally be employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions or suspensions are sterile and generally free of undesirable matter. These formulations may be sterilized by conventional, well known sterilization techniques. The formulations may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of the compositions of the present disclosure in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs. For IV administration, the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3- butanediol.

In some embodiments, the formulations of the compositions of the present disclosure can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, for example, by employing ligands attached to the liposome, or attached directly to the oligonucleotide, that bind to surface membrane protein receptors of the cell resulting in endocytosis. By using liposomes, particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo. (See, e.g., Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin.

Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46: 1576-1587, 1989).

V. Administration

The compositions of the present disclosure can be administered by any suitable means, including oral, parenteral and topical methods. Transdermal administration methods, by a topical route, can be formulated as applicator sticks, suspensions, creams, ointments, pastes, jellies, paints, powders, and aerosols.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the compounds of the present invention. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The compound form of the present invention can be present in any suitable amount, and can depend on various factors including, but not limited to, weight and age of the subject, state of the disease, and the like as is known to those of ordinary skill in the art. Suitable dosage ranges for the compound forms disclosed herein include from about 10 mg to about 100 mg, or about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg.

The compound forms disclosed herein can be administered at any suitable frequency, interval and duration.

The compounds of the present disclosure can be co-administered with a second active agent.

In some embodiments, co-administration can be accomplished by co-formulation, such as by preparing a single pharmaceutical composition including both the compound of the present disclosure and a second active agent. In other embodiments, the compound of the present disclosure and the second active agent can be formulated separately. VI. Methods of Treatment

The salts and solid forms of ketanserin of the present disclosure can be used as a 5-HT2 serotonin receptor modulator alone, or in combination therapy, such as in combination with a psychedelic for example to modulate the activity of the psychedelic. In one embodiment, such a combination of a disclosed salt and/or solid form of ketanserin with a psychedelic can be used for increasing neuronal plasticity. The salts and solid forms of the present disclosure can also be used to treat any brain disease. The salts and solid forms of the present disclosure can also be used for increasing at least one of translation, transcription or secretion of neurotrophic factors.

In some embodiments, a form of ketanserin of the present disclosure is used to treat neurological diseases. In some embodiments the form of ketanserin is used as a monotherapy to treat neurological diseases. In other embodiments, the ketanserin form disclosed herein is used in combination with one more pyschedelics to treat neurological diseases. By way of example, in some embodiments, the form of ketanserin has, alone or in combination, anti-addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof. In some embodiments, the neurological disease is a neuropsychiatric disease. In some embodiments, the neuropsychiatric disease is a mood or anxiety disorder. In some embodiments, the neurological disease is a migraine, headaches (e.g., cluster headache), post-traumatic stress disorder (PTSD), anxiety, depression, neurodegenerative disorder, Alzheimer’s disease, Parkinson’s disease, psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, Chronic traumatic encephalopathy (CTE), traumatic brain injury, stroke and addiction (e.g., substance use disorder). In some embodiments, the neurological disease is a migraine or cluster headache. In some embodiments, the neurological disease is a neurodegenerative disorder, dementia, Alzheimer’s disease, or Parkinson’s disease. In some embodiments, the neurological disease is dementia. In some embodiments, the neurological disease is a psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, post- traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety. In some embodiments, the neuropsychiatric disease is a psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety. In some embodiments, the neuropsychiatric disease or neurological disease is post- traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), schizophrenia, depression, or anxiety. In some embodiments, the neuropsychiatric disease or neurological disease is addiction (e.g., substance use disorder). In some embodiments, the neuropsychiatric disease or neurological disease is depression. In some embodiments, the neuropsychiatric disease or neurological disease is anxiety. In some embodiments, the neuropsychiatric disease or neurological disease is post-traumatic stress disorder (PTSD). In some embodiments, the neurological disease is stroke or traumatic brain injury. In some embodiments, the neuropsychiatric disease or neurological disease is schizophrenia.

In some embodiments, a form of ketanserin of the present disclosure is used in combination with a psychedelic for increasing neuronal plasticity and has, for example, anti- addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof. In some embodiments, decreased neuronal plasticity is associated with a neuropsychiatric disease. In some embodiments, a form of ketanserin described herein is used for treating a brain disorder. In some embodiments, the compounds described herein are used for increasing at least one of translation, transcription, or secretion of neurotrophic factors.

In some embodiments, the present disclosure provides a method of treating a disease, including administering to a subject in need thereof, a therapeutically effective amount of a form of ketanserin of the present disclosure. In some embodiments, the disease is a musculoskeletal pain disorder including fibromyalgia, muscle pain, joint stiffness, osteoarthritis, rheumatoid arthritis, muscle cramps. In some embodiments, the present invention provides a method of treating a disease of women’s reproductive health including premenstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS), post-partum depression, and menopause.

In certain embodiments, a form of ketanserin disclosed herein is used alone or in combination to treat hypertension: hypertensive crisis during or after surgery, hypertension at pre-eclampsy or HELLP syndrome with a diastolic blood pressure of 110 mm Hg or higher. In certain other embodiments, a form of ketanserin disclosed herein is used alone or in combination to treat microcircular failure during sepsis and purpura fulminans.

In some embodiments, the forms of ketanserin of the present disclosure have activity as 5-HT2A modulators. In some embodiments, the compounds of the present disclosure elicit a biological response by activating the 5-HT2A receptor (e.g., allosteric modulation or modulation of a biological target that activates the 5-HT2A receptor). 5-HT2A agonism has been correlated with the promotion of neural plasticity (Ly et al., 2018). 5-HT2A antagonists abrogate the neuritogenesis and spinogenesis effects of hallucinogenic compounds with 5-HT2A agonist activity, for example., DMT, LSD, and DOI. In some embodiments, the ketanserin forms of the present disclosure are used as 5-HT2A modulators in combination with a psychedelic to promote neural plasticity (e.g., cortical structural plasticity). In some embodiments, promotion of neural plasticity includes, for example, increased dendritic spine growth, increased synthesis of synaptic proteins, strengthened synaptic responses, increased dendritic arbor complexity, increased dendritic branch content, increased spinogenesis, increased neuritogenesis, or any combination thereof. In some embodiments, increased neural plasticity includes, for example, increased cortical structural plasticity in the anterior parts of the brain.

Methods of Treating a Brain Disorder

In some embodiments, the present disclosure provides a method of treating a disease, including administering to a subject in need thereof, a therapeutically effective amount of a ketanserin form of the present disclosure. In such embodiments the form of ketanserin may be combined with other therapeutic agents, such as a psychedelic. In some embodiments, the disease is a musculoskeletal pain disorder including fibromyalgia, muscle pain, joint stiffness, osteoarthritis, rheumatoid arthritis, muscle cramps. In some embodiments, the present disclosure provides a method of treating a disease of women’s reproductive health including premenstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS), post-partum depression, and menopause. In some embodiments, the present disclosure provides a method of treating a brain disorder, including administering to a subject in need thereof, a therapeutically effective amount of a form of ketanserin of the present disclosure. In some embodiments, the present disclosure provides a method of treating a brain disorder with combination therapy, including administering to a subject in need thereof, a therapeutically effective amount of a form of ketanserin of the present disclosure and at least one additional therapeutic agent.

In some embodiments, 5-HT2A modulators (e.g., 5-HT2A agonists), such as psychedelics, are used to treat a brain disorder and a form of ketanserin disclosed herein is used to modulate the effect of the agonist. In some embodiments, the brain disorders comprise decreased neural plasticity, decreased cortical structural plasticity, decreased 5-HT2A receptor content, decreased dendritic arbor complexity, loss of dendritic spines, decreased dendritic branch content, decreased spinogenesis, decreased neuritogenesis, retraction of neurites, or any combination thereof.

In some embodiments, a form of ketanserin of the present disclosure is used to treat brain disorders. In some embodiments, the form of ketanserin is used in combination with psychedelics with anti -addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof. In some embodiments, the brain disorder is a neuropsychiatric disease. In some embodiments, the neuropsychiatric disease is a mood or anxiety disorder. In some embodiments, brain disorders include, for example, migraine, cluster headache, post-traumatic stress disorder (PTSD), anxiety, depression, panic disorder, suicidality, schizophrenia, and addiction (e.g., substance abuse disorder). In some embodiments, brain disorders include, for example, migraines, addiction (e.g., substance use disorder), depression, and anxiety.

In some embodiments, the present disclosure provides a method of treating a brain disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a form of ketanserin disclosed herein.

In some embodiments, the brain disorder is a neurodegenerative disorder, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, addiction, anxiety, post-traumatic stress disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or substance use disorder.

In some embodiments, the brain disorder is a neurodegenerative disorder, Alzheimer’s, or Parkinson’s disease. In some embodiments, the brain disorder is a psychological disorder, depression, addiction, anxiety, or a post-traumatic stress disorder. In some embodiments, the brain disorder is depression. In some embodiments, the brain disorder is addiction. In some embodiments, the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury or substance use disorder. In some embodiments, the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder. In some embodiments, the brain disorder is stroke or traumatic brain injury. In some embodiments, the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, or substance use disorder. In some embodiments, the brain disorder is schizophrenia. In some embodiments, the brain disorder is alcohol use disorder. Combination Therapy In particular embodiments of treating the disorders described above, combination therapy is used. In such therapy a form of ketanserin described herein is administered in combination with a psychedelic.

Psychedelics

In some embodiments, the psychedelic for use in combination with the present ketanserin forms is selected from the group consisting of psilocybin, psilocin, baeocystin, norbaeocystin, lisurgide, ibogaine, mescaline (3,4,5-trimethoxy-phenethylamine), phenethylamine (PEA), carboxamindotryptamine, proscaline (2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine), metaescaline (2-(3 -ethoxy-4, 5 -dimethoxyphenyl)ethanamine), allylescaline (4-Allyloxy-3,5- dimethyloxy phenylethylamine), methallylescaline (4-Methallyloxy-3,5- dimethoxyphenethylamine), 3,4-Methylenedioxy-A (MDA), 3,4-methylenedioxy-N- ethylamphetamine (MDE), asymbescaline (3,4-Diethoxy-5-methoxyphenethylamine), mescaline-NBOMe, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, LSZ, LSM-775, l-(4- Bromofuro[2,3-f] [l]benzofuran-8-yl)propan-2-amine, 25I-NBOH, N-(2-Methoxybenzyl)-2- (3,4,5-trimethoxyphenyl)ethanamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-iodo- phenethylamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-chloro-phenethylamine, N-(2- hydroxybenzyl)-2,5-dimethoxy-4-bromo-phenethylamine, 4-Allyloxy-3,5- dimethyloxyphenylethylamine, N-(2-fluorobenzyl)-2,5-dimethoxy-4-iodo-phenethylamine, 2,5- dimethoxy-4-tert-butylthio-phenethylamine, 2,5-dimethoxy-4-propylthio-phenethylamine, 2,5- dimethoxy-4-propylphenethylamine, 2,5-dimethoxy-4-nitrophenethylamine, 2, 5 -dimethoxy -4- nitroamphetamine, 2,5-dimethoxy-4-methylphenethylamine, 2,5-dimethoxy-4-isopropylthio- phenethylamine, 2,5-dimethoxy-4-iodophenethylamine, 2,5-dimethoxy-4-iodoamphetamine, 2,5- dimethoxy-4-fluorophenethylamine, 2,5-dimethoxy-4-ethylthio-phenethylamine, 2, 5 -dimethoxy - 4-ethylphenethylamine, 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine, 2,5- dimethoxy-4-chlorophenethylamine, 2,5-dimethoxy-4-chloroamphetamine, 2,5-dimethoxy-4- bromoamphetamine, 2,5-dimethoxy-4-bromo-P-ketophenethylamine, 2,5-dimethoxy-4-(2- fluoroethylthio)-phenethylamine, 2-(4-propyl-2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-(4-methyl-2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-(4-fluoro-2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-(4-chl oro-2, 5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-Bromo-4,5-methylenedioxy-A (2-Br-4,5-MDA), 4- Bromo-3,5-dimethoxy-A (4-Br-3,5-DMA), 3,4-Dimethyl-2,5-dimethoxy-PEA (2C-G), 3,4- Trimethylene-2,5-dimethoxy-PEA (2C-G-3), 3,4-Trimethylene-2,5-dimethoxy-A (G-3), 3,4- T etram ethylene-2, 5 -dimethoxy -PEA (2C-G-4), 3, 4-Tetram ethylene-2, 5 -dimethoxy- A (G-4),

3.4-Norbornyl-2,5-dimethoxy-PEA (2C-G-5), 3,4-Norbornyl-2,5-dimethoxy-A (G-5), 1,4- Dimethoxynaphthyl-2-ethylamine (2C-G-N), l,4-Dimethoxynaphthyl-2-isopropylamine (G-N),

2.5 -Dimethoxy -PEA (2C-H), 4-Ethoxy-3,5-dimethoxy-A (3C-E), 4-Ethoxy-3,5-dimethoxy- PEA, 4-Benzyloxy-3,5-dimethoxy-A (3C-BZ), 4-Isopropoxy-2,5-dimethoxy-PEA (2C-O-4), 4- Methylseleno-2,5-dimethoxy-PEA (2C-SE), 4-Methylthio-2,5-dimethoxy-PEA (2C-T), 4- Isopropylthio-2,6-dimethoxy-PEA (psi-2C-T-4), 4-(2 -Methoxy ethylthio)-2,5-dimethoxy -PEA (2C-T-13), 4-Cyclopropylthio-2, 5 -dimethoxy -PEA (2C-T-15), 4-(s)-Butylthio-2,5-dimethoxy- PEA (2C-T-17), 4- Acetoxy -N-methyl-N-ethyltryptamine (4-AcO-MET), 4-Acetoxy-N- methyl-N-allyltryptamine (4-AcO-MALT), 4-Acetyloxy-N,N-diallyltryptamine (4-AcO- DALT), N,N,N-trimethyl-4-phosphoryloxytryptamine (aeruginascin), 4-Hydroxy-N,N,N- trimethyltryptamine, [3-(2-Dimethylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate, 4- hydroxytryptamine, 4-hydroxy-N,N-dimethyltryptamine, [3-(2-methylaminoethyl)-lH-indol-4- yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3- (aminoethyl)-lH-indol-4-yl] dihydrogen phosphate, [3-(2- trimethylaminoethyl )-lH-indol-4-yl] dihydrogen phosphate, and 4-hydroxy-N,N,N-trimethyltryptamine, 6-Allyl-N,N-diethyl-NL, N,N-Dibutyl-T, N,N-Diethyl-T, N,N-Diisopropyl-T, alpha-methyl-T, 5-Methyoxy-alpha-methyl-T, 2,alpha-Dimethyl-T, alpha, N- Dimethyl-T, N,N-Dipropyl-T, N-Ethyl-N-isopropyl-T, alpha-Ethyl-T, 6,N,N-Triethyl-NL, 3,4- Dihydro-7-m ethoxy 1-methyl-C, 7-Methyoxy-l-methyl-C, N,N-Dibutyl-4-hydroxy-T, N,N- Diethyl-4-hydroxy-T, N,N-Diisopropyl-4-hydroxy-T, N,N-Dimethyl-4-hydroxy-T, N,N- Dimethyl-5- hydroxy-T, N,N-Dipropyl-4-hydroxy-T, N-Ethyl-4-hydroxy-N-methyl-T, 4- Hydroxy-N-isopropyl-N-methyl-T,4-Hydroxy-N-methyl-N-propyl-T, 4-Hydroxy-N,N- tetramethylene-T, Ibogaine, N-Butyl-N-methyl-T, N,N-Diisopropyl-4,5-methylenedioxy-T, N,N-Diisopropyl-5,6-methylenedioxy-T, N,N-Dimethyl-4, 5 -m ethylenedi oxy-T, 2,N- Dimethyl-4,5-methylenedioxy-A, N,N-Dimethyl-5,6-methylenedioxy-T, N-Isopropyl-N- methyl-5,6-methylenedioxy-T, N,N-Diethyl-2-methyl-T, 2,N,N-Trimethyl-T, N-Acetyl-5- methoxy-T, N,N-Diethyl-5-methoxy-T, N,N-Diisopropyl-5-methoxy-T, N-Isopropyl-4- methoxy-N-methyl-T, N-Isopropyl-5-methoxy-N-methyl-T,5,6-Dimethoxy-N4sopropyl-N- methyl-T, 5-Methoxy-N-methyl-T, 5-Methoxy-N,N-tetramethylene-T, 6-Methoxy-l- methyl-l,2,3,4-tetrahydro-C, 5-Methoxy-2,N,N-trimethyl-T, N,N-Dimethyl-5-methylthio- T, N-Isopropyl-N-methyl-T, alpha Methyl-T, N-Ethyl-T, N-Methyl-T, 6-Propyl-N L, N,N- T etram ethylene-T, Tryptamine, 7-Methoxy-l-methyl-l,2,3,4-tetrahydro-C, alpha, N- Dimethyl-5-methoxy-T, alpha-Ethyl-3, 4, 5 -trimethoxy -PEA (AEM), 4-Methylthio-2,5- dimethoxy-A (ALEPH), 4-Ethylthio-2, 5 -dimethoxy- A (ALEPH-2), 4-Isopropylthio-2,5- dimethoxy-A (ALEPH-4), 4-Phenylthio-2,5-dimethoxy-A (ALEPH-6), 4-Propylthio-2,5- dimethoxy-A (ALEPH-7), 2,5-Dimethoxy-alpha-ethyl-4-methyl-PEA (ARIADNE), 4-Butoxy- 3, 5 -dimethoxy -PEA, 2,5-Dimethoxy-4,N-dimethyl-A (BEATRICE), 2,5-Bismethylthio-4- methyl-A (BIS-TOM), 4-Bromo-2,5,beta-trimethoxy-PEA (BOB), 2,5,beta-Trimethoxy-4- methyl-PEA (BOD), beta-Methoxy-3,4-methylenedioxy-PEA (BOH), 2,5-Dimethoxy-beta- hydroxy-4-methyl-PEA (BOHD), 3,4,5,beta-Tetramethoxy-PEA (BOM), 4- Cyclopropylmethoxy-3,5-dimethoxy-PEA (CPM), 4-Trideuteromethyl-3,5-dimethoxy-PEA (4- D), 3,4,5-trimethoxy-beta,beta-dideuterophenethylamine (beta-D), 4-Methyl-3,5-Dimethoxy- PEA, 2,4-Dimethoxy-A (2,4-DMA), 2, 5 -Dimethoxy- A (2,5-DMA), 3,4-Dimethoxy-A (3,4- DMA), 2-(2,5-Dimethoxy-4-methylphenyl)-cyclopropylamine (DMCPA), 3,4-Dimethoxy- b eta-hydroxy -PEA (DME), 2,5-Dimethoxy-3,4-methylenedioxy-A (DMMDA), 2,3- Dimethoxy-4,5-methylenedioxy-A (DMMDA-2), 3,4-Dimethoxy-PEA (DMPEA), 2,5- dimethoxy-4-(n)-amylamphetamine (DO AM), 4-(2-Fluoroethyl)-2, 5 -dimethoxy- A (DOEF), 4- Ethyl-2,5-dimethoxy-A (DOET), 4-Methyl-2,6-dimethoxy-A (psi-DOM), 4-Propyl-2,5- dimethoxy-A (DOPR), 2,4,5-Triethoxy-A (EEE), ,4-Diethoxy-5-methoxy-A (EEM), 2,5- Diethoxy-4-methoxy-A (EME), 2-Ethoxy-4,5-dimethoxy-A (EMM), N, alpha-diethyl-3, 4- methylenedioxy-PEA (ETHYL-J), N-Ethyl-alpha-propyl-3,4-methylenedioxy-PEA (ETHYLIC), Benzofuran-2-methyl-5-methoxy-6-(2-aminopropane), Benzofuran-2,2-dimethyl-5- methoxy-6-(2-aminopropane), N-Hydroxy-N-methyl-3,4-methylenedioxy-A (FLEA), 3,4- Dimethyl-2,5-dimethoxy-A, 2,5-Dimethoxy-N-hydroxy-4-ethylthio-PEA (HOT-2), 2,5- Dimethoxy-N-hydroxy-4-(n)-propylthio-PEA (HOT-7), 2,5-Dimethoxy-N-hydroxy-4-(s)- butylthio-PEA (HOT-17), 2,5-Dimethoxy-N,N-dimethyl-4-iodo-A (IDNNA), 2,3,4- Trimethoxy-PEA (IM), 3,5-Dimethoxy-4-isopropoxy-PEA (IP), 5-Ethoxy-2-methoxy-4- methyl-A (IRIS), alpha-Ethyl-3,4-methylenedioxy-PEA, 3 -Methoxy-4, 5 -methylenedioxy -PEA,

3 -Methoxy-4, 5 -methylenedi oxy- A (MMDA), 2-Methoxy-4,5-methylenedioxy-A (MMDA-2), 2-Methoxy-3,4-methylenedioxy-A (MMDA-3a), 4-Methoxy-2,3-methylenedioxy-A (MMDA- 3b), 4-methoxyamphetamine, N-Allyl-3,4-methylenedioxy-A (MDAL), N-Butyl-3,4- m ethyl enedioxy-A (MDBU), N-Benzyl-3,4-methylenedioxy-A (MDBZ), N- Cyclopropylmethyl-3,4-methylenedioxy-A (MDCPM), N,N-Dimethyl-3,4-methylenedioxy-A (MDDM), N-(2-Hydroxyethyl)-3,4-m ethylenedi oxy-A, N-Isopropyl-3,4-methylenedioxy-A (MDIP), N-Methyl-3,4-ethylenedioxy-A (MDMC), N-Methoxy-3,4-methyl enedioxy-A, N-(2- Methoxyethyl)-3,4-methylenedi oxy-A, alpha, alpha, N-Trimethyl-3,4-methylenedioxy-PEA (MDMP), N-Hydroxy-3,4-methylenedi oxy-A (MDOH), 3,4-Methylenedioxy-PEA, alpha, alpha-Dimethyl-3,4-methylenedi oxy -PEA (MDPH), N-Propargyl-3,4-methylenedioxy-A (MDPL), N-Propyl-3,4-methylenedioxy-A (MDPR), 3,4-Dimethoxy-5-ethoxy-PEA (ME), 3- methoxy-4,5-Ethylenedioxy-A (MED A), 2-Methoxy-4,5-diethoxy-A (MEE), 2,5-Dimethoxy-

4-ethoxy-A (MEM), 3-Methoxy-4-ethoxy-PEA, 5-Bromo-2,4-dimethoxy-A, 5-Methylthio-2,4- dimethoxy-A, N-Methyl-2,5-dimethoxy-A, 4-Bromo-2,5-dimethoxy-N-methyl-A, N-Methyl- alpha-ethyl-3,4-methylenedioxy-PEA, N-Methyl-alpha-propyl-3,4-methylenedioxy-PEA, N- Methyl-4-methoxy-A, N-Methyl-2-methoxy-4, 5 -methylenedi oxy- A, 2, 4-Dimeth oxy-5 -ethoxy - A (MME), 3,4-Dimethoxy-5-propoxy-PEA (MP), 2,5-Dimethoxy-4-propoxy-A (MPM), 2- Methylthio-4,5-dimethoxy-A, 3,5-Dimethoxy-4-phenethyloxy-PEA (PE), 4-Propynyloxy-3,5- dimethoxy-PEA, 3,5-Diethoxy-4-methoxy-PEA, 3,4,5-Tetramethoxy-A, 4-Eth oxy-3 -ethylthio-

5-methoxy-PEA, 3-Ethoxy-4-ethylthio-5-methoxy-PEA, 3,4-Diethoxy-5-methylthio-PEA, 4- Thiobutoxy-3, 5 -dimethoxy -PE A, 4-Ethoxy-5-methoxy-3-methylthio-PEA (3-TE), 3,5- Dimethoxy-4-ethylthio-PEA (4-TE), 2-Methylthio-3,4-dimethoxy-PEA (2-TIM), 3- Methylthio-2,4-dimethoxy-PEA (3-TIM), 4-Methylthio-2,3-dimethoxy-PEA (4-TIM), 3- Methylthio-4,5-dimethoxy-PEA (3-TM), 4-Methylthio-3, 5 -dimethoxy -PEA (4-TM), 3,4,5- Trimethoxy-A (TMA), 2,4,5-Trimethoxy-A (TMA-2), 2,3,4-Trimethoxy-A (TMA-3), 2,3,5- Trimethoxy-A (TMA-4), 2,3,6-Trimethoxy-A (TMA-5), 2,4,6-Trimethoxy-A (TMA-6), 4,5- Dimeth oxy-3 -ethylthio-PEA (3-TME), 3-Ethoxy-5-methoxy-4-methylthio-PEA (4-TME), 3- Ethoxy-4-methoxy-5-methylthio-PEA (5-TME), 2-Methylthio-3,4-methylenedioxy-A, 4,5- Thiom ethyl eneoxy-2-methoxy-A, 2,4,5-Trimethoxy-PEA, 4-Ethyl-5-methoxy-2-methylthio-A (2-TOET), 4-Ethyl-2-methoxy-5-methylthio-A (5-TOET), 4-Ethyl-2-methoxy-5-methylthio-A (2-TOM), 2-Methoxy-4-methyl-5-methylthio-A (5-TOM), 2-Methoxy-4-methyl-5- methylsulfinyl-A (TOMSO), 4-Propylthio-3,5-dimethoxy-PEA (TP), 3,4,5-Triethoxy-PEA (TRIS), 3-Ethoxy-5-ethylthio-4-methoxy-PEA (3-TSB), 3,5-Diethoxy-4-methylthio-PEA (4- TSB), 4,5-Diethoxy-3-ethylthio-PEA (3-T-TRIS), 3,5-Diethoxy-4-ethylthio-PEA (4-T-TRIS), 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone (ketamine), 5-methoxy-2,3-dihydro-lH- inden-2-amine (MEAI), N-methyl-N-allyltryptamine (MALT),N-ethyl-N-propyltryptamine (EPT), 5 -Methoxy -N,N-diallyltryptamine (5-MeO-DALT), 6-Methoxy-N,N- dimethyltryptamine (6-MeO-DMT), 6-fluoro-N,N, -dimethyltryptamine (6-Fluoro-DMT), N- methyl-N-propyltryptamine (MPT), N-Methyl-N-isopropyltryptamine (MiPT), N,N- Dimethyl-N-allyltryptamine (DMALT), 4-Acetoxy-N,N,N-trimethyltryptamine (4-AcO- TMT), 4-Acetoxy-N,N-dimethyl-N-ethyltryptamine (4-OAc-DMET), 4-Acetoxy-N,N- dimethyl-N-propyltryptamine (4-AcO-DMPT), N-(4-bromophenyl)adamantan-2-amine (bromantane), 3-(6-(4-fluoro-3-methoxyphenoxy)pyrimidin-4-yl)-5,5- dimethylimidazolidine-2, 4-dione, N-(4-((2-fluorobenzyl)oxy)benzyl)-2- (trifluoromethyl)thiazole-4-carboxamide, 4-{trans-2-[4-(3-Fluorophenyl)pyrimidin-2- yl]cyclopropyl}benzenesulfonamide, sodium 6-methoxy-2-methyl-3-(3,4,5- trimethoxybenzoyl)benzofuran-7-yl phosphate, l-ethyl-6-(indan-2-ylamino)-3-(morpholine- 4-carbonyl)-l,8-naphthyridin-4-one, 4-((lS,3S)-3-(5-cyclopentyl-l,2,4-oxadiazol-3-yl)-2,2- dimethylcyclopropyl)benzenesulfonamide, (2S,5R)-5-(4-((l-(5-fluoro-2- (trifluoromethoxy)phenyl)-lH-tetrazol-5-yl)oxy)phenyl)pyrrolidine-2-carboxamide, N-(4- fluorophenethyl)-3-methylisoxazole-4-sulfonamide, (7-hydroxy-6-methoxy-2- methylbenzofuran-3-yl)(3,4,5-trimethoxyphenyl)methanone(7-hydroxy-6-methoxy-2- methylbenzofuran-3-yl)(3,4,5-trimethoxyphenyl)methanone, 6-((2, 3 -dihydro- lH-inden-2- yl)amino)- 1 -ethy 1-3 -(1 -methyl- 1 H-imidazol-2-yl)- 1 , 8-naphthy ridin-4( 1 H)-one, 2-(2- ( Allyloxy )-5-fluorophenyl)cyclopropyl)methanamine, l,5-dimethyl-N-(2- (trifluoromethyl)pyridin-4-yl)-lH-indole-3-carboxamide, (2-(5-Fluoro-2-(2- fluoroethoxy)phenyl)cyclopropyl)methanamine, (2-(5-Chloro-2-(2- fluoroethoxy)phenyl)cyclopropyl)methanamine, (2-(5-Chloro-2-((2- fluoroallyl)oxy)phenyl)cyclopropyl)m ethanamine, 5, 6-dimeth oxy-2, 3 -dihydro- lH-inden-2- amine, N-N-disisopropyltryptamine-4-glutarate, 2-methoxy-7-methyl-5,6,7,8,9, 10- hexahydropyrido[3',2':4,5]pyrrolo[2,3-d]azepine, l-(5-methoxy-lH-indol-l-yl)-N,N,2- trimethylpropan-2-amine, 2-(5-methoxy-lH-pyrrolo[2,3-c]pyridin-l-yl)-N,N- dimethylethanamine, (R)-N,N-diethyl-l,3,4,5-tetrahydrobenzo[cd]indol-4-amine, (S)-N,N- diethyl-l,3,4,5-tetrahydrobenzo[cd]indol-4-amin, 2-(4-allyl-2,5- dimethoxyphenyl)ethanamine, N-Ethyl-2-(5-Fluoro-lH-Indol-3-YL)-N-Methylethan-l- Amine, (R)-2-(methylamino)-2 -phenylcyclohexanone, (R)-2-(D3-methylamino)-2- phenylcyclohexanone, (S)-2-(methylamino)-2-phenylcyclohexanone, (S)-2-(D3 - methylamino)-2-phenylcyclohexanone, (S)-3-(2,5-dimethoxy-4- (trifluoromethyl)phenyl)piperidine, 3-methyl-methcathinone (3-MMC), 3-(2-(Bis(Methyl- D3) Amino)Ethyl- 1 , 1 ,2,2-D4)- lH-Indol-4-YL(9Z, 12Z)-Octadeca-9, 12-Dienoate, (R)-3 -(( 1 - (Methyl-d3)Pyrolidin-2-YL)Methyl)-lH-Indol-4-OL, 5-(2-methylaminopropyl)benzofuran, 6-(2- methylaminopropyl)benzofuran, 2-chloro-N,N, -dimethyltryptamine, 2-bromo-N,N,- dimethyltryptamine, 2-bromo-4-acetoxy-N,N-dimethyltryptamine, 2-chloro-4-methoxy- N,N, -dimethyltryptamine, 1 -(3 -(2-(dimethy lamino)ethyl)- 1 H-indol-4-yl)-N- methylmethanesulfonamide, DMT-alpha,alpha-d2 (DMT-d2), psilocin-alpha,alpha-d2 (psilocin-d2), aeruginascin-alpha-alpha-d2 (aeruginascin-d2), razoxane, dexrazoxane, N- Allyl-3,4-methylenedi oxy-amphetamine (MDAL), N-Butyl-3,4-m ethylenedi oxyamphetamine (MDBU), N-Benzyl-3,4-methylenedioxyamphetamine (MDBZ), N-Cyclopropylmethyl-3,4- m ethylenedi oxyamphetamine (MDCPM), N,N-Dimethyl-3,4-methylenedioxyamphetamine (MDDM), N-(2-Hydroxyethyl)-3,4-methylenedioxy amphetamine (MDHOET), N-Isopropyl-3,4- m ethylenedi oxyamphetamine (MDIP), N-Methyl-3,4-ethylenedioxyamphetamine (MDMC), N- Methoxy-3,4-m ethylenedi oxyamphetamine (MDMEO), N-(2 -Methoxy ethyl)-3, 4- methylenedi oxyamphetamine (MDMEOET), alpha, alpha, N-Trimethyl-3, 4- methylenedioxyphenethylamine (MDMP), 3,4-Methylenedioxy-N-methylphentermine, N- Hydroxy-3,4-methylenedioxyamphetamine (MDOH), 3, 4-Methylenedi oxyphenethylamine (MDPEA), alpha, alpha-Dimethyl-3,4-methylenedi oxyphenethylamine (MDPH; 3,4- m ethylenedi oxyphentermine), N-Propargyl-3,4-methylenedioxyamphetamine (MDPL), 3,4- methylenedi oxy -N-methyl-a-ethylphenylethylamine, 3, 4-Methylenedi oxyamphetamine (MDA), ethylone, (also known as 3,4-methylenedioxy-N ethylcathinone), and N-Propyl-3,4 methylenedioxyamphetamine (MDPR), or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analog, derivative, prodrug, or combinations thereof. In some embodiments, the psychedelic is selected from the group consisting of psilocybin, psilocin, baeocystin, norbaeocystin, lisurgide, LSD, dimethyltryptamine, carboxamindotryptamine, ibogaine, tabernanthalog, 3, 4-methylenedi oxy-methamphetamine (MDMA), 1-acetyl LSD, O-acetyl psilocin, mescaline (3, 4, 5 -trimethoxy phenethylamine), proscaline (2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine), metaescaline (2-(3 -ethoxy-4, 5- dimethoxyphenyl)ethanamine), allylescaline (4-Allyloxy-3,5-dimethyloxy phenylethylamine), methallylescaline (4-Methallyloxy-3,5 dimethoxyphenethylamine), and asymbescaline (3,4- Diethoxy-5-methoxyphenethylamine). In some embodiments, the psychedelic is psilocybin or psilocin. In some embodiments, the psychedelic is [3-(2-dimethylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N- dimethyltryptamine, [3-(2-methylaminoethyl)-lH-indol- 4-yl] dihydrogen phosphate, 4- hydroxy-N-m ethyltryptamine, [3 -(aminoethyl)- 1 H-indol-4-yl] dihydrogen phosphate, 4- hydroxytryptamine, [3 -(2 -trimethylaminoethyl)- 1 H-indol-4-yl] dihydrogen phosphate, or 4- hydroxy -N,N,N-trimethyltryptamine. In some embodiments, the psychedelic is 1-acetyl LSD (ALD-52). In some embodiments, the psychedelic is O-acetyl psilocin (psilacetin).

[0001] In some embodiments, the psychedelic is LSD. In some embodiments, the LSD derivative is 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, LSZ, LSM-775, l-(4- Bromofuro[2,3-f] [l]benzofuran-8-yl)propan-2-amine.

[0002] In some embodiments, the psychedelic is mescaline. In some embodiments, the mescaline derivative is mescaline-NBOMe, proscaline (2-(3, 5 -dimethoxy -4- propoxyphenyl)ethanamine), or metaescaline (2-(3-ethoxy-4,5-dimethoxyphenyl)ethanamine). [0003] In some embodiments, the psychedelic is a phenethylamine or a tryptamine, selected from 25LNBOH, N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine, N-(2- hydroxybenzyl)-2,5-dimethoxy-4-iodo-phenethylamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4- chloro-phenethylamine, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-bromo-phenethylamine, 4- Allyloxy-3,5-dimethyloxyphenylethylamine, N-(2-fluorobenzyl)-2,5-dimethoxy-4-iodo- phenethylamine, 2,5-dimethoxy-4-tert-butylthio-phenethylamine, 2,5-dimethoxy-4-propylthio- phenethylamine, 2,5-dimethoxy-4-propylphenethylamine, 2,5-dimethoxy-4-nitrophenethylamine, 2,5-dimethoxy-4-nitroamphetamine, 2,5-dimethoxy-4-methylphenethylamine, 2,5-dimethoxy-4- methylamphetamine, 2,5-dimethoxy-4-isopropylthio-phenethylamine, 2,5-dimethoxy-4- iodophenethylamine, 2,5-dimethoxy-4-iodoamphetamine, 2,5-dimethoxy-4- fluorophenethylamine, 2,5-dimethoxy-4-ethylthio-phenethylamine, 2, 5 -dimethoxy -4- ethylphenethylamine, 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine, 2, 5 -dimethoxy - 4-chlorophenethylamine, 2,5-dimethoxy-4-chloroamphetamine, 2,5-dimethoxy-4- bromophenethylamine, 2,5-dimethoxy-4-bromoamphetamine, 2,5-dimethoxy-4-bromo-P- ketophenethylamine, 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine, 2-(4-propyl-2,5- dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-methyl-2,5- dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-iodo-2,5-dimethoxyphenyl)- N-[(2-methoxyphenyl)methyl]ethanamine, 2-(4-fluoro-2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-(4-chl oro-2, 5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine, 4-AcO-MET, 4-AcO-MALT and 4-AcO-DALT, Aeruginascin or N,N,N-trimethyl-4-phosphoryloxytryptamine, 4-Hydroxy-N,N,N- trimethyltryptamine, 5-meo-DMT, Ibogaine,, [3-(2-Dimethylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, 4-hydroxy-N,N-dimethyl- tryptamine, [3-(2- methylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-m ethyltryptamine, [3- (aminoethyl)-lH-indol-4-yl] dihydrogen phosphate, [3 -(2- trimethylaminoethyl )-lH-indol-4-yl] dihydrogen phosphate, and 4-hydroxy-N,N,N-trimethyltryptamine, 6-Allyl-N,N-diethyl-NL, N,N-Dibu- tyl-T, N,N-Diethyl-T, N,N-Diisopropyl-T, 5-Methyoxy-alpha-methyl-T, N,N- Dimethyl-T, 2,alpha-Dimethyl-T, alpha, N-Dimethyl-T, N,N-Dipropyl-T, N-Ethyl-N-isopropyl- T, alpha-Ethyl-T, 6,N,N-Triethyl-NL, 3,4-Dihydro-7-methoxy- 1-methyl-C, 7-Methyoxy-l- methyl-C, N,N-Dibutyl-4-hydroxy-T, N,N-Diethyl -4-hydroxy-T, N,N-Diisopropyl-4-hydroxy- T, N,N-Dimethyl-4-hydroxy-T, N,N-Dimethyl-5- hydroxy-T, N, N-Dipropyl-4-hydroxy-T, N-Ethyl-4- hydroxy -N-methyl-T, 4-Hydroxy-N-isopropyl-N-methyl-T, 4-Hydroxy-N- methyl-N-propyl-T, 4-Hydroxy-N,N-tetram-ethylene-T Ibogaine, N,N-Diethyl-L, N-Butyl- N-methyl-T, N,N-Diisopropyl-4,5-methylenedioxy-T, N,N-Diisopropyl- 5,6- methylenedioxy-T, N,N-Dimethyl-4, 5 -methylenedi oxy- T, N,N-Dimethyl-5,6- methylenedioxy-T, N-Isopropyl-N- methyl-5,6-methylenedioxy-T, N,N-Diethyl-2-methyl- T, 2,N,N-Trimethyl-T, N-Acetyl-5-methoxy-T, N,N-Diethyl-5-methoxy-T, N,N- Diisopropyl-5-methoxy-T, 5-Methoxy-N, N-dimethyl-T, N-Isopropyl-4-methoxy-N-methyl- T, N-Iso- propyl-5-methoxy-N-methyl-T,5,6-Dimethoxy-N-isopropyl-N-methyl-T, 5- Methoxy -N-methyl-T, 5-Methoxy-N,N-tetramethylene-T, 6-Methoxy- 1 -methy 1 - 1 ,2,3 ,4- tetrahydro-C, 5-Methoxy-2,N,N-trimethyl-T, N,N- Dimethyl-5-methylthio-T, N-Isopropyl- N-methyl-T, alpha- Methyl-T, N-Ethyl-T, N-Methyl-T, 6-Propyl-N L, N,N-

Tetramethylene-T, Tryptamine, 7-Methoxy-l-methyl-l,2,3,4-tetrahydro-C, and alpha, N- Dimethyl-5-methoxy-T.

In some embodiments, the psychedelic is selected from the group consisting of:

or a pharmaceutically acceptable salt, ester, solvate, metabolite, deuterated analog, derivative, prodrug, or combinations thereof. In some embodiments, the psilocybin or psilocin is present in the form of an extract from a mushroom and/or truffle (sclerotium). In some embodiments, the mushroom or truffle is from the genus PsHocybe, GymnopHus, Panaeolus, Copelandia, Hypholoma, Pluteus, Inocybe, Conocybe, Panaeolina, Gerronema, Agrocybe, Galerina and/or Mycena. In some embodiments, the mushroom or truffle is P. azurescens, P. semilanceala, P. cyanescens, P. cubensis, P. subcube nsis, P. tam pane nsis, P. mexicana, P. atlantis, and/or P. semilanceata.

In particular embodiments the psychedelic is selected from psilocybin, (9-acetyl-psilocin (4-Acetoxy-DMT), LSD, ALD-52, 1P-LSD, mescaline, DMT, 5-MeO-DMT, ibogaine, 2C-B, MDMA, DOM (l-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane), R-MDMA, S-MDMA, MBDB, methylone, R-methylone, S-methylone, MDEA, S-MDEA, N-ethyl-2-(5-fluoro-lH- indol-3-yl)-N-methylethan-l-amine, 4-OH-DiPT hemi-glutarate, 5,6-dimethoxy-2-aminoindane, 5 -methoxy -2-aminoindane, 2-Br-LSD, MDA, R-MDA, S-MDA, and MDAI.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is psilocybin, wherein the ketanserin is administered in from about 10 mg to about 80 mg, from about 30 mg to about 50 mg, or about 40 mg and psilocybin is administered in between from about 10 mg to about 50 mg, or from about 25 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is (9-acetyl-psilocin (4- Acetoxy-DMT). In such embodiments, ketanserin is administered in an amount of from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 4-Acetoxy-DMT is administered in an amount between about 5 mg to about 50 mg, or about 10 mg to about 25 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is LSD, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is ALD-52, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and ALD-52 is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is 1P-LSD, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 1P-LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is DMT, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and DMT is administered in an amount between from about 1 mg and about 60 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is 5-MeO-DMT, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-MeO-DMT is administered in an amount between from about 1 mg and about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is mescaline, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and mescaline is administered in an amount between from about 50 mg and about 800 mg, or between from about 200 mg and 500 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is ibogaine, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and ibogaine is administered between from about 50 mg and about 1,000 mg, or between from about 500 mg and 800 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is 2C-B, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 2C-B is administered in an amount between from about 1 mg and 40 mg. In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is MDMA, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and MDMA is administered between from about 50 mg and about 200 mg, or between from about 80 mg and 120 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form described herein is DOM, wherein ketanserin is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and DOM is administered between about 0.5 mg and about 15 mg, or about 5 mg.

In some embodiments, the serotonin receptor modulator for use with the psychedelic (R)- MDMA is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and the (A)-MDMA is administered between about 50 mg and about 200 mg, or between about 80 mg and 120 mg.

In some embodiments, the serotonin receptor modulator for use with the psychedelic (5)- MDMA is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and the CS')-MDMA is administered between about 50 mg and about 200 mg, or between about 80 mg and 120 mg.

In some embodiments, the serotonin receptor modulator for use with MBDB is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and MBDB is administered in about 10 mg to about 500 mg or about 150 mg to about 250 mg or about 180 mg or about 210 mg or about 250 mg.

In some embodiments, the serotonin receptor modulator for use with the methylone is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and the methylone is administered in about 10 mg to about 500mg or about lOOmg to about 250 mg or about 120mg or about 150 mg or about 180mg or about 250 mg.

In some embodiments, the serotonin receptor modulator for use with (A)-methylone is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg, and the (R)-methylone is administered in about 10 mg to about 500 mg or about 100 mg to about 250 mg or about 120 mg or about 150 mg or about 180 mg or about 250 mg. In some embodiments, the serotonin receptor modulator for use with (S)-methylone is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg, and the (S)-methylone is administered in about 10 mg to about 500 mg or about 100 mg to about 250 mg or about 120 mg or about 150 mg or about 180 mg or about 250 mg.

In some embodiments, the serotonin receptor modulator for use with A-ethyl-3,4- methylenedioxyamphetamine (MDEA) is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and the N-ethyl-3,4- methylenedioxyamphetamine (MDEA) is administered in about 10 mg to about 300mg or about lOOmg to about 180mg or about 120mg or about 150 mg or about 160mg.

In some embodiments, the serotonin receptor modulator for use with the (5)-A-ethyl-3,4- methylenedioxyamphetamine (S-MDEA) is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and the (A')-Methyl- 3, 4-m ethylenedi oxyamphetamine (S-MDEA) disclosed herein is administered in about 10 mg to about 300mg or about lOOmg to about 180mg or about 120mg or about 150 mg or about 160mg.

In some embodiments, the serotonin receptor modulator for use with the N-ethyl-2-(5- fluoro-lH-indol-3-yl)-N-methylethan-l-amine is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg, and the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine is administered from about 100 ug to 100 mg, or from 1 mg to 20 mg, or from 15 mg to 30 mg.

In some embodiments, the serotonin receptor modulator for use with 4-OH-DiPT hemiglutarate hydrochloride disclosed herein is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg, and the 4-OH-DiPT hemi -glutarate is administered in about 1 mg to about 50 mg, or about 3mg to about 10 mg, 15mg, 20mg, 25mg, or 30mg.

In some embodiments, the serotonin receptor modulator for use with the psychedelic 5,6- dimethoxy-2-aminoindane is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5,6-dimethoxy-2-aminoindane is administered in about 20 mg to about 300 mg or about 60 mg to about 180 mg or about 160 mg to about 300 mg or about 1.6 mg per kg to about 4.8 mg per kg or about 99.2 mg to about 297.6 mg. In some embodiments, the serotonin receptor modulator for use with the psychedelic 5- methoxy-2-aminoindane is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-methoxy-2-aminoindane is administered in about 20mg to about 300mg or about 60 mg to about 180 mg or about 160 mg to about 300 mg or about 1.6 mg per kg to about 4.8 mg per kg or about 99.2 mg to about 297.6 mg.

In some embodiments, the serotonin receptor modulator for use with 2-Br-LSD is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 2-Br-LSD is administered in about 10 micrograms to l.Omg or about 1.8mg or about 30 micrograms per kg or about 0.1 mg to about 50 mg or about 1 mg to about 20 mg or 20mg to about 30mg.

In some embodiments, the serotonin receptor modulator for use with the psychedelic MDAI is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and MDAI is administered in about 40 mg to about 300 mg or about 60 mg to about 180 mg or about 60 mg or about 80 mg or about 100 mg or about 180 mg.

In some embodiments, the serotonin receptor modulator for use with the psychedelic MDA is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and MDA is administered in about 10 mg to about 250 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 75 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 165 mg, about 180 mg, or about 200 mg.

In some embodiments, the serotonin receptor modulator for use with the psychedelic R- MDA is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and R-MDA is administered in about 10 mg to about 250 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 75 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 165 mg, about 180 mg, or about 200 mg.

In some embodiments, the serotonin receptor modulator for use with the psychedelic S- MDA is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and S-MDA is administered in about 10 mg to about 250 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 75 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 165 mg, about 180 mg, or about 200 mg. In certain embodiments, such as those described above a disclosed ketanserin form is coadministered with a psychedelic in the same or in separate compositions. In one embodiment, the psychedelic is administered in a modified release formulation such that the subject is effectively pretreated with ketanserin prior to release of an effective amount of the psychedelic. Thus, in some embodiments, the ketanserin form described is administered or released from a composition provided herein prior to the administration and/or release of the psychedelic. This allows pretreatment to attenuate activation of the serotonin receptor by the psychedelic. In some embodiments, the ketanserin form is administered or released from the composition provided herein to pretreat a subject at least about 30 minutes to about 360 minutes prior to administration to a subject or release of the psychedelic from a modified release formulation, such as from about 30 minutes to about 270 minutes prior, or from about 45 minutes to about 240 minutes, such as from about 60 minutes to about 180 minutes prior. In some embodiments, the ketanserin form described herein attenuates the activation of the serotonin receptor when the ketanserin is administered or released from the composition provided herein to pretreat at most about 3 hours prior to administration or release of the psychedelic. In some embodiments, the ketanserin form described herein attenuates the activation of the serotonin receptor when the ketanserin is administered or released from the composition provided herein to pretreat the subject at most about 1.5 hours prior to the release of the psychedelic. In some embodiments, the ketanserin form described herein attenuates the activation of the serotonin receptor when the ketanserin is administered or released from the composition provided herein to pretreat the subject at least about 45 minutes prior to at most about 3 hours prior, such as about 1.5 hours prior to the release of the psychedelic. In some embodiments, the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat at about or most about 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.25 hours, 1.5 hours, 2 hours, or 3 hours prior to the release of the psychedelic. In some embodiments, the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat at most about 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, or more than 9 hours prior to the release of the psychedelic. In some embodiments, the ketanserin form effectively attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat in a range of about 5 minutes to about 3 hours, about 10 minutes to about 3 hours, about 20 minutes to about 3 hours, such as from about 30 minutes to about 3 hours, from about 40 minutes to about 3 hours, about 50 minutes to about 3 hours, about 1 hour to about 3 hours, about 5 minutes to about 2 hours, about 10 minutes to about 2 hours, about 20 minutes to about 2 hours, about 30 minutes to about 2 hours, about 40 minutes to about 2 hours, about 50 minutes to about 2 hours, about 1 hour to about 2 hours, about 5 minutes to about 1 hour, about 10 minutes to about 1 hour, about 20 minutes to about 1 hour, about 30 minutes to about 1 hour, about 40 minutes to about 1 hour, or about 50 minutes to about 1 hour prior to the release of the psychedelic.

In a preferred embodiment, the ketanserin form is administered at about 1 hour to about 3 hours prior to the administration of the psychedelic.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the psilocybin.

In some preferred embodiments, psychedelic is psilocybin, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of psilocybin.

In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of 4-Acetoxy- DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy- DMT, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the 4- Acetoxy-DMT. In some preferred embodiments, psychedelic is 4-Acetoxy-DMT, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 4-Acetoxy-DMT.

In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the LSD.

In some preferred embodiments, psychedelic is LSD, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of LSD.

In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD- 52, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the ALD- 52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the ALD-52.

In some preferred embodiments, psychedelic is ALD-52, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of ALD-52.

In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P- LSD, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the 1P- LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the 1P-LSD.

In some preferred embodiments, psychedelic is 1P-LSD, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 1P-LSD.

In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the mescaline.

In some preferred embodiments, psychedelic is mescaline, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of mescaline.

In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the DMT.

In some preferred embodiments, psychedelic is DMT, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DMT.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the 5-MeO- DMT.

In some preferred embodiments, psychedelic is 5-MeO-DMT, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the ibogaine.

In some preferred embodiments, psychedelic is ibogaine, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of ibogaine. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C- B, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C- B, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the 2C-B.

In some preferred embodiments, psychedelic is 2C-B, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 2C-B.

In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the MDMA.

In some preferred embodiments, psychedelic is MDMA, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of MDMA.

In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the DOM.

In some preferred embodiments, psychedelic is DOM, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM.

In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the (R)- MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the (R)- MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the (R)- MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the (R)- MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the (R)- MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the (R)-MDMA. In some embodiments, the psychedelic is (R)-MDMA, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the (R)- MDMA. In some preferred embodiments, psychedelic is (R)-MDMA, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of (R)-MDMA.

In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)- MDMA, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the (S)- MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the (S)-MDMA. In some embodiments, the psychedelic is (S)-MDMA, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the (S)-MDMA.

In some preferred embodiments, psychedelic is (S)-MDMA, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of (S)-MDMA.

In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the MBDB.

In some preferred embodiments, psychedelic is MBDB, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of MBDB.

In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 .minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the methylone.

In some preferred embodiments, psychedelic is methylone, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of (R)- methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the (R)- methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the (R)-methylone. In some embodiments, the psychedelic is (R)-methylone, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the (R)- methylone.

In some preferred embodiments, psychedelic is (R)-methylone, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of (R)-methylone.

In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of (S)- methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the (S)- methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the (S)-methylone. In some embodiments, the psychedelic is (S)-methylone, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the (S)- methylone.

In some preferred embodiments, psychedelic is (S)-methylone, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of (S)-methylone.

In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of N-ethyl-3,4-methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the N-ethyl-3,4-methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the N-ethyl-3,4-m ethylenedi oxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the N-ethyl-3,4-methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the N-ethyl-3,4-methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the N-ethyl-3,4-m ethylenedi oxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the N-ethyl-3,4-methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the N-ethyl-3,4-m ethylenedi oxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the N-ethyl-3,4-methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the N-ethyl-3,4- methylenedioxyamphetamine (MDEA). In some embodiments, the psychedelic is N-ethyl-3,4- methylenedioxyamphetamine (MDEA), wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the N-ethyl-3,4-methylenedioxyamphetamine (MDEA).

In some preferred embodiments, psychedelic is N-ethyl-3,4-methylenedioxyamphetamine (MDEA), wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of N-ethyl-3,4-m ethylenedi oxyamphetamine (MDEA).

In some embodiments, the psychedelic is (S)-N-ethyl-3,4-methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of (S)-N-ethyl-3,4-methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4-methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the (S)-N- ethyl-3,4-methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4-methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl- 3, 4-m ethylenedi oxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the (S)-N-ethyl-3,4-methylenedioxyamphetamine (S- MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the (S)-N-ethyl-3, 4-m ethylenedi oxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4-methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the (S)-N- ethyl-3,4-methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4-methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the (S)-N- ethyl-3,4-methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4-methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the (S)-N- ethyl-3,4-methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4-methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-

3, 4-m ethylenedi oxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-

3, 4-m ethylenedi oxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the (S)-N-ethyl-3, 4-m ethylenedi oxyamphetamine (S- MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-

3, 4-m ethylenedi oxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the (S)-N-ethyl-3, 4-m ethylenedi oxyamphetamine (S- MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-

3, 4-m ethylenedi oxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the (S)-N-ethyl-3,4-methylenedioxyamphetamine (S- MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-

3, 4-m ethylenedi oxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the (S)-N-ethyl-3, 4-m ethylenedi oxyamphetamine (S- MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-

3, 4-m ethylenedi oxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the (S)-N-ethyl-3, 4-m ethylenedi oxyamphetamine (S-

MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA). In some embodiments, the psychedelic is (S)-N-ethyl-

3, 4-m ethylenedi oxyamphetamine (S-MDEA), wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the (S)-N-ethyl-3, 4-m ethylenedi oxyamphetamine (S-

MDEA).

In some preferred embodiments, psychedelic is (S)-N-ethyl-3,4- methylenedioxyamphetamine (S-MDEA), wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of (S)-N-ethyl-3,4- methylenedi oxyamphetamine (S-MDEA).

In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the N-ethyl-2-(5-fluoro- lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5- fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the N-ethyl- 2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the N-ethyl-2- (5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the N-ethyl-2- (5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the N-ethyl- 2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the N-ethyl-2- (5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the N-ethyl- 2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the N-ethyl-2- (5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan- 1 -amine.

In some preferred embodiments, psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan- 1 -amine.

In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi- glutarate, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi- glutarate, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi- glutarate, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi- glutarate, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi- glutarate, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the 4-OH-DiPT hemi- glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the 4-OH-DiPT hemi- glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi- glutarate, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the 4-OH-DiPT hemi- glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the 4-OH-DiPT hemi- glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi- glutarate, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the 4-OH-DiPT hemi- glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the 4-OH-DiPT hemi- glutarate.

In some preferred embodiments, psychedelic is 4-OH-DiPT hemi-glutarate, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 4-OH-DiPT hemi-glutarate.

In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6- dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is

5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is

5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is

5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy- 2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy- 2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy- 2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some preferred embodiments, psychedelic is 5,6-dimethoxy-2-aminoindane, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5,6-dimethoxy-2-aminoindane.

In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5- methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5- methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5- methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5- methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the 5-methoxy-2-aminoindane.

In some preferred embodiments, psychedelic is 5 -methoxy -2-aminoindane, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-methoxy-2-aminoindane.

In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2- Br-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the 2-Br-LSD.

In some preferred embodiments, psychedelic is 2-Br-LSD, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 2-Br-LSD.

In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the MDAI.

In some preferred embodiments, psychedelic is MDAI, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of MDAI.

In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the MDA.

In some preferred embodiments, psychedelic is MDA, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of MDA.

In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the R-MDA. In some embodiments, the psychedelic is R- MDA, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the R- MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the R-MDA.

In some preferred embodiments, psychedelic is R-MDA, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of R-MDA.

In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 15 minutes prior to the administration or release of S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 30 minutes prior to the S-MDA. In some embodiments, the psychedelic is S- MDA, wherein the ketanserin form is administered to pretreat at least 60 minutes prior to the S- MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 90 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 120 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 150 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat between about 15 minutes and about 150 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat between about 30 minutes and about 180 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 180 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 210 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 210 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 240 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 240 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 270 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 270 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 300 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 300 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 330 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 330 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat between about 60 minutes and about 360 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form is administered to pretreat at least 360 minutes prior to the S-MDA.

In some preferred embodiments, psychedelic is S-MDA, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of S-MDA. In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is psilocybin, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, from about 30 mg to about 50 mg, or about 40 mg and psilocybin is administered in between from about 10 mg to about 50 mg, or from about 25 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is O-acetyl-psilocin (4- Acetoxy-DMT). In such embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered in an amount of from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 4- Acetoxy-DMT is administered in an amount between about 5 mg to about 50 mg, or about 10 mg to about 25 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is LSD, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is 2-Br-LSD, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 2-Br-LSD is administered in from about 10 micrograms to 1.0 mg or about 1.8 mg or about 30 micrograms per kg or about 0.1 mg to about 50 mg or about 1 mg to about 20 mg or about 20 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is ALD-52, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and ALD-52 is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is 1P-LSD, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 1P-LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is DMT, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and DMT is administered in an amount between from about 1 mg and about 60 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is 5-MeO-DMT, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-MeO-DMT is administered in an amount between from about 1 mg and about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is mescaline, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and mescaline is administered in an amount between from about 50 mg and about 800 mg, or between from about 200 mg and 500 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is ibogaine, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and ibogaine is administered between from about 50 mg and about 1,000 mg, or between from about 500 mg and 800 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is 2C-B, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 2C-B is administered in an amount between from about 1 mg and 40 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is MDMA, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and MDMA is administered between from about 50 mg and about 200 mg, or between from about 80 mg and 120 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is R-MDMA, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and R-MDMA is administered between from about 50 mg and about 200 mg, or between from about 80 mg and 120 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is S-MDMA, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and S-MDMA is administered between from about 50 mg and about 200 mg, or between from about 80 mg and 120 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is MDEA, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and MDEA is administered in about 10 mg to about 300 mg or about 100 mg to about 180 mg or about 120 mg or about 150 mg or about 160 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is S-MDEA, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and S-MDEA is administered in about 10 mg to about 300 mg or about 100 mg to about 180 mg or about 120 mg or about 150 mg or about 160 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is MBDB, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and MBDB is administered in about 10 mg to about 500 mg or about 150 mg to about 250 mg or about 180 mg or about 210 mg or about 250 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is MDAI, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and MDAI is administered between from about 40 mg to about 300 mg or about 60 mg to about 180 mg or about 60 mg or about 80 mg or about 100 mg or about 180 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is methylone, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and methylone is administered in about lOmg to about 500mg or about lOOmg to about 250mg or about 120mg or about 150mg or about 180mg or about 250mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is S-methylone, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and S-methylone is administered in about lOmg to about 500mg or about lOOmg to about 250mg or about 120mg or about 150mg or about 180mg or about 250mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is R-methylone, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and R-methylone is administered in about lOmg to about 500mg or about lOOmg to about 250mg or about 120mg or about 150mg or about 180mg or about 250mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is N-ethyl-2-(5-fhioro-lH- indol-3-yl)-N-methylethan-l -amine, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and N-ethyl-2-(5-fluoro-lH- indol-3-yl)-N-methylethan-l-amine is administered from about 100 ug to 100 mg, or from Img to 20 mg, or from 15 to 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is 4-OH-DiPT hemiglutarate, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 4-OH-DiPT hemi -glutarate is administered in about 1 mg to about 50 mg, or about 3mg to about lOmg, 15mg, 20mg, 25mg, or 30mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5,6-dimethoxy-2-aminoindane is administered in about 20 mg to about 300 mg or about 60 mg to about 180 mg or about 160 mg to about 300 mg or about 1.6 mg per kg to about 4.8 mg per kg or about 99.2 mg to about 297.6 mg. In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is 5-methoxy-2-aminoindane, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5 -methoxy -2-aminoindane is administered in about 20 mg to about 300 mg or about 60 mg to about 180 mg or about 160 mg to about 300 mg or about 1.6 mg per kg to about 4.8 mg per kg or about 99.2 mg to about 297.6 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is DOM, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and DOM is administered between about 0.5 mg and about 15 mg, or about 5 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is MDA, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and MDA is administered in about 10 mg to about 250 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 75 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 165 mg, about 180 mg, or about 200 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is R-MDA, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and R-MDA is administered in about 10 mg to about 250 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 75 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 165 mg, about 180 mg, or about 200 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is S-MDA, wherein the ketanserin form is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and S-MDA is administered in about 10 mg to about 250 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 75 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 165 mg, about 180 mg, or about 200 mg. In certain embodiments, such as those described above a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is co-administered with a psychedelic in the same or in separate compositions. In one embodiment, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered prior to the psychedelic. In one embodiment, the psychedelic is administered in a modified release formulation such that the subject is effectively pretreated with ketanserin prior to release of an effective amount of the psychedelic. In some embodiments ketanserin is part of a single fixed dose formulation that releases ketanserin first followed by psychedelic on two different release profiles. In another embodiment the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered first as a single dosage and after a length of time, the psychedelic is administered as a second dosage separate from the first dosage. Thus, in some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, described is administered or released from a composition provided herein prior to the administration and/or release of the psychedelic. This allows pretreatment to attenuate activation of the serotonin receptor by the psychedelic. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered or released from the composition provided herein to pretreat a subject at least about 30 minutes to about 360 minutes prior to administration to a subject or release of the psychedelic from a modified release formulation, such as from about 30 minutes to about 270 minutes prior, or from about 45 minutes to about 240 minutes, such as from about 60 minutes to about 180 minutes prior. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, described herein attenuates the activation of the serotonin receptor when the ketanserin is administered or released from the composition provided herein to pretreat at most about 3 hours prior to administration or release of the psychedelic. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, described herein attenuates the activation of the serotonin receptor when the ketanserin is administered or released from the composition provided herein to pretreat the subject at most about 1.5 hours prior to the release of the psychedelic. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, described herein attenuates the activation of the serotonin receptor when the ketanserin is administered or released from the composition provided herein to pretreat the subject at least about 45 minutes prior to at most about 3 hours prior, such as about 1.5 hours prior to the release of the psychedelic. In some embodiments, the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat at about or most about 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.25 hours, 1.5 hours, 2 hours, or 3 hours prior to the release of the psychedelic. In some embodiments, the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat at most about 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, or more than 9 hours prior to the release of the psychedelic. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, effectively attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat in a range of about 5 minutes to about 3 hours, about 10 minutes to about 3 hours, about 20 minutes to about 3 hours, such as from about 30 minutes to about 3 hours, from about 40 minutes to about 3 hours, about 50 minutes to about 3 hours, about 1 hour to about 3 hours, about 5 minutes to about 2 hours, about 10 minutes to about 2 hours, about 20 minutes to about 2 hours, about 30 minutes to about 2 hours, about 40 minutes to about 2 hours, about 50 minutes to about 2 hours, about 1 hour to about 2 hours, about 5 minutes to about 1 hour, about 10 minutes to about 1 hour, about 20 minutes to about 1 hour, about 30 minutes to about 1 hour, about 40 minutes to about 1 hour, or about 50 minutes to about 1 hour prior to the release of the psychedelic.

In a preferred embodiment, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered at about 1 hour to about 3 hours prior to the administration of the psychedelic.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of psilocybin.

In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the 4-Acetoxy- DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4- Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the 4-Acetoxy- DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the 4-Acetoxy- DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the 4-Acetoxy- DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the 4-Acetoxy- DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the 4-Acetoxy- DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the 4-Acetoxy- DMT.

In some preferred embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 4-Acetoxy-DMT.

In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of LSD.

In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the 2- Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the 2- Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the 2- Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the 2- Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the 2- Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the 2-Br-LSD. In some preferred embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 2-Br-LSD.

In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the ALD-52.

In some preferred embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of ALD-52.

In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the 1P-LSD.

In some preferred embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 1P-LSD.

In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the mescaline.

In some preferred embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of mescaline.

In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the DMT.

In some preferred embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DMT.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of 5- MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5- MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the ibogaine.

In some preferred embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of ibogaine.

In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the 2C- B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the 2C-B.

In some preferred embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 2C-B.

In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the MDMA.

In some preferred embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of MDMA.

In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R- MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R- MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the R-MDMA.

In some preferred embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of R-MDMA.

In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the S- MDMA.

In some preferred embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of S-MDMA.

In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the MDEA.

In some preferred embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of MDEA.

In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the S-MDEA.

In some preferred embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of S-MDEA.

In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the MBDB.

In some preferred embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of MBDB.

In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the MDAI.

In some preferred embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of MDAI.

In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the methylone.

In some preferred embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the R-methylone. In some embodiments, the psychedelic is R- methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the R-methylone. In some preferred embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of R-methylone.

In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the S-methylone. In some embodiments, the psychedelic is S- methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the S-methylone.

In some preferred embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of S-methylone.

In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the N-ethyl-2-(5- fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l -amine.

In some preferred embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)- N-methylethan-1 -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of N-ethyl-2-(5-fluoro-lH- indol-3 -yl)-N-methylethan- 1 -amine.

In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4- OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the 4- OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the 4- OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the 4- OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the 4- OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the 4- OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the 4- OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the 4- OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the 4-OH-DiPT hemi-glutarate.

In some preferred embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 4-OH-DiPT hemi-glutarate.

In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6- dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the 5,6-dimethoxy-2- aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6- dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the 5,6-dimethoxy-2- aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6- dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the 5,6-dimethoxy-2- aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the 5,6-dimethoxy-2-aminoindane.

In some preferred embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5,6-dimethoxy-2-aminoindane.

In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5 -methoxy -2-aminoindane. In some embodiments, the psychedelic is 5 -methoxy -2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-methoxy -2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the 5-methoxy -2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the 5- methoxy-2-aminoindane. In some preferred embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-methoxy-2-aminoindane.

In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the DOM.

In some preferred embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM.

In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the MDA.

In some preferred embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of MDA.

In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the R-MDA.

In some preferred embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of R-MDA.

In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 15 minutes prior to the administration or release of S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 30 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 60 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 90 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 120 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 150 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 15 minutes and about 150 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 30 minutes and about 180 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 180 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 210 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 210 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 240 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 240 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 270 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 270 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 300 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 300 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 330 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat at least 330 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 360 minutes prior to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to pretreat at least 360 minutes prior to the S-MDA.

In some preferred embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of S-MDA.

In certain embodiments, such as those described above a ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is co-administered with a psychedelic in the same or in separate compositions. In one embodiment, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered after the psychedelic. In one embodiment, the psychedelic is administered in a modified release formulation such that the subject is effectively post-treated with ketanserin after release of an effective amount of the psychedelic. In some embodiments ketanserin is part of a single fixed dose formulation that releases psychedelic first followed by ketanserin on two different release profiles. In another embodiment the psychedelic is administered first as a single dosage and after a length of time, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered as a second dosage separate from the first dosage. Thus, in some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, described is administered or released from a composition provided herein after the administration and/or release of the psychedelic. This allows post-treatment to attenuate activation of the serotonin receptor by the psychedelic. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered or released from the composition provided herein to post-treat a subject at least about 30 minutes to about 360 minutes post to administration to a subject or release of the psychedelic from a modified release formulation, such as from about 30 minutes to about 270 minutes post, or from about 45 minutes to about 240 minutes, such as from about 60 minutes to about 180 minutes post. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, described herein attenuates the activation of the serotonin receptor when the ketanserin is administered or released from the composition provided herein to post-treat at most about 3 hours post to administration or release of the psychedelic. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, described herein attenuates the activation of the serotonin receptor when the ketanserin is administered or released from the composition provided herein to post-treat the subject at most about 1.5 hours post to the release of the psychedelic. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, described herein attenuates the activation of the serotonin receptor when the ketanserin is administered or released from the composition provided herein to post-treat the subject at least about 45 minutes post to at most about 3 hours post, such as about 1.5 hours post to the release of the psychedelic. In some embodiments, the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to post-treat at about or most about 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.25 hours, 1.5 hours, 2 hours, or 3 hours post to the release of the psychedelic. In some embodiments, the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to post-treat at most about 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, or more than 9 hours post to the release of the psychedelic. In some embodiments, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, effectively attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to post-treat in a range of about 5 minutes to about 3 hours, about 10 minutes to about 3 hours, about 20 minutes to about 3 hours, such as from about 30 minutes to about 3 hours, from about 40 minutes to about 3 hours, about 50 minutes to about 3 hours, about 1 hour to about 3 hours, about 5 minutes to about 2 hours, about 10 minutes to about 2 hours, about 20 minutes to about 2 hours, about 30 minutes to about 2 hours, about 40 minutes to about 2 hours, about 50 minutes to about 2 hours, about 1 hour to about 2 hours, about 5 minutes to about 1 hour, about 10 minutes to about 1 hour, about 20 minutes to about 1 hour, about 30 minutes to about 1 hour, about 40 minutes to about 1 hour, or about 50 minutes to about 1 hour post to the release of the psychedelic. In a preferred embodiment, the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered at about 1 hour to about 3 hours post to the administration of the psychedelic.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of psilocybin.

In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the 4-Acetoxy- DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the 4- Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the 4- Acetoxy -DMT. In some embodiments, the psychedelic is 4-Acetoxy- DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the 4- Acetoxy -DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4- Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy- DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4- Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4- Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4- Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4- Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the 4-Acetoxy-DMT. In some embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the 4-Acetoxy-DMT.

In some preferred embodiments, the psychedelic is 4-Acetoxy-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 4-Acetoxy-DMT.

In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of LSD.

In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the 2- Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the 2- Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the 2-Br-LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the 2-Br- LSD. In some embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the 2-Br-LSD.

In some preferred embodiments, the psychedelic is 2-Br-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 2-Br-LSD.

In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the ALD-52. In some embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the ALD-52.

In some preferred embodiments, the psychedelic is ALD-52, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of ALD-52.

In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the 1P-LSD. In some embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the 1P-LSD.

In some preferred embodiments, the psychedelic is 1P-LSD, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 1P-LSD.

In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the mescaline. In some embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the mescaline.

In some preferred embodiments, the psychedelic is mescaline, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of mescaline.

In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the DMT. In some embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the DMT.

In some preferred embodiments, the psychedelic is DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of DMT.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of 5- MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the 5- MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the ibogaine. In some embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the ibogaine.

In some preferred embodiments, the psychedelic is ibogaine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of ibogaine.

In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the 2C-B. In some embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the 2C-B.

In some preferred embodiments, the psychedelic is 2C-B, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 2C-B. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the MDMA. In some embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the MDMA.

In some preferred embodiments, the psychedelic is MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of MDMA.

In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the R-MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the R- MDMA. In some embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the R-MDMA.

In some preferred embodiments, the psychedelic is R-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of R-MDMA.

In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the S-MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the S- MDMA. In some embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the S-MDMA.

In some preferred embodiments, the psychedelic is S-MDMA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of S-MDMA.

In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the MDEA. In some embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the MDEA.

In some preferred embodiments, the psychedelic is MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of MDEA.

In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the S-MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the S- MDEA. In some embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the S-MDEA.

In some preferred embodiments, the psychedelic is S-MDEA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of S-MDEA.

In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the MBDB. In some embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the MBDB.

In some preferred embodiments, the psychedelic is MBDB, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of MBDB.

In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the MDAI. In some embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the MDAI.

In some preferred embodiments, the psychedelic is MDAI, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of MDAI.

In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the methylone. In some embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the methylone.

In some preferred embodiments, the psychedelic is methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of methylone.

In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the R-methylone. In some embodiments, the psychedelic is R- methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the R-methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the R- methylone. In some embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the R-methylone.

In some preferred embodiments, the psychedelic is R-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of R-methylone.

In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the S-methylone. In some embodiments, the psychedelic is S- methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the S-methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the S- methylone. In some embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the S-methylone.

In some preferred embodiments, the psychedelic is S-methylone, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of S-methylone.

In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the N-ethyl-2-(5- fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3- yl)-N-methylethan-l -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the N-ethyl-2-(5-fhioro-lH-indol-3-yl)-N-methylethan-l- amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N- methylethan-1 -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l- amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fhioro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine. In some embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l-amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the N- ethyl-2-(5-fluoro-lH-indol-3-yl)-N-methylethan-l -amine.

In some preferred embodiments, the psychedelic is N-ethyl-2-(5-fluoro-lH-indol-3-yl)- N-methylethan-1 -amine, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of N-ethyl-2-(5-fluoro-lH- indol-3 -yl)-N-methylethan- 1 -amine.

In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH- DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH- DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH- DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH- DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH- DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the 4- OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the 4- OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the 4- OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the 4- OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the 4-OH-DiPT hemi -glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the 4- OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the 4- OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the 4-OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the 4- OH-DiPT hemi-glutarate. In some embodiments, the psychedelic is 4-OH-DiPT hemi-glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the 4- OH-DiPT hemi-glutarate. In some preferred embodiments, the psychedelic is 4-OH-DiPT hemi -glutarate, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 4-OH-DiPT hemi -glutarate.

In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6- dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the 5,6-dimethoxy-2- aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6- dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the 5,6-dimethoxy-2- aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6- dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the 5,6-dimethoxy-2- aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the 5,6-dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the 5,6- dimethoxy-2-aminoindane. In some embodiments, the psychedelic is 5,6-dimethoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the 5,6-dimethoxy-2-aminoindane.

In some preferred embodiments, the psychedelic is 5,6-dimethoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5,6-dimethoxy-2-aminoindane.

In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2- aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5 -methoxy -2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the 5-methoxy -2-aminoindane. In some embodiments, the psychedelic is 5 -methoxy -2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the 5-methoxy -2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5 -methoxy -2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5 -methoxy -2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the 5-methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the 5- methoxy-2-aminoindane. In some embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74- 76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the 5- methoxy-2-aminoindane.

In some preferred embodiments, the psychedelic is 5-methoxy-2-aminoindane, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5-methoxy-2-aminoindane.

In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the DOM. In some embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the DOM.

In some preferred embodiments, the psychedelic is DOM, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of DOM.

In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the MDA. In some embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the MDA.

In some preferred embodiments, the psychedelic is MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of MDA.

In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the R-MDA. In some embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the R-MDA.

In some preferred embodiments, the psychedelic is R-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of R-MDA.

In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 15 minutes post to the administration or release of S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 30 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 60 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 90 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 120 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 150 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 15 minutes and about 150 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 30 minutes and about 180 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 180 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 210 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 210 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 240 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 240 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 270 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 270 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 300 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 300 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 330 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat at least 330 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 360 minutes post to the S-MDA. In some embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106- 110, 140, 157, or 178, is administered to post-treat at least 360 minutes post to the S-MDA.

In some preferred embodiments, the psychedelic is S-MDA, wherein the ketanserin form disclosed herein, including those described in any one of Tables 74-76, 83, 106-110, 140, 157, or 178, is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of S-MDA. In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin free form Pattern A is psilocybin, wherein the ketanserin free form Pattern A is administered in from about 10 mg to about 80 mg, from about 30 mg to about 50 mg, or about 40 mg and psilocybin is administered in between from about 10 mg to about 50 mg, or from about 25 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin free form Pattern A is LSD, wherein the ketanserin free form Pattern A is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin free form Pattern A is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-MeO-DMT is administered in an amount between from about 1 mg and about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-malate salt Pattern A is psilocybin, wherein the ketanserin L- malate salt Pattern A is administered in from about 10 mg to about 80 mg, from about 30 mg to about 50 mg, or about 40 mg and psilocybin is administered in between from about 10 mg to about 50 mg, or from about 25 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-malate salt Pattern A is LSD, wherein the ketanserin L-malate salt Pattern A is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-malate salt Pattern A is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-MeO-DMT is administered in an amount between from about 1 mg and about 30 mg. In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin succinate salt Pattern A is psilocybin, wherein the ketanserin succinate salt Pattern A is administered in from about 10 mg to about 80 mg, from about 30 mg to about 50 mg, or about 40 mg and psilocybin is administered in between from about 10 mg to about 50 mg, or from about 25 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin succinate salt Pattern A is LSD, wherein the ketanserin succinate salt Pattern A is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin succinate salt Pattern A is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-MeO-DMT is administered in an amount between from about 1 mg and about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin succinate salt Pattern H is psilocybin, wherein the ketanserin succinate salt Pattern H is administered in from about 10 mg to about 80 mg, from about 30 mg to about 50 mg, or about 40 mg and psilocybin is administered in between from about 10 mg to about 50 mg, or from about 25 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin succinate salt Pattern H is LSD, wherein the ketanserin succinate salt Pattern H is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin succinate salt Pattern H is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-MeO-DMT is administered in an amount between from about 1 mg and about 30 mg. In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-tartrate salt Pattern A is psilocybin, wherein the ketanserin L- tartrate salt Pattern A is administered in from about 10 mg to about 80 mg, from about 30 mg to about 50 mg, or about 40 mg and psilocybin is administered in between from about 10 mg to about 50 mg, or from about 25 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-tartrate salt Pattern A is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-tartrate salt Pattern A is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-MeO-DMT is administered in an amount between from about 1 mg and about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-tartrate salt Pattern L is psilocybin, wherein the ketanserin L- tartrate salt Pattern L is administered in from about 10 mg to about 80 mg, from about 30 mg to about 50 mg, or about 40 mg and psilocybin is administered in between from about 10 mg to about 50 mg, or from about 25 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-tartrate salt Pattern L is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-tartrate salt Pattern L is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-MeO-DMT is administered in an amount between from about 1 mg and about 30 mg. In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-tartrate salt Pattern Q is psilocybin, wherein the ketanserin L- tartrate salt Pattern Q is administered in from about 10 mg to about 80 mg, from about 30 mg to about 50 mg, or about 40 mg and psilocybin is administered in between from about 10 mg to about 50 mg, or from about 25 mg to about 30 mg.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-tartrate salt Pattern Q is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and LSD is administered in an amount between from about 1 microgram to about 400 micrograms, or from about 50 micrograms to about 200 micrograms.

In some embodiments of the methods for treating diseases described herein, the psychedelic used in combination with ketanserin L-tartrate salt Pattern Q is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered in from about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and 5-MeO-DMT is administered in an amount between from about 1 mg and about 30 mg.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 30 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 60 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 90 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 120 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat at least 360 minutes prior to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 30 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 60 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 90 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 120 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat at least 360 minutes prior to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 30 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 60 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 90 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 120 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5- MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5- MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5- MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5- MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5- MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5- MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5- MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat at least 360 minutes prior to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 15 minutes post to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 30 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 60 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to posttreat at least 90 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 120 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat at least 360 minutes post to the psilocybin. In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 15 minutes post to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 30 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 60 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 90 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 120 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat at least 360 minutes post to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 15 minutes post to the administration or release of 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 30 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 60 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 90 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 120 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 180 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 210 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat at least 360 minutes post to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin free form Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- malate salt Pattern A is administered to pretreat at least 30 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 60 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 90 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 120 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- malate salt Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 360 minutes prior to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin L- malate salt Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 30 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 60 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 90 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 120 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 360 minutes prior to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 30 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 60 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 90 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 120 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat at least 360 minutes prior to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 15 minutes post to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- malate salt Pattern A is administered to post-treat at least 30 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 60 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to posttreat at least 90 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 120 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 360 minutes post to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin L- malate salt Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 15 minutes post to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 30 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 60 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 90 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 120 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 360 minutes post to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of LSD. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 15 minutes post to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 30 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 60 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 90 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 120 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 180 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 210 minutes post to the 5- MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L- malate salt Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat at least 360 minutes post to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-malate salt Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 30 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 60 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 90 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 120 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 360 minutes prior to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 30 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 60 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 90 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 120 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 360 minutes prior to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 30 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 60 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 90 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 120 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat at least 360 minutes prior to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 15 minutes post to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 30 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 60 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to posttreat at least 90 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 120 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 360 minutes post to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 15 minutes post to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 30 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 60 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 90 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 120 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 360 minutes post to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 15 minutes post to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 30 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 60 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 90 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 120 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 180 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 210 minutes post to the 5- MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat at least 360 minutes post to the 5-MeO-DMT. In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 15 minutes prior to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 30 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 60 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 90 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 120 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 15 minutes and about 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 30 minutes and about 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 360 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 360 minutes prior to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 15 minutes prior to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 30 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 60 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 90 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 120 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 15 minutes and about 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 30 minutes and about 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 360 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 360 minutes prior to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 15 minutes prior to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 30 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 60 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 90 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 120 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat at least 360 minutes prior to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 15 minutes post to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 30 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 60 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to posttreat at least 90 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 120 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 15 minutes and about 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 30 minutes and about 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 360 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 360 minutes post to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 15 minutes post to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 30 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 60 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 90 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 120 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 15 minutes and about 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 30 minutes and about 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 360 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 360 minutes post to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 15 minutes post to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 30 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 60 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 90 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 120 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 15 minutes and about 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 30 minutes and about 180 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 180 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 210 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 210 minutes post to the 5- MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 360 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat at least 360 minutes post to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin succinate salt Pattern H is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern A is administered to pretreat at least 30 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 60 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 90 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 120 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 360 minutes prior to the psilocybin. In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 30 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 60 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 90 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 120 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 360 minutes prior to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin L- tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 15 minutes prior to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 30 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 60 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 90 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 120 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat at least 360 minutes prior to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 15 minutes post to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern A is administered to post-treat at least 30 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 60 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 90 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 120 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 360 minutes post to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 15 minutes post to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 30 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 60 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 90 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 120 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 360 minutes post to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin L- tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 15 minutes post to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 30 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 60 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 90 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 120 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 15 minutes and about 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 30 minutes and about 180 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 180 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 210 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 210 minutes post to the 5- MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L- tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 360 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat at least 360 minutes post to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern A is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 15 minutes prior to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern L is administered to pretreat at least 30 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 60 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 90 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 120 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern L is administered to pretreat between about 15 minutes and about 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 30 minutes and about 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 360 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 360 minutes prior to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 15 minutes prior to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 30 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 60 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 90 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 120 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 15 minutes and about 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 30 minutes and about 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 360 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 360 minutes prior to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin L- tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of LSD. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 15 minutes prior to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 30 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 60 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 90 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 120 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat at least 360 minutes prior to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 15 minutes post to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern L is administered to post-treat at least 30 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 60 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to posttreat at least 90 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 120 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 15 minutes and about 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 30 minutes and about 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 360 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 360 minutes post to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 15 minutes post to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 30 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 60 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 90 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 120 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 15 minutes and about 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 30 minutes and about 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 360 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 360 minutes post to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin L- tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 15 minutes post to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 30 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 60 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 90 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 120 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 15 minutes and about 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 30 minutes and about 180 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 180 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 210 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 210 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 240 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 270 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 300 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 330 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 360 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat at least 360 minutes post to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern L is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5-MeO-DMT.

In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 15 minutes prior to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern Q is administered to pretreat at least 30 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 60 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 90 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 120 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern Q is administered to pretreat between about 15 minutes and about 150 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 30 minutes and about 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 180 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 210 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 240 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 270 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 300 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 330 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 360 minutes prior to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 360 minutes prior to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 15 minutes prior to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 30 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 60 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 90 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 120 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 15 minutes and about 150 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 30 minutes and about 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 180 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 210 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 240 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 270 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 300 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 330 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 360 minutes prior to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 360 minutes prior to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin L- tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 15 minutes prior to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 30 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 60 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 90 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 120 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 15 minutes and about 150 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 30 minutes and about 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 180 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 210 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 240 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 270 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 300 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 330 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 360 minutes prior to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat at least 360 minutes prior to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of 5-MeO-DMT. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 15 minutes post to the administration or release of psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern Q is administered to post-treat at least 30 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 60 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 90 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 120 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 15 minutes and about 150 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 30 minutes and about 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 180 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 210 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 240 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 270 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 300 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 330 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 360 minutes post to the psilocybin. In some embodiments, the psychedelic is psilocybin, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 360 minutes post to the psilocybin.

In some preferred embodiments, the psychedelic is psilocybin, wherein the ketanserin L- tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of psilocybin.

In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 15 minutes post to the administration or release of LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 30 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 60 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 90 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 120 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 15 minutes and about 150 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 30 minutes and about 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 180 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 210 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 240 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 270 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 300 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 330 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 360 minutes post to the LSD. In some embodiments, the psychedelic is LSD, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 360 minutes post to the LSD.

In some preferred embodiments, the psychedelic is LSD, wherein the ketanserin L- tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of LSD.

In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 15 minutes post to the administration or release of 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 30 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 60 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 90 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 120 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 15 minutes and about 150 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 30 minutes and about 180 minutes post to the 5-MeO- DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 180 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 210 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 210 minutes post to the 5- MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L- tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 240 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 270 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 300 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO- DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 330 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 360 minutes post to the 5-MeO-DMT. In some embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat at least 360 minutes post to the 5-MeO-DMT.

In some preferred embodiments, the psychedelic is 5-MeO-DMT, wherein the ketanserin L-tartrate salt Pattern Q is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of 5-MeO-DMT.

Examples

Example 1: General methods and abbreviations:

• The following analytical techniques were used to characterize the solid form samples, as is known to those of skill in the art

Table 69: Analytical techniques

Example 2: Ketanserin Salt screening

Summary

• Ketanserin is a small molecule with 1 acidic pKa of 10.14 and 1 basic pKa of 7.42 according to measurement by titration method. Ketanserin free base form Pattern A was used in this salt screening study. The free base form Pattern A is an anhydrate. • Based on the pKa(s) of TR-06, 11 Class I acids and 4 Class II acids were selected as salt forming agents. Ethanol, acetonitrile and THF were used as screening solvents. 1.0 equivalent or 0.5 equivalents of selected counter ions were applied in the screening. Slurry equilibration was used as crystallization method. In total, about 57 salt screening experiments were conducted.

• According to the salt screening results, 19 salts and their polymorphs were identified, including a HC1 Pattern A, a HC1 Pattern B, a sulfate Pattern A, a L-tartrate Pattern A, a fumarate Pattern A, a fumarate Pattern B, a citrate Pattern A, a L-malate Pattern A, a maleate Pattern A, a maleate Pattern B, a succinate Pattern A, a p-Tosylate Pattern A, an esylate Pattern A, an esylate Pattern B, an esylate Pattern C, a mesylate Pattern A, a mesylate Pattern B, a besylate Pattern A, a besylate Pattern B. All these salt hits were further characterized by DSC, TGA, ^XH-NMR, KF and IC.

• Among these salts hits, the L-tartrate Pattern A, the L-malate Pattern A and the succinate Pattern A show good physicochemical characteristics including high crystallinity, high melting point, reasonable stoichiometry and good counter ion safety. Therefore, they were selected as salt candidates for scale-up and full evaluation in comparison with the free base form Pattern A in terms of stability, solubility and hygroscopicity.

Salt Candidates Evaluation

The following salt candidates were fully evaluated:

• free base form Pattern A, anhydrate

• L-tartrate Pattern A, hydrate

• L-malate Pattern A, anhydrate; and,

• succinate Pattern A anhydrate.

Chemial and Physicochemical Properties

Crystallinity and thermal properties

• The free base form Pattern A is an anhydrate of high crystallinity. DSC shows a melting Tonset of 235.1°C. Decomposition was observed upon melting. TGA shows 0.5% weight loss at 220°C. HPLC shows 99.1% chemical purity. ’H-NMR shows no residual solvent.

• L-tartrate Pattern A is a hydrate and is highly crystalline. DSC shows a dehydration peak from Tonset of 32.7°C, followed by a melting peak at Tonset of 140.1°C with an enthalpy of 43J/g. TGA shows a 3.2% weight loss at 130°C. HPLC shows 99.0% chemical purity. 'H-NMR shows a stoichiometry of 1 : 1.05 for the free form and L-tartaric acid, and 0.2% EtOH residue by weight. KF shows a water content of 4.1% by weight, equivalent to 0.9 water molecule.

• L-malate Pattern A is an anhydrate and is highly crystalline. DSC shows a melting peak at Tonset of 157.6°C and decomposition upon melting. TGA shows a 0.6% weight loss at 150°C. HPLC shows 98.9% chemical purity. ^XH-NMR shows a stoichiometry of 1 : 1.06 for the free form and L-malic acid, and no residual solvent.

• Succinate Pattern A is an anhydrate and is highly crystalline. DSC shows a melting peak at Tonset of 186.9°C and decomposition upon melting. TGA shows 0.6% weight loss at 150°C. HPLC shows 99.1% chemical purity. ^XH-NMR shows a stoichiometry of 1 :0.98 for the free form and succinic acid, and no residual solvent.

Initial Chemical Purity

• The free base form Pattern A, the L-tartrate Pattern A, the L-malate Pattern A, and the succinate Pattern A have chemical purity of 99.1%, 99.0%, 98.9%, and 99.1%, respectively.

All in all, the free base form Pattern A and the 3 salt candidates show good physicochemical characteristics, including high crystallinity, high melting point, reasonable stoichiometry and good stability. All the salts show solubility similar to that of the free form in test media except pH 4.5 buffer and FeSSIF-vl.

Approximate Solubility at 25 °C

Approximate solubility at 25°C was determined as follows: About 5 mg of ketanserin was weighed into a 2-mL glass vial and aliquots of 20 pL of each solvent were added to get a clear solution. The maximum volume of each solvent added was 1 mL. Approximate solubility at 25°C was determined by visual observation.

Based on the solubility results summarized below and the experience of one skilled in the art, ethanol, acetonitrile and THF were selected as screening solvents.

Table 71 Approximate solubility at 25°C

Counter ion selection

Ketanserin is a free base with pKa values of 7.42 and 10.14, accordingly 11 Class I acids and 4 Class II acids were selected as candidates to form salts with the free base (Table 72). Table 72: Counter ions used for salt screening

Screening experiments

Slurry equilibration

Using the selected acidic counter ions and solvents, slurry equilibration was applied as screening method. About 50 mg of ketanserin and 1.0 or 0.5 equiv. of counter ions were added to a screening solvent in a 2-mL glass vial. The resultant mixtures were stirred at 50°C for 2 hours and then at 25° C for 4 days. The suspensions obtained were filtered through a 0.45-pm nylon membrane filter by centrifugation at 14,000 rpm. Solids were analyzed by XRPD (Table 73) after being dried at 50°C under vacuum for 2 hours.

The screening results were summarized in Table 73. These salt hits were further characterized according by XRPD, DVS, ^TH NMR, TGA, DSC. The salts produced include those characterized by XRPD as illustrated in Figures 1 - 20.

Table 73: Slurry equilibration

Explanation “AF”: Amorphous form

Example 3: Characterization of salt hits

According to the salt screening results of Example 2, obtained salt hits were further characterized by DSC, DVS, TGA, 'H-NME IC, and KF (Karl Fischer). Based on the data obtained from these characterization techniques, L-tartrate, L-malate, maleate and succinate salts were prepared as follows:

Salt hits are summarized in the following Tables

Table 74. Characterization of Salt Summary

Explanation “//”: Not carried out. Table 75: Characterization of Salt Summary

Explanation Not carried out. Table 76: Characterization of Salt Summary

Explanation Not carried out. Scaled-up Preparation of Salt Candidates

L-tartrate Pattern A, L-malate Pattern A and succinate Pattern A were scaled up successfully. These scale-up batches are the same polymorphs as those of the screening samples. A new polymorph, maleate Pattern B was also scaled up.

Preparation of L-tartrate Pattern A

L-tartrate Pattern A was prepared using the procedure below.

500 mg of free base form Pattern A and 1.05 equiv. of L-tartaric acid were weighed into a 20 mL glass vial. 9 mL of ethanol and 0.45 mL water were added to the vial under stirring at 50°C. (suspension).

About 5 mg of L-tartrate Pattern A seeds was added to the above suspension.

After stirring at 50°C for 2 hours, the suspension was cooled to 25°C and agitation was maintained at 25°C for 6 days (suspension).

Solids were filtered through a 0.45-pm nylon membrane filter by centrifugation at 14,000 rpm and then dried at 50°C under vacuum for 2 hours.

483 mg of L-tartrate Pattern A was obtained as an off-white solid in 69% yield.

Preparation of L-malate Pattern A

L-malate Pattern A was prepared using the procedure below.

500 mg of free base form Pattern A and 1.05 equiv. of L-malic acid were weighed into a 20-mL glass vial. 9 mL of ACN was added to the vial under stirring at 50°C (suspension).

About 5 mg of L-malate Pattern A seeds was added to the above suspension.

After stirring at 50°C for 2 hours, the suspension was cooled to 25°C and agitation was maintained at 25°C for about 6 days (suspension).

Solids were filtered through a 0.45-pm nylon membrane filter by centrifugation at 14,000 rpm and then dried at 50°C under vacuum for about 2 hours.

500 mg of L-malate Pattern A was obtained as an off-white solid in 74% yield.

Preparation of maleate Pattern B

Maleate Pattern B was prepared using the procedure below. 500 mg of free base form Pattern A and 1.05 equiv. of maleic acid were weighed into a 20-mL glass vial. 8 mL of ACN was added into the vial under stirring at 50°C (suspension).

About 5 mg of maleate Pattern A was added into the above suspension.

Instead of maleate Pattern A, a new polymorph Pattern B (Figures 51 and 52 exhibiting a DSC and ¹HNMR) was obtained.

Preparation of succinate Pattern A

Succinate Pattern A was prepared using the procedure below.

500 mg of free base form Pattern A and 1.05 equiv. of succinic acid were weighed into a 20-mL glass vial. 8 mL of ACN was added to the vial under stirring at 50°C (suspension).

About 5 mg of succinate Pattern A seeds was added to the above suspension.

504 mg of succinate Pattern A was obtained as an off-white solid in 77% yield.

The chemical structure of the product, ketanserin succinate (anhydrate), is represented as

The form produced in this example, ketanserin succinate Pattern A, is an anhydrate of the monosuccinate salt. This form was obtained from most of solvent systems by equilibration experiments, including with MEK, 1,4-di oxane, THF/toluene, TFE/IPAc, TFE/MTBE, TFE/acetone as solvents. This form also can be obtained from fast evaporation, slow cooling, fast cooling, anti-solvent addition and vapor diffusion procedures. Succinate Pattern A is of high crystallinity. DSC shows a melting peak at Tonset of 191.4°C. Decomposition occurs upon melting. TGA shows about 1.6% weight loss at about 160°C. ¹HNMR shows the stoichiometry of ketanserin: succinic acid is 1: 1.1 with no detectable residual solvent. Based on competitive experiment results, the Pattern A polymorph form converted to Pattern H at 25°C and 5°C.

The material produced in this example was used as starting material for production of different forms of ketanserin, as described in Example 4. Further Characterization data of scaled-up salts is provided in Table 77.

Table 77: Characterization data of scaled-up salts

Bulk Stability Study

The free form and the 3 salt candidates were stored for 1 week at 25°C/92% RH in an open container, at 40°C/75% RH in an open container and at 60°C in a closed container. Samples after the stress were characterized by XRPD and HPLC, and inspected for color change. All these physical forms were physically and chemically stable under these conditions. Characterization details are included in Table 78.

Table 78: Bulk Stability Study

Explanation A: no change of color;

Solubility of Free base form Pattern A, L-tartrate Pattern A, L-malate Pattern A, and Succinate Pattern A 20 mg of free base form Pattern A, 28.8 mg of L-tartrate Pattern A, 26.8 mg of L-malate Pattern

A and 26.0 mg of succinate Pattern A were each accurately weighed into a 20-mL vial, to which was added 10 mL aqueous buffer. The salt amount used is equivalent to 20 mg anhydrous free form. These suspensions were stirred at 400 rpm at 37°C. Samples of these suspensions drawn at 2 hours and 24 hours, were centrifuged at 14,000 rpm for 5 min. The supernatants were analyzed by HPLC, and the solids (wet cakes) were characterized by XRPD (Table 79)

Table 79

• All the free form Pattern A and 3 salt candidates show pH-dependent solubility profiles. o In pH 1.2 buffer, the solubility is 0.64-1.37 mg/mL. o In pH 4.5 buffer, the free form shows ~0.5 mg/mL solubility, but the 3 salts show about 2 mg/mL solubility. o In pH 6.8 buffer, the free form and the salts show -0.02 mg/mL solubility. o In pure water, the 3 salts had higher solubility (1.6-1.9 mg/mL) - due to the lower pH (3.87-4.70) conferred by the weakly acidic salt on dissolution - than the free form (0.001 mg/mL; pH 7.24). o In SGF and FaSSIF-vl, similar solubility was observed for the free form and the salt candidates. In FeSSIF-vl, the 3 salts show -1.5 mg/mL solubility, which is higher than that of free form (-0.43 mg/mL).

• After the solubility test, residue solids were analyzed by XRPD. The free form and the 3 salts converted to a new HC1 salt (Pattern B) in pH 1.2 buffer. In the pH 1.2 buffer, the salts dissociated to give the free form, which formed a salt with the HC1 from the buffer. In other media (pH 6.8 phosphate buffer, FaSSIF-vl), the salts also dissociated to give the free form.

Hygroscopicity

• Hygroscopicity of the free base form Pattern A and the 3 salt candidates at 25°C was evaluated by dynamic vapor sorption (DVS) test.

• The free base form Pattern A is slightly hygroscopic. It absorbs 0.2% water from 40%RH to 90%RH at 25°C. After the DVS test, the sample was still the free base form Pattern A (XRPD).

• The L-tartrate Pattern A is hygroscopic, absorbing 2.4% water from 40%RH to 95%RH at 25°C. It undergoes dehydration below 40%RH, which shows reversibility of desorption and sorption. After the DVS test, the sample was still the L-tartrate Pattern A (XRPD).

• The L-malate Pattern A is slightly hygroscopic in below 70%RH, absorbing 2.0% water from 40%RH to 70%RH at 25°C. But it becomes very hygroscopic above 70%RH, absorbing 6.1% water from 70%RH to 95%RH. After the DVS test, the sample was still the L-malate Pattern A.

• The succinate Pattern A is slightly hygroscopic. It absorbs 0.7% water from 40%RH to 95%RH. After the DVS test, the sample was still the succinate Pattern A. Hygroscopicity data is contained in Tables 80 and 81

Table 80

Table 81

Example 4: Ketanserin Succinate Polymorph screening

The free base and salt forms of ketanserin were screened for different solid forms of each solid form, such as polymorphs, according to the following methods exemplified herein for the ketanserin succinate salt. In general, polymorphic behaviors of the succinate salt were investigated by equilibration, slow evaporation, fast evaporation, slow cooling, fast cooling, antisolvent addition and vapor diffusion experiments. Surprisingly, ketanserin succinate salt exhibits polymorphic behaviors not previously reported. In total, five forms were identified to be polymorphs or pseudo-polymorphs of the mono-succinate salt, including three anhydrates of mono-succinate salt, named as Pattern A, C and H, as well as two hydrates of the monosuccinate salt, named as Pattern D and F. In addition, three forms with a different stoichiometric ratio, named as Pattern B, E and G, were obtained.

The methods exemplified for the ketanserin succinate salt are applicable to other forms of ketanserin as is understood by those of skill in the art.

Summary

• Succinate Pattern A was used as starting material in the polymorph screening.

Polymorphic behaviors of ketanserin succinate salt were investigated by equilibration, slow evaporation, fast evaporation, slow cooling, fast cooling, antisolvent addition and vapor diffusion experiments. • Ketanserin succinate salt exhibits polymorphic behaviors. In total, 5 forms were identified to be polymorphs or pseudo-polymorphs of the mono-succinate salt, including: o 3 anhydrates of mono-succinate salt, called Pattern A, C and H o 2 hydrates of the mono-succinate salt, called Pattern D and F o Additionally, 3 patterns with non-stoichiometric ratios, called Pattern B, E and G, were also obtained.

• Succinate Pattern A is an anhydrate of ketanserin mono-succinate salt. It was the starting polymorphic form and obtained from most of solvent systems in equilibration experiments. Additionally, in MEK, 1,4-di oxane, THF/toluene, TFE/IPAc, TFE/MTBE, TFE/acetone as solvents, Pattern A was obtained in fast evaporation, slow cooling, fast cooling, anti-solvent addition and vapor diffusion experiments. Succinate Pattern A, is of high crystallinity. DSC shows a melting peak at Tonset of 191.4°C. Decomposition occurs upon melting. TGA shows a 1.6% weight loss at 160°C. 'H-NMR shows a 1 : 1.1 stoichiometry for ketanserin : succinic acid and no detectable residual solvent. In competitive equilibration experiments, the Pattern A converted into Pattern H at 25°C and 5°C.

• Succinate Pattern B is an anhydrate with a non-stoichiometric ratio (ketanserin free form : succinic acid=l :4.3), obtained from EtOH by fast evaporation. Succinate Pattern B is of high crystallinity. DSC shows a melting peak at Tonset of 107.7°C. Decomposition occurs upon melting. TGA shows a 2.4% weight loss at 100°C. ’H-NMR shows a ketanserin : succinic acid stoichiometric ratio of 1 :4.3, and no detectable residual solvent.

• Succinate Pattern C is an anhydrate of ketanserin mono-succinate salt, obtained from THF and EtOAc by fast evaporation. Succinate Pattern C is of high crystallinity. DSC shows a melting peak at Tonset of 182.7°C. Decomposition occurs upon melting. TGA shows a 0.5% weight loss at 100°C. 'H-NMR shows a stoichiometry of 1 : 1.1 for ketanserin : succinic acid, and no detectable residual solvent. Pattern C is a metastable form. In DVS studies, Pattern C is stable at relative humidity from 0%RH to 30%RH, but converted to Pattern F at relative humidities >30%RH at 25°C. In competitive equilibration experiments, Pattern C converted into Pattern H at 25°C and 5°C, and converted into Pattern A at 50°C. • Succinate Pattern D is a hydrate of ketanserin mono-succinate salt, obtained from some experiments in ACN, MTBE, THF, TFE/IPA and TFE by slow evaporation and fast evaporation. Pattern D is of high crystallinity. It contains 2.1 equivalents (7.0% by weight) of water (Karl Fischer). DSC shows a dehydration peak at Tonset of 39.9°C with an enthalpy of 59 J/g, an endothermic peak at Tonset of 112.4°C with an enthalpy of 14 J/g and an exothermic peak at Tonset of 128.1 °C with an enthalpy of 17 J/g. It melts with a Tonset of 183.5°C. Decomposition occurs upon melting. TGA shows a 4.2% weight loss at 113°C. ’H-NMR shows a 1 : 1.1 stoichiometric ratio for ketanserin : succinic acid, and no detectable residual solvent. Pattern D was not reproducible; repeated experiments to produce this pattern gave Pattern A with several extra peaks, suggesting the instability of the Pattern D polymorph.

• Succinate Pattern E is likely a hydrate of ketanserin hemi-succinate salt, obtained from TFE/MTBE by slow cooling. Succinate Pattern E is of high crystallinity. DSC shows dehydration peaks at Tonset of 30.7°C with an enthalpy of 35 J/g and Tonset of 87.0°C with an enthalpy of 38 J/g, and a melting peak at Tonset of 187°C. Decomposition occurs upon melting. TGA shows a 1.2% weight loss at 35°C, 7.9% weight loss from 35°C to 135°C. ’H-NMR shows a stoichiometry of 1 :0.6 for ketanserin : succinic acid, and no detectable residual solvent. There was insufficient material to determine water content (Karl Fischer). No hemi-succinate was obtained in previous salt screening study.

• Succinate Pattern F is a hydrate of ketanserin mono-succinate salt, obtained from THF by slow evaporation and fast evaporation. Pattern F is of high crystallinity. It contains 1.4 equivalents (4.7% by weight) of water (Karl Fischer). DSC shows a dehydration peak at Tonset of 35.7°C with an enthalpy of about 62 J/g, an endothermic peak at Tonset of 99.7°C with an enthalpy of 26J/g, and an exothermic peak at Tonset of 116.4°C with an enthalpy of 31 J/g, and melts at Tonset of 182.6°C. Decomposition occurs upon melting. TGA shows a 6.4% weight loss at 113°C. ’H-NMR shows a 1 : 1.1 stoichiometry for ketanserin : succinic acid, and no detectable residual solvent. After dehydration, it converted into a mixture of succinate Pattern A and succinate Pattern C at 90°C. From DVS experiments, Pattern F is stable at relative humidities >30%RH, but converted to Pattern C when relative humidity is <30%RH at 25 °C. • Succinate Pattern G is a dissociation product (ketanserin free form : succinic acid =

1 :0.2), obtained from DMSO/water by antisolvent addition. Succinate Pattern G is of medium crystallinity. 'H-NMR shows a 1 :0.2 stoichiometry for ketanserin : succinic acid, and no detectable residual solvent. No further investigation was conducted for Pattern G.

• Succinate Pattern H is an anhydrate of ketanserin mono-succinate salt, obtained from TFE/water mixtures in water activity experiments. Succinate Pattern H is of high crystallinity. DSC shows a melting peak at Tonset of 179.9°C. Decomposition occurs upon melting. TGA shows a 0.8% weight loss at 175°C. 'H-NMR shows a 1 :1.0 stoichiometry for ketanserin : succinic acid, and no detectable residual solvent. In competitive equilibration experiments, Pattern H converted into Pattern A at 50°C. Polymorphic interrelationships are summarized in Section 1.2 in this report.

Ketanserin free base form Pattern A was obtained in some screening experiments, suggesting the ease of succinate salt dissociation.

Interrelationship of polymorphs

• Relative stability of the anhydrates Patterns A, C and H was investigated in competitive equilibration experiments. Pattern A and Pattern H are enantiotropically related, they are stable at different temperatures, Pattern H converted to Pattern A at 50°C, Pattern A converted to Pattern H at 25°C and 5°C. So that they have a transition temperature between 25°C and 50°C. The results show that Pattern A is more stable at 50°C, and Pattern H is more stable at 25°C and 5°C.

• Relative stability of the anhydrate Pattern A and the hydrate Pattern F was investigated in water activity experiments. However, Pattern H was obtained in water, and a mixture of Pattern H and Pattern A was obtained in water activity 0.6 and 0.8 solvent mixtures, suggesting the lower stability of hydrate Pattern F even if water activity is high.

• Interconversion relationship between succinate salt hydrate Pattern F and anhydrates was investigated by variable temperature XRPD and DVS. Pattern F converted into a mixture of succinate salt anhydrate Pattern A and Pattern C after dehydration in variable temperature XRPD experiments. DVS experiments show that hydrate Pattern F is stable when relative humidity is >30%RH at 25°C. It starts to lose water when relative humidity decreases to 30%RH at 25°C, giving Pattern C. Formation of Pattern C and Pattern F is humidity-dependent.

Screening conditions of polymorphs and pseudo-polymorphs of ketanserin sulfate salt are summarized in Tables 82 and 83.

Table 82 Summary of screening conditions of polymorphs and pseudo-polymorphs of ketanserin succinate salt

Table 83 Summary of characterization of polymorphs and pseudo-polymorphs of ketanserin succinate salt

Explanation:

not carried out Approximate solubility at 25°C and 50°C was determined as follows:

Solubility at 25 °C: About 5mg of Succinate Pattern A was weighed to a 2mL glass vial.

20pL aliquots of each solvent were added to dissolve the drug substance at 25°C. About lOmg of Succinate Pattern A was weighed to a 2mL glass vial. 20pL aliquots of each solvent were added to dissolve the drug substance at 50°C.

Solubility at 50 °C: About 10 mg of succinate Pattern A was weighed into a 2-mL glass vial.

Aliquots (20 pL) of each solvent were added to dissolve the drug substance at 50°C. Vortex and sonication were applied to assist dissolution. Max. volume of each solvent added is 1 mL. Approximate solubility was determined by visual observation.

Table 84. Approximate solubility of ketanserin succinate at 25°C and 50°C

Equilibration with solvents at 25°C for 2 weeks

Based on approximate solubility results, about 40 - 80 mg of Succinate Pattern A was equilibrated in solvents at 25°C for 2 weeks with a stirring bar on a magnetic stirring plate at a rate of 400 rpm. Obtained suspension was filtered through a 0.45pm nylon membrane filter by centrifugation at 14,000 rpm. Solid parts (wet cakes) were investigated by XRPD.

Black material was obtained from some samples, which was confirmed to be a carried- over impurity from ketanserin free form.

Table 85: Equilibration with solvents at 25°C for 2 weeks

Explanation Not carried out

Water activity is calculated by UNIFAC method.

No comments

Equilibration with solvents at 50°C for 1 week Based on approximate solubility results, about 40-150mg of Succinate Pattern A was equilibrated in the solvents of Table 86 at 50°C for 1 week with a stirring bar on a magnetic stirring plate at a rate of 400 rpm. Obtained suspension was filtered through a 0.45pm nylon membrane filter by centrifugation at 14,000 rpm. Solid parts (wet cakes) were investigated by XRPD. For samples with different XRPD patterns, additional analysis was performed. Table 86: Equilibration with solvents at 50°C for 1 week

Explanation “//”: Not carried out

No comments.

Water activity is calculated by UNIFAC method. Equilibration under a temperature cycle

Based on approximate solubility results, about 40mg of Succinate Pattern A-was equilibrated in the solvents of Table 87 under a temperature cycle between 5°C to 50°C at a heating/cooling rate of 0.1°C /min for about 10 cycles. The equilibration was executed with a stirring bar on a magnetic stirring plate at a rate of 400 rpm. Obtained suspension was filtered through a 0.45pm nylon membrane filter by centrifugation at 14,000 rpm. Solid parts (wet cakes) were investigated by XRPD.

Table 87: Equilibration under a temperature cycle

Explanation “//”: Not carried out

No comments.

Water activity is calculated by UNIFAC method. Crystallization at room temperature by slow evaporation

Based on approximate solubility results, about 30mg of Succinate Pattern A-was dissolved in the solvents of Table 88. Obtained solutions were filtered through a 0.45pm nylon membrane filter by centrifugation at 14,000 rpm. Obtained clear solutions were slowly evaporated in ambient condition (about 25°C, 50%RH). Solid residues will be investigated by XRPD. For samples with different XRPD patterns, additional analysis including HPLC, DSC, TGA, ^XH-NMR and KF was performed.

Table 88: Crystallization at room temperature by slow evaporation

Crystallization at room temperature by fast evaporation

Based on approximate solubility results, about 30mg of Succinate Pattern A was dissolved in the solvents of Table 89. Obtained solutions were filtered through a 0.45pm nylon membrane filter by centrifugation at 14,000 rpm. Obtained clear solutions were fast evaporated at room temperature (about 25°C) under a dry nitrogen flow. Solid residues were investigated by XRPD. For samples with different XRPD patterns, additional analysis including HPLC, DSC, TGA, 'H-NMR, KF and HPLC was performed. The use of ethanol resulted in an XRPD of Pattern B; ethyl acetate in pattern C; and acetonitrile and MTBE both resulted in Pattern D.

Succinate Pattern B is an anhydrate with a different stoichiometric ratio (ketanserin: succinic acid=l :4.3). Succinate Pattern B was obtained from EtOH by the fast evaporation procedure described herein. Succinate Pattern B is of high crystallinity. DSC shows a melting peak at Tonset of 107.7°C. Decomposition occurs upon melting. TGA shows about 2.4% weight loss at about 100°C. ’H-NMR shows stoichiometry of ketanserin: succinic acid is 1 :4.3 and no detectable residual solvent.

Succinate Pattern C is an anhydrate of the mono-succinate salt. It was obtained as described above from THF and EA by fast evaporation. Succinate Pattern C is of high crystallinity. DSC shows a melting peak at Tonset of 182.7°C. Decomposition occurs upon melting. TGA shows about 0.5% weight loss at about 100°C. ¹HNMR shows that the stoichiometry of ketanserin: succinic acid is 1 :1.1 with no detectable residual solvent. Pattern C is a metastable form. From DVS result of Pattern F, the Pattern C is stable at relative humidity from 0%RH to 30%RH, and converted to Pattern F when relative humidity is higher than 30%RH at 25°C. Based on competitive experiment results, the Pattern C form converted to Pattern H at 25°C and 5°C, and converted to Pattern A at 50°C.

Succinate Pattern D is a hydrate of the ketanserin mono-succinate salt. It was obtained from ACN, MTBE, THF, TFE/IPA and TFE by slow evaporation and fast evaporation experiments. Pattern D is of high crystallinity. It contains about 2.1 equivalents (7.0% by weight) of water according to KF result. DSC shows a dehydration peak at Tonset of 39.9°C with an enthalpy of about 59J/g, an endothermic peak at Tonset of 112.4°C with an enthalpy of about 14J/g and an exothermic peak at Tonset of 128.1°C with an enthalpy of about 17J/g. Then it melts at Tonset of 183.5°C. Decomposition occurs upon melting. TGA shows about 4.2% weight loss at about 113°C. ¹HNMR shows that the stoichiometry of ketanserin: succinic acid is 1 : 1.1 with no detectable residual solvent.

Data from crystallization at room temperature by fast evaporation experiments is summarized in Table 89. Table 89. Crystallization at room temperature by fast evaporation

Crystallization from hot saturated solutions by slow cooling

Based on approximate solubility results, about 40mg of Succinate Pattern A was dissolved in the minimal amount of selected solvents at 50°C. Obtained solutions were filtered through a 0.45pm nylon membrane filter by syringe. Obtained clear solutions were cooled to 5°C at 0.1°C /min. Solid residues were investigated by XRPD. Notably the use of TFE/MTBE (1/1) resulted in formation of Pattern E. For samples with different XRPD patterns, additional analysis including HPLC, DSC, TGA and 'H-NMR were performed. Succinate Pattern E is a hydrate of hemi-succinate salt. As described above, Pattern E was obtained from TFE/MTBE by a slow cooling procedure. Succinate Pattern E is of high crystallinity. DSC shows dehydration peaks at Tonset of 30.7°C with an enthalpy of 35 J/g and Tonset of 87.0°C with an enthalpy of 38 J/g and then followed by a melting peak at Tonset of 187°C. Decomposition occurs upon melting. TGA shows about 1.2% weight loss at about 35°C, 7.9% weight loss from about 35°C to 135°C. ¹HNMR shows that the stoichiometry of ketanserin: succinic acid is 1 :0.6 with no detectable residual solvent. Data from crystallization from hot saturated solutions by slow cooling experiments is sumarized in Table 90.

Table 90. Crystallization from hot saturated solutions by slow cooling

Explanation Not carried out.

No comments.

Crystallization from hot saturated solutions by fast cooling Based on approximate solubility results, 40 mg of succinate Pattern A was dissolved in the minimal amount of selected solvents at 50°C. The resultant solutions were filtered through a 0.45- pm nylon syringe membrane filter, and the filtrates were put into a 0°C ice bath and agitated. Precipitates were collected by centrifugation filtration through a 0.45-pm nylon membrane filter at 14,000 rpm. The recovered solids (wet cakes) were analyzed by XRPD. For clear solutions obtained after fast cooling, anti-solvent was added.

Data from crystallization from hot saturated solutions by fast cooling experiments is summarized in Table 91.

Table 91: Crystallization from hot saturated solutions by fast cooling

Explanation “//”: Not carried out.

No comments.

Crystallization by addition of anti-solvent Based on approximate solubility results, 40-80mg of Succinate Pattern A was dissolved in the minimal amount of selected good solvents at ambient temperature (about 25°C). Then half of the solution was transferred to 8mL or 20mL glass vial with a stirring bar. The glass vial was placed on a magnetic stirring plate at a rate of 400 rpm. To each of these clear stirred (400 rpm) solutions, was added slowly 4-fold in volume of anti-solvent. Precipitates were collected by centrifugation filtration through a 0.45pm nylon membrane filter at 14,000 rpm. Solid parts (wet cakes) were investigated by XRPD. For samples with different XRPD patterns, 'H-NMR was performed. Notably, Pattern G was formed from the use of DMSO as the solvent and water as the anti-solvent.

Succinate Pattern G is a dissociation product (free form: succinic acid=l :0.2). As described above, Pattern G was obtained from DMSO/water by antisolvent addition experiment. Succinate Pattern G produced herein is of medium crystallinity. ¹HNMR shows stoichiometry of ketanserin: succinic acid is 1 :0.2 and no detectable residual solvent.

Clear solutions obtained after anti-solvent addition were slow evaporated.

Data from crystallization by addition of anti-solvent is summarized in Table 92. Table 92: Crystallization by addition of anti-solvent

Explanation Not carried out.

No comments. Crystallization by vapor diffusion

Based on approximate solubility results, about 80mg of Succinate Pattern A was dissolved in the minimal amount of selected solvents in a 4mL or 8mL glass vial without lid at ambient temperature (about 25°C). Then uncapped vial was placed inside a 40-mL glass vial, to which was added anti-solvent, and the 40-mL vial was capped and placed at ambient condition for up to 7 days. Precipitates were collected by centrifugation filtration through a 0.45pm nylon membrane filter at 14,000 rpm. Solid parts (wet cakes) were investigated by XRPD.

Data from crystallization by vapor diffusion is summarized in Table 93.

Table 93: Crystallization by vapor diffusion

Crystallization by heat-cool DSC

Polymorphic behavior of drug substance will be investigated by two different heat-cool DSC cycles. A Tzero pan and a Tzero hermetic lid with a pin hole will be used for this experiment. Exemplary heat-cool DSC cycles will be: Cycle 1

Step 1 : 30°C to melt at 10°C/min;

Step 2: melt to -20°C at 20°C/min;

Step 3: reheat to melt/decomposition at 10°C/min.

Cycle 2

Step 1 : 30°C to melt at 10°C/min;

Step 2: melt to -20°C at 2°C/min;

Step 3: reheat to melt/decomposition at 10°C/min.

Thermal events will be observed and recorded as is known to those of ordinary skill in the art.

Competitive Equilibration Experiments

To determine the relative stability of anhydrates ketanserin succinate Pattern A, succinate Pattern C and succinate Pattern H, competitive equilibration experiments were conducted in different solvent systems.

Approximately 5 mg of succinate Pattern A and ~5 mg of Succinate Pattern C were added to 0.4 mL saturated solutions in selected solvents. After 6 days, ~4 mg Succinate Pattern H was added to each of these mixtures for competitive equilibration. The suspensions were stirred at 5°C, 25°C and 50°C, and solids were recovered as wet cakes by centrifugation filtration and analyzed by XRPD.

Data from competitive equilibration experiments are summarized in Tables 94 and 95.

Table 94. Competitive Equilibration Experiments

A further equilibration study was performed: Approximately 4 mg of succinate Pattern A and ~4 mg of Succinate Pattern H were added to 0.4 mL saturated solutions of selected solvents. The resultant suspensions were stirred at 33°C and 41°C for ~14 days. Solids were recovered as wet cakes by centrifugation filtration and analyzed by XRPD. Table 95. Competitive Equilibration Experiments

Water Activity Experiments

The water activity experiments were conducted at 25°C in different solvent systems to determine the critical water activity between succinate Pattern A and succinate Pattern F.

Approximately 5 mg of succinate Pattern A and ~5 mg of succinate Pattern F were added to 0.15 mL saturated solutions. The resultant suspensions were stirred at 25°C for 1 week. Solids were recovered as wet cakes by centrifugation filtration and analyzed by XRPD. Samples exhibiting new XRPD patterns were further analyzed by DSC, TGA and ^-NMR. Table 96. Water activity experiments

Explanation water activity is calculated by UNIFAC method, no comment. Variable Temperature XRPD (VT-XRPD) experiments

Interconversion relationship of succinate Pattern F, succinate Pattern A, and succinate Pattern C was investigated by variable temperature XRPD.

Succinate Pattern F was used as the starting material. One temperature cycle was applied. Initial

XRPD analysis was carried out under ambient condition. All the other XRPD analyses were subsequently conducted in nitrogen atmosphere at each temperature step of the cycle. Cycle: 25°C (initial)-90°C (10 min)-150°C (10 min) -25°C (10 min).

Table 96A. Competitive Equilibration Experiments

Evaluation of Ketanserin succinate Pattern A and Pattern H

Ketanserin succinate Pattern A and succinate Pattern H were evaluated for their stability, solubility, hygroscopicity and feasibility in formulation processing.

Physicochemical characteristics

Physicochemical characteristics of crystalline ketanserin succinate Pattern H and Pattern A are summarized in Table 97. Table 97: Physicochemical Characteristics

Bulk Stability

• Bulk stability of ketanserin succinate Pattern A and Pattern H was evaluated at 25°C/92%RH in an open container, at 40°C/75%RH in an open container, and at 60°C in a tight container over 1 week.

• Ketanserin succinate Pattern A is physically and chemically stable under all of these conditions. • Ketanserin succinate Pattern H is physically and chemically stable under all these conditions.

Table 98: Bulk Stability

Explanation The bulk stability data of succinate Pattern A was from salt screening example.

Hygroscopicity and water sorption and desorption experiments

• Hygroscopicity of ketanserin succinate Pattern A, Pattern H and Pattern F was evaluated using dynamic vapor sorption (DVS) at 25°C. • Ketanserin succinate Pattern A is slightly hygroscopic, absorbing 1.0% water from

0%RH to 95%RH at 25°C. After subjection to DVS testing, the sample was still succinate Pattern A. • Ketanserin succinate Pattern H is slightly hygroscopic, absorbing 0.5% water from 0%RH to 95%RH at 25°C. After subjection to DVS testing, the sample was still succinate Pattern H.

• Ketanserin succinate Pattern F is slightly hygroscopic, absorbing 1.5% water from 40%RH to 95%RH at 25°C. The dehydration-rehydration process is reversible. The polymorph was still Pattern F after the DVS test, but there was form transition during the water sorption and desorption process, as described below.

Water sorption and desorption behavior of the succinate Pattern A, succinate Pattern F and succinate Pattern H was investigated by DVS at 25°C. XRPD was recorded after the DVS test to determine form change.

Table 99: Hygroscopicity and water sorption and desorption

Explanation “N/A”: Not applicable Compression simulation experiments

Approximately 30 mg of succinate Pattern H and succinate Pattern A were each compressed for 5 minutes under 2 mPa, 5 mPa and 10 mPa with a hydraulic press. Potential form change and degree of crystallinity were monitored by XRPD.

Table 100: Compression simulation experiments

Dry grinding simulation experiments

Approximately 30 mg of succinate Pattern H and succinate Pattern A were each ground manually with a mortar and a pestle for 5 min. Potential form change and degree of crystallinity were monitored by XRPD.

Table 101: Dry grinding simulation experiments

Succinate Pattern H

Succinate Pattern A

Wet granulation simulation experiments

Water or ethanol was added dropwise to 30 mg of succinate Pattern H or succinate Pattern A until the sample is wetted sufficiently. The wet sample was ground gently with a mortar and a pestle for 5 min. After granulation, the sample was dried under ambient condition for 10 min. Potential form change and degree of crystallinity were monitored by XRPD.

Table 102: Wet granulation simulation experiments

Succinate Pattern H

• Feasibility of formulation process for ketanserin succinate Pattern A and Pattern H was evaluated in compression, grinding and granulation simulation experiments.

• Ketanserin succinate Pattern A shows good tolerance to compression and wet granulation (water or EtOH) with no form change and a slight decrease in crystallinity. After dry grinding, the succinate Pattern A showed no form change, but its crystallinity decreased.

• Ketanserin succinate Pattern H shows good tolerance to compression and wet granulation (water or EtOH) with no form change and slight or no obvious crystallinity decrease. After dry grinding, the succinate Pattern H showed no form change, but its crystallinity decreased.

Example 5: Production of Polymorphs of Ketanserin Succinate

Succinate Pattern A was prepared using the procedure below. • To a stirred, warm (50°C) mixture of 5.5 g of free base form Pattern A in 100 mL of ACN in a 100 mL glass vial, was added slowly succinic acid (1.79 g; 1.05 equiv) to give a suspension.

• To the resultant suspension was added 63.3 mg of succinate Pattern A seeds. • After stirring at 50°C for 2 hours, the suspension was cooled to 25°C and stirring was maintained at 25°C.

• Succinate Pattern A was obtained as an off-white solid (6.859 g, 94% yield).

Physicochemical characteristics of succinate Pattern A are presented in Table 103.

Table 103: Characterization of Ketanserin Succinate Pattern A

Succinate Pattern C was attempted to be prepared using the following procedure. This procedure resulted in the formation of Pattern F. • Approximately 200 mg of succinate Pattern A was added to THF (18 mL), and the resultant mixture was filtered through a 0.45-pm nylon membrane filter at 14,000 rpm, to give a clear filtrate.

• To the clear solution (filtrate) was added 2 mg succinate Pattern C seeds.

• The resultant seeded solution was fast evaporated at ~25°C/~51%RH under a dry nitrogen flow. Instead of succinate Pattern C, succinate Pattern F was obtained.

• Physicochemical characteristics of succinate Pattern F are presented in Table 104.

Succinate Pattern F is a hydrate of mono-succinate salt. Pattern F produced herein is of high crystallinity. It contains about 1.4 equivalents (4.7% by weight) of water according to KF result. DSC shows a dehydration peak at Tonset of 35.7°C with an enthalpy of about 62J/g, an endothermic peak at Tonset of 99.7°C with an enthalpy of about 26J/g and an exothermic peak at Tonset of 116.4°C with an enthalpy of 31 J/g. Then it melts at Tonset of 182.6°C. Decomposition occurs upon melting. TGA shows about 6.4% weight loss at about 113°C. ’H-NMR shows stoichiometry of ketanserin: succinic acid is 1 : 1.1 with no detectable residual solvent. After dehydration, it converted to a mixture of succinate Pattern A and succinate Pattern C at 90°C. From DVS results of Pattern F, the Pattern F form is stable when relative humidity is higher than 30%RH.

Table 104: Pattern F characterization data summary

Succinate Pattern D was attempted to be prepared by using the following procedure. This procedure resulted in the formation of Pattern A.

• Approximately 200 mg of succinate Pattern A was added with 14 mL TFE/IPA (1/1, v/v). A clear solution was obtained by filtration through a 0.45-pm nylon membrane filter at

14,000 rpm.

• To the clear solution was added 2 mg succinate Pattern D seeds.

• The seeded solution was fast evaporated at room temperature (about 25°C) under a dry nitrogen flow. Instead of Pattern D, a pattern comprised of Succinate Pattern A plus several extra peaks, was obtained.

Succinate Pattern F was attempted to be prepared by using the following procedure. This procedure resulted in the formation of Pattern A.

• Approximately 200 mg of succinate Pattern A was added to THF(18 mL). A clear solution was obtained by filtration through a 0.45-pm nylon membrane filter at 14,000 rpm.

• To the clear solution was added 2 mg succinate Pattern F seeds. The seeded solution was slowly evaporated in ambient condition (about 25°C, 50%RH). Instead of Pattern F, a mixture of succinate Pattern A and free base form Pattern A was obtained.

Succinate Pattern F was attempted to be prepared by using the following procedure. This procedure resulted in the formation of Pattern C.

• Approximately 110 mg of succinate Pattern A was added to THF (12 mL). A clear solution was obtained by filtration through a 0.45-pm nylon membrane filter at 14,000 rpm.

• To the clear solution was added 2 mg succinate Pattern F seeds.

• The seeded solution was fast evaporated at ~25°Cd 19%RH under a dry nitrogen flow. Instead of succinate Pattern F, succinate Pattern C was obtained.

Succinate Pattern H was prepared by using the following procedure.

• Approximately 200 mg of succinate Pattern A was added to 0.2 mL TFE/water (v/v, 6/4), giving a suspension.

• To the suspension was added 5 mg succinate Pattern H seeds.

• The resultant suspension was kept stirring (400 rpm) at 25°C for ~2 days.

• The solids were recovered by centrifugation at 14,000 rpm and dried at 50°C under vacuum for ~2 hours.

• The succinate Pattern H was obtained as a white solid (112 mg, 56% yield).

Succinate Pattern H was also prepared by using the following procedure.

• Approximately 200 mg of succinate Pattern A was added to 0.2 mLTFE/water (v/v, 6/4), giving a suspension.

• To the suspension was added 5 mg succinate Pattern H seeds.

• The resultant suspension was kept stirring (400 rpm) at 25°C for |3 days.

• Solids were recovered by centrifugation at 14,000 rpm and dried at 50°C under vacuum for ~2 hours.

• Succinate Pattern H was obtained as a white solid. Succinate Pattern H is an anhydrate of the mono-succinate salt. Succinate Pattern H is of high crystallinity as illustrated in the representative XRPD pattern. DSC shows a melting peak at Tonset of 179.9°C. Decomposition occurs upon melting. TGA shows about 0.8% weight loss at about 175°C. ¹HNMR shows that the stoichiometry of ketanserimsuccinic acid is 1 : 1.0 with no detectable residual solvent. Based on competitive experiment results, the Pattern H form converted to Pattern A at 50°C.

Example 6: Production of Polymorphs of Ketanserin L-Tartrate

Summary

• Ketanserin L-tartrate Pattern A was used as starting material in the polymorph screening. Polymorphic behaviors of ketanserin L-tartrate salt were investigated by equilibration, slow evaporation, fast evaporation, slow cooling, fast cooling, anti-solvent addition and vapor diffusion experiments.

• In total, 20 forms were identified to be polymorphs or pseudo-polymorphs of the mono- L-tartrate salt, including: o 2 anhydrates of mono-L-tartrate salt, called Patterns Q and T. o 2 hydrates of mono-L-tartrate salt, called Patterns A and L. o 7 solvates of mono-L-tartrate salt, called Patterns I, J, K, M, N, R, and S. o 4 hetero-solvates of mono-L-tartrate salt, called Patterns B, C, H and O. o 5 isomorphic solvates of mono-L-tartrate salt, called Groups 1, 2, 3, 4 and 5. o Additionally, 5 patterns with non-stoichiometric ratios, called Patterns D, E, F, G and P, were also obtained.

A summary of exemplary solid forms and methods for their production is provided in Table 105.

Table 105: Summary of ketanserin -L-tartrate solid forms

Characterization data is summarized in Tables 106-111:

Table 106: Summary of characterization of polymorphs

Table 107: Summary of characterization of polymorphs

Table 108: Summary of characterization of polymorphs

Table 109: Summary of characterization of polymorphs

Table 110: Summary of characterization of polymorphs

Table 110A: Properties of Ketanserin Free base form Pattern A

Table 111 : Properties of Ketanserin L-Tartrate Pattern A

Representative procedures described in Table 105 are described in additional detail below to illustrate various methods for preparing ketanserin- L-tartrate solid forms.

Preparation of L-tartrate Pattern A in ethanol/water

L-tartrate Pattern A, was prepared using the procedure below. lOOmg of free base form Pattern A and 1.05 equiv. of L-tartaric acid were weighed into an 8mL glass vial. 1 ,9mL of ethanol and 0. ImL water was added into the vial under stirring at 50°C and 400rpm (suspension).

About 3mg of L-tartrate Pattern A seeds were added into above suspension.

After stirring at 50°C for 2 hours, the suspension was cooled to 25°C and kept stirring at 25°C and 400rpm for about 3 days (suspension). Solids were filtered through a 0.45pm nylon membrane filter by centrifugation at 14,000rpm and then dried at 50°C under vacuum for about 3 hours. L-tartrate Pattern A was obtained. This procedure was used to produce ketanserin- L- tartrate Pattern A to use as the starting material for the identification and production of alternative solid forms of ketanserin, including the solid forms described in Tables 106-111.

Preparation of L-tartrate Pattern Q

L-tartrate Pattern Q was prepared using the procedure below. 500 mg of L-tartrate Pattern A was weighed into an 8 mL glass vial. 3 mL of MEK/water (9/1, v/v) was added into the vial under stirring at 50°C and 400 rpm, which resulted in a suspension that converted to a gel-like sample in about 0.5h. After stirring at 50°C for 7 days, the resultant sample was isolated by centrifugation at 14,000 rpm. The resultant solids were dried at 50°C under vacuum for 3 hours to yield L-tartrate Pattern Q was obtained as white solids (257 mg, 51.4% yield). An XRPD diffractogram for this crystalline form is provided in Figure 59.

Approximate solubility at 25 °C and 50 °C.

Solubility at 25°C. About 5 mg of ketanserin L-tartrate Pattern A was weighed into a 2-mL glass vial. Aliquots (20 pL) of each solvent were added to dissolve the drug substance at 25°C. Samples with solubility less than 5 mg/mL at 25°C were heated to 50°C. Solubility at 50°C. About 10 mg of L-tartrate Pattern A was weighed into a 2-mL glass vial. Aliquots (20 pL) of each solvent were added to dissolve the drug substance at 50°C.

Vortexing and sonication were applied to assist dissolution. The maximum volume of each solvent added was 1 mL. Approximate solubility was determined by visual observation. Results are summarized in Table 112. Table 112: Approximate solubility at 25°C and 50°C

Equilibration with solvents at 25°C for 1 week

Based on approximate solubility results, 40-120 mg of ketanserin L-tartrate Pattern A was equilibrated in solvents at 25°C for 2 weeks with stirring (400 rpm). Suspensions were filtered through a 0.45 pm nylon membrane filter by centrifugation at 14,000 rpm, and the recovered solids (wet cakes) were analyzed by XRPD. For samples exhibiting new XRPD patterns, additional analysis (DSC, TGA and 'H-NMRj was performed. Results are summarized in Table 113. Table 113: Equilibration with solvents at 25°C for 2 weeks

*: Water activity (a.w.) is calculated using UNIFAC method.

Equilibration with solvents at 50°C for 1 week Based on approximate solubility results, about 40-120mg of L-tartrate Pattern Awas equilibrated in solvents at 50°C for 1 week with a stirring bar on a magnetic stirring plate at a rate of 400 rpm. Obtained suspension was filtered through a 0.45pm nylon membrane filter by centrifugation at 14,000 rpm. Solid parts (wet cakes) were investigated by XRPD. For samples with different XRPD patterns, additional analysis including HPLC, DSC, TGA, ’H-NMR and KF was performed. The results are summarized in Table 114 below.

Table 114: Equilibration with solvents at 50°C for 1 week

The procedure described above is representative of solid form production via equilibration - as is recognized by those of ordinary skill in the art and illustrated below, the conditions, such as temperature and solvent system can be varied to produce alternative forms of ketanserin L- tartrate.

For example, ketanserin L-tartrate Pattern A was stirred in trifluoroethanol: water (1 : 1 : vokvol; water activity 0.86) at 25°C for 2 weeks with stirring (400 rpm). The suspension was filtered through a 0.45 pm nylon membrane filter by centrifugation at 14,000 rpm, and the recovered solids (wet cake) were analyzed by XRPD, yielding crystalline ketanserin L-tartrate having Pattern P (Figure 53). Proton NMR analysis of ketanserin L-tartrate, Pattern P indicated that the stoichiometry of this salt is 1 : 1.8 ketanserin to tartaric acid. Additional forms produced by equilibration at 25°C for 2 weeks with stirring (400 rpm) include ketanserin L-tartrate salt Group 5 (l,4-Dioxane/water=4/l (v/v), water activity of 0.87); ketanserin L-tartrate salt Group 4 (DMF/toluene 1 : 1 (v/v)), and ketanserin L-tartrate Pattern R (2-Me-THF/water 9: 1 (v/v) water activity 0.90) XRPD provided as Figure 54.

Equilibration under a temperature cycle

Based on approximate solubility results, about 40-120mg of L-tartrate Pattern Awas equilibrated in solvents under a temperature cycle between 5°C to 50°C at a heating/cooling rate of 0.1°C /min for 10 cycles. The equilibration was executed with a stirring bar on a magnetic stirring plate at a rate of 300-400 rpm. Obtained suspension was filtered through a 0.45pm nylon membrane filter by centrifugation at 14,000 rpm. Solid parts (wet cakes) were investigated by XRPD. The results are summarized in Table 115. For samples with different XRPD patterns, additional analysis including HPLC, DSC, TGA, ’H-NMR and KF was performed.

Table 115: Equilibration under a temperature cycle

*:Water activity (a.w.) is calculated by UNIFAC method.

Crystallization at room temperature by slow evaporation

Based on approximate solubility results, 30 mg of L-tartrate Pattern Awas dissolved in each solvent, and the resultant solutions were filtered through a 0.45 pm nylon membrane filter by centrifugation at 14,000 rpm. The clear filtrates were slowly evaporated in ambient condition (~25°C, 50%RH). Solid residues were analyzed by XRPD. Samples with new XRPD patterns were further analyzed by DSC, TGA and 'H-NMR.

Slow evaporation from ethanol yielded crystalline ketanserin L-tartrate Pattern S (XRPD Figure 55). Slow evaporation from THF yielded crystalline ketanserin L-tartrate Pattern B (XRPD Figure 56). Slow evaporation from acetone yielded crystalline ketanserin L-tartrate Pattern K (XRPD Figure 57).

Additional results are summarized in Table 116

Table 116: Crystallization at room temperature by slow evaporation

Crystallization at room temperature by fast evaporation

Based on approximate solubility results, about 30mg of L-tartrate Pattern A was dissolved in solvents. Obtained solutions were filtered through a 0.45pm nylon membrane filter by centrifugation at 14,000 rpm. Obtained clear solutions were fast evaporated at room temperature (about 25°C) under a dry nitrogen flow. Solid residues will be investigated by XRPD. Notably, crystals of Pattern C were obtained using THF as the solvent and crystals of Group 3 were obtained using acetone as the solvent. For samples with different XRPD patterns, additional analysis including HPLC, DSC, TGA, 'H-NMR and KF was performed.

Additional results are summarized in Table 117.

Table 117: Crystallization at room temperature by fast evaporation

Crystallization from hot saturated solutions by slow cooling

Based on approximate solubility results, 50 mg of ketanserin L-tartrate Pattern A was dissolved in the minimal amount of a selected solvent system at 50°C. The resultant solutions were filtered through a 0.45 pm nylon membrane filter by syringe, and the clear filtrates were cooled to 5°C at 0. l°C/min. Recovered solid residues were analyzed by XRPD. Sample exhibiting new XRPD pattern were further analyzed by DSC, TGA and ’H-NMR.

For clear solutions obtained after slow cooling, addition of anti-solvent or slow evaporation was carried out.

Using this method yielded the results set forth in Table 118:

Table 118 Crystallization from hot saturated solutions by slow cooling

Crystallization from hot saturated solutions by fast cooling

Based on approximate solubility results, 40 mg of L-tartrate Pattern A was dissolved in the minimal amount of selected solvents at 50°C. The resultant solutions were filtered through a 0.45 pm nylon syringe membrane filter, and the filtrates were put into a 0°C ice bath and agitated. Precipitates were collected by centrifugation filtration through a 0.45 pm nylon membrane filter at 14,000 rpm. The recovered solids (wet cakes) were analyzed by XRPD. Samples exhibiting new XRPD pattern were further analyzed by DSC, TGA and ’H-NMR.

For clear solutions obtained after fast cooling, addition of anti-solvent or slow evaporation was carried out. Using this method with DMSO/EtOH (1 : 1, v/v) as the solvent, crystals of ketanserin L-tartrate salt Group 4 were obtained.

For clear solutions obtained after fast cooling, addition of anti-solvent or slow evaporation was carried out.

Additional results are summarized in Table 119. Table 119: Crystallization from hot saturated solutions by fast cooling

Crystallization by addition of anti-solvent

Based on approximate solubility results, about 50mg of L-tartrate Pattern Awas dissolved in the minimal amount of selected good solvents at ambient temperature (about 25°C). 3-4 fold of anti-solvent was added into the obtained clear solutions slowly until a large amount of solids precipitated out. Precipitates were collected by centrifugation filtration through a 0.45pm nylon membrane filter at 14,000 rpm. Solid parts (wet cakes) will be investigated by XRPD. The results are summarized in Table 120. For samples with different XRPD patterns, additional analysis including HPLC, DSC, TGA, 'H-NMR and KF was performed. Table 120: Crystallization by addition of anti-solvent

Not carried out

Crystallization by vapor diffusion

Based on approximate solubility results, 50 mg of L-tartrate Pattern A was dissolved in the minimal amount of selected solvents in a uncapped 4-mL glass vial at ambient temperature (~25°C). Then uncapped vial was placed inside a 40-mL glass vial, to which was added antisolvent, and the 40-mL vial was capped and placed at ambient condition for up to 7 days. Precipitates were collected by centrifugation filtration through a 0.45 pm nylon membrane filter at 14,000 rpm, and recovered solids (wet cakes) were analyzed by XRPD. Using this method L- tartrate salt of Group 4 was obtained using several solvent/anti solvent pairings, including DMF/MTBE, DMF/acetonitrile and trifluorethanol/THF.

Table 121. Crystallization by Vapor Diffusion

Crystallization by heat-cool DSC

Polymorphic behavior of ketanserin L-tartrate Pattern A was investigated using two different heatcool DSC cycles. A Tzero pan and a Tzero hermetic lid with a pin hole were used for this experiment. Table 122: Crystallization by heat-cool DSC

Water Activity Experiments

Approximately 5 mg of ketanserin L-tartrate Pattern A and 5 mg of L-tartrate Pattern Q were added to each 0.5-mL saturated solution. The resultant suspensions were stirred at 25°C for 1 week. Solids were recovered as wet cakes by centrifugation filtration and analyzed by XRPD.

Table 123 Water Activity Experiments

Water activity is calculated using UNIFAC method.

Variable temperature XRPD (VT-XRPD) Ketanserin L-tartrate Pattern A was investigated by variable temperature XRPD for determining potential new polymorphs.

Ketanserin L-tartrate Pattern A was used as the starting material for variable temperature XRPD. One temperature cycle was applied. Initial XRPD analysis was carried out under ambient condition. All the other XRPD analyses were subsequently conducted in nitrogen atmosphere at each temperature step of the cycle. Cycle: 25°C (initial)- 100°C (5 min)-150°C (5 min)-25°C. Table 124: Variable temperature XRPD (VT-XRPD)

An XRPD diffractogram overlay showing the change in the sample following heating is provided in Figure 162.

Variable humidity XRPD (VH-XRPD) Experiments

Interconversion relationship of ketanserin L-tartrate Pattern L and Q was investigated by variable humidity XRPD.

Ketanserin L-tartrate Pattern Q was used as the starting material. One RH cycle was applied at 25°C. XRPD analysis was carried out in each specific relative humidity. Cycle: Initial-40%RH (4 h)-60%RH (4 h) -70%RH (4 h)-80%RH (4 h)-90%RH (4 h)- 95%RH (4 h)-40%RH (4 h)- 10%RH (4 h)- 0%RH (4 h)-40%RH (4 h)- 95%RH (4 h) -40%RH (4 h).

Table 125: Variable humidity XRPD (VH-XRPD)

Evaluation of Ketanserin L-tartrate Pattern A and Pattern Q

Ketanserin L-tartrate Pattern A and L-tartrate Pattern Q were evaluated for their stability, hygroscopicity and feasibility in formulation processing.

Physicochemical Properties

Physicochemical Properties of Ketanserin L-Tartrate Pattern A and Pattern Q are summarized in Table 126. Table 126: Physicochemical Properties

Bulk Stability

• Bulk stability of ketanserin L-tartrate Pattern A and Pattern Q was evaluated after 1 week of storage at 25°C/92%RH in an open container, at 40°C/75%RH in an open container, and at 60°C in a tightly closed container.

• Ketanserin L-tartrate Pattern A is chemically stable under all of these conditions. The crystallinity became higher when it was exposed to 25°C/92%RH and 40°C/75%RH. However, form change (new form) was observed after exposure to 60°C for 1 week.

• Ketanserin L-tartrate Pattern Q is chemically stable under all these conditions. It is physically stable after exposed to 60°C for 1 week. But it converted to low crystalline

Pattern L after exposure to 25°C/92%RH for 1 week. Besides, form change (new form) was observed after it was exposed to 40°C/75%RH. Discoloration occurred after exposure to 25°C/92%RH and 40°C/75%RH.

Table 127: Physicochemical Properties

Variable relative humidity experiments in desiccators

About 15 mg of ketanserin L-tartrate Pattern Q was weighed into a 2-mL glass vial. The solids were exposed in desiccators with different relative humidities at 25°C for about 6 days. The results show that the Pattern Q is physically stable after exposure to <84%RH for 6 days.

Table 128: Variable relative humidity experiments in desiccators

Hygroscopicity

• Hygroscopicity of ketanserin L-tartrate Pattern A, Pattern L and Pattern Q was evaluated using dynamic vapor sorption (DVS) at 25°C.

• Ketanserin L-tartrate Pattern A is hygroscopic, absorbing about 3.45% water from 40%RH to 95%RH at 25°C. It shows reversible desorption-sorption behavior to different humidity conditions. After subjection to DVS testing, the sample was still L-tartrate Pattern A.

• Ketanserin L-tartrate Pattern L is slightly hygroscopic, absorbing about 1.1% water from 40%RH to 95%RH. After subjection to DVS testing, obtained sample was still Pattern L, but there was form transition during the water sorption and desorption process.

• Ketanserin L-tartrate Pattern Q is hygroscopic, absorbing about 19.5% water from 40%RH to 95%RH. Form transition occurred during the water sorption and desorption process, and the result is consistent with Pattern L. After subjection to DVS testing, it converted to Pattern L with low crystallinity.

Water sorption and desorption experiments

Water sorption and desorption behaviors of ketanserin L-tartrate Pattern A, ketanserin L-tartrate Pattern L and ketanserin L-tartrate Pattern Q were investigated by DVS at 25°C. XRPD was recorded after the DVS test to determine form change.

Table 129: Water sorption and desorption experiments

Formulation process analysis

• Feasibility of formulation processes for ketanserin L-tartrate Pattern A and Pattern L was evaluated in compression, grinding and granulation simulation experiments. • Ketanserin L-tartrate Pattern A shows good tolerance to compression with no form change and a slight decrease in crystallinity. After dry grinding for 1 min, no form change and crystallinity decrease was observed, but an amorphous form was obtained after dry grinding for 3 min and 5 min. For wet granulation with water, no form change occurred, but form change was observed after wet granulation with EtOH. • Ketanserin L-tartrate Pattern Q shows good tolerance to compression with no form change and a slight decrease in crystallinity. Dry grinding for 1 min and 3 min led to no form change and crystallinity slightly decreased, but almost amorphous form was obtained after dry grinding for 5 min. For wet granulation with water, amorphous form was obtained. For wet granulation with EtOH, no form change was observed and crystallinity decreased.

• Additional details are provided below. Compression simulation experiments

15-30 mg of ketanserin L-tartrate Pattern A and Pattern Q were respectively compressed for 5 minutes under 2 mPa, 5 mPa and 10 mPa with a hydraulic press. Potential form change and degree of crystallinity were monitored by XRPD.

Table 130: Compression simulation experiments

Dry grinding simulation experiments 15-30 mg of ketanserin L-tartrate Pattern A and Pattern Q were each ground manually with a mortar and a pestle for 5 min, 3 min and 1 min. Potential form change and degree of crystallinity were monitored by XRPD. Table 131: Dry grinding simulation experiments

Wet granulation simulation experiments

Water or ethanol was added dropwise to 15-30 mg of ketanserin L-tartrate Pattern A or Pattern Q until the sample was wetted sufficiently. The wet sample was ground gently with in a mortar and a pestle. After granulation, the sample was dried under ambient condition for 10 min. Potential form change and degree of crystallinity were monitored by XRPD.

Table 132: Dry grinding simulation experiments

Preparation of polymorphs

Ketanserin L-tartrate Pattern A + 4 extra peaks was prepared using the procedure below.

• 500 mg of free form ketanserin Pattern A and 199 mg of L-tartaric acid (1.05 eq.) were weighed into a 20-mL glass vial. 9 mL of ethanol and 0.45 mL water were added into the vial under stirring at 50°C and 400 rpm to give a suspension.

• To the resultant suspension was added with 5 mg of ketanserin L-tartrate Pattern A seeds.

• After stirring at 50°C for 2 hours, the suspension was cooled to 25°C and stirring was remained at 25°C for about 6 days. • Solids were filtered through a 0.45 pm nylon membrane filter by centrifugation at 14,000 rpm and then dried at 50°C under vacuum for about 4 hours.

• Ketanserin L-tartrate Pattern A + 4 extra peaks was obtained as white solids (580 mg ,83% yield).

Physicochemical characteristics of mixture ketanserin L-tartrate Pattern A + 4 extra peaks are presented in Table 133

Table 133

Ketanserin L-tartrate salt Group 5 was prepared using the procedure below.

• 100 mg of free form ketanserin Pattern A and 40 mg of L-tartaric acid (1.05 eq.) were weighed into an 8-mL glass vial. 1.9 mL of acetone and 0.1 mL water were added into the vial under stirring at 50°C and 400 rpm. (gel)

• To the resultant sample was added 3 mg of ketanserin L-tartrate Pattern A seeds .

• After stirring at 50°C for 2 hours, the sample was cooled to 25°C and stirring was remained at 25°C for about 1 day (suspension).

• Solids were filtered through a 0.45 pm nylon membrane filter by centrifugation at 14,000 rpm and then dried at 50°C under vacuum for about 3 hours.

• Ketanserin L-tartrate salt Group 5 was obtained.

Physicochemical characteristics of ketanserin L-tartrate salt Group 5 are presented in Table 134.

Table 134 Ketanserin L-tartrate salt Group 5 physicochemical characteristics

Ketanserin L-tartrate Pattern A + 2 extra peaks was prepared using the procedure below.

• 100 mg of free base form Pattern A and 40 mg of L-tartaric acid (1.05 eq.) were weighed into an 8-mL glass vial. 1.9 mL of ACN and 0.1 mL water were added into the vial under stirring at 50°C and 400 rpm (gel).

• To the resultant sample was added 3 mg of ketanserin L-tartrate Pattern A seeds.

• After stirring at 50°C for 2 hours, the sample was cooled to 25°C and stirring remained at 25°C for about 1 day (suspension).

• Ketanserin L-tartrate Pattern A + 2 extra peaks was obtained.

Physicochemical characterizations of ketanserin L-tartrate Pattern A + 2 extra peaks are presented in Table 135

Table 135

Ketanserin L-tartrate Pattern A was prepared using the procedure below.

• 100 mg of free form ketanserin Pattern A and 40 mg of L-tartaric acid (1.05 eq.) were weighed into an 8-mL glass vial. 1.9 mL of ethanol and 0.1 mL water were added into the vial under stirring at 50°C and 400 rpm (suspension).

• After stirring at 50°C for 2 hours, the sample was cooled to 25°C and stirring (400 rpm) maintained at 25°C for about 3 days.

• Ketanserin L-tartrate Pattern A was obtained.

Physicochemical characterizations of ketanserin L-tartrate Pattern A are reported in Table 136.

Table 136

Ketanserin L-tartrate Pattern A was prepared using the procedure below. • 8 g of free form ketanserin Pattern A and 3.2 g of L-tartaric acid (1.05 eq.) were weighed into the Easymaxl02basic reactor. 114 mL of ethanol and 6 mL water were added into the reactor under stirring at 50°C and 300 rpm (suspension).

• To the resultant suspension was added 160 mg of ketanserin L-tartrate Pattern A seeds. • After stirring at 50°C for 8 hours, the solids were recovered by centrifugation at 4,000 rpm through a 0.45 pm nylon membrane filter.

• Resultant solids were dried at ambient environment for 12 hours, at 50°C under vacuum for 4 hours and at 70°C under vacuum for 4 hours.

• Ketanserin L-tartrate Pattern A was obtained as yellow solids (9.25 g, 82% yield). Physicochemical characteristics of ketanserin L-tartrate Pattern A are presented in Table 137.

Table 137

Ketanserin L-tartrate Pattern L was prepared using the procedure below.

• 200 mg of ketanserin L-tartrate Pattern A was weighed into an 8-mL glass vial. 1.8 mL of MEK/water (9/1, v/v) was added into the vial under stirring at 50°C and 400 rpm

(suspension).

• It converted into a gel-like sample in about 0.5 h (gel). • After stirring at 50°C for 7 days, the resultant sample was isolated by centrifugation at 14,000 rpm.

• Ketanserin L-tartrate Pattern L was obtained as white solids.

Physicochemical characterizations of ketanserin L-tartrate Pattern L are presented in Table 138. Table 138

Ketanserin L-tartrate Pattern Q was prepared using the procedure below. • 500 mg of ketanserin L-tartrate Pattern A was weighed into an 8-mL glass vial. 3 mL of MEK/water (9/1, v/v) was added into the vial under stirring at 50°C and 400 rpm (suspension).

• It converted into a gel-like sample in about 0.5h (gel). • After stirring at 50°C for 7 days, the resultant sample was isolated by centrifugation at

14,000 rpm.

• The resultant solids were dried at 50°C under vacuum for 3 hours.

• Ketanserin L-tartrate Pattern Q was obtained as white solids (257 mg, 51.4% yield).

Physicochemical characterizations of ketanserin L-tartrate Pattern Q are presented in Table 139. Table 139

Additional characterization of representative ketanserin L-tartrate solid forms is provided below:

L-tartrate Pattern A is a channel hydrate of ketanserin mono-L-tartrate salt. It is the was obtained from EtOH, MTBE, toluene, 2-Me-THF by equilibration. L-tartrate Pattern A described herein is of high crystallinity (Figure 61). It contains 0.8 equivalents (2.5% by weight) of water (Karl Fischer). DSC shows a dehydration peak at Tonset of 24.5°C with an enthalpy of 36 J/g and a melting peak at Tonset of 140.6°C with an enthalpy of 47 J/g. TGA shows a 1.5% weight loss at 95°C. 'H-NMR shows a 1 : 1 stoichiometry for ketanserin : L-tartaric acid and 0.4% EtOH residue by weight (0.05 equivalent). In water activity experiments, the Pattern A converted into Pattern L when a.w. > 0.5.

L-tartrate Pattern B is a hetero- solvate of ketanserin mono-L -tartrate salt, obtained from THF by slow evaporation. L-tartrate Pattern Bis of high crystallinity (Figure 56). DSC shows multiple thermal events. TGA shows a 15.4% weight loss at 165°C. 'H-NMR shows a 1 : 1 stoichiometry for ketanserin : L-tartaric acid, 20.0% BHT by weight (0.6 equivalent) and 1.3% THF by weight (0.1 equivalent). BHT is an anti-oxidant used in commercial THF, which is not removed from the solids by evaporation of THF.

L-tartrate Pattern C is a hetero-solvate of ketanserin mono-L -tartrate salt, obtained from THF by fast evaporation. L-tartrate Pattern C is of medium crystallinity (Figures 22 and 29). It contains 1.6 equivalents (4.5% by weight) of water (Karl Fischer). DSC shows a desolvation/dehydration peak at Tonset of 43.3°C with an enthalpy of 165 J/g and a dehydration/desolvation peak at Tonset of 136.9°C with an enthalpy of 20 J/g and a melting peak at Tonset of 179.9°C. Decomposition occurs upon melting. TGA shows a 6.0% weight loss at 65°C, and a 4.7% weight loss from 65°C to 150°C. ’H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, 1.4% THF by weight (0.1 equivalent) and 8.6% BHT by weight (0.3 equivalent).

L-tartrate Pattern D is a dissociation product (ketanserin free form: L-tartaric acid = 1 :0.2), obtained from DMSO/toluene by slow cooling. L-tartrate Pattern D is of high crystallinity (Figure 58). 'H-NMR shows a 1 :0.2 stoichiometry for ketanserin : L-tartaric acid.

L-tartrate Pattern E is a dissociation product (ketanserin free form: L-tartaric acid = 1 :0.8), obtained from DMSO/MeOH by anti-solvent addition. L-tartrate Pattern E is of high crystallinity (Figure 31). 'H-NMR shows a 1 :0.8 stoichiometry for ketanserin : L-tartaric acid.

L-tartrate Pattern F is a dissociation product (ketanserin free form : L-tartaric acid = 1 :0.7), obtained from water by equilibration. L-tartrate Pattern F is of medium crystallinity (Figure 32). 'H-NMR shows a 1 :0.7 stoichiometry for ketanserin : L-tartaric acid.

L-tartrate Pattern G is a dissociation product (ketanserin free form : L-tartaric acid = 1 :0.7), obtained from MeOH or MeOH/DCM by equilibration. L-tartrate Pattern G is of high crystallinity (Figure 33). 'H-NMR shows a 1 :0.7 stoichiometry for ketanserin : L-tartaric acid. L-tartrate Pattern H is a hetero-solvate of ketanserin mono-L -tartrate salt, obtained from acetone by equilibration. L-tartrate Pattern H is of high crystallinity (Figure 34). It contains 0.3 equivalents (1.1% by weight) of water (Karl Fischer). DSC shows a desolvation/dehydration peak at Tonset of 117.7°C with an enthalpy of 59 J/g and a melting peak at Tonset of 192.4°C. Decomposition occurs upon melting. TGA shows a 7.6% weight loss at 160°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 3.1% acetone by weight (0.3 equivalent).

L-tartrate Pattern I is a solvate of ketanserin mono-L -tartrate salt, obtained from ACN by equilibration at 50°C. L-tartrate Pattern I is of high crystallinity (Figure 36). DSC shows a desolvation peak at Tonset of 71 ,6°C with an enthalpy of 17 J/g and a melting peak at Tonset of 182.8°C. Decomposition occurs upon melting. TGA shows a 4.7% weight loss at 165°C. ¹H- NMR shows a stoichiometry of 1 :1 for ketanserin : L-tartaric acid, and 5.7% ACN by weight (0.8 equivalent).

L-tartrate Pattern J is a solvate of ketanserin mono-L -tartrate salt, obtained from EtOAc by equilibration. L-tartrate Pattern J is of medium crystallinity (Figure 37). DSC shows a desolvation peak at Tonset of 89.2°C with an enthalpy of 21 J/g and a melting peak at Tonset of 138.8°C with an enthalpy of 21 J/g. TGA shows a 5.7% weight loss at 165°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 4.6% ACN by weight (0.3 equivalent). L-tartrate Pattern K is a solvate of ketanserin mono-L -tartrate salt, obtained from acetone by slow evaporation. L-tartrate Pattern K is of high crystallinity (Figure 57). DSC shows a desolvation peak at Tonset of 119.1 °C with an enthalpy of 85 J/g and a melting peak at Tonset of 148.2°C. Decomposition occurs upon melting. TGA shows a 3.0% weight loss at 140°C and an 8.0% weight loss from 140°C to 170°C. ’H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 10.2% acetone by weight (1.1 equivalents).

L-tartrate Pattern L is a hydrate of ketanserin mono-L -tartrate salt, obtained from water and MEK/water by equilibration. Pattern L is of high crystallinity (Figure 40). It contains 2.9 equivalents (8.6% by weight) of water (Karl Fischer). DSC shows a dehydration peak at Tonset of 47.9°C with an enthalpy of 235 J/g and a melting peak at Tonset of 147.5°C with an enthalpy of 53 J/g. TGA shows an 8.6% weight loss at 85°C. ’H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and no detectable residual solvent. After drying at 50°C under vacuum, Pattern L converted to Pattern Q.

L-tartrate Pattern M is a solvate of ketanserin mono-L -tartrate salt, obtained from

DMSO/acetone and DMSOZEtOH by equilibration and slow cooling. L-tartrate Pattern M is of high crystallinity (Figure 41). DSC shows a desolvation peak at Tonset of 133.7°C with an enthalpy of 78 J/g and a melting peak at Tonset of 186.4°C. Decomposition occurs upon melting. TGA shows a 5.5% weight loss at 160°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L -tartaric acid, and 22.2% DMSO by weight (2.0 equivalents).

L-tartrate Pattern N is a solvate of ketanserin mono-L -tartrate salt, obtained from ACN by equilibration. L-tartrate Pattern N is of low crystallinity (Figure 42). DSC shows desolvation peaks at Tonset of 94.4°C with an enthalpy of 8 J/g and at Tonset of 126.8°C with an enthalpy of 21 J/g, a melting peak at Tonset of 188.8°C. Decomposition occurs upon melting. TGA shows a 2.2% weight loss at 100°C, and a 5.2% weight loss from 100°C to 165°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 12.5% ACN by weight (1.9 equivalents). L-tartrate Pattern O is a hetero-solvate of ketanserin mono-L -tartrate salt, obtained from EtOH/water by equilibration. L-tartrate Pattern O is of high crystallinity (Figure 43). It contains 2.7 equivalents (8.0% by weight) of water (Karl Fischer). DSC shows a desolvation/dehydration peak at Tonset of 50.6°C with an enthalpy of 210 J/g and a melting peak at Tonset of 191.7°C. Decomposition occurs upon melting. TGA shows a 13.4% weight loss at 140°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 1.7% EtOH by weight (0.2 equivalent).

L-tartrate Pattern P is a non-stoichiometric product (ketanserin free form : L-tartaric acid = 1 : 1.8), obtained from TFE/water by equilibration. L-tartrate Pattern P is of high crystallinity (Figure 53). 'H-NMR shows a 1 : 1.8 stoichiometry for ketanserin : L-tartaric acid.

L-tartrate Pattern Q is an anhydrate of ketanserin mono-L -tartrate salt, obtained by drying L- tartrate Pattern L at 50°C under vacuum. L-tartrate Pattern Q is of high crystallinity (Figure 59). DSC shows a melting peak at Tonset of 148.8°C with an enthalpy of 57 J/g. TGA shows a 0.6% weight loss at 175°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and no detectable residual solvent. In water activity experiments, the Pattern Q converted into Pattern L when a.w. > 0.5. And after DVS, Pattern Q converted to Pattern L as well.

L-tartrate Pattern R is a solvate of ketanserin mono-L -tartrate salt, obtained from 2-Me- THF/water by equilibration. L-tartrate Pattern R is of medium crystallinity (Figure 54). DSC shows desolvation peaks at Tonset of 57.1°C with an enthalpy of 145 J/g and at Tonset of 101.0°C with an enthalpy of 2 J/g and a melting peak at Tonset of 188.0°C. Decomposition occurs upon melting. TGA shows a 7.1% weight loss at 85°C, a 2.8% weight loss from 85°C to 155°C. ¹H- NMR shows a stoichiometry of 1 :1 for ketanserin : L-tartaric acid, and 9.9% 2-Me-THF by weight (0.7 equivalent).

L-tartrate Pattern S is a solvate of ketanserin mono-L-tartrate salt, obtained from EtOH by slow evaporation. L-tartrate Pattern S is of high crystallinity (Figure 55). DSC shows desolvation peaks at Tonset of 64.6°C with an enthalpy of 70 J/g and at Tonset of 110.5°C with an enthalpy of 9 J/g and a melting peak at Tonset of 195.8°C. Decomposition occurs upon melting. TGA shows a 4.2% weight loss at 95°C, and a 2.9% weight loss from 95°C to 155°C. ’H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 3.3% EtOH by weight (0.4 equivalent). L-tartrate Pattern T is an anhydrate of ketanserin mono-L-tartrate salt, obtained by heating L- tartrate Pattern A to 100°C during VT-XRPD. It has same XRPD pattern as Pattern A. L-tartrate Pattern T is of medium crystallinity (Figure 60). It is a metastable anhydrate that converted back to Pattern A at ambient environment.

L-tartrate salt Group 1 is an isomorphic solvate of ketanserin mono-L-tartrate salt, obtained from MEK and DCM by equilibration. L-tartrate salt Group 1 is of high crystallinity (Figure 62). DSC shows a desolvation peak at Tonset of 162.1°C with an enthalpy of 39 J/g and a melting peak at Tonset of 195.7°C. Decomposition occurs upon melting. TGA shows a 3.9% weight loss at 175°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 1.5% DCM by weight (0.1 equivalent).

L-tartrate salt Group 2 is an isomorphic solvate of ketanserin mono- L-tartrate salt, obtained from 1,4-di oxane and THF by equilibration and slow evaporation. L-tartrate salt Group 2 is of medium crystallinity (Figure 38). DSC shows multiple thermal events. TGA shows 9.2% weight loss at 165°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 13.9% 1,4-di oxane by weight (1.0 equivalents).

L-tartrate salt Group 3 is an isomorphic solvate of ketanserin mono-L-tartrate salt, obtained from TFE/MTBE, TFE/IPA and acetone by cooling and fast evaporation. L-tartrate salt Group 3 is of low crystallinity (Figure 30). DSC shows a desolvation peak at Tonset of 100.7 °C with an enthalpy of 74 J/g and a melting peak at Tonset of 195.7°C. Decomposition occurs upon melting. TGA shows a 12.1% weight loss at 150°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 16.8% TFE by weight (1.1 equivalents).

L-tartrate salt Group 4 is an isomorphic solvate of ketanserin mono-L-tartrate salt, obtained from DMF/toluene by equilibration, DMF/ACN, DMSOZEtOH, DMSO/acetone by cooling, DMF/MTBE, DMF/l,4-dioxane by anti-solvent addition, DMF/MTBE, DMF/ACN, TFE/THF by vapor diffusion. L-tartrate salt Group 4 is of high crystallinity (Figure 28). DSC shows a desolvation peak at Tonset of 113.7°C with an enthalpy of 87 J/g and a melting peak at Tonset of 177.4°C. Decomposition occurs upon melting. TGA shows a 6.2% weight loss at 150°C. ¹H- NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 13.8% DMF by weight (1.2 equivalents).

L-tartrate salt Group 5 is an isomorphic solvate of ketanserin mono- L-tartrate salt, obtained from 1,4-dioxane/water by equilibration, DMF/water by cooling. L-tartrate salt Group 5 is of high crystallinity (Figure 39). It contains 3.0 equivalents (8.0% by weight) of water (Karl Fischer). DSC shows desolvation/dehydration peaks at Tonset of 66.8°C with an enthalpy of 259 J/g and at Tonset of 100.7°C with an enthalpy of 16 J/g, then followed by a melting peak at Tonset of 194.9°C. Decomposition occurs upon melting. TGA shows a 10.0% weight loss at 85°C, and a 7.1% weight loss from 85°C to 155°C. 'H-NMR shows a stoichiometry of 1 : 1 for ketanserin : L-tartaric acid, and 12.7% 1,4-dioxane by weight (0.9 equivalent).

Example 7: Production of Polymorphs of Ketanserin Free Form

• Free base form Pattern A was used as starting material in the polymorph screening. Polymorphic behaviors of ketanserin free form were investigated by equilibration, slow evaporation, fast evaporation, slow cooling, fast cooling, anti-solvent addition and vapor diffusion experiments.

• Ketanserin free form exhibits polymorphic behaviors. In total, 4 forms were identified to be polymorphs or pseudo-polymorphs of the free form, including: o 1 anhydrate of the free form, called Pattern A. o 1 hydrate of the free form, called Pattern B. o 2 heterosolvates of the free form, called Pattern C and Pattern D. Table 140: Summary of characterization of polymorphs and pseudo-polymorphs of ketanserin free form

Explanation: “*” Free base form Pattern B was only obtained in ketanserin salt screening example “*” Free base form Pattern D was only obtained in the polymorph screening for ketanserin L-malate example

Table 141: Summary of screening conditions affording polymorphs and pseudo- polymorphs of ketanserin free form

Approximate solubility at 25°C and 50°C

Solubility at 25°C. About 5 mg of free base form Pattern A, was weighed into a 4-mL glass vial. Aliquots (20 pL) of each solvent were added to dissolve the drug substance at 25°C.

Solubility at 50°C. About 10 mg of free base form Pattern A, was weighed into a 4-mL glass vial.

Aliquots (20 pL) of each solvent were added to dissolve the drug substance at 50°C.

Vortexing and sonication were applied to assist dissolution. The maximum volume of each solvent added was 4 mL. Approximate solubility was determined by visual observation. Table 142: Approximate solubility at 25°C and 50°C

Equilibration with solvents at 25°C for 2 weeks

Based on approximate solubility results, about 50 mg of free base form Pattern A was equilibrated in solvents at 25°C for 2 weeks with stirring (400 rpm). Suspensions were filtered through a 0.45- pm nylon membrane filter by centrifugation at 14,000 rpm, and the recovered solids (wet cakes) were analyzed by XRPD.

Table 143: Equilibration with solvents at 25°C for 2 weeks

Equilibration with solvents at 50°C for 1 week

Based on approximate solubility results, about 50 mg of free base form Pattern A was equilibrated in solvents at 50°C for 1 week with stirring (400 rpm). Suspensions were filtered through a 0.45-pm nylon membrane filter by centrifugation at 14,000 rpm, and recovered solids (wet cakes) were analyzed by XRPD. For samples exhibiting new XRPD patterns, additional analysis (DSC, TGA and ’H-NMR) was performed. Table 144: Equilibration with solvents at 50°C for 1 week

Equilibration under a temperature cycle

Based on approximate solubility results, about 50 mg of free base form Pattern A was equilibrated with stirring (400 rpm) in solvents using a temperature cycle between 5°C to 50°C at a heating/cooling rate of 0.1°C /min for about 10 cycles. Suspensions were filtered through a 0.45-pm nylon membrane filter by centrifugation at 14,000 rpm, and recovered solids (wet cakes) were analyzed by XRPD.

Table 145: Equilibration under a temperature cycle

Crystallization at room temperature by fast evaporation

Based on approximate solubility results, about 30 mg of free base form Pattern A was dissolved in each solvent, and resultant solutions were filtered through a 0.45-pm nylon membrane filter by centrifugation at 14,000 rpm. The clear filtrates were fast evaporated at room temperature (~25°C) under a dry nitrogen flow. Solid residues were analyzed by XRPD.

Table 146: Crystallization at room temperature by fast evaporation

Crystallization from hot saturated solutions by slow cooling Based on approximate solubility results, about 50 mg of free base form Pattern A was dissolved in the minimal amount of selected solvents at 50°C. The resultant solutions were filtered through a 0.45-pm nylon membrane filter by syringe, and the clear filtrates were cooled to 5°C at 0. l°C/min. Recovered solid residues were analyzed by XRPD. Clear solutions were cooled to - 20°C for further crystallization.

Table 147: Crystallization from hot saturated solutions by slow cooling

Crystallization from hot saturated solutions by fast cooling

Based on approximate solubility results, about 50 mg of free base form Pattern A was dissolved in the minimal amount of selected solvents at 50°C. The resultant solutions were filtered through a 0.45-pm nylon syringe membrane filter, and the filtrates were put into a 0°C ice bath and agitated. Precipitates were collected by centrifugation filtration through a 0.45-pm nylon membrane filter at 14,000 rpm. The recovered solids (wet cakes) were analyzed by XRPD. Clear solutions or hazy suspensions were cooled to -20°C for further crystallization.

Table 148: Crystallization from hot saturated solutions by fast cooling

Crystallization by addition of anti-solvent

Based on approximate solubility results, about 50 mg of free base form Pattern A was dissolved in the minimal amount of a selected good solvent at ambient temperature (~25°C). To each of these clear stirred (400 rpm) solutions, was added slowly 1-4 fold volume of anti-solvent.

Precipitates were collected by centrifugation filtration through a 0.45-pm nylon membrane filter at 14,000 rpm, giving solids (wet cakes) which were analyzed by XRPD. Clear solutions obtained after anti-solvent addition were cooled to -20°C for further crystallization.

Table 149: Crystallization by addition of anti-solvent

Crystallization by reverse addition of anti-solvent

Based on approximate solubility results, about 50 mg of free base form Pattern A was dissolved in the minimal amount of a selected good solvent at ambient temperature (~25°C). To each of these clear stirred (400 rpm) solutions, was added quickly into 4-fold volume of anti-solvent.

Precipitates were collected by centrifugation filtration through a 0.45-pm nylon membrane filter at 14,000 rpm, giving solids (wet cakes) which were analyzed by XRPD. Clear solutions obtained after anti-solvent addition were cooled to -20°C for further crystallization. Table 150: Crystallization by reverse addition of anti-solvent

Crystallization by vapor diffusion

Based on approximate solubility results, about 50 mg of free base form Pattern A was dissolved in the minimal amount of selected solvents in a uncapped 4-mL glass vial at ambient temperature (~25°C). Then the uncapped vial was placed inside a 40-mL glass vial, to which was added anti- solvent, and the 40-mL vial was capped and placed at ambient condition for up to 13 days.

Precipitates were collected by centrifugation filtration through a 0.45-pm nylon membrane filter at 14,000 rpm, and recovered solids (wet cakes) were analyzed by XRPD.

Table 151: Crystallization by vapor diffusion

Evaluation of Free base form Pattern A

Physicochemical characteristics

Physicochemical characteristics of Free base form Pattern A are summarized below.

Table 152: Physicochemical characteristics

Bulk Stability

• Bulk stability of ketanserin free base form Pattern A was evaluated after 1 week storage at 25°C/92%RH in an open container, at 40°C/75%RH in an open container, and at 60°C in a tightly closed container.

• Ketanserin free base form Pattern A, is physically and chemically stable under all of these conditions.

Table 153: Bulk Stability

Hygroscopicity

• Hygroscopicity of ketanserin free base form Pattern A was evaluated using dynamic vapor sorption (DVS) at 25°C.

• Ketanserin free base form Pattern A is slightly hygroscopic, absorbing 0.4% water from 0%RH to 95%RH at 25°C. After subjection to DVS testing, the sample was still free base form Pattern A.

Water Sorption and Desorption Experiments

Water sorption and desorption behavior of the free base form Pattern A was investigated by DVS at 25°C with a cycle of 40-0-95-0-40%RH, dm/dt 0.002, min. equilibration time 60 min and max. equilibration time 360 min. XRPD was recorded after the DVS test to determine form change.

Table 154: Water Sorption and Desorption Experiments

Feasibility of formulation process

• Feasibility of formulation process for ketanserin free base form Pattern A was evaluated in compression, grinding and granulation simulation experiments. • Ketanserin free base form Pattern A shows good tolerance to compression and wet granulation (water or ethanol) with no form change and a slight decrease in crystallinity.

Dry grinding simulation experiments

Approximately 20 mg of free base form Pattern A was ground manually with a mortar and a pestle for 1 min, 3 min, and 5 min. Potential form change and degree of crystallinity were monitored by XRPD.

Table 155 :Dry grinding simulation experiments

Wet granulation simulation experiments

Water or ethanol was added dropwise to about 30 mg of free base form Pattern A until the sample was wetted sufficiently. The wet sample was ground gently with a mortar and a pestle for 5 min. After granulation, the sample was dried under ambient condition for 10 min. Potential form change and degree of crystallinity were monitored by XRPD.

Table 156: Wet granulation simulation experiments

Additional characterization data for representative solid forms of ketanserin free form (free base ketanserin) are provided below. Free base form Pattern A is an anhydrate of ketanserin free form. It was the starting polymorphic form and obtained from most of solvent systems in equilibration, slow evaporation, fast evaporation, slow cooling, fast cooling, antisolvent addition and vapor diffusion experiments. Free base form Pattern A is of high crystallinity. DSC shows a melting peak at Tonset of 238.1°C. Decomposition occurs upon melting. TGA shows about 0.4% weight loss at ~220°C. 'H-NMR shows a 0.6% (0.027 equiv.) residual dimethylacetamide (DMAc), the solvent from which Pattern A was isolated.

Free base form Pattern B is likely a monohydrate, obtained from acetonitrile (ACN) by slurry equilibration experiments from ketanserin salt screening in the presence of sulfuric acid. Free base form Pattern B, is of medium crystallinity. DSC shows a dehydration peak at Tonset of 114.2°C with an enthalpy of 114J/g. TGA shows a 4.9% weight loss at 150°C. 'H-NMR shows 1.1% (0.1 equiv. by molar ratio) residual ACN. Based on TGA and 'H-NMR results, Pattern B contains about 3.8% water, equal to 0.83 equivalent. Pattern B is likely a metastable form and not reproducible.

Free base form Pattern C is likely a TFE/water heterosolvate, obtained from trifluoroethanol (TFE) by equilibration and cooling. Free base form Pattern C is of high crystallinity. DSC shows a desolvation peak at Tonset of 71 ,6°C and a melting peak at Tonset of 236.4°C.

Decomposition occurs upon melting. TGA shows a 17.0% weight loss from 26°C to 100°C. ¹H- NMR shows 11.2% (0.5 equiv. by molar ratio) residual TFE. After desolvation, Pattern C converted to Pattern A.

Free base form Pattern D is a DMF/water heterosolvate, obtained from DMF by slurry equilibration from ketanserin L-malate salt polymorph screen. Pattern D is of high crystallinity. It contains 0.3 equiv. (1.5% by weight) of water (Karl Fischer). DSC shows a dehydration peak at Tonset of 47.4°C with an enthalpy of 95J/g, a desolvation peak at Tonset of 178.4°C with an enthalpy of 35 J/g. It melts with a Tonset of 235.8°C. Decomposition occurs upon melting. TGA shows a 1.4% weight loss from 33°C to 100°C and a 6.4% weight loss from 100°C to 220°C. 'H-NMR shows 8.9% (0.5 equiv.) residual DMF. After desolvation, Pattern D converted to practically amorphous form. Preparation of polymorphs

Preparation of Free base form Pattern A

Pattern A was prepared to 300mg using the procedure below.

520mg of free base form Pattern A was weighed into an 8mL glass vial. 1 ,5mL of DMAc was added into the vial under stirring at 25°C to obtain a suspension (suspension).

After stirring at 25°C for 3 days and 50°C for 1 day, solids were collected by filtering through a 0.45pm nylon membrane filter by centrifugation at 14,000 rpm and then dried at 60°C under vacuum for about 3 hours and at 40°C under vacuum for about 18 hours. 300mg of free base form Pattern A was obtained as an off-white solid in 57% yield.

Attempted preparation of ketanserin free base form Pattern B

• To a stirred (25°C) mixture of 300 mg of free base form Pattern A in 2.9 mL of ACN in an 8 mL glass vial, was added slowly 433 pL of H2SO4 (1.05 equiv, 0.1 mL of H2SO4 was diluted with 0.9 mL ACN) to give a suspension.

• To the resultant suspension was added 10 mg of free base form Pattern B seeds.

• After stirring at 25°C for 3 days, a small amount of suspension was filtered through a 0.45-pm nylon membrane filter by centrifugation at 14,000 rpm and then the solids were characterized by XRPD.

• Ketanserin sulfate Pattern B was obtained instead of ketanserin free base Pattern B.

Physicochemical characteristics of sulfate Pattern B are presented in Table 157.

Table 157: Physicochemical characteristics of sulfate Pattern B

Example 8: Production of Polymorphs of Ketanserin Malate

Summary

• L-malate Pattern A was used as starting material in the polymorph screen. Polymorphic behaviors of ketanserin L-malate were investigated by equilibration, fast evaporation, slow cooling, fast cooling, anti-solvent addition, reverse anti-solvent addition and vapor diffusion experiments.

• Ketanserin L-malate exhibits polymorphic behaviors. In total, 6 forms were identified to be polymorphs or pseudo-polymorphs of the L-malate, including:

• 2 anhydrates of L-malate, called Pattern A and Pattern D.

• 4 solvates or heterosolvates, called Pattern B, Pattern C, Pattern C*, and Pattern E.

Polymorph Screening

Approximate solubility at 25 °C and 50 °C

Solubility at 25°C. About 5 mg of L-malate Pattern A was weighed into a 2-mL glass vial. Aliquots (20 pL) of each solvent were added to dissolve the drug substance at 25°C.

Solubility at 50°C. About 10 mg of L-malate Pattern A was weighed into a 2-mL glass vial. Aliquots (20 pL) of each solvent were added to dissolve the drug substance at 50°C.

Vortexing and sonication were applied to assist dissolution. The maximum volume of each solvent added is 1 mL. Approximate solubility was determined by visual observation.

Table 158: Approximate solubility at 25 °C and 50 °C

Equilibration with solvents at 25°C for 2 weeks

Based on approximate solubility results, about 50 mg of L-malate Pattern A was equilibrated in solvents at 25°C for 2 weeks with stirring (400 rpm). Suspensions were filtered through a 0.45 pm nylon membrane filter by centrifugation at 14,000 rpm, and the recovered solids (wet cakes) were analyzed by XRPD.

Table 159: Equilibration with solvents at 25°C for 2 weeks

Equilibration with solvents at 50°C for 1 week

Based on approximate solubility results, about 50 mg of L-malate Pattern A was equilibrated in solvents at 50°C for 1 week with stirring (400 rpm). Suspensions were filtered through a 0.45 pm nylon membrane filter by centrifugation at 14,000 rpm, and recovered solids (wet cakes) were analyzed by XRPD. For samples exhibiting new XRPD patterns, additional analysis (DSC, TGA and 'H-NMR j was performed.

Table 160: Equilibration with solvents at 50°C for 1 week

Equilibration under a temperature cycle

Based on approximate solubility results, about 50 mg of L-malate Pattern A was equilibrated with stirring (400 rpm) in solvents using a temperature cycle between 5°C and 50°C at a heating/cooling rate of 0.1°C /min for 10 cycles. Suspensions were filtered through a 0.45-pm nylon membrane filter by centrifugation at 14,000 rpm, and recovered solids (wet cakes) were analyzed by XRPD. Table 161: Equilibration under a temperature cycle

Crystallization at room temperature by fast evaporation

Based on approximate solubility results, about 30 mg of L-malate Pattern A was dissolved in each solvent, and resultant solutions were filtered through a 0.45-pm nylon membrane filter by centrifugation at 14,000 rpm. The clear filtrates were fast evaporated at room temperature (~25°C) under a dry nitrogen flow. Solid residues were analyzed by XRPD. Table 162: Crystallization at room temperature by fast evaporation

Crystallization from hot saturated solutions by slow cooling

Based on approximate solubility results, about 50 mg of L-malate Pattern Awas dissolved in the minimal amount of a selected solvent at 50°C. The resultant solutions were filtered through a 0.45-pm nylon membrane filter by syringe, and the clear filtrates were cooled to 5°C at 0.1°C /min. Recovered solid residues were analyzed by XRPD. Samples exhibiting new XRPD patterns were further analyzed by DSC, TGA and ’H-NMR.

Table 163: Crystallization from hot saturated solutions by slow cooling

Crystallization from hot saturated solutions by fast cooling

Based on approximate solubility results, about 50 mg of L-malate Pattern A was dissolved in the minimal amount of selected solvents at 50°C. The resultant solutions were filtered through a 0.45-pm nylon syringe membrane filter, and the filtrates were put into a 0°C ice bath and agitated. Precipitates were collected by centrifugation filtration through a 0.45-pm nylon membrane filter at 14,000 rpm. The recovered solids (wet cakes) were analyzed by XRPD.

Table 164: Crystallization from hot saturated solutions by fast cooling

Crystallization by addition of anti-solvent

Based on approximate solubility results, about 50mg of L-malate Pattern A was dissolved in the minimal amount of selected solvents at ambient temperature (about 25°C). 3-4 folds of antisolvent were added into the obtained clear solutions slowly until a large amount of solids precipitated out. Precipitates were collected by centrifugation filtration through a 0.45 m nylon membrane filter at 14,000 rpm. Solid parts (wet cakes) were investigated by XRPD. The Pattern C form of ketanserin L-malate was isolated according to this procedure after one day using DMAc (O.lmL) as the solvent and EA (0.4mL) as the anti-solvent and using DMAc (O.lmL) as the solvent and 2-MeTHF as the anti-solvent. The Pattern E form of ketanserin L- malate was isolated according to this procedure after seven days using DMAc (O.lmL) as the solvent and EA (0.4mL) as the anti-solvent and using DMAc (0. ImL) as the solvent and 2- MeTHF as the anti-solvent.

For samples with different XRPD patterns, additional analysis including HPLC, DSC, TGA, ¹H- NMR and KF was performed. Table 165: Crystallization by addition of anti-solvent

“*”: Precipitation was observed in DMSO and DMF during experiment, suggesting form change in these two solvents.

Samples AS5 and AS6 were prepared using the same method. But before filtration and anti-solvent addition, precipitation was obtained in DMF for both samples. The L-malate dissociated to amorphous form first. Then it converted to free base form Pattern A or free base form Pattern D in DMF

Crystallization by reverse addition of anti-solvent

Based on approximate solubility results, about 50 mg of L-malate Pattern A was dissolved in the minimal amount of a selected good solvent at ambient temperature (~25°C). To each clear stirred (400 rpm) solution was added quickly 4-fold volume anti-solvent. Precipitates were collected by centrifugation filtration through a 0.45-pm nylon membrane filter at 14,000 rpm, giving solids (wet cakes) which were analyzed by XRPD. Samples exhibiting new XRPD patterns were analyzed also by 'H-NMR. Table 166: Crystallization by reverse addition of anti-solvent

Crystallization by vapor diffusion

Based on approximate solubility results, about 50 mg of L-malate Pattern A was dissolved in the minimal amount of a selected solvent in a uncapped 4-mL glass vial at ambient temperature (~25°C). The uncapped vial was placed inside a 40-mL glass vial, to which was added antisolvent, and the 40-mL vial was capped and placed at ambient condition for up to 7 days. Precipitates were collected by centrifugation filtration through a 0.45-pm nylon membrane filter at 14,000 rpm, and recovered solids (wet cakes) were analyzed by XRPD.

Table 167: Crystallization by reverse addition of anti-solvent

Interrelationship investigation of polymorphs

Competitive Equilibration experiments

To determine the relative stability of anhydrates ketanserin L-malate Pattern A and L-malate Pattern D, competitive equilibration experiments were conducted in different solvent systems.

Approximately 3-5 mg of L-malate Pattern A and ~5 mg of L-malate Pattern D were added to 0.5 mL saturated solutions in selected solvents. The suspensions were stirred at 25°C and 50°C and solids were recovered as wet cakes by centrifugation filtration and analyzed by XRPD.

Table 168: Competitive Equilibration experiments

Evaluation of L-Malate Pattern A

• Feasibility of formulation process for ketanserin L-malate Pattern A was evaluated in compression, grinding, and granulation simulation experiments. • Ketanserin L-malate Pattern A shows poor tolerance to compression and dry grinding with no form change but decreased crystallinity. During wet granulation with water or ethanol, the L-malate Pattern A partially dissociated to free base form Pattern A

L-Malate Pattern A physicochemical characteristics are summarized in Table 169 Table 169: L-Malate Pattern A physicochemical characteristics

Bulk Stability

• Bulk stability of ketanserin L-malate Pattern A was evaluated after 1 week of storage at 25°C/92%RH in an open container, at 40°C/75%RH in an open container, and at 60°C in a tightly closed container.

• L-malate Pattern A is physically and chemically stable under all of these conditions. About 1% degradation was detected after 1 week at 25°C/92%RH, 40°C/75%RH, and 60°C.

Table 170: L-Malate Pattern A bulk stability

Hygroscopicity

• Hygroscopicity of ketanserin L-malate Pattern A was evaluated using dynamic vapor sorption (DVS) at 25°C. • Ketanserin L-malate Pattern A, is hygroscopic at 80%RH but very hygroscopic at

95%RH, absorbing 4.2% water from 0%RH to 80%RH and absorbing 15.6% water from 0%RH to 95%RH. After subjection to DVS testing, the sample was still L-malate Pattern A.

Water sorption and desorption experiments Water sorption and desorption behavior of the L-malate Pattern A was investigated by DVS at 25°C with a cycle of 40-0-95-0-40%RH, dm/dt 0.002, min. equilibration time 60 min and max. equilibration time 360 min. XRPD was recorded after the DVS test to determine form change.

Table 171: L-Malate Pattern A bulk stability

“N/A”:Not applicable.

Compression simulation experiments

Approximately 20 mg of L-malate Pattern A was compressed for 5 minutes under 2 mPa, 5 mPa and 10 mPa with a hydraulic press. Potential form change and degree of crystallinity were monitored by XRPD.

Table 172: Compression simulation experiments

Dry grinding simulation experiments Approximately 50 mg of L-malate Pattern A was ground manually with a mortar and a pestle for 1 min, 3 min, and 5 min. Potential form change and degree of crystallinity were monitored by XRPD. Table 173: Dry grinding simulation experiments

Wet granulation simulation experiments

Water or ethanol was added dropwise to ~50 mg of L-malate Pattern A until the sample was wetted sufficiently. The wet sample was ground gently with a mortar and a pestle for 5 min. After granulation, the sample were dried under ambient condition for 10 min. Potential form change and degree of crystallinity were monitored by XRPD.

Table 174: Wet granulation simulation experiments

Additional characterization of representative solid forms of ketanserin L-malate is provided below.

L-malate Pattern A is an anhydrate of ketanserin L-malate. It was the starting polymorphic form and obtained from most of solvent systems in equilibration experiments. Additionally, in 1 ,4-di oxane, TFE/EtO Ac, TFE/ACN, MeOH/MTBE, THF/heptane, and MeOH/ACN as solvents, Pattern A was obtained in fast evaporation, slow cooling, reverse anti-solvent addition, and vapor diffusion experiments. L-malate Pattern A is of medium crystallinity. DSC shows a melting peak at Tonset of 145.9°C with an enthalpy of 56 J/g. TGA shows about 0.4% weight loss at ~140°C. ^XH-NMR shows a stoichiometry of 1 : 1.0 for ketanserin:L-malic acid and no detectable residual solvent. L-malate Pattern A showed no form change in most of organic solvents, suggesting it is a stable form.

L-malate Pattern B is a THF solvate of ketanserin L-malate, obtained from THF by slow cooling. L-malate Pattern B is of low crystallinity. DSC shows two desolvation peaks at Tonset of 102.5°C and 128.7°C. TGA shows a 9.6% weight loss from 32°C to 150°C. 'H-NMR shows a stoichiometry of 1 : 1. 1 for ketanserin: L-malic acid and 10.3% THF residue (equal to 0.76 equiv. by molar ratio) by weight.

L-malate Pattern D is an anhydrate of ketanserin L-malate, obtained from EtOH by equilibration. L-malate Pattern D is of medium crystallinity. DSC shows a melting peaks at Tonset of 152.0°C with an enthalpy of 56 J/g. TGA shows a 0.5% weight loss at 130°C. 'H-NMR shows a stoichiometry of 1 : 1.1 for ketanserin: L-malic acid and no detectable residual solvent. L-malate Pattern D was obtained only from ethanol. It is not reproducible.

Group 1: L-malate Pattern C and L-malate Pattern C* are isomorphic.

L-malate Pattern C is likely a dimethylacetamide (DMAc) solvate of ketanserin L-malate, obtained from DMAc/EA by anti-solvent addition. L-malate Pattern C is of low crystallinity. After equilibrating in DMAc/EA at 25°C for 7 days, Pattern C converted to DMAc solvate Pattern E

L-malate Pattern C* is a DMAc/2-MeTHF heterosolvate of ketanserin L-malate, obtained from DMAc/2-MeTHF by anti-solvent addition. L-malate Pattern C* has a structure that is isomorphic with L-malate Pattern C. Pattern L-malate Pattern C* is of low crystallinity. ’H- NMR shows a stoichiometry of 1 :1.1 for ketanserin:L-malic acid and 9.5% DMAc (equal to 0.6 equiv. by molar ratio) and 6.0% 2-MeTHF (equal to 0.4 equiv. by molar ratio) residue by weight. After equilibrating in DMAc/THF at 25°C for 7 days, Pattern C* converted to Pattern E L-malate Pattern E is a DMAc solvate of ketanserin L-malate, obtained from DMAc/EA by anti-solvent addition. L-malate Pattern E is of high crystallinity. DSC shows a desolvation peak at Tonset 74.0°C with an enthalpy of 108J/g and an endothermic peak at Tonset 182.4°C with enthalpy of 200 J/g. TGA shows a 1.7% weight loss at 70°C. 'H-NMR shows a stoichiometric ratio of 1 : 1.0 for ketanserin:L-malic acid and 8.4% (equal to 0.5 equiv. by molar ratio) residual DMAc by weight. Ketanserin free base form Pattern A was obtained in some screening experiments, suggesting there is risk of dissociation for L-malate. Similar dissociation behavior was observed for the ketanserin L-tartrate salt.

Interrelationship of polymorphs

Relative stability of the anhydrates L-malate Patterns A and anhydrate L-malate Pattern D was investigated in competitive equilibration experiments. However, salt dissociation occurred at 25°C and 50°C, and the interconversion relationship between L-malate Pattern A and L-malate Pattern D could not be determined.

Preparation of polymorphs

L-malate Pattern A was prepared using the procedure below.

• To a stirred, warm (50°C) mixture of 7.0 g of free base form Pattern A in 90 mL of ACN in a 100-mL glass vial, was added slowly L-malic acid (2.5 g, 1.05 equiv.) to give a suspension.

• To the resultant suspension was added ~10 mg of L-malate Pattern A seeds.

• After stirring at 50°C for 4 hours, the suspension was cooled to 25°C and stirring was maintained at 25°C.

• L-malate Pattern A was obtained as an off-white solid (8.5 g, 91% yield).

Attempted preparation of L-malate Pattern D

• Approximately 500 mg of L-malate Pattern A was added to EtOH (8 mL), giving a suspension.

• The resultant suspension was kept stirring (400 rpm) at 50°C for 7 days.

• The solids were recovered by centrifugation at 14,000 rpm. Instead of pure L-malate Pattern D, a physical mixture of L-malate Pattern D and free base form Pattern A was obtained.

• Physicochemical characteristics are presented in Table 175.

Table 175

Attempted preparation of L-malate Pattern D trial 2

• Approximately 450 mg of L-malate Pattern A was added to EtOH (8 mL), giving a suspension. • The resultant suspension was kept stirring (400rpm) at 50°C for 3 days.

Physicochemical characteristics are presented in Table 176 Table 176

Further details regarding the preparation and characterization of ketanserin L-malate polymorphs and pseudo-polymorphs is summarized in Tables 177 and 178. Table 177: Summary of screening conditions affording polymorphs and pseudopolymorphs of ketanserin L-malate

Table 178: Summary of characterization of polymorphs and pseudo-polymorphs of ketanserin L-malate

Example 9: Administration of Ketanserin to Modulate Psychedelic Effects

This example describes using ketanserin forms disclosed herein to modulate the effects of psychedelics. In particular, a ketanserin dose was administered in an oral or intravenous (IV) dosage form to end or reduce the intensity of a psychedelic trip. These studies support the administration of similar dosages to human subjects, such as administering ketanserin dosages of from about 10 mg to about 100 mg, about 30 mg to about 50 mg, from about 40 mg to about 80 mg, or about 40 mg, about 60 mg, or about 80 mg.

Animals for all studies

Male C57BL/6J mice (approximately 25g) were group housed in stock room B20D of the Saretius animal at the University of Reading. Animals were maintained under a 12 h light/dark cycle, at 23°C with humidity controlled

Protocol 1: Effect of intravenous ketanserin on LSD-induced head twitches in mice.

Animals

6 Male C57BL/6J mice (approximately 25g) were group housed in stock room B20D of the Saretius animal at the University of Reading. Animals were maintained under a 12 h light/dark cycle, at 23°C with humidity controlled according to Home Office regulations.

Formulation

Lysergic acid dimethylamine tartrate (LSD, 67.2% free base content) was formulated in saline at a concentration of 0.063 mg free base /mL to give doses of 0.32 mg/kg when administered ip in a 5 mL/kg dosing volume. Ketanserin Tartrate (74.7% free base content) was dissolved in Vehicle 2 (DMSO: Cremophor EL: Hydroxypropyl-P-cyclodextrin (20% in water) [10: 10:80]) at concentrations of 0.4 mg/ml to give a dose of 2 mg/kg when administered iv in a 5 mL/kg dosing volume.

Procedure

At T= -60 min, C57BL/6J mice were individually housed into transparent observation cages with bedding removed and left to habituate.

At T=-2 min, mice will placed into heated cages at 40°C

At T= 0 h, groups of 3 mice were dosed intraperitoneally with LSD (0.32 mg/kg). Following dosing, mice were replaced into the heated cages and head-twitch responses continuously scored for 8 min. After 8 min, mice were intravenously dosed via the lateral tail vein with Vehicle 2 (DMSO: Cremophor :HPCD) or ketanserin (2 mg/kg) in 5 mL/kg dosing volumes. Mice were replaced into the observation cages and head twitch behavior was monitored until 40 min after agonist dosing.

Mice were dosed intraperitoneally with LSD (0.32 mg/kg) and head-twitch responses were continuously scored for 8 minutes. After 8 minutes, mice were intravenously dosed with either vehicle (DMSO: Cremophor :HPCD) or ketanserin (2 mg/kg). Cumulative head-twitch behavior was measured every 2 minutes until 40 minutes after agonist dosing. As demonstrated in this example, administration of ketanserin completely suppressed the head-twitch response. Figure 67 provides a graph comparing LSD-induced head twitches in mice with and without administration of ketanserin after T= 8 minutes.

Figure 68 provides a bar chart showing head twitches occurring before and after control or antagonist administration (left bar in each pair is LSD/vehicle and right is LSD/ketanserin). Post-administration of ketanserin (right hand pair of Figure 68) resulted in complete suppression of head twitch.

Table 179: Synopsis of mouse twitch test pilot schedule

Protocol 2 Effect of intravenous ketanserin on psilocybin induced head twitches in mice. Formulation

Psilocybin (free base) was formulated in saline at a concentration of 0.4 mg/mL to give a dose of 2 mg/kg when administered ip in a 5 mL/kg dosing volume.

Ketanserin Tartrate (74.7% free base content) was dissolved in Vehicle 2 (DMSO: Cremophor EL: Hydroxypropyl-P-cyclodextrin (20% in water) [10: 10:80]) at concentrations of 0.4 mg/ml to give a dose of 2 mg/kg when administered iv in a 5 mL/kg dosing volume.

Procedure At T= -60 min, C57BL/6J mice were individually housed into transparent observation cages with bedding removed and left to habituate.

At T=-3 min, mice will placed into heated cages at 40°C

At T= 0 h, groups of 3 mice were dosed intraperitoneally with psilocybin (2 mg/kg). Following dosing, mice were replaced into the heated cages and head-twitch responses continuously scored for 7 min. After 7 min, mice were intravenously dosed via the lateral tail vein with either Vehicle 2 (DMSO:cremophor:HPCD [10: 10:80]) or ketanserin (2 mg/kg) in Vehicle 2 in 5 mL/kg dosing volumes. Mice were replaced into the observation cages and head twitch behavior was monitored until 40 min after agonist dosing.

Table 180: Synopsis of mouse twitch test pilot schedule

Mice were dosed intraperitoneally with psilocybin (2 mg/kg) and head-twitch responses were continuously scored for 7 minutes. After 7 minutes, mice were intravenously dosed with either vehicle (DMSO:cremophor:HPCD) or ketanserin (2 mg/kg). Cumulative head-twitch behavior was measured every 2 minutes until 40 minutes after agonist dosing. As demonstrated in this example, administration of ketanserin completely suppressed the head-twitch response. Figure 69 provides a graph produced from this example, comparing psilocybin induced head twitches in mice with and without administration of ketanserin after T= 7 minutes. Figure 70 provides a bar chart showing head twitches occurring before and after control or antagonist administration (left bar in each pair is psilocybin/vehicle and right is psilocybin/ketanserin). Post-administration of ketanserin (right hand pair of Figure 70) resulted in complete suppression of head twitch.

Example 10: LSD-induced neural changes and ketanserin studies

This example demonstrates the effect of 5-HT2A receptor antagonism on psychedelic drug induced hallucinations and detection of LSD-induced neural changes in humans that are uncoupled from hallucinations.

Materials and Methods

Source of Data

The used dataset was acquired in the course of a registered clinical trial (ClinicalTrials.gov Identifier: NCT02451072) entitled: The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers. Participants, study design, neuroimaging data acquisition, preprocessing and global brain connectivity calculation are detailed in Preller et al. (eLife. 2018 Oct 25;7:e35082. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor, PMID: 30355445). The relevant methodological sections pertinent to the current analysis are summarized below.

Participants

24 subjects were included in the dataset («=19 males; mean age = 25.0 years, standard deviation = 3.6 years, range = 20-34 years). All included subjects were healthy, as confirmed by medical history, physical examination, blood analysis, electrocardiography, the MiniInternational Neuropsychiatric Interview (MINI-SCID) [Sheehan et al., 1998], the DSM-IV selfrating questionnaire for Axis-II personality disorders (SCIS-II) [Fydrich et al., 1997], and the Hopkins Symptom Checklist (SCL-90 R) [Franke, 1995], Subjects were required to abstain from prescription or illicit drugs, alcohol, smoking and caffeine.

Study design

The study was designed as a fully double-blind, randomized, within-subject cross-over study. During a session, subjects were pretreated with either a placebo or the 5-HT2A receptor antagonist Ketanserin 60 minutes before being treated with either a placebo or LSD. Thus, each subject participated in 3 sessions in which they underwent each of the following pretreatment + treatment conditions in a randomized, balanced order: a) Placebo + placebo b) Placebo + LSD c) Ketanserin + LSD

Two resting-state scans were performed, one 75 and the other 300 minutes after treatment. To assess participants’ experience, a retrospective self-report questionnaire (5D-ASC, [Dittrich, 1998]) was administered 720 minutes after treatment, and a shorter version of the 5D-ASC 180, 250 and 360 minutes after treatment.

Neuroimaging data acquisition

MRI data was acquired using a whole-brain gradient-echo planar imaging (EPI) sequence on a Philips Achieva 3.0T whole-body scanner. For each resting-scan, 240 volumes were acquired (total scan duration: 10 minutes). Additionally, high-resolution Tl-weighted (via a 3D magnetization-prepared rapid gradient-echo sequence, MP-RAGE) and T2-weighted (via a turbo spin-echo sequence) anatomical images were acquired. Preprocessing

MRI data was preprocessed following the methods developed by the Human Connectome Project (Glasser et al., 2013, NeuroImage). For T1 -weighted and T2-weighted images, a biasfield correction was applied, the images were warped to the MNI-152 template, followed by brain-extraction, within-subjects registration, and individual cortical and subcortical anatomical segmentation (Reuter et al., 2012, NeuroImage). For functional MRI (BOLD) images, corrections for field inhomogeneity distortion, phase encoding direction distortions, susceptibility artifacts, and motion were applied. Subsequently, BOLD images were registered to the structural images, and non-brain tissue was removed via a brain-mask. Then, BOLD time series were high-pass filtered, and the ventricle, white matter and global (mean gray matter) signal were regressed out of the gray matter time series. Finally, frames were excluded if the sum of the displacements across all six rigid body movement correction parameters exceeded 0.5 mm or the normalized root mean square of intensity differences between a given frame and its preceding frame exceeded 1.6 times the median across scans.

Parcellation

For some of the analyses, voxel-wise time series were parcellated using the Cole- Anticevic Brain-wide Network-Parcellation atlas (CAB-NP) (Ji et al., NeuroImage, 2019) Figure 71. Parcellated time-series were generated with Connectome Workbench. Functional connectivity (FC) and global brain connectivity (GBC) calculation

Functional connectivity (FC) was calculated as the Pearson correlation coefficient between each pair of voxels’ or each pair of parcels’ BOLD time series, resulting in voxel x voxel or parcel x parcel FC matrix, respectively. Fisher-z transformed FC matrices, FCz, were obtained by applying a Fisher-z transform individually to each element of a matrix:

where i and j denote parcels or voxels. To avoid extreme values resulting from the Fisher z- transform, correlations coefficients above 0.999999 or below -0.999999 were treated as 0.999999 and -0.999999, respectively.

Global brain connectivity (GBC) was then calculated as the average across rows of the Fisher-z transformed FC matrices:

where, again, z and j denote parcels or voxels, and N is the number of parcels or voxels. The GBC metric provides an interpretable reduction of the full functional connectivity matrix whereby the map reflects the average connectivity of each voxel to all other voxels. This metric is highly desirable as a feature space reduction procedure without biasing the effects towards any one area.

The difference in FC and GBC across any two conditions, i.e.: AFC = FC(condition 2) - FC(condition 1); and AGBC = GBC(condition 2) - GBC(condition 1) were analyzed. Typically, these are matched for the scan time, i.e., early (75-min), late (300-min), or average (combined early and late). Visualization

Two types of visualizations are provided:

CIFTI brain maps: In the first visualization a surface-based representation and volume-based representation of the data were highlighted where the shade of grayscale reflects the AGBC value for a given contrast. The intensity of the value in the image reflects a Z statistic, where for instance a value of 1 can be interpreted in 1 standard deviation along a standard Z distribution indicating the difference between the relevant conditions (i.e. AGBC). Here lighter shades of grayscale denote higher GBC for the first condition relative to the second condition, whereas darker shades of grayscale denote lower GBC for the first condition relative to the second condition.

Chord plots: In the second visualization, a standard ‘chord’ plot was shown where each segment along the circle indicates a given left hemisphere cortical parcel from the CAB-NP parcellation (described above) (Figures 83-101). The ‘chord’ connecting any two nodes reflects the difference across two conditions in functional connectivity (i.e. an edge) between any two nodes. That is, the value represents AFC between two relevant conditions. Each chord plot visualizes the difference in connectivity (AFC) between the conditions indicated on the left of each row, for the session indicated at the top of each column. Positive and negative contrasts are rendered, respectively, in red and blue hues. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. For better visibility Figs. 84-89 show positive and negative contrasts in separate panels. Statistical analysis

AGBC contrasts were evaluated using a 1 -sample t-test. Confidence intervals were calculated as

where x is the mean of the observed contrasts, s their standard deviation, n the number of samples (subjects), and c is the 97.5th percentile of the t distribution with n-1 degrees of freedom. Raw p-values were adjusted for multiple comparisons using the Benjamini -Hochberg FDR correction. Chord plots are shown in Figures 83-101. Each chord plot visualizes the difference in connectivity (AFC) between the conditions indicated on the left of each row, for the session indicated at the top of each column. Positive and negative contrasts are rendered, respectively, in red and blue hues. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. For better visibility Figs. 84-89 show positive and negative contrasts in separate panels.

Results

Pretreatment with ketanserin, compared to pretreatment with placebo, leads to distinct neural changes at the early time point (75 minutes)

There was clear neural evidence that pretreatment with ketanserin, compared to pretreatment with placebo, led to differences at the whole-brain level at the early time point (75 minutes). This was apparent by visual inspection of dense GBC maps (Fig. 72 and Fig. 73). A more quantitative inspection of the two different pretreatment conditions at the early time point (75 minutes) is shown in Fig. 77 (left panel). While GBC changes between the two different pretreatment conditions have a net negative correlation (r=-0.42, see also Table 181).

Table 181: Correlations between GBC changes in parcels induced by Pla+LSD and

Ket+LSD (relative to Pla+Pla)

Next, pretreatment effects on FC values were investigated. FC contrasts between all condition pairs and for all time points are shown in Fig. 76. A closer, quantitative inspection of the connectivity contrasts between for the 718 parcels of the CAP-NP parcellation shows that FC changes between the two pretreatment conditions are only mildly correlated (r=0.13, see Fig. 78 left panel and Table 182). Note that, due to the large number of connections (~ 260,000) this mild correlation is nonetheless strongly significant.

Table 182: Correlations between FC changes in parcels induced by Pla+LSD and Ket+LSD relative to Pla+Pla)

Pretreatment with ketanserin and pretreatment with placebo lead to similar neural changes at the late time point

At the late time point (after 300 minutes), GBC changes in the two different pretreatment conditions are strongly positively correlated. This is immediately apparent by visual inspection (Fig. 74 and Fig. 75). Moreover, Fig. 77 (right panel) confirms this observation quantitatively. The correlation between the AGBC changes across parcels was 0.8 (see also Table 181).

This strong correlation was corroborated when analyzing FC contrasts. The correlation across connections between AFC values for the two different pretreatment conditions was found to be 0.64 (see Fig. 78 right panel and Table 182). A FC values were slightly stronger in the Pla+LSD as compared to the Ket+LSD condition.

Parcels that might underlie effects

For which parcels a contrast’s distribution across subjects is significant was tested. For each contrast, t-statistics, corresponding p-values, confidence intervals and FDR-BH corrected p- values were all calculated using 1 -sample t-tests. Confidence intervals are visualized in Fig. 79 and Fig. 80 for the early and late time point, respectively. Desaturated (light) shades of grayscale were used in these figures when a parcel’s contrast was not significant after FDR correction (i. e. when pcorrected > 0.05). Nonetheless, as shown above (Fig. 77), the overall pattern of contrasts across parcels resembled the Pla+LSD - vs - Pla+Pla pattern of contrasts, especially at the late time point. FC Network Matrix

For networks defined in the CAP-NP atlas, pairwise comparison of FC was made for each network pair for the different test conditions at early, late and average session time points. For each network pair, all connection contrasts (i.e. AFC values) between these two networks were averaged resulting in a network x network FC contrast matrix (Fig. 81).

Pretreatment with ketanserin prevents self-reported altered states of consciousness in LDS- treated subjects

• Test subjects treated with Pla+LSD exhibited substantial self-reported altered states of consciousness at the 180-minute, 250-minute and 360-minute time points (Fig. 82). Pretreatment with ketanserin prevented significant self-reported altered states of consciousness at all time points tested in the Ket+LSD test subject group (Fig. 82, right graph).

Conclusions

Clear effects of pretreatment with ketanserin at the early time point in conjunction with LSD that were distinct from placebo (75 min after treatment administration) were observed. At this early time point, connections that exhibit a change under Ket+LSD may reflect additional therapeutic targets that were not blocked by Ketanserin, but were modulated by LSD.

A different picture was observed at the later time point (300 minutes after treatment administration). Here, both GBC and FC changes were strongly correlated when examining maps for Pla+LSD and Ket+LSD (across parcels and connections, respectively). This indicated that even in the absence of psychotomimetic effects of LSD at this later time point there were neural effects that strongly resemble the fully psychotomimetic state when only LSD is administered. Importantly, despite these similarities in neural effects, the two conditions differed behavi orally: when subjects received a placebo pre-treatment they reported psychotomimetic effects of LSD, but when they received ketanserin as pre-treatment they did not (Preller et al., eLife, 2018). Notably, the Pla+LSD group GBC maps did not significantly differ between 75 minutes and 300 minutes indicating that the LSD effects alone produced a robust and consistent effect across time. This contrasted with the Ket+LSD map which significantly changed from 75 minutes to 300 minutes. The finding that the LSD effects were comparable from 75 minutes to 300 minutes was consistent with the 5D-ASC scale data showing the psychotomimetic effects in the Pla+LSD group were still significantly elevated from placebo at the 360 minute timepoint (Fig. 82). This indicated that the neural effects observed via imaging of the Ket+LSD condition at 300 minutes reveal neural changes of the core effects of LSD.

However, while ketanserin pretreatment blocked all of the psychotomimetic effects of LSD at all timepoints and many of the immediate neural changes induced by LSD at 75 minutes, these LSD induced neural changes reached near full effect within 300 minutes in the presence of ketanserin and in the absence of psychotomimetic effects. This is the first evidence showing that while pretreatment with ketanserin fully blocked the behavioral effects of LSD (the “trip”), it did not block the neural changes induced by LSD that are thought to underlie its potential therapeutic effects.

Seed Contrast Maps and Gene expression maps

Methods

Contrast Maps

To generate AGBCz contrast maps we calculated GBC maps from z-scored FC matrices via

where i and j denote parcels, N is the number of parcels in the parcellation and FCztj is the Fisher z-transformed Pearson correlation between BOLD time series in parcels i and j. We then subtracted GBCz contrast maps of two specified conditions at specified time points to arrive at AGBCz contrast maps.

Seed Contrast Maps

We also calculated seed maps averaged across parcels in a network. A seed map for a given parcel i gives the Pearson correlation of the BOLD time series in parcel i with all other parcels in the parcellation. Here, we calculated seed contrast maps by subtracting two seed maps of two specified conditions and time points, for a fixed parcel i. We then averaged these seed contrast maps across all parcels belonging to an indicated network, here either the Cingulo- Opercular network or the Visual network (combining the Visual 1 and Visual2 networks). Fig. 71 shows the parcellation using the Cole- Anticevic Brain-wide Network-Parcellation atlas (CAB-NP) (Ji et al., NeuroImage, 2019). When visualizing the resulting seed contrast maps we only plot parcels outside the indicated network, to focus on connectivity contrasts with parcels outside the network.

Gene Expression Maps

Gene expression maps were derived from the Allen Human Brain Atlas [Hawrylycz et al., Nature, 2012,]. The publicly available DNA microarray data were processed as described in Burt et al. [Nature Neuroscience, 2018] and mapped to the 180 left hemisphere parcels of the Human Connectome Project’s Multi-Modal Parcellation [Glasser et al., Nature, 2016],

Stability of gene expression maps across donors was measured in terms of differential stability [Burt et al., Nature Neuroscience, 2018], Differential stability across cortical areas, DSc measures the mean pairwise correlation between any two donors’ individual gene expression maps for a given gene, g:

where rs denotes Spearman correlation, n is the number of subjects for which a gene probe was available and bt(g) is the vector of expression values across parcels for donor z and gene g.

Results

Neural effects ofKet at the 75min time point

We contrast the Pla+LSD and the Ket+LSD conditions. To this end, we also decompose the effect of LSD into a map, m, that will be completely blocked if Ketanserin was administered alone (i.e. m=-Ket, such that m+Ket=0), and a residual map which we here refer to as the “OtherTarget” map. I.e. we have

[Pla+LSD] = -Ket + OtherTarget.

Moreover, assuming a linear superposition of the maps that would be obtained with Ket alone, and with LSD alone, the Ket+LSD map is:

[Ket+LSD] = Ket + [-Ket + OtherTarget] = OtherTarget.

Thus, the Pla+LSD vs Ket+LSD contrast is given by

[Pla+LSD] - [Ket+LSD] = (-Ket + OtherTarget) - OtherTarget = -Ket which is the map that is blocked by Ketanserin.

This contrast for the AGBCz measure at 75min is shown in Figure 102. We find the most positive contrasts in parcels of the visual network, and the most negative contrasts in parcels of the cingulo-opercular network. Moreover, seed connectivity contrasts averaged across parcels of the visual networks were strongly positive with superior temporal regions, whereas seed connectivity contrasts averaged across parcels of the cingulo-opercular network were strongly positive with visual regions and strongly negative with regions of the anterior cingulate cortex (Fig. 103).

Neural Effects ofKet at the 300 Min Time Point

We consider again the Pla+LSD vs Ket+LSD contrast which approximately reveals the effects of Ketanserin as shown above. At the 300min time point both LSD and Ket effects are weaker overall. Nonetheless, inspecting the Pla+LSD vs Ket+LSD contrast for the AGBCz metric we find again strong positive contrasts in parcels of the visual network and strong negative contrasts in parcels of the cingulo-opercular network (Fig. 104). On the other hand, seed connectivity contrasts differ (Fig. 105). Seed connectivity contrast maps averaged across parcels of the visual networks are weak overall, whereas seed connectivity contrasts maps averaged across parcels of the cingulo-opercular network show strong positive contrasts with visual networks and superior temporal regions.

Differences between the late and early time points for the Ket+LSD vs Pla+Pla condition

We have previously observed that the Pla+LSD vs Pla+Pla contrast for the AGBCz metric showed a similar pattern for the 75 min and the 300 min time point. That same pattern was also observed for the Ket+LSD vs Pla+Pla contrast at the 300 min time point, but not at the 75 min time point. We examined the changes that occurred for the Ket+LSD vs Pla+Pla contrast between the 75 min and the 300 min time point. The strongest positive changes appear in visual networks, whereas the strongest negative changes occur in the cingulo-opercular network (Fig. 106). We also investigated changes of the Ket+LSD vs Pla+Pla contrast between the 75 min and 300 min time points at the level of seed connectivities (Fig. 107). Seed connectivity contrasts averaged across parcels of visual networks were strongly positive with somatomotor and superior temporal regions. On the other hand, seed connectivity contrasts averaged across parcels of the cingulo-opercular network were strongly positive with visual regions and strongly negative with somatomotor and anterior cingulate regions. Temporal Ket+LSD changes appear similar to effects that Ket blocks

We compared the pattern of changes between the 300 min and 75 min time point for the AGBCz Ket+LSD vs Pla+Pla contrast to the Pla+LSD vs Ket+LSD contrast at 75min (Fig. 108). Note that we have previously identified the latter as the approximate neural pattern that is blocked by Ket. We find a strong correlation between the same contrasts at the level of AFC (Fig. 108 left). We also find an even stronger correlation (r=0.90, Fig. 108 right) at the level of AGBCz. This highlights that AGBCz is a highly sensitive metric for revealing effects of timedependent change in LSD during administration of ketanserin. Importantly, this result shows that the temporal change of the neural effect of LSD with concurrent Ketanserin administration is similar to the neural effect of LSD that Ketanserin blocked at the early timepoint (at 75 min). In other words, the temporal change in neural LSD effects with Ketanserin administration is as follows: It goes from a pattern driven by Ketanserin blocking the LSD neural effect at 75 min, towards a neural pattern that resembles a pure LSD effect but without the psychotomimetic effects at 300 min. This prominent neural effect of LSD returning by 300 min supports a therapeutic effect of LSD without the associated psychotomimetic effects, ma

Alignment of gene expression maps with contrast maps

We calculated the Pearson correlation of the AGBCz contrast maps with all gene expression maps (Fig. 109). Compared to all gene expression maps, the alignment of the HTR2A map was very high with the 75 min Pla+LSD vs Pla+Pla contrast map, with the 300 min Pla+LSD vs Pla+Pla contrast maps and the 300 min Ket+LSD vs Pla+Pla contrast map. On the other hand, compared to all gene expression maps the alignment of the HTR2A map with the 75 min Ket+LSD vs Pla+Pla contrast map was very low and negative. This supports involvement of the 5HT2A receptor in the therapeutic effects of LSD but without the psychotomimetic effects that are mediated by this receptor. This supports the combination of a 5HT2A receptor antagonist with a psychedelic where the 5HT2A receptor antagonist allows a small amount of 5HT2A receptor activation that is large enough to have therapeutic effects but not large enough to cause psychotomimetic effects.

Discussion We found that the AGBCz changes for the Ket+LSD vs Pla+Pla contrast between the 75 min and 300 min time points resemble specifically the approximate neural effect map that Ket blocks. Thus, at the 300 min time point, the neural effects of the Ket+LSD condition are dominated by LSD, whereas the behavioral effects are dominated by Ket, i.e. subjects do not experience psychotomimetic effects. This regime, with neural effects of LSD clearly present but neural effects of Ket almost subsided, might provide the benefits of LSD encoded in its neural effects, but without its usual psychotomimetic side effects.

Example 11: Crystallization of Ketanserin Succinate

Solubility studies in common single solvent systems indicated that ketanserin free base (Pattern A) has poor solubility in most solvents except acetic acid, dimethyl sulfoxide (DMSO) and dimethylacetamide (DMAc), and that ketanserin succinate (Pattern H) has low solubility in most solvents except DMSO and DMAc. Ketanserin succinate Pattern H exhibited good stability in a mixture of acetic acid/water/acetone (1 : 1 :3, N/N/V, -65 mg/mL) at 30°C for up to 24 h, and was both chemically and physically (solid-state) stable after storage at 60°C for at least 4 days and at ambient temperature (15-25°C) for at least 9 days.

Preliminary studies indicated that crystallization from an acetic acid / water system to give Pattern H was promising, but the isolated yield was low (-45%). Dissociation of succinate occurred when the salt was washed with water, but not when the salt was washed with acetone, so acetone was selected as wash solvent. After optimization, crystallization from a mixture of acetic acid/water/acetone (0.5/0.5/10.5, v/v/v) at 25°C, followed by cooling to 10°C and isolation, could give ketanserin succinate Pattern H in -84% yield. In addition, an excess of succinic acid in the range of 1.3 -1.6 equivalents relative to ketanserin free base would minimize dissociation and formation of solid-state form Pattern I (acetic acid solvate of ketanserin succinate). Stress tests showed that fast anti-solvent addition and fast cooling delivered mainly polymorph Pattern A, so anti-solvent addition and cooling should be slow and well controlled in order to produce Pattern H. Other stress test results demonstrated stability of the solution after a hold time of 24 h after dissolution, and a hold time of 34 h at the final condition (10°C), indicating the robustness of the process.

Verification experiments on the scale of 10 g, 250 g and 800 g were carried out to demonstrate process feasibility. The experiments afforded ketanserin succinate Pattern H in 99.4% purity and 76-79% yield, a 1 : 1 stoichiometry of free base and acid (1H-NMR) and a particle size D90 -32 - 53 pm.

Ketanserin succinate Pattern H can be produced with residual acetic acid levels at -7400 ppm in the 800-g (non-GMP) batch. Lab trials conducted to reduce acetic acid levels by slurrying at different temperatures led to partial loss of the succinic acid (XRPD) due to low basicity of ketanserin. Slurrying in different solvents (MeOH, acetone/H2O, IPA/H2O, IP A, EtOAc) also led to partial loss of succinic acid. Acetic acid levels were reduced from 7400 to 6900 ppm after drying at 60 - 70°C for 18 hours, but were not reduced further after prolonging drying to 120 hours. The specification for acetic acid was set at NMT 10,000 ppm.

The PSD for ketanserin succinate produced on 10, 250 and 800 g scale was within the range: D90: <125 pm, D50: 40-75 pm.

Succinate Pattern H preparation

To prepare ketanserin succinate salt (Pattern H), a 5 g of ketanserin free base (Pattern A) and 1.05 equivalents succinic acid were slurried in acetonitrile (8 V) to give initially ketanserin succinate salt (Pattern A), of which the wet solid was re-slurried in a mixture of trifluoroethanol (TFE) and water to give ketanserin succinate salt (Pattern H) in 65% yield. The results are summarized in Table 183.

Table 183: Slurry experiment to successively prepare ketanserin succinate Pattern A and Pattern H

Solubility and chemical stability study

Solubility study of ketanserin free base (Pattern A)

Solubility of ketanserin free base (Pattern A) was measured in several solvents at different temperatures by gravimetric method, and the results are presented in Table 184. Ketanserin free base has poor solubility in most of the studied solvents, except for acetic acid, DMSO and DMAc. Table 184: Solubility of ketanserin free base (Pattern A) in single solvents at 50°C and 25°C

Solubility study of ketanserin succinate (Pattern H)

The solubility of ketanserin succinate (Pattern H) was determined in several solvents at different temperatures by gravimetric method, and the results are presented in Table 185. The succinate salt has poor solubility in all studied solvents, except for DMSO and DMAc. Furthermore, the solubility of ketanserin succinate (Pattern H) was determined in solvent mixtures, mainly composed of TFE/water and acetic acid/water at 50°C and 25°C, as summarized in Table 186.

Table 185: Solubility of ketanserin succinate (Pattern H) in single solvents at 50°C and 25°C

Table 186: Solubility of ketanserin succinate (Pattern H) in mixed solvents at 50°C and

25°C

Solution state chemical stability study of ketanserin succinate

The chemical stability of a solution of ketanserin succinate in AcOH/water/acetone at 30°C under N2 protection was assessed. The details and results, summarized in Table 187, indicate good stability of ketanserin succinate in AcOH/water/acetone solution at 30°C for 24 h. Table 187: Chemical stability of ketanserin succinate solution

Solid state stability study of ketanserin succinate (Pattern H)

The stability of ketanserin succinate (Pattern H) was assessed after exposure of the solid to 60°C under vacuum, and after holding the wet solid under ambient temperatures (15-25°C), by monitoring purity, KF and XRPD. The results summarized in Table 188 demonstrate the chemical and physical (solid-state form) stability of ketanserin succinate (Pattern H) for up to 4 days at 60°C, and up to 9 days at ambient temperatures (15-25°C).

Table 188: Drying stability of ketanserin succinate (Pattern H)

Preliminary crystallization experiments

The results for several preliminary crystallization experiments are shown in Table 189.

DMSO/water and DMAc/water systems afforded succinate Pattern A. Succinate Pattern H was obtained in TFE/water and acetic acid/water systems, but dissociation of the succinic acid occurred when the solid was washed with water. No dissociation occurred when the wet-cake was rinsed with acetone, so acetone was chosen as wash solvent.

Table 189: Preliminary crystallization experiments

Optimization of crystallization conditions

Yield improvement and reduction of residual acetic acid

Residual acetic acid and low isolated yields were observed in preliminary crystallization experiments. The results from several experiments conducted in temary/quatemary systems to resolve these issues, are summarized in Table 190. Crystallization in AcOH/water/acetone system was promising.

Table 190: Optimization crystallization experiments

Succinic acid stoichiometry study

Slightly differing succinic acid stoichiometries (0.95, 1.05, 1.1 and 1.2 eq) were assessed for their impact on quality and yield. The results, presented in Table 191, show that 1.1 equivalents succinic acid gave product in the highest isolated yield.

Table 191: Investigation of succinic acid stoichiometry

Induction time study To study the induction time after dissolution, an experiment with ketanserin free base and 1.1 eq succinic acid was carried out. The results, summarized in Table 192, indicate that the induction time was < 3 h.

Table 192: Induction time study

Dissolved volume and ratio study

To study the effect of dissolved volume and ratio on isolated yield, several experiments using magnetic stirring with different volumes and ratios were carried out. The results, summarized in Table 193, show that AcOH/water/acetone (1 : 1 :0.5, v/v/v), AcOH/water/acetone (1 : 1 :0.75, v/v/v) and AcOH/water/acetone (1 : 1 :1, v/v/v) gave the best yields.

Table 193: Dissolved volume and ratio investigation

Verification experiments

Preliminary verification experiment

To verify the optimized process, a 10 g scale experiment with mechanical stirring was carried out. The results, shown in Table 194, indicate the persistence of Pattern H with an extra peak from Pattern A (seen overlay XRPD as below) even after extension of the slurrying time.

Table 194: Preliminary verification experiment

Investigation of parameters contributing to emergence of Pattern A peak with Pattern H in

10-g scale experiment: Three parameters differed for verification on 10 g scale compared with those used for smaller scale experiments:

1. Different stirring type;

2. Holding time after seeding;

3. Volume of acetone before seeding; The results in Table 195 show that form conversion is impacted by stirrer type, but not by holding time after seeding or acetone volume before seeding. Table 195: Investigation of parameters potentially impacting form conversion

Competitive ripening of ketanserin succinate solid-state forms Pattern A and Pattern H

To study the thermodynamic stability of ketanserin succinate Pattern H and Pattern A, several competitive ripening experiments in AcOH/water/acetone were carried out. The results, shown in Table 196, indicate the greater stability of Pattern H in all studied solvent systems.

Table 196: competitive ripening

Form Conversion Experiments

To verify the greater stability of Pattern H relative to Pattern A observed in the competitive ripening experiments (Table 196), several experiments were conducted to interrogate form conversion at different temperatures and solvent ratios. The results, summarized in Table 197, show the conversion of Pattern A into Pattern H in all experiments.

Table 197: Form conversion experiments

Verification on 50 g scale

To further verify the process, an experiment at 50 g scale was conducted to extend the holding time after seed loading from 1-5 hours to 17 hours. The results, shown in Table 198, indicate that the experiment went smoothly to give pure Pattern H.

Table 198: Further verification experiment on 50 g scale

Preliminary stress tests

To study the robustness of process, several stress tests were carried out.

Stress test of fast anti-solvent addition and fast cooling To study the robustness of process, two stress tests involving fast anti-solvent addition and fast cooling were conducted. The results, summarized in Table 199, show that Pattern A was mainly obtained when the anti-solvent was added quickly (5 h vs 16 h normal) and temperature was cooled quickly (2 h vs 5 h normal). Slower rates of anti-solvent addition and cooling should be used to minimize formation of Pattern A. Table 199: Stress test involving fast anti-solvent addition + fast cooling

Stress test of long hold time after dissolution

A stress test was conducted to study a longer hold time (18 h) after dissolution. The results, presented in Table 200, show the formation of a new solid-state form Pattern I during a 24 h hold time after dissolution.

Table 200: Stress test involving prolonged hold time of 18-h

Preparation of new form Pattern I

The new solid-state form Pattern I was prepared on 5 g scale for characterization. The process used for its preparation is presented in Table 201.

Table 201: Preparation of new form Pattern I

Competitive ripening of Pattern A/Pattern H/Pattern I

To study the thermodynamic stability of ketanserin succinate Pattern I, Pattern H and Pattern A, several competitive ripening experiments in AcOH/water/acetone were carried out. The results, shown in Table 202, indicate that a 1 : 1 : 1 mixture of Patterns A, H and I can give rise cleanly to Pattern I in a solvent system containing a greater proportion of AcOH and water relative to acetone.

Table 202: Competitive ripening

Identification of Pattern I

A distinct solid-state form (Pattern I) was identified, and XRPD/DSC for Pattern I differed from those for Pattern H.

The 'H-NMR spectra showed that the acetic acid content of Pattern I was high (-12%), while the content of succinic acid was just 0.52 eq. There are three possibilities for the identity of Pattern I:

1) Pattern I is the solvate (acetic acid) of ketanserin succinate salt;

2) Pattern I is the solvate (acetic acid) of ketanserin acetic acid salt;

3) Partial salt dissociation occurred first, followed by formation of acetic acid solvate of ketanserin free base.

Possibility of Pattern I as acetic acid solvate of ketanserin succinate salt

If Pattern I is the acetic acid solvate of ketanserin succinate salt, Pattern H should be obtained after desolvation or loss of acetic acid (peak at ~150°C). When the sample with the endotherm at ~150°C was heated to 165°C (DSC) and cooled to room temperature, the XRPD and DSC were re-run. The XRPD obtained after heating on DSC, was not Pattern H. Pattern I was not the acetic acid solvate of ketanserin succinate salt.

Possibility of Pattern I as acetic acid solvate of ketanserin acetate salt

Since ketanserin salt formation was carried out in AcOH/water/acetone system, formation of ketanserin acetate salt is a possibility. To verify this hypothesis, an experiment with freebase (1.0X) and acetic acid (1.1 V) was carried out at 25°C, and the XRPD of the resultant solid was collected. The XRPD of the solid was not Pattern I. Pattern I is not ketanserin acetate salt.

Possibility of initial partial salt dissociation followed by acetic acid solvation of ketanserin freebase and/or ketanserin succinate salt

Dissociation of the succinate salt was observed during polymorph screening. Since the crystallization process was conducted in AcOH/water/acetone, it is possible that partial succinate salt dissociation occurred initially, followed by formation of acetic acid solvate with the dissociated free base. To verify this hypothesis, XRPD, DSC and 'H-NMR data were collected before and after solvate melting (165°C). NMR data indicated that the succinic acid content in Pattern I was just 0.52 equiv. The characteristic peaks of ketanserin free base were evident in the XRPD after heating the Pattern I sample to 165°C. The succinate salt dissociated in the crystallization system.

Further optimization to avoid Pattern I formation

During process development, Pattern I emerged after dissolution in AcOH/water/acetone, and after (partial) succinate salt dissociation. Two parameters explored to suppress Pattern I formation included (1) increasing the amount of succinic acid, and (2) reducing the volume of acetic acid.

Increasing the amount of succinic acid

The effect of increasing succinic acid stoichiometry on Pattern I formation was studied. The procedure and results are summarized in Table 203. The results indicate that use of 1.5 eq succinic acid would give Pattern H.

Table 203: Suppressing Pattern I formation by increasing succinic acid stoichiometry

Reducing the volume of acetic acid

The effect of reducing the volume of acetic acid on Pattern I formation was also studied.

The procedure and results are summarized in Table 204. The results show that a lower volume of acetic acid (e.g. 0.25 V) would give Pattern H exclusively. Table 204: Suppression of Pattern I formation by reducing acetic acid volume

To confirm the processing conditions, an experiment was conducted on 1-gram scale. The results, presented in Table 205, show the recovery of product exclusively as Pattern H and in 66% yield.

Table 205: Verification experiment

Stress tests

Long hold time after dissolution

To determine whether dissociation occurs under optimized conditions, two stress tests involving a long hold time of ~24 h after dissolution were carried out. The results, presented in Table 206, show that pure Pattern H is obtained using 1.5 eq succinic acid even with a long hold time of 24 h. These are the recommended processing conditions to afford Pattern H exclusively.

Table 206: Stress tests using long hold times

Long hold times at final 10°C condition

To study the robustness of the final holding condition at 10°C, a stress test using hold times of 10 and 34 h was conducted. The results, presented in Table 207, show that these hold times had no significant impact on purity. Table 207: Long hold times at final 10 °C condition

Further optimization of succinic acid equivalents

To study the range of succinic acid equivalents, two experiments using 1.3 eq and 1.6 eq were carried out. The results, presented in Table 208, show that 1.3-1.6 eq succinic acid affords pure Pattern H.

Table 208: Effect of succinic acid equivalents

Seeding point study

To find the seeding point, several experiments with different solvent volumes were carried out. The results were shown in Table 209. Table 209: Seeding point study

Further verification and scale up

Further verification on 10-gram scale

To further verify the process, an experiment on 10 g scale was conducted. The results are shown in Table 210. The experiment went smoothly, giving product as Pattern H, in 99.4% purity, 75.7% yield and 0.52% residual AcOH.

Table 210: Verification experiment on 10g scale

Verification on 250-gram scale

To further verify the process, a 250 g scale experiment was carried out. The experiment went smoothly, delivering ketanserin succinate as Pattern H, in 99.4% purity, 79% yield and D90 32 um.

Table 211: Process verification on 250-gram scale

Removal of residual acetic acid

For reduction of residual acetic acid, extended drying times and re-slurrying were studied. Extended drying time For further reduction of residual acetic acid, extended drying times at 60°C were studied.

The results, summarized in Table 212, show that extended drying times do not purge residual acetic acid.

Table 212: extending drying time

Re-slurrying for controlling residual acetic acid

The effect of re-slurrying at 10°C and 25°C on residual acetic acid levels was studied. The results, presented in Table 213, indicate that re-slurrying in acetone at 25°C gives negligible reduction (from 0.65% to 0.50%) in residual acetic acid levels.

Table 213: Re-slurrying experiments

PSD control

The target PSD is D90: <125 um, D50: 40-75 um. The PSD for several batches, presented in Table 214, are all within the target range. Table 214: PSD summary

Summary

A crystallization process was developed successfully for ketanserin succinate. The finalized process is summarized as follows:

Process under nitrogen atmosphere:

1. Dissolve net 1.0 X ketanserin free base (Pattern A) and 1.5 eq succinic acid in 1.6 V AcOH/water/acetone (1:1:0.5, v/v/v) at 20°C-30 °C.

2. Polish fdter and wash with 0.2 V AcOH/water/acetone (1:1:0.5, v/v/v) at 20-30°C. 3. Add 1.3 V acetone at 20-30°C.

4. Add 0.5-1 % seed (Pattern H).

5. Hold for 12-24 h at 20-30°C (confirm Pattern H).

6. Add 13.49 V over NLT 16 h at 20-30°C.

7. Adjust R1 to 10° C over 5 h.

8. Stir R1 for 12 h at 10°C.

9. Filter and wash with 4-8 V acetone 3 times.

10. Dry wet cake under vacuum at 45°C-55°C for 24 h.

The process was demonstrated on 250 g scale, and the subsequent manufacturing on kilogram scale was also completed successfully. The key conclusions from process development work are summarized below:

1. Total eight solid-state forms (from Pattern A to Pattern H) were identified for ketanserin succinate. Pattern A, C and H are anhydrates of mono-succinate salt, Pattern D and F are hydrates of the mono-succinate salt, Pattern B is an anhydrate with a non-stoichiometric ratio succinate salt, Pattern E is likely a hydrate of ketanserin hemi-succinate salt, and Pattern G is a dissociation product obtained in DMSO/water by anti-solvent addition. Pattern H was selected for development.

2. Solubility studies indicated that ketanserin free base (Pattern A) has poor solubility in almost studied solvents except acetic acid, DMSO and DMAc.

3. Solubility studies indicated that compound ketanserin succinate (Pattern H) has low solubility in most solvents except DMSO and DMAc.

4. Solution state chemical stability studies indicated that ketanserin succinate shows good stability in acetic acid/water/acetone at 30°C for 24 h.

5. Solid state chemical stability study indicated that ketanserin succinate was both chemically and physically (solid-state form) stable for 4 days at 60°C and 9 days at ambient (15-25°C).

6. Preliminary crystallization studies indicated that crystallization in acetic acid / water system was promising for producing Pattern H, but isolated yields were low (-45%). Furthermore, succinate salt dissociation occurred when the solid was washed with water, but not when washed with acetone, so acetone was selected as wash solvent. After optimization, crystallization in a solvent system comprised of acetic acid/water/acetone (0.5:0.5: 10.5 v/v/v) at 25°C followed by cooling to 10°C, ketanserin succinate Pattern H could be obtained in satisfactory yield (-84%). In addition, 1.3-1.6 eq (target: 1.5 eq) succinic acid is the recommended range to give Pattern H with suppression of Pattern I formation. Verification experiments on 10 g, 250 g and 800 g scales were carried out to demonstrate the process. The experiments went smoothly, and afforded ketanserin succinate as Pattern H, in 99.4% purity, 76-79% yield, a 1.0/1.0 freebase/acid ratio (H-NMR) and particle size D90: -32 - 53 um, and residual acetic acid levels -6600 ppm. These residual acetic acid levels were not significantly reduced by extended drying times or re-slurrying without salt dissociation. The PSD results for batches on different scales were all within the target range (D90: <125um, D50: 40-75 um). Stress tests indicated that fast anti-solvent addition and fast cooling gave mainly ketanserin succinate Pattern A, so anti-solvent addition and cooling should be slow and well controlled to produce ketanserin succinate Pattern H. The results from stress tests involving hold times -24 h after dissolution and at the final condition (10°C) demonstrated good chemical and physical stability, indicating a robust process.

Embodiments

1. A solid form of ketanserin.

2. The solid form of embodiment 1, wherein the solid form of ketanserin is a salt of ketanserin.

3. The solid form of embodiment 1, wherein the salt of ketanserin is a crystalline salt.

Solid forms of free base form Pattern A

4A. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.5 °29, 21.0 °29, and 14.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

4B. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by signals at 9.5 °29, 21.0 °29, and 14.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

4C. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °29, 21.9 °29, 14.2 °29, 4.7 °29, and 29.1 °29 (±9.2 °29; ±9.1 °29; or ±9.9 °29; Cu Kal radiation).

4D. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °29, 21.9 °29, 14.2 °29, 4.7 °29, 29.1 °29, 27.6 °29, and 26.8 °29 (±9.2 °29; ±9.1 °29; or ±9.9 °29; Cu Kal radiation).

4E. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °29, 21.9 °29, 14.2 °29, 4.7 °29, 29.1 °29, 27.6 °29, 26.8 °29, 17.5 °29, 18.8 °29, and 19.7 °29 (±9.2 °29; ±9.1 °29; or ±9.9 °29; Cu Kal radiation).

4F. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.0 °29, 20.2 °29, and 27.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

4G. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by signals at 21.0 °20, 20.2 °20, and 27.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

4H. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 20.2 °20, 27.7 °20, 18.9 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

41. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

41 The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, 16.4 °20, and 9.5 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

4K. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, and 14.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

4L. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by signals at 9.4 °20, 20.9 °20, and 14.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

4M. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °20, 14.1 °20, 4.7 °20, and 20.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 4N. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, and 19.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

40. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, 18.8 °20, and 10.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

4P. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 1.

4Q. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 44.

4R. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 63.

4S. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 116.

4T. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by any combination of the XRPD peaks set forth in Table 2.

4U. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by any combination of the XRPD peaks set forth in Table 3.

4V. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by any combination of the XRPD peaks set forth in Table 4. 4W. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 141.

4X. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a melting event at about 235.1 °C.

Solid forms of free base form Pattern B

5 A. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern B is a crystalline polymorph of free base form Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 16.8 °29, 26.2 °29, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

5B. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern B is a crystalline polymorph of free base form Pattern B characterized by signals at 16.8 °20, 26.2 °20, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

5C. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern B is a crystalline polymorph of free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °29, 26.2 °20, 27.0 °20, 16.2 °20, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

5D. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern B is a crystalline polymorph of free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °29, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, and 21.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

5E. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern B is a crystalline polymorph of free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °29, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, 22.3 °20, 13.5 °20, and 13.9 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

5F. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern B is a crystalline polymorph of free base form Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 2. 5G. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern B is a crystalline polymorph of free base form Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 45.

5H. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern B is a crystalline polymorph of free base form Pattern B characterized by any combination of the XRPD peaks set forth in Table 5.

51. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern B is a crystalline polymorph of free base form Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 144.

Solid forms of free base form Pattern C

6A. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern C is a crystalline polymorph of free base form Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 14.9 °29, 22.3 °29, and 7.4 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

6B. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern C is a crystalline polymorph of free base form Pattern C characterized by signals at 14.9 °20, 22.3 °20, and 7.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

6C. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern C is a crystalline polymorph of free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 22.3 °29, 7.4 °29, 9.5 °29, and 11.1 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

6D. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern C is a crystalline polymorph of free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 22.3 °29, 7.4 °29, 9.5 °29, 11.1 °29, 3.7 °29, and 14.2 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

6E. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern C is a crystalline polymorph of free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 22.3 °29, 7.4 °29, 9.5 °29, 11.1 °29, 3.7 °29, 14.2 °29, 18.6 °20, and 21.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). 6F. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern C is a crystalline polymorph of free base form Pattern C characterized by a XRPD diffractogram substantially similar to that shown in FIG. 46.

6G. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern C is a crystalline polymorph of free base form Pattern C characterized by any combination of the XRPD peaks set forth in Table 6.

6H. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern C is a crystalline polymorph of free base form Pattern C characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 147.

61. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern C is a crystalline polymorph of free base form Pattern C characterized by a melting event at about 236.4 °C.

Solid forms of free base form Pattern D

7A. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern D is a crystalline polymorph of free base form Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 8.8 °29, 16.1 °29, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

7B. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern D is a crystalline polymorph of free base form Pattern D characterized by signals at 8.8 °20, 16.1 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

7C. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern D is a crystalline polymorph of free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °29, 16.1 °20, 17.5 °20, 18.9 °20, and 10.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

7D. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern D is a crystalline polymorph of free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °29, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, and 17.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

7E. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern D is a crystalline polymorph of free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °29, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, 3.5 °20, 4.0 °20, and 21.5 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

7F. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern D is a crystalline polymorph of free base form Pattern D characterized by a XRPD diffractogram substantially similar to that shown in FIG. 64.

7G. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern D is a crystalline polymorph of free base form Pattern D characterized by any combination of the XRPD peaks set forth in Table 7.

7H. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern D is a crystalline polymorph of free base form Pattern D characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 150.

71. The solid form of any one of the previous embodiments, wherein the solid form of free base form Pattern D is a crystalline polymorph of free base form Pattern D characterized by a melting event at about 235.8 °C.

Solid forms of ketanserin hydrochloride Pattern A

8A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern A is a crystalline polymorph of ketanserin hydrochloride Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, and 24.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

8B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern A is a crystalline polymorph of ketanserin hydrochloride Pattern A characterized by signals at 15.5 °29, 18.3 °29, and 24.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

8C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern A is a crystalline polymorph of ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °26, and 25.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). 8D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern A is a crystalline polymorph of ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20, and 14.1 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

8E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern A is a crystalline polymorph of ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °26, 25.2 °20, 22.9 °20, 14.1 °20, 5.3 °20, 28.5 °20, and 16.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

8F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern A is a crystalline polymorph of ketanserin hydrochloride Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 3.

8G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern A is a crystalline polymorph of ketanserin hydrochloride Pattern A characterized by any combination of the XRPD peaks set forth in Table 8.

8H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern A is a crystalline polymorph of ketanserin hydrochloride Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 128. Solid forms of ketanserin hydrochloride Pattern B

9A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern B is a crystalline polymorph of ketanserin hydrochloride Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, and 26.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

9B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern B is a crystalline polymorph of ketanserin hydrochloride Pattern B characterized by signals at 25.6 °29, 14.8 °29, and 26.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

9C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern B is a crystalline polymorph of ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, and 13.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

9D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern B is a crystalline polymorph of ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20, and 14.5 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

9E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern B is a crystalline polymorph of ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20, 14.5 °20, 29.8 °20, 13.8 °20, and 17.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

9F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern B is a crystalline polymorph of ketanserin hydrochloride Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 17.

9G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin hydrochloride Pattern B is a crystalline polymorph of ketanserin hydrochloride Pattern B characterized by any combination of the XRPD peaks set forth in Table 9.

Solid forms of ketanserin sulfate Pattern A

10 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern A is a crystalline polymorph of ketanserin sulfate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 23.6 °20, 22.5 °20, and 8.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

IOB. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern A is a crystalline polymorph of ketanserin sulfate Pattern A characterized by signals at 23.6 °29, 22.5 °29, and 8.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

IOC. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern A is a crystalline polymorph of ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °20, 22.5 °20, 8.9 °20, 16.5 °20, and 25.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

IOD. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern A is a crystalline polymorph of ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °20, 22.5 °20, 8.9 °20, 16.5 °20, 25.0 °20, 13.9 °20, and 21.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

IOE. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern A is a crystalline polymorph of ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °20, 22.5 °20, 8.9 °20, 16.5 °20, 25.0 °20, 13.9 °20, 21.1 °20, 14.9 °20, 17.4 °20, and 15.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

IOF. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern A is a crystalline polymorph of ketanserin sulfate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 4.

IOG. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern A is a crystalline polymorph of ketanserin sulfate Pattern A characterized by any combination of the XRPD peaks set forth in Table 10.

IOH. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern A is a crystalline polymorph of ketanserin sulfate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 136.

IOI. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern A is a crystalline polymorph of ketanserin sulfate Pattern A characterized by a melting event at about 236.6 °C.

Solid forms of ketanserin fumarate Pattern A

11 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern A is a crystalline polymorph of ketanserin fumarate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 24.8 °20, 9.7 °20, and 23.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

1 IB. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern A is a crystalline polymorph of ketanserin fumarate Pattern A characterized by signals at 24.8 °29, 9.7 °29, and 23.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

11C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern A is a crystalline polymorph of ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °20, 23.1 °20, 27.1 °20, and 8.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

1 ID. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern A is a crystalline polymorph of ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °20, 23.1 °20, 27.1 °20, 8.1 °20, 26.0 °20, and 21.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

1 IE. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern A is a crystalline polymorph of ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °20, 23.1 °20, 27.1 °20, 8.1 °20, 26.0 °20, 21.0 °20, 16.2 °20, 23.5 °20, and 17.9 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

1 IF. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern A is a crystalline polymorph of ketanserin fumarate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 5.

I IG. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern A is a crystalline polymorph of ketanserin fumarate Pattern A characterized by any combination of the XRPD peaks set forth in Table 11.

I IH. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern A is a crystalline polymorph of ketanserin fumarate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 124.

I II. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern A is a crystalline polymorph of ketanserin fumarate Pattern A characterized by a melting event at about 220.4 °C.

Solid forms of ketanserin fumarate Pattern B 12 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern B is a crystalline polymorph of ketanserin fumarate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 9.6 °20, and 23.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

12B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern B is a crystalline polymorph of ketanserin fumarate Pattern B characterized by signals at 15.3 °29, 9.6 °29, and 23.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

12C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern B is a crystalline polymorph of ketanserin fumarate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 9.6 °20, 23.1 °20, 3.8 °20, and 19.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

12D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern B is a crystalline polymorph of ketanserin fumarate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 9.6 °20, 23.1 °20, 3.8 °20, 19.1 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20;

Cu Kai radiation).

12E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern B is a crystalline polymorph of ketanserin fumarate Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 6.

12F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern B is a crystalline polymorph of ketanserin fumarate Pattern B characterized by any combination of the XRPD peaks set forth in Table 12.

12G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern B is a crystalline polymorph of ketanserin fumarate Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 126.

12H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin fumarate Pattern B is a crystalline polymorph of ketanserin fumarate Pattern B characterized by a melting event at about 233.2 °C.

Solid forms of ketanserin citrate Pattern A 13 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin citrate Pattern A is a crystalline polymorph of ketanserin citrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, and 3.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

13B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin citrate Pattern A is a crystalline polymorph of ketanserin citrate Pattern A characterized by signals at 14.1 °29, 19.8 °29, and 3.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

13C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin citrate Pattern A is a crystalline polymorph of ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, and 7.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

13D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin citrate Pattern A is a crystalline polymorph of ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, and 21.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

13E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin citrate Pattern A is a crystalline polymorph of ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, 20.7 °20, 10.1 °20, and 15.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

13F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin citrate Pattern A is a crystalline polymorph of ketanserin citrate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 7.

13G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin citrate Pattern A is a crystalline polymorph of ketanserin citrate Pattern A characterized by any combination of the XRPD peaks set forth in Table 13. 13H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin citrate Pattern A is a crystalline polymorph of ketanserin citrate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 119.

Solid forms of ketanserin maleate Pattern A

14 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern A is a crystalline polymorph of ketanserin maleate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, and 24.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

14B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern A is a crystalline polymorph of ketanserin maleate Pattern A characterized by signals at 11.2 °29, 26.1 °29, and 24.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

14C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern A is a crystalline polymorph of ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, and 25.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

14D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern A is a crystalline polymorph of ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, and 15.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

14E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern A is a crystalline polymorph of ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °20, 9.1 °20, 16.6 °20, and 22.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

14F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern A is a crystalline polymorph of ketanserin maleate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 8. 14G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern A is a crystalline polymorph of ketanserin maleate Pattern A characterized by any combination of the XRPD peaks set forth in Table 14.

14H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern A is a crystalline polymorph of ketanserin maleate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 131.

141. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern A is a crystalline polymorph of ketanserin maleate Pattern A characterized by a melting event at about 246.8 °C.

Solid forms of ketanserin p-tosylate Pattern A

15 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin p-tosylate Pattern A is a crystalline polymorph of ketanserin p-tosylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.8 °20, 3.3 °20, and 23.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

15B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin p-tosylate Pattern A is a crystalline polymorph of ketanserin p-tosylate Pattern A characterized by signals at 21.8 °29, 3.3 °29, and 23.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

15C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin p-tosylate Pattern A is a crystalline polymorph of ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °20, 3.3 °20, 23.2 °20, 21.1 °20, and 10.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

15D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin p-tosylate Pattern A is a crystalline polymorph of ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °20, 3.3 °20, 23.2 °20, 21.1 °20, 10.0 °20, 8.6 °20, and 23.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

15E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin p-tosylate Pattern A is a crystalline polymorph of ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °20, 3.3 °20, 23.2 °20, 21.1 °20, 10.0 °20, 8.6 °20, 23.0 °20, 27.0 °20, 17.9 °20, and 21.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

15F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin p-tosylate Pattern A is a crystalline polymorph of ketanserin p-tosylate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 9.

15G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin p-tosylate Pattern A is a crystalline polymorph of ketanserin p-tosylate Pattern A characterized by any combination of the XRPD peaks set forth in Table 15.

15H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin p-tosylate Pattern A is a crystalline polymorph of ketanserin p-tosylate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 139.

151. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin p-tosylate Pattern A is a crystalline polymorph of ketanserin p-tosylate Pattern A characterized by a melting event at about 230.4 °C.

Solid forms of ketanserin esylate Pattern A

16 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern A is a crystalline polymorph of ketanserin esylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, and 22.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

16B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern A is a crystalline polymorph of ketanserin esylate Pattern A characterized by signals at 20.9 °29, 10.4 °29, and 22.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

16C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern A is a crystalline polymorph of ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, and 14.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

16D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern A is a crystalline polymorph of ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, and 26.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

16E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern A is a crystalline polymorph of ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, 24.9 °20, 13.3 °20, and 22.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

16F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern A is a crystalline polymorph of ketanserin esylate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 10.

16G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern A is a crystalline polymorph of ketanserin esylate Pattern A characterized by any combination of the XRPD peaks set forth in Table 16.

16H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern A is a crystalline polymorph of ketanserin esylate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 121.

Solid forms of ketanserin esylate Pattern B

17 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern B is a crystalline polymorph of ketanserin esylate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 21.8 °20, 22.1 °20, and 10.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

17B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern B is a crystalline polymorph of ketanserin esylate Pattern B characterized by signals at 21.8 °29, 22.1 °29, and 10.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

17C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern B is a crystalline polymorph of ketanserin esylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °20, 22.1 °20, 10.9 °20, 24.9 °20, and 26.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 17D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern B is a crystalline polymorph of ketanserin esylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °20, 22.1 °20, 10.9 °20, 24.9 °20, 26.5 °20, and 27.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

17E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern B is a crystalline polymorph of ketanserin esylate Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 11.

17F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern B is a crystalline polymorph of ketanserin esylate Pattern B characterized by any combination of the XRPD peaks set forth in Table 17.

17G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern B is a crystalline polymorph of ketanserin esylate Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 122.

Solid forms of ketanserin esylate Pattern C

18 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern C is a crystalline polymorph of ketanserin esylate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

18B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern C is a crystalline polymorph of ketanserin esylate Pattern C characterized by signals at 10.5 °29, 5.3 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

18C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern C is a crystalline polymorph of ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, and 23.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

18D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern C is a crystalline polymorph of ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, and 19.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

18E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern C is a crystalline polymorph of ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, 15.5 °20, 28.6 °20, and 7.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

18F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern C is a crystalline polymorph of ketanserin esylate Pattern C characterized by a XRPD diffractogram substantially similar to that shown in FIG. 12.

18G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern C is a crystalline polymorph of ketanserin esylate Pattern C characterized by any combination of the XRPD peaks set forth in Table 18.

18H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin esylate Pattern C is a crystalline polymorph of ketanserin esylate Pattern C characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 123.

Solid forms of ketanserin mesylate Pattern A

19 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern A is a crystalline polymorph of ketanserin mesylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, and 27.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

19B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern A is a crystalline polymorph of ketanserin mesylate Pattern A characterized by signals at 24.0 °29, 23.1 °29, and 27.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

19C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern A is a crystalline polymorph of ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, and 17.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 19D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern A is a crystalline polymorph of ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, and 14.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

19E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern A is a crystalline polymorph of ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, 14.9 °20, 20.3 °20, 29.6 °20, and 15.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

19F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern A is a crystalline polymorph of ketanserin mesylate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 13.

19G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern A is a crystalline polymorph of ketanserin mesylate Pattern A characterized by any combination of the XRPD peaks set forth in Table 19.

19H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern A is a crystalline polymorph of ketanserin mesylate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 134.

Solid forms of ketanserin mesylate Pattern B

20A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern B is a crystalline polymorph of ketanserin mesylate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, and 23.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

20B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern B is a crystalline polymorph of ketanserin mesylate Pattern B characterized by signals at 23.1 °29, 27.6 °29, and 23.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

20C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern B is a crystalline polymorph of ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, and 23.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

20D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern B is a crystalline polymorph of ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, and 15.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

20E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern B is a crystalline polymorph of ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, 15.8 °20, 18.9 °20, 15.5 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

20F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern B is a crystalline polymorph of ketanserin mesylate Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 14.

20G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern B is a crystalline polymorph of ketanserin mesylate Pattern B characterized by any combination of the XRPD peaks set forth in Table 20.

20H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin mesylate Pattern B is a crystalline polymorph of ketanserin mesylate Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 135.

Solid forms of ketanserin be sy late Pattern A

21 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern A is a crystalline polymorph of ketanserin besylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.6 °20, 4.8 °20, and 24.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

21B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern A is a crystalline polymorph of ketanserin besylate Pattern A characterized by signals at 9.6 °29, 4.8 °29, and 24.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). 21C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern A is a crystalline polymorph of ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °20, 4.8 °20, 24.1 °20, 17.2 °20, and 22.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

2 ID. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern A is a crystalline polymorph of ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °20, 4.8 °20, 24.1 °20, 17.2 °20, 22.6 °20, 21.0 °20, and 20.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

2 IE. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern A is a crystalline polymorph of ketanserin besylate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 15.

21F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern A is a crystalline polymorph of ketanserin besylate Pattern A characterized by any combination of the XRPD peaks set forth in Table 21.

21G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern A is a crystalline polymorph of ketanserin besylate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 117.

Solid forms of ketanserin besylate Pattern B

22A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern B is a crystalline polymorph of ketanserin besylate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, and 3.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

22B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern B is a crystalline polymorph of ketanserin besylate Pattern B characterized by signals at 21.7 °29, 9.9 °29, and 3.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

22C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern B is a crystalline polymorph of ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, and 23.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

22D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern B is a crystalline polymorph of ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

22E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern B is a crystalline polymorph of ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, 13.3 °20, 4.9 °20, and 20.0 °20 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

22F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern B is a crystalline polymorph of ketanserin besylate Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 16.

22G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern B is a crystalline polymorph of ketanserin besylate Pattern B characterized by any combination of the XRPD peaks set forth in Table 22.

22H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin besylate Pattern B is a crystalline polymorph of ketanserin besylate Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 118.

Solid forms of ketanserin succinate Pattern A

23 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

23B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by signals at 15.3 °29, 19.4 °29, and 11.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). 23C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, and 9.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

23D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, 9.8 °20, 24.6 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

23E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, 9.8 °20, 24.6 °20, 21.5 °20, 20.8 °20, 25.3 °20, and 3.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

23F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, and 9.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

23 G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by signals at 15.3 °29, 19.4 °29, and 9.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

23H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

231. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

23 J. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °20, 20.8 °20, 21.5 °20, and 18.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

23K. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

23L. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by signals at 15.3 °29, 23.0 °29, and 11.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

23M. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

23N. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, and 21.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

230. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, 25.0 °20, 15.0 °20, and 24.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 23P. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 20.

23Q. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 112.

23R. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 113.

23 S. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by any combination of the XRPD peaks set forth in Table 23.

23T. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by any combination of the XRPD peaks set forth in Table 24.

23U. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by any combination of the XRPD peaks set forth in Table 25.

23 V. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 177.

23W. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a melting event at about 186.9 °C.

Solid forms of ketanserin succinate Pattern B

24A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern B is a crystalline polymorph of ketanserin succinate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 26.2 °20, 20.0 °20, and 27.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

24B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern B is a crystalline polymorph of ketanserin succinate Pattern B characterized by signals at 26.2 °29, 20.0 °29, and 27.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

24C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern B is a crystalline polymorph of ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, and 18.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

24D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern B is a crystalline polymorph of ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, 18.2 °20, 25.7 °20, and 31.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

24E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern B is a crystalline polymorph of ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, 18.2 °20, 25.7 °20, 31.5 °20, 8.7 °20, 20.4 °20, and 16.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

24F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern B is a crystalline polymorph of ketanserin succinate Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 21.

24G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern B is a crystalline polymorph of ketanserin succinate Pattern B characterized by any combination of the XRPD peaks set forth in Table 26.

24H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern B is a crystalline polymorph of ketanserin succinate Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 180.

Solid forms of ketanserin succinate Pattern C

25A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 19.8 °20, 26.4 °20, and 15.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 25B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by signals at 19.8 °29, 26.4 °29, and 15.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

25C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, and 9.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

25D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, 9.9 °20, 15.0 °20, and 15.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

25E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, 9.9 °20, 15.0 °20, 15.9 °20, 22.4 °20, 18.1 °20, and 16.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

25F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 19.8 °20, 9.9 °20, and 25.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

25G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by signals at 19.8 °29, 9.9 °29, and 25.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

25H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °26, 9.9 °26, 25.0 °20, 26.4 °20, and 10.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

251. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °20, 9.9 °20, 25.0 °20, 26.4 °20, 10.1 °20, 15.2 °20, and 27.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

25J. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °20, 9.9 °20, 25.0 °20, 26.4 °20, 10.1 °20, 15.2 °20, 27.9 °20, 13.3 °20, 16.3 °20, and 24.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

25K. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by a XRPD diffractogram substantially similar to that shown in FIG. 22.

25L. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by a XRPD diffractogram substantially similar to that shown in FIG. 115.

25M. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by any combination of the XRPD peaks set forth in Table 27.

25N. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by any combination of the XRPD peaks set forth in Table 27A.

250. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 183.

25P. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern C is a crystalline polymorph of ketanserin succinate Pattern C characterized by a melting event at about 187.2 °C.

Solid forms of ketanserin succinate Pattern D 26A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern D is a crystalline polymorph of ketanserin succinate Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 5.0 °20, 26.7 °20, and 27.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

26B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern D is a crystalline polymorph of ketanserin succinate Pattern D characterized by signals at 5.0 °29, 26.7 °29, and 27.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

26C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern D is a crystalline polymorph of ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, and 21.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

26D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern D is a crystalline polymorph of ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, 21.7 °20, 10.9 °20, and 14.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

26E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern D is a crystalline polymorph of ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, 21.7 °20, 10.9 °20, 14.7 °20, 8.7 °20, 4.4 °20, and 16.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

26F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern D is a crystalline polymorph of ketanserin succinate Pattern D characterized by a XRPD diffractogram substantially similar to that shown in FIG. 23.

26G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern D is a crystalline polymorph of ketanserin succinate Pattern D characterized by any combination of the XRPD peaks set forth in Table 28. 26H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern D is a crystalline polymorph of ketanserin succinate Pattern D characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 186.

261. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern D is a crystalline polymorph of ketanserin succinate Pattern D characterized by a melting event at about 183.5 °C.

Solid forms of ketanserin succinate Pattern E

27A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern E is a crystalline polymorph of ketanserin succinate Pattern E characterized by two or more, or three XRPD signals selected from the group consisting of 14.9 °20, 21.0 °20, and 4.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

27B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern E is a crystalline polymorph of ketanserin succinate Pattern E characterized by signals at 14.9 °29, 21.0 °29, and 4.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

27C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern E is a crystalline polymorph of ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 21.0 °20, 4.7 °20, 22.3 °20, and 11.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

27D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern E is a crystalline polymorph of ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 21.0 °20, 4.7 °20, 22.3 °20, 11.1 °20, 7.4 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

27E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern E is a crystalline polymorph of ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 21.0 °20, 4.7 °20, 22.3 °20, 11.1 °20, 7.4 °20, 8.8 °20, 9.4 °20, 21.3 °20, and 4.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 27F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern E is a crystalline polymorph of ketanserin succinate Pattern E characterized by a XRPD diffractogram substantially similar to that shown in FIG. 24.

27G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern E is a crystalline polymorph of ketanserin succinate Pattern E characterized by any combination of the XRPD peaks set forth in Table 29.

27H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern E is a crystalline polymorph of ketanserin succinate Pattern E characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 189.

271. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern E is a crystalline polymorph of ketanserin succinate Pattern E characterized by a melting event at about 187.0 °C.

Solid forms of ketanserin succinate Pattern F

28A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern F is a crystalline polymorph of ketanserin succinate Pattern F characterized by two or more, or three XRPD signals selected from the group consisting of 26.9 °20, 26.5 °20, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

28B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern F is a crystalline polymorph of ketanserin succinate Pattern F characterized by signals at 26.9 °29, 26.5 °29, and 14.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

28C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern F is a crystalline polymorph of ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, and 12.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

28D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern F is a crystalline polymorph of ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, 12.1 °20, 16.9 °20, and 4.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). 28E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern F is a crystalline polymorph of ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, 12.1 °20, 16.9 °20, 4.5 °20, 16.6 °20, 25.0 °20, and 10.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

28F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern F is a crystalline polymorph of ketanserin succinate Pattern F characterized by a XRPD diffractogram substantially similar to that shown in FIG. 25.

28G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern F is a crystalline polymorph of ketanserin succinate Pattern F characterized by any combination of the XRPD peaks set forth in Table 30.

28H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern F is a crystalline polymorph of ketanserin succinate Pattern F characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 192.

281. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern F is a crystalline polymorph of ketanserin succinate Pattern F characterized by a melting event at about 182.6 °C.

Solid forms of ketanserin succinate Pattern G

29A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern G is a crystalline polymorph of ketanserin succinate Pattern G characterized by two or more, or three XRPD signals selected from the group consisting of 21.0 °20, 21.8 °20, and 11.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

29B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern G is a crystalline polymorph of ketanserin succinate Pattern G characterized by signals at 21.0 °29, 21.8 °29, and 11.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

29C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern G is a crystalline polymorph of ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, and 10.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 29D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern G is a crystalline polymorph of ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, 20.2 °20, and 27.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

29E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern G is a crystalline polymorph of ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, 20.2 °20, 27.7 °20, 26.9 °20, 18.9 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

29F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern G is a crystalline polymorph of ketanserin succinate Pattern G characterized by a XRPD diffractogram substantially similar to that shown in FIG. 26.

29G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern G is a crystalline polymorph of ketanserin succinate Pattern G characterized by any combination of the XRPD peaks set forth in Table 31.

29H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern G is a crystalline polymorph of ketanserin succinate Pattern G characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 195.

Solid forms of ketanserin succinate Pattern H

30 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by two or more, or three XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, and 27.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

30B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by signals at 24.9 °29, 23.1 °29, and 27.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

30C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, and 25.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

30D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, and 13.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

30E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, 13.2 °20, 17.7 °20, 20.8 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

3 OF. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by a XRPD diffractogram substantially similar to that shown in FIG. 27.

30G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by any combination of the XRPD peaks set forth in Table 32.

3 OH. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 196.

301. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by a melting event at about 179.9 °C.

Solid forms of ketanserin L-tartrate Pattern A

31 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, and 15.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

3 IB. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by signals at 21.6 °29, 13.9 °29, and 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

31C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of21.6 °20, 13.9 °29, 15.6 °20, 21.7 °20, and 25.3 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

3 ID. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, and 15.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

3 IE. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, 21.7 °29, 25.3 °29, 16.6 °29, 15.1 °29, 12.6 °29, 20.9 °29, and 7.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

3 IF. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, and 25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

31G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by signals at 21.6 °29, 13.9 °29, and 25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

31H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, and 16.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). 311. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, and 12.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

31 J. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, 12.7 °20, 21.0 °20, 22.3 °20, and 18.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

3 IK. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

3 IL. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by signals at 21.6 °29, 15.6 °29, and 14.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

3 IM. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, and 20.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

3 IN. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, 17.5 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

310. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, 17.5 °20, 25.3 °20, 7.8 °20, 21.1 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

3 IP. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 18.

3 IQ. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 61.

31R. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 110.

31 S. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by any combination of the XRPD peaks set forth in Table 33.

3 IT. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by any combination of the XRPD peaks set forth in Table 34.

31U. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by any combination of the XRPD peaks set forth in Table 35.

31V. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 199.

31 W. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a melting event at about 141.2 °C.

3 IX. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a melting event at about 140.6 °C.

Solid forms of ketanserin L-tartrate Pattern B 32A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern B is a crystalline polymorph of ketanserin L-tartrate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 10.8 °29, 21.6 °29, and 14.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

32B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern B is a crystalline polymorph of ketanserin L-tartrate Pattern B characterized by signals at 10.8 °29, 21.6 °29, and 14.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

32C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern B is a crystalline polymorph of ketanserin L-tartrate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 21.6 °20, 14.7 °29, 20.1 °29, and 17.8 °29 (±9.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

32D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern B is a crystalline polymorph of ketanserin L-tartrate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 21.6 °20, 14.7 °29, 20.1 °20, 17.8 °29, 32.6 °29, and 16.9 °29 (±9.2 °29; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

32E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern B is a crystalline polymorph of ketanserin L-tartrate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °29, 21.6 °29, 14.7 °29, 20.1 °29, 17.8 °29, 32.6 °29, 16.9 °29, 25.3 °29, 19.8 °29, and 20.9 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

32F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern B is a crystalline polymorph of ketanserin L-tartrate Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 56.

32G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern B is a crystalline polymorph of ketanserin L-tartrate Pattern B characterized by any combination of the XRPD peaks set forth in Table 36. 32H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern B is a crystalline polymorph of ketanserin L-tartrate Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 202.

321. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern B is a crystalline polymorph of ketanserin L-tartrate Pattern B characterized by a melting event at about 152.0 °C.

Solid forms of ketanserin L-tartrate Pattern C

33A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern C is a crystalline polymorph of ketanserin L-tartrate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 13.2 °20, 11.7 °20, and 25.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

33B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern C is a crystalline polymorph of ketanserin L-tartrate Pattern C characterized by signals at 13.2 °29, 11.7 °29, and 25.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

33C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern C is a crystalline polymorph of ketanserin L-tartrate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

33D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern C is a crystalline polymorph of ketanserin L-tartrate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, 27.0 °20, 17.6 °20, and 26.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

33E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern C is a crystalline polymorph of ketanserin L-tartrate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °20, 11.7 °20, 25.4 °20, 18.8 °20, 27.0 °20, 17.6 °20, 26.6 °20, 8.8 °20, 14.6 °20, and 24.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 33F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern C is a crystalline polymorph of ketanserin L-tartrate Pattern C characterized by a XRPD diffractogram substantially similar to that shown in FIG. 29.

33G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern C is a crystalline polymorph of ketanserin L-tartrate Pattern C characterized by any combination of the XRPD peaks set forth in Table 37.

33H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern C is a crystalline polymorph of ketanserin L-tartrate Pattern C characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 205.

331. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern C is a crystalline polymorph of ketanserin L-tartrate Pattern C characterized by a melting event at about 179.9 °C.

Solid forms of ketanserin L-tartrate Pattern D

34A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern D is a crystalline polymorph of ketanserin L-tartrate Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 21.0 °20, 9.5 °20, and 14.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

34B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern D is a crystalline polymorph of ketanserin L-tartrate Pattern D characterized by signals at 21.0 °29, 9.5 °29, and 14.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

34C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern D is a crystalline polymorph of ketanserin L-tartrate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 9.5 °20, 14.2 °20, 10.7 °20, and 27.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

34D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern D is a crystalline polymorph of ketanserin L-tartrate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 9.5 °20, 14.2 °20, 10.7 °20, 27.7 °20, 4.7 °20, and 26.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). 34E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern D is a crystalline polymorph of ketanserin L-tartrate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 9.5 °20, 14.2 °20, 10.7 °20, 27.7 °20, 4.7 °20, 26.9 °20, and 20.2 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

34F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern D is a crystalline polymorph of ketanserin L-tartrate Pattern D characterized by a XRPD diffractogram substantially similar to that shown in FIG. 58.

34G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern D is a crystalline polymorph of ketanserin L-tartrate Pattern D characterized by any combination of the XRPD peaks set forth in Table 38.

34H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern D is a crystalline polymorph of ketanserin L-tartrate Pattern D characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 208.

Solid forms of ketanserin L-tartrate Pattern E

35 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern E is a crystalline polymorph of ketanserin L-tartrate Pattern E characterized by two or more, or three XRPD signals selected from the group consisting of 6.2 °20, 17.1 °20, and 24.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

35B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern E is a crystalline polymorph of ketanserin L-tartrate Pattern E characterized by signals at 6.2 °29, 17.1 °29, and 24.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

35C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern E is a crystalline polymorph of ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °20, 17.1 °20, 24.3 °20, 11.8 °20, and 22.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

35D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern E is a crystalline polymorph of ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °29, 17.1 °29, 24.3 °20, 11.8 °20, 22.8 °20, 19.0 °20, and 14.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

35E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern E is a crystalline polymorph of ketanserin L-tartrate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.2 °29, 17.1 °20, 24.3 °29, 11.8 °29, 22.8 °29, 19.0 °29, 14.5 °29, 25.6 °29, 12.3 °29, and 24.7 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

35F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern E is a crystalline polymorph of ketanserin L-tartrate Pattern E characterized by a XRPD diffractogram substantially similar to that shown in FIG. 31.

35G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern E is a crystalline polymorph of ketanserin L-tartrate Pattern E characterized by any combination of the XRPD peaks set forth in Table 39.

35H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern E is a crystalline polymorph of ketanserin L-tartrate Pattern E characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 209.

Solid forms of ketanserin L-tartrate Pattern F

36 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern F is a crystalline polymorph of ketanserin L-tartrate Pattern F characterized by two or more, or three XRPD signals selected from the group consisting of 21.7 °29, 15.5 °29, and 16.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

36B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern F is a crystalline polymorph of ketanserin L-tartrate Pattern F characterized by signals at 21.7 °29, 15.5 °29, and 16.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

36C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern F is a crystalline polymorph of ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 15.5 °29, 16.8 °29, 12.5 °29, and 14.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation). 36D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern F is a crystalline polymorph of ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 15.5 °20, 16.8 °20, 12.5 °20, 14.0 °20, 7.7 °20, and 16.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

36E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern F is a crystalline polymorph of ketanserin L-tartrate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 15.5 °20, 16.8 °20, 12.5 °20, 14.0 °20, 7.7 °20, 16.5 °20, 14.9 °20, 20.9 °20, and 17.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

36F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern F is a crystalline polymorph of ketanserin L-tartrate Pattern F characterized by a XRPD diffractogram substantially similar to that shown in FIG. 32.

36G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern F is a crystalline polymorph of ketanserin L-tartrate Pattern F characterized by any combination of the XRPD peaks set forth in Table 40.

36H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern F is a crystalline polymorph of ketanserin L-tartrate Pattern F characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 210.

Solid forms of ketanserin L-tartrate Pattern G

37 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern G is a crystalline polymorph of ketanserin L-tartrate Pattern G characterized by two or more, or three XRPD signals selected from the group consisting of 6.4 °20, 17.4 °20, and 14.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

37B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern G is a crystalline polymorph of ketanserin L-tartrate Pattern G characterized by signals at 6.4 °29, 17.4 °29, and 14.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

37C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern G is a crystalline polymorph of ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, and 12.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

37D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern G is a crystalline polymorph of ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, 24.9 °20, and 25.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

37E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern G is a crystalline polymorph of ketanserin L-tartrate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.4 °20, 17.4 °20, 14.7 °20, 18.5 °20, 12.1 °20, 24.9 °20, 25.8 °20, 16.2 °20, 22.7 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

37F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern G is a crystalline polymorph of ketanserin L-tartrate Pattern G characterized by a XRPD diffractogram substantially similar to that shown in FIG. 33.

37G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern G is a crystalline polymorph of ketanserin L-tartrate Pattern G characterized by any combination of the XRPD peaks set forth in Table 41.

37H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern G is a crystalline polymorph of ketanserin L-tartrate Pattern G characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 211.

Solid forms of ketanserin L-tartrate Pattern H

38 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern H is a crystalline polymorph of ketanserin L-tartrate Pattern H characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °20, 14.9 °20, and 7.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

38B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern H is a crystalline polymorph of ketanserin L-tartrate Pattern H characterized by signals at 21.6 °29, 14.9 °29, and 7.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). 38C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern H is a crystalline polymorph of ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, and 13.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

38D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern H is a crystalline polymorph of ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, 13.0 °20, 18.3 °20, and 16.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

38E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern H is a crystalline polymorph of ketanserin L-tartrate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 14.9 °20, 7.4 °20, 3.7 °20, 13.0 °20, 18.3 °20, 16.7 °20, 20.9 °20, 22.4 °20, and 25.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

38F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern H is a crystalline polymorph of ketanserin L-tartrate Pattern H characterized by a XRPD diffractogram substantially similar to that shown in FIG. 34.

38G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern H is a crystalline polymorph of ketanserin L-tartrate Pattern H characterized by any combination of the XRPD peaks set forth in Table 42.

38H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern H is a crystalline polymorph of ketanserin L-tartrate Pattern H characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 212.

381. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern H is a crystalline polymorph of ketanserin L-tartrate Pattern H characterized by a melting event at about 192.4 °C.

Solid forms of ketanserin L-tartrate Pattern I

39 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern I is a crystalline polymorph of ketanserin L-tartrate Pattern I characterized by two or more, or three XRPD signals selected from the group consisting of 15.8 °20, 26.4 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

39B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern I is a crystalline polymorph of ketanserin L-tartrate Pattern I characterized by signals at 15.8 °29, 26.4 °29, and 17.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

39C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern I is a crystalline polymorph of ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, and 16.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

39D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern I is a crystalline polymorph of ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, 16.3 °20, 5.4 °20, and 12.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

39E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern I is a crystalline polymorph of ketanserin L-tartrate Pattern I characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.8 °20, 26.4 °20, 17.5 °20, 27.6 °20, 16.3 °20, 5.4 °20, 12.2 °20, 24.0 °20, 26.6 °20, and 18.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

39F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern I is a crystalline polymorph of ketanserin L-tartrate Pattern I characterized by a XRPD diffractogram substantially similar to that shown in FIG. 36.

39G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern I is a crystalline polymorph of ketanserin L-tartrate Pattern I characterized by any combination of the XRPD peaks set forth in Table 43.

39H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern I is a crystalline polymorph of ketanserin L-tartrate Pattern I characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 215. 391. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern I is a crystalline polymorph of ketanserin L-tartrate Pattern I characterized by a melting event at about 182.8 °C.

Solid forms of ketanserin L-tartrate Pattern J

40A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern J is a crystalline polymorph of ketanserin L-tartrate Pattern J characterized by two or more, or three XRPD signals selected from the group consisting of 15.5 °20, 21.8 °20, and 23.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

40B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern J is a crystalline polymorph of ketanserin L-tartrate Pattern J characterized by signals at 15.5 °29, 21.8 °29, and 23.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

40C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern J is a crystalline polymorph of ketanserin L-tartrate Pattern J characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, and 26.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

40D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern J is a crystalline polymorph of ketanserin L-tartrate Pattern J characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, 26.2 °20, 16.6 °20, and 5.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

40E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern J is a crystalline polymorph of ketanserin L-tartrate Pattern J characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 21.8 °20, 23.3 °20, 15.2 °20, 26.2 °20, 16.6 °20, 5.8 °20, 17.1 °20, 19.2 °20, and 13.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

40F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern J is a crystalline polymorph of ketanserin L-tartrate Pattern J characterized by a XRPD diffractogram substantially similar to that shown in FIG. 37. 40G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern J is a crystalline polymorph of ketanserin L-tartrate Pattern J characterized by any combination of the XRPD peaks set forth in Table 44.

40H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern J is a crystalline polymorph of ketanserin L-tartrate Pattern J characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 218.

401. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern J is a crystalline polymorph of ketanserin L-tartrate Pattern J characterized by a melting event at about 138.8 °C.

Solid forms of ketanserin L-tartrate Pattern K

41 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern K is a crystalline polymorph of ketanserin L-tartrate Pattern K characterized by two or more, or three XRPD signals selected from the group consisting of 4.9 °20, 9.8 °20, and 19.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

41B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern K is a crystalline polymorph of ketanserin L-tartrate Pattern K characterized by signals at 4.9 °29, 9.8 °29, and 19.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

41C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern K is a crystalline polymorph of ketanserin L-tartrate Pattern K characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °20, 9.8 °20, 19.6 °20, 16.3 °20, and 14.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

4 ID. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern K is a crystalline polymorph of ketanserin L-tartrate Pattern K characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °20, 9.8 °20, 19.6 °20, 16.3 °20, 14.7 °20, 24.2 °20, and 19.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

4 IE. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern K is a crystalline polymorph of ketanserin L-tartrate Pattern K characterized by a XRPD diffractogram substantially similar to that shown in FIG. 57. 41F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern K is a crystalline polymorph of ketanserin L-tartrate Pattern K characterized by any combination of the XRPD peaks set forth in Table 45.

41G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern K is a crystalline polymorph of ketanserin L-tartrate Pattern K characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 221.

41H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern K is a crystalline polymorph of ketanserin L-tartrate Pattern K characterized by a melting event at about 148.2 °C.

Solid forms of ketanserin L-tartrate Pattern L

42A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by two or more, or three XRPD signals selected from the group consisting of 11.7 °20, 13.2 °20, and 18.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

42B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by signals at 11.7 °29, 13.2 °29, and 18.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

42C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

42D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, 27.0 °20, 17.6 °20, and 14.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

42E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °20, 13.2 °29, 18.8 °29, 25.5 °29, 27.0 °29, 17.6 °29, 14.6 °29, 25.6 °29, 19.7 °29, and 8.8 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

42F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by a XRPD diffractogram substantially similar to that shown in FIG. 40.

42G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by any combination of the XRPD peaks set forth in Table 46.

42H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 224.

421. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by a melting event at about 147.5 °C.

Solid forms of ketanserin L-tartrate Pattern M

43 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern M is a crystalline polymorph of ketanserin L-tartrate Pattern M characterized by two or more, or three XRPD signals selected from the group consisting of 19.9 °29, 20.5 °29, and 10.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

43B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern M is a crystalline polymorph of ketanserin L-tartrate Pattern M characterized by signals at 19.9 °29, 20.5 °29, and 10.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

43C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern M is a crystalline polymorph of ketanserin L-tartrate Pattern M characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.9 °29, 20.5 °29, 10.0 °20, 29.4 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

43D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern M is a crystalline polymorph of ketanserin L-tartrate Pattern M characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.9 °20, 20.5 °20, 10.0 °20, 29.4 °20, 10.7 °20, 25.2 °20, and 22.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

43E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern M is a crystalline polymorph of ketanserin L-tartrate Pattern M characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.9 °20, 20.5 °20, 10.0 °20, 29.4 °20, 10.7 °20, 25.2 °20, 22.3 °20, 15.7 °20, 22.9 °20, and 30.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

43F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern M is a crystalline polymorph of ketanserin L-tartrate Pattern M characterized by a XRPD diffractogram substantially similar to that shown in FIG. 41.

43 G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern M is a crystalline polymorph of ketanserin L-tartrate Pattern M characterized by any combination of the XRPD peaks set forth in Table 47.

43H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern M is a crystalline polymorph of ketanserin L-tartrate Pattern M characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 227.

431. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern M is a crystalline polymorph of ketanserin L-tartrate Pattern M characterized by a melting event at about 186.4 °C.

Solid forms of ketanserin L-tartrate Pattern N

44A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern N is a crystalline polymorph of ketanserin L-tartrate Pattern N characterized by two or more, or three XRPD signals selected from the group consisting of 16.9 °20, 23.6 °20, and 15.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

44B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern N is a crystalline polymorph of ketanserin L-tartrate Pattern N characterized by signals at 16.9 °29, 23.6 °29, and 15.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

44C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern N is a crystalline polymorph of ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °20, 23.6 °20, 15.2 °20, 17.9 °20, and 8.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

44D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern N is a crystalline polymorph of ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °20, 23.6 °20, 15.2 °20, 17.9 °20, 8.9 °20, 18.5 °20, and 20.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

44E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern N is a crystalline polymorph of ketanserin L-tartrate Pattern N characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.9 °20, 23.6 °20, 15.2 °20, 17.9 °20, 8.9 °20, 18.5 °20, 20.4 °20, 3.7 °20, 7.6 °20, and 9.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

44F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern N is a crystalline polymorph of ketanserin L-tartrate Pattern N characterized by a XRPD diffractogram substantially similar to that shown in FIG. 42.

44G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern N is a crystalline polymorph of ketanserin L-tartrate Pattern N characterized by any combination of the XRPD peaks set forth in Table 48.

44H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern N is a crystalline polymorph of ketanserin L-tartrate Pattern N characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 230.

441. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern N is a crystalline polymorph of ketanserin L-tartrate Pattern N characterized by a melting event at about 188.8 °C.

Solid forms of ketanserin L-tartrate Pattern O

45A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern O is a crystalline polymorph of ketanserin L-tartrate Pattern O characterized by two or more, or three XRPD signals selected from the group consisting of 18.6 °20, 9.9 °20, and 11.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

45B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern O is a crystalline polymorph of ketanserin L-tartrate Pattern O characterized by signals at 18.6 °29, 9.9 °29, and 11.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

45C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern O is a crystalline polymorph of ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, 11.6 °20, 5.0 °20, and 13.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

45D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern O is a crystalline polymorph of ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.6 °29, 9.9 °29, 11.6 °20, 5.0 °20, 13.3 °20, 25.4 °20, and 26.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

45E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern O is a crystalline polymorph of ketanserin L-tartrate Pattern O characterized by two or more, or three or more XRPD signals selected from the group consisting of l8.6 °29, 9.9 °29, 11.6 °20, 5.0 °20, 13.3 °29, 25.4 °29, 26.9 °29, 14.8 °29, 17.6 °29, and 29.5 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

45F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern O is a crystalline polymorph of ketanserin L-tartrate Pattern O characterized by a XRPD diffractogram substantially similar to that shown in FIG. 43.

45G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern O is a crystalline polymorph of ketanserin L-tartrate Pattern O characterized by any combination of the XRPD peaks set forth in Table 49.

45H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern O is a crystalline polymorph of ketanserin L-tartrate Pattern O characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 233.

451. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern O is a crystalline polymorph of ketanserin L-tartrate Pattern O characterized by a melting event at about 191.7 °C.

Solid forms of ketanserin L-tartrate Pattern P 46A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern P is a crystalline polymorph of ketanserin L-tartrate Pattern P characterized by two or more, or three XRPD signals selected from the group consisting of 13.3 °20, 16.6 °20, and 18.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

46B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern P is a crystalline polymorph of ketanserin L-tartrate Pattern P characterized by signals at 13.3 °29, 16.6 °29, and 18.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

46C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern P is a crystalline polymorph of ketanserin L-tartrate Pattern P characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.3 °29, 16.6 °29, 18.5 °20, 26.9 °29, and 25.1 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

46D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern P is a crystalline polymorph of ketanserin L-tartrate Pattern P characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.3 °29, 16.6 °29, 18.5 °20, 26.9 °20, 25.1 °20, 15.9 °20, and 20.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

46E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern P is a crystalline polymorph of ketanserin L-tartrate Pattern P characterized by two or more, or three or more XRPD signals selected from the group consisting of l3.3 °29, 16.6 °29, 18.5 °29, 26.9 °29, 25.1 °29, 15.9 °29, 20.6 °29, 18.2 °29, 14.1 °29, and 23.6 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

46F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern P is a crystalline polymorph of ketanserin L-tartrate Pattern P characterized by a XRPD diffractogram substantially similar to that shown in FIG. 53.

46G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern P is a crystalline polymorph of ketanserin L-tartrate Pattern P characterized by any combination of the XRPD peaks set forth in Table 50. 46H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern P is a crystalline polymorph of ketanserin L-tartrate Pattern P characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 236.

Solid forms of ketanserin L-tartrate Pattern Q

47A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 14.2 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

47B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by signals at 15.3 °29, 14.2 °29, and 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

47C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 14.2 °29, 21.5 °20, 26.0 °20, and 23.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

47D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 14.2 °29, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, and 17.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

47E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of l5.3 °29, 14.2 °20, 21.5 °20, 26.0 °29, 23.9 °29, 12.0 °29, 17.8 °29, 14.5 °29, 18.1 °29, and 9.7 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

47F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by a XRPD diffractogram substantially similar to that shown in FIG. 59. 47G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by any combination of the XRPD peaks set forth in Table 51.

47H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 237.

471. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by a melting event at about 148.8 °C.

Solid forms of ketanserin L-tartrate Pattern R

48A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern R is a crystalline polymorph of ketanserin L-tartrate Pattern R characterized by two or more, or three XRPD signals selected from the group consisting of 13.2 °20, 25.4 °20, and 26.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

48B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern R is a crystalline polymorph of ketanserin L-tartrate Pattern R characterized by signals at 13.2 °29, 25.4 °29, and 26.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

48C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern R is a crystalline polymorph of ketanserin L-tartrate Pattern R characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °20, 25.4 °20, 26.8 °20, 14.5 °20, and 11.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

48D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern R is a crystalline polymorph of ketanserin L-tartrate Pattern R characterized by two or more, or three or more XRPD signals selected from the group consisting of 13.2 °20, 25.4 °20, 26.8 °20, 14.5 °20, 11.0 °20, 11.2 °20, and 18.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

48E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern R is a crystalline polymorph of ketanserin L-tartrate Pattern R characterized by two or more, or three or more XRPD signals selected from the group consisting of l3.2 °20, 25.4 °29, 26.8 °20, 14.5 °20, 11.0 °20, 11.2 °20, 18.6 °20, 17.5 °20, 26.3 °20, and 5.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

48F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern R is a crystalline polymorph of ketanserin L-tartrate Pattern R characterized by a XRPD diffractogram substantially similar to that shown in FIG. 54.

48G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern R is a crystalline polymorph of ketanserin L-tartrate Pattern R characterized by any combination of the XRPD peaks set forth in Table 52.

48H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern R is a crystalline polymorph of ketanserin L-tartrate Pattern R characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 240.

481. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern R is a crystalline polymorph of ketanserin L-tartrate Pattern R characterized by a melting event at about 188.0 °C.

Solid forms of ketanserin L-tartrate Pattern S

49A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern S is a crystalline polymorph of ketanserin L-tartrate Pattern S characterized by two or more, or three XRPD signals selected from the group consisting of 6.3 °20, 18.5 °20, and 11.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

49B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern S is a crystalline polymorph of ketanserin L-tartrate Pattern S characterized by signals at 6.3 °29, 18.5 °29, and 11.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

49C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern S is a crystalline polymorph of ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °20, 18.5 °20, 11.6 °20, 13.2 °20, and 11.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

49D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern S is a crystalline polymorph of ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °20, 18.5 °20, 11.6 °20, 13.2 °20, 11.9 °20, 17.3 °20, and 14.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

49E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern S is a crystalline polymorph of ketanserin L-tartrate Pattern S characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.3 °20, 18.5 °20, 11.6 °20, 13.2 °20, 11.9 °20, 17.3 °20, 14.6 °20, 16.2 °20, 19.0 °20, and 22.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

49F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern S is a crystalline polymorph of ketanserin L-tartrate Pattern S characterized by a XRPD diffractogram substantially similar to that shown in FIG. 55.

49G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern S is a crystalline polymorph of ketanserin L-tartrate Pattern S characterized by any combination of the XRPD peaks set forth in Table 53.

49H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern S is a crystalline polymorph of ketanserin L-tartrate Pattern S characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 243.

491. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern S is a crystalline polymorph of ketanserin L-tartrate Pattern S characterized by a melting event at about 195.8 °C.

Solid forms of ketanserin L-tartrate Pattern T

50A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern T is a crystalline polymorph of ketanserin L-tartrate Pattern T characterized by two or more, or three XRPD signals selected from the group consisting of 21.5 °20, 21.4 °20, and 15.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

50B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern T is a crystalline polymorph of ketanserin L-tartrate Pattern T characterized by signals at 21.5 °29, 21.4 °29, and 15.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

50C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern T is a crystalline polymorph of ketanserin L-tartrate Pattern T characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.5 °20, 21.4 °20, 15.8 °20, 15.0 °20, and 15.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

50D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern T is a crystalline polymorph of ketanserin L-tartrate Pattern T characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.5 °20, 21.4 °20, 15.8 °20, 15.0 °20, 15.5 °20, 17.4 °20, and 17.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

50E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern T is a crystalline polymorph of ketanserin L-tartrate Pattern T characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.5 °20, 21.4 °20, 15.8 °20, 15.0 °20, 15.5 °20, 17.4 °20, 17.1 °20, 14.5 °20, 12.6 °20, and 14.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

50F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern T is a crystalline polymorph of ketanserin L-tartrate Pattern T characterized by a XRPD diffractogram substantially similar to that shown in FIG. 60.

50G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Pattern T is a crystalline polymorph of ketanserin L-tartrate Pattern T characterized by any combination of the XRPD peaks set forth in Table 54.

Solid forms of ketanserin L-tartrate Group 1

51 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by two or more, or three XRPD signals selected from the group consisting of 15.6 °20, 21.8 °20, and 23.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

5 IB. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by signals at 15.6 °29, 21.8 °29, and 23.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

51C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, and 17.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

5 ID. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, 26.3 °20, and 16.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

5 IE. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 21.8 °20, 23.3 °20, 15.1 °20, 17.2 °20, 26.3 °20, 16.6 °20, 5.8 °20, 26.0 °20, and 27.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

5 IF. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by two or more, or three XRPD signals selected from the group consisting of 21.9 °20, 15.6 °20, and 23.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

51G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by signals at 21.9 °29, 15.6 °29, and 23.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

51H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, and 17.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

511. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, 5.9 °20, and 26.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). 51 J. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.9 °20, 15.6 °20, 23.3 °20, 26.4 °20, 17.2 °20, 5.9 °20, 26.0 °20, 27.6 °20, 23.0 °20, and 15.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

5 IK. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by a XRPD diffractogram substantially similar to that shown in FIG. 35.

5 IL. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by a XRPD diffractogram substantially similar to that shown in FIG. 62.

5 IM. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by any combination of the XRPD peaks set forth in Table 55.

5 IN. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by any combination of the XRPD peaks set forth in Table 55A.

510. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 246.

5 IP. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 1 is a crystalline polymorph of ketanserin L-tartrate Group 1 characterized by a melting event at about 195.7 °C.

Solid forms of ketanserin L-tartrate Group 2

52A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 2 is a crystalline polymorph of ketanserin L-tartrate Group 2 characterized by two or more, or three XRPD signals selected from the group consisting of 19.8 °20, 15.3 °20, and 25.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

52B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 2 is a crystalline polymorph of ketanserin L-tartrate Group 2 characterized by signals at 19.8 °29, 15.3 °29, and 25.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

52C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 2 is a crystalline polymorph of ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °26, 15.3 °26, 25.2 °26, 22.1 °26, and 9.9 °26 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

52D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 2 is a crystalline polymorph of ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °26, 15.3 °26, 25.2 °26, 22.1 °26, 9.9 °26, 18.2 °26, and 21.6 °26 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

52E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 2 is a crystalline polymorph of ketanserin L-tartrate Group 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °26, 15.3 °26, 25.2 °26, 22.1 °26, 9.9 °26, 18.2 °26, 21.6 °26, 29.4 °26, 17.0 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

52F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 2 is a crystalline polymorph of ketanserin L-tartrate Group 2 characterized by a XRPD diffractogram substantially similar to that shown in FIG. 38.

52G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 2 is a crystalline polymorph of ketanserin L-tartrate Group 2 characterized by any combination of the XRPD peaks set forth in Table 56.

52H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 2 is a crystalline polymorph of ketanserin L-tartrate Group 2 characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 249.

521. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 2 is a crystalline polymorph of ketanserin L-tartrate Group 2 characterized by a melting event at about 189.4 °C.

Solid forms of ketanserin L-tartrate Group 3 53 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by two or more, or three XRPD signals selected from the group consisting of 24.2 °20, 4.6 °20, and 25.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

53B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by signals at 24.2 °29, 4.6 °29, and 25.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

53C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, and 9.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

53D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, 15.6 °20, and 15.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

53E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.2 °20, 4.6 °20, 25.6 °20, 25.8 °20, 9.2 °20, 15.6 °20, 15.5 °20, 16.9 °20, 14.4 °20, and 18.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

53F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by two or more, or three XRPD signals selected from the group consisting of 24.3 °20, 25.7 °20, and 15.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

53G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by signals at 24.3 °29, 25.7 °29, and 15.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation). 53H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.3 °20, 25.7 °20, 15.4 °20, 16.9 °20, and 14.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

531. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.3 °26, 25.7 °26, 15.4 °26, 16.9 °26, 14.5 °26, 26.3 °26, and 20.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

53 J. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.3 °26, 25.7 °26, 15.4 °26, 16.9 °26, 14.5 °26, 26.3 °26, 20.3 °20, 9.7 °20, 4.7 °20, and 9.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

53K. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by a XRPD diffractogram substantially similar to that shown in FIG. 30.

53L. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by a XRPD diffractogram substantially similar to that shown in FIG. 114.

53M. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by any combination of the XRPD peaks set forth in Table 57.

53N. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by any combination of the XRPD peaks set forth in Table 58.

530. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 252. 53P. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 3 is a crystalline polymorph of ketanserin L-tartrate Group 3 characterized by a melting event at about 195.7 °C.

Solid forms of ketanserin L-tartrate Group 4

54A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 4 is a crystalline polymorph of ketanserin L-tartrate Group 4 characterized by two or more, or three XRPD signals selected from the group consisting of 15.6 °20, 22.2 °20, and 19.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

54B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 4 is a crystalline polymorph of ketanserin L-tartrate Group 4 characterized by signals at 15.6 °29, 22.2 °29, and 19.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

54C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 4 is a crystalline polymorph of ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

54D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 4 is a crystalline polymorph of ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, 21.9 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

54E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 4 is a crystalline polymorph of ketanserin L-tartrate Group 4 characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.6 °20, 22.2 °20, 19.8 °20, 20.6 °20, 25.3 °20, 21.9 °20, 17.0 °20, 10.0 °20, 6.2 °20, and 29.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

54F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 4 is a crystalline polymorph of ketanserin L-tartrate Group 4 characterized by a XRPD diffractogram substantially similar to that shown in FIG. 28. 54G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 4 is a crystalline polymorph of ketanserin L-tartrate Group 4 characterized by any combination of the XRPD peaks set forth in Table 59.

54H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 4 is a crystalline polymorph of ketanserin L-tartrate Group 4 characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 255.

541. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 4 is a crystalline polymorph of ketanserin L-tartrate Group 4 characterized by a melting event at about 177.4 °C.

Solid forms of ketanserin L-tartrate Group 5

55 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 5 is a crystalline polymorph of ketanserin L-tartrate Group 5 characterized by two or more, or three XRPD signals selected from the group consisting of 10.1 °29, 18.9 °29, and 15.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

55B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 5 is a crystalline polymorph of ketanserin L-tartrate Group 5 characterized by signals at 10.1 °29, 18.9 °29, and 15.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

55C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 5 is a crystalline polymorph of ketanserin L-tartrate Group 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.1 °29, 18.9 °29, 15.1 °20, 13.3 °29, and 18.4 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

55D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 5 is a crystalline polymorph of ketanserin L-tartrate Group 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of lO.l °20, 18.9 °29, 15.1 °20, 13.3 °29, 18.4 °29, 16.7 °29, and 26.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

55E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 5 is a crystalline polymorph of ketanserin L-tartrate Group 5 characterized by two or more, or three or more XRPD signals selected from the group consisting of lO.l °20, 18.9 °20, 15.1 °20, 13.3 °20, 18.4 °20, 16.7 °20, 26.4 °20, 14.3 °20, 23.7 °20, and 20.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

55F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 5 is a crystalline polymorph of ketanserin L-tartrate Group 5 characterized by a XRPD diffractogram substantially similar to that shown in FIG. 39.

55G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 5 is a crystalline polymorph of ketanserin L-tartrate Group 5 characterized by any combination of the XRPD peaks set forth in Table 60.

55H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 5 is a crystalline polymorph of ketanserin L-tartrate Group 5 characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 258.

551. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-tartrate Group 5 is a crystalline polymorph of ketanserin L-tartrate Group 5 characterized by a melting event at about 194.9 °C.

Solid forms of ketanserin L-malate Pattern A

56A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 16.1 °20, 17.5 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

56B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by signals at 16.1 °20, 17.5 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

56C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.5 °20, 8.8 °20, 18.8 °20, and 24.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

56D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.5 °20, 8.8 °20, 18.8 °20, 24.2 °20, 10.4 °20, and 16.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

56E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.5 °20, 8.8 °20, 18.8 °20, 24.2 °20, 10.4 °20, 16.3 °20, 26.4 °20, 23.4 °20, and 20.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

56F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

56G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by signals at 16.1 °29, 17.6 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

56H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, and 24.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

561. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, 26.5 °20, and 10.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

56J. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, 26.5 °20, 10.4 °20, 20.2 °20, 23.5 °20, and 20.7°20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 56K. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 17.5 °26, 16.0 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

56L. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by signals at 17.5 °29, 16.0 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

56M. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, and 26.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

56N. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, 18.8 °20, and 23.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

560. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, 18.8 °20, 23.4 °20, 20.1 °20, 18.3 °20, and 24.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

56P. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 19.

56Q. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 65. 56R. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 111.

56S. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by any combination of the XRPD peaks set forth in Table 61.

56T. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by any combination of the XRPD peaks set forth in Table 62.

56U. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by any combination of the XRPD peaks set forth in Table 63.

56V. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 166.

56W. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a melting event at about 157.5 °C.

Solid forms of ketanserin L-malate Pattern B

57A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern B is a crystalline polymorph of ketanserin L-malate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 18.0 °20, 21.2 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

57B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern B is a crystalline polymorph of ketanserin L-malate Pattern B characterized by signals at 18.0 °29, 21.2 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

57C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern B is a crystalline polymorph of ketanserin L-malate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.0 °20, 21.2 °20, 8.8 °20, 4.0 °20, and 24.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

57D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern B is a crystalline polymorph of ketanserin L-malate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.0 °20, 21.2 °20, 8.8 °20, 4.0 °20, 24.4 °20, 14.5 °20, and 11.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

57E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern B is a crystalline polymorph of ketanserin L-malate Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 47.

57F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern B is a crystalline polymorph of ketanserin L-malate Pattern B characterized by any combination of the XRPD peaks set forth in Table 64.

57G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern B is a crystalline polymorph of ketanserin L-malate Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 266.

Solid forms of ketanserin L-malate Pattern C

58 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C is a crystalline polymorph of ketanserin L-malate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 20.9 °20, 27.5 °20, and 16.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

58B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C is a crystalline polymorph of ketanserin L-malate Pattern C characterized by signals at 20.9 °29, 27.5 °29, and 16.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

58C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C is a crystalline polymorph of ketanserin L-malate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 27.5 °20, 16.8 °20, 20.1 °20, and 9.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation). 58D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C is a crystalline polymorph of ketanserin L-malate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 27.5 °20, 16.8 °20, 20.1 °20, 9.4 °20, 3.4 °20, and 10.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

58E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C is a crystalline polymorph of ketanserin L-malate Pattern C characterized by a XRPD diffractogram substantially similar to that shown in FIG. 66.

58F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C is a crystalline polymorph of ketanserin L-malate Pattern C characterized by any combination of the XRPD peaks set forth in Table 65.

Solid forms of ketanserin L-malate Pattern C*

59A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C* is a crystalline polymorph of ketanserin L-malate Pattern C* characterized by two or more, or three XRPD signals selected from the group consisting of 17.2 °20, 22.6 °20, and 3.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

59B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C* is a crystalline polymorph of ketanserin L-malate Pattern C* characterized by signals at 17.2 °29, 22.6 °29, and 3.4 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

59C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C* is a crystalline polymorph of ketanserin L-malate Pattern C* characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.2 °20, 22.6 °20, 3.4 °20, 26.2 °20, and 21.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

59D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C* is a crystalline polymorph of ketanserin L-malate Pattern C* characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.2 °20, 22.6 °20, 3.4 °20, 26.2 °20, 21.3 °20, 18.5 °20, and 9.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation). 59E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C* is a crystalline polymorph of ketanserin L-malate Pattern C* characterized by a XRPD diffractogram substantially similar to that shown in FIG. 48.

59F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C* is a crystalline polymorph of ketanserin L-malate Pattern C* characterized by any combination of the XRPD peaks set forth in Table 66.

59G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern C* is a crystalline polymorph of ketanserin L-malate Pattern C* characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 170.

Solid forms of ketanserin L-malate Pattern D

60A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern D is a crystalline polymorph of ketanserin L-malate Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 9.4 °20, 24.4 °20, and 16.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

60B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern D is a crystalline polymorph of ketanserin L-malate Pattern D characterized by signals at 9.4 °29, 24.4 °29, and 16.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

60C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern D is a crystalline polymorph of ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 24.4 °20, 16.5 °20, 18.9 °20, and 15.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

60D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern D is a crystalline polymorph of ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 24.4 °20, 16.5 °20, 18.9 °20, 15.5 °20, 14.7 °20, and 19.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

60E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern D is a crystalline polymorph of ketanserin L-malate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 24.4 °20, 16.5 °20, 18.9 °20, 15.5 °20, 14.7 °20, 19.1 °20, 26.8 °20, 22.7 °20, and 17.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

60F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern D is a crystalline polymorph of ketanserin L-malate Pattern D characterized by a XRPD diffractogram substantially similar to that shown in FIG. 49.

60G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern D is a crystalline polymorph of ketanserin L-malate Pattern D characterized by any combination of the XRPD peaks set forth in Table 67.

60H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern D is a crystalline polymorph of ketanserin L-malate Pattern D characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 171.

601. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern D is a crystalline polymorph of ketanserin L-malate Pattern D characterized by a melting event at about 152.0 °C.

Solid forms of ketanserin L-malate Pattern E

61 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern E is a crystalline polymorph of ketanserin L-malate Pattern E characterized by two or more, or three XRPD signals selected from the group consisting of 10.8 °20, 10.2 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

61B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern E is a crystalline polymorph of ketanserin L-malate Pattern E characterized by signals at 10.8 °29, 10.2 °29, and 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

61C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern E is a crystalline polymorph of ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 10.2 °20, 21.5 °20, 20.3 °20, and 14.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

6 ID. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern E is a crystalline polymorph of ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 10.2 °20, 21.5 °20, 20.3 °20, 14.9 °20, 5.4 °20, and 24.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

6 IE. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern E is a crystalline polymorph of ketanserin L-malate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.8 °20, 10.2 °20, 21.5 °20, 20.3 °20, 14.9 °20, 5.4 °20, 24.0 °20, 30.3 °20, 30.9 °20, and 33.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

61F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern E is a crystalline polymorph of ketanserin L-malate Pattern E characterized by a XRPD diffractogram substantially similar to that shown in FIG. 50.

61G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern E is a crystalline polymorph of ketanserin L-malate Pattern E characterized by any combination of the XRPD peaks set forth in Table 68.

61H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern E is a crystalline polymorph of ketanserin L-malate Pattern E characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 174.

611. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin L-malate Pattern E is a crystalline polymorph of ketanserin L-malate Pattern E characterized by a melting event at about 182.4 °C.

Solid forms of ketanserin sulfate Pattern B

62A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern B is a crystalline polymorph of ketanserin sulfate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 5.9 °20, 18.9 °20, and 22.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

62B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern B is a crystalline polymorph of ketanserin sulfate Pattern B characterized by signals at 5.9 °29, 18.9 °29, and 22.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

62C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern B is a crystalline polymorph of ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °20, 18.9 °20, 22.2 °20, 7.5 °20, and 18.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

62D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern B is a crystalline polymorph of ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °20, 18.9 °20, 22.2 °20, 7.5 °20, 18.7 °20, 14.3 °20, and 24.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

62E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern B is a crystalline polymorph of ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °20, 18.9 °20, 22.2 °20, 7.5 °20, 18.7 °20, 14.3 °20, 24.3 °20, 20.6 °20, 18.2 °20, and 16.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

62F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern B is a crystalline polymorph of ketanserin sulfate Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 262.

62G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern B is a crystalline polymorph of ketanserin sulfate Pattern B characterized by any combination of the XRPD peaks set forth in Table 10A.

62H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern B is a crystalline polymorph of ketanserin sulfate Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 263.

621. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin sulfate Pattern B is a crystalline polymorph of ketanserin sulfate Pattern B characterized by a melting event at 143.5 °C.

Solid forms of ketanserin maleate Pattern B

63 A. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern B is a crystalline polymorph of ketanserin maleate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 18.1 °20, 8.8 °20, and 6.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

63B. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern B is a crystalline polymorph of ketanserin maleate Pattern B characterized by signals at 18.1 °29, 8.8 °29, and 6.0 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

63C. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern B is a crystalline polymorph of ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °20, 8.8 °20, 6.0 °20, 17.6 °20, and 26.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

63D. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern B is a crystalline polymorph of ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °20, 8.8 °20, 6.0 °20, 17.6 °20, 26.9 °20, 16.6 °20, and 17.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

63E. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern B is a crystalline polymorph of ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °20, 8.8 °20, 6.0 °20, 17.6 °20, 26.9 °20, 16.6 °20, 17.2 °20, 13.8 °20, 23.5 °20, and 21.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

63F. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern B is a crystalline polymorph of ketanserin maleate Pattern B characterized by a XRPD diffractogram substantially similar to that shown in FIG. 261.

63 G. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern B is a crystalline polymorph of ketanserin maleate Pattern B characterized by any combination of the XRPD peaks set forth in Table 14A.

63H. The solid form of any one of the previous embodiments, wherein the solid form of ketanserin maleate Pattern B is a crystalline polymorph of ketanserin maleate Pattern B characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 52.

In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.

Claims

We claim:

1. A solid form of ketanserin.

2. The solid form of claim 1, wherein the solid form of ketanserin is a salt of ketanserin.

3. The solid form of any one of the previous claims, wherein the salt of ketanserin is a crystalline salt.

4. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.5 °29, 21.0 °29, and 14.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

5. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by signals at 9.5 °29, 21.0 °29, and 14.2 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

6. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °29, 21.0 °29,

14.2 °29, 4.7 °29, and 20.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

7. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °29, 21.0 °29,

14.2 °29, 4.7 °29, 20.1 °29, 27.6 °29, and 26.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

8. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °29, 21.0 °29,

14.2 °29, 4.7 °29, 20.1 °29, 27.6 °29, 26.8 °29, 17.5 °29, 18.8 °29, and 10.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

9. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.0 °29, 20.2 °29, and 27.7 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

777

10. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by signals at 21.0 °20, 20.2 °20, and 27.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

11. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 20.2 °29,

27.7 °20, 18.9 °20, and 17.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

12. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 20.2 °29,

27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, and 10.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

13. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 20.2 °29,

27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, 16.4 °20, and 9.5 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

14. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, and 14.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

15. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by signals at 9.4 °20, 20.9 °20, and 14.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

16. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, 14.1 °20, 4.7 °20, and 20.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

17. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29,

778

14.1 °26, 4.7 °26, 20.1 °20, 17.5 °20, and 19.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

18. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, 18.8 °20, and 10.6 °20 (±0.2 °20; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

19. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 1.

20. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 44.

21. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 63.

22. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 116.

23. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by any combination of the XRPD peaks set forth in Table 2.

24. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by any combination of the XRPD peaks set forth in Table 3.

25. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by any combination of the XRPD peaks set forth in Table 4.

26. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 141.

779

27. The solid form of any one of the previous claims, wherein the solid form of free base form Pattern A is a crystalline polymorph of free base form Pattern A characterized by a melting event at about 235.1 °C.

28. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 16.1 °20, 17.5 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

29. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by signals at 16.1 °29, 17.5 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

30. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.5 °20, 8.8 °20, 18.8 °20, and 24.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

31. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.5 °20, 8.8 °20, 18.8 °20, 24.2 °20, 10.4 °20, and 16.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

32. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.5 °20, 8.8 °20, 18.8 °20, 24.2 °20, 10.4 °20, 16.3 °20, 26.4 °20, 23.4 °20, and 20.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

33. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

780

34. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by signals at 16.1 °29, 17.6 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

35. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, and 24.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

36. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, 26.5 °20, and 10.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

37. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.1 °20, 17.6 °20, 8.8 °20, 18.9 °20, 24.2 °20, 26.5 °20, 10.4 °20, 20.2 °20, 23.5 °20, and 20.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

38. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 17.5 °20, 16.0 °20, and 8.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

39. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by signals at 17.5 °29, 16.0 °29, and 8.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

40. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting

781 of 17.5 °26, 16.0 °26, 8.8 °20, 20.7 °20, and 26.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

41. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, 18.8 °20, and 23.4 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

42. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.5 °20, 16.0 °20, 8.8 °20, 20.7 °20, 26.4 °20, 18.8 °20, 23.4 °20, 20.1 °20, 18.3 °20, and 24.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

43. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 19.

44. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 65.

45. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 111.

46. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by any combination of the XRPD peaks set forth in Table 61.

47. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by any combination of the XRPD peaks set forth in Table 62.

48. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by any combination of the XRPD peaks set forth in Table 63.

782

49. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 166.

50. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-malate Pattern A is a crystalline polymorph of ketanserin L-malate Pattern A characterized by a melting event at about 157.5 °C.

51. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

52. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by signals at 15.3 °29, 19.4 °29, and 11.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

53. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, and 9.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

54. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, 9.8 °20, 24.6 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

55. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, 9.8 °20, 24.6 °20, 21.5 °20, 20.8 °20, 25.3 °20, and 3.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

56. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, and 9.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

57. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by signals at 15.3 °29, 19.4 °29, and 9.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

58. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

59. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

60. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °20, 20.8 °20, 21.5 °20, and 18.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

61. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, and 11.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

62. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by signals at 15.3 °29, 23.0 °29, and 11.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

63. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, and 21.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

64. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, and 21.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

65. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, 25.0 °20, 15.0 °20, and 24.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

66. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 20.

67. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 112.

68. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 113.

69. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by any combination of the XRPD peaks set forth in Table 23.

70. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by any combination of the XRPD peaks set forth in Table 24.

71. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by any combination of the XRPD peaks set forth in Table 25.

72. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 177.

73. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern A is a crystalline polymorph of ketanserin succinate Pattern A characterized by a melting event at about 186.9 °C.

74. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by two or more, or three XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, and 27.1 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

75. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by signals at 24.9 °29, 23.1 °29, and 27.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

76. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, and 25.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

77. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, and 13.2 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

78. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, 13.2 °20, 17.7 °20, 20.8 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

786

79. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by a XRPD diffractogram substantially similar to that shown in FIG. 27.

80. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by any combination of the XRPD peaks set forth in Table 32.

81. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 196.

82. The solid form of any one of the previous claims, wherein the solid form of ketanserin succinate Pattern H is a crystalline polymorph of ketanserin succinate Pattern H characterized by a melting event at about 179.9 °C.

83. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, and 15.6 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

84. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by signals at 21.6 °29, 13.9 °29, and 15.6 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

85. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, 21.7 °29, and 25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kal radiation).

86. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, 21.7 °29, 25.3 °29, 16.6 °29, and 15.1 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

787

87. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, 15.1 °20, 12.6 °20, 20.9 °20, and 7.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

88. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

89. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by signals at 21.6 °29, 13.9 °29, and 25.3 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

90. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, and 16.6 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

91. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, and 12.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

92. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, 12.7 °20, 21.0 °20, 22.3 °20, and 18.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

93. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A

788 characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, and 14.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

94. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by signals at 21.6 °29, 15.6 °29, and 14.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

95. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, and 20.5 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

96. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, 17.5 °20, and 25.3 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

97. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, 17.5 °20, 25.3 °20, 7.8 °20, 21.1 °20, and 17.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

98. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 18.

99. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 61.

100. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a XRPD diffractogram substantially similar to that shown in FIG. 110.

789

101. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by any combination of the XRPD peaks set forth in Table 33.

102. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by any combination of the XRPD peaks set forth in Table 34.

103. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by any combination of the XRPD peaks set forth in Table 35.

104. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 199.

105. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a melting event at about 141.2 °C.

106. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern A is a crystalline polymorph of ketanserin L-tartrate Pattern A characterized by a melting event at about 140.6 °C.

107. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by two or more, or three XRPD signals selected from the group consisting of 11.7 °20, 13.2 °20, and 18.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

108. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by signals at 11.7 °29, 13.2 °29, and 18.8 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

109. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °20, 13.2 °20, 18.8 °20, 25.5 °20, and 27.0 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

790

110. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °20, 13.2 °29, 18.8 °29, 25.5 °29, 27.0 °29, 17.6 °29, and 14.6 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

111. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °20, 13.2 °29, 18.8 °29, 25.5 °29, 27.0 °29, 17.6 °29, 14.6 °29, 25.6 °29, 19.7 °29, and 8.8 °29 (±0.2 °29; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

112. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by a XRPD diffractogram substantially similar to that shown in FIG. 40.

113. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by any combination of the XRPD peaks set forth in Table 46.

114. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 224.

115. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern L is a crystalline polymorph of ketanserin L-tartrate Pattern L characterized by a melting event at about 147.5 °C.

116. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °29, 14.2 °29, and 21.5 °29 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

117. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by signals at 15.3 °29, 14.2 °29, and 21.5 °29 (±0.2 °29; ±0.1 °29; or ±0.0 °29; Cu Kai radiation).

791

118. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °26, 14.2 °26, 21.5 °26, 26.0 °20, and 23.9 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kai radiation).

119. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, and 17.8 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °29; Cu Kai radiation).

120. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by two or more, or three or more XRPD signals selected from the group consisting of l5.3 °20, 14.2 °20, 21.5 °20, 26.0 °20, 23.9 °20, 12.0 °20, 17.8 °20, 14.5 °20, 18.1 °20, and 9.7 °20 (±0.2 °20; ±0.1 °20; or ±0.0 °20; Cu Kal radiation).

121. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by a XRPD diffractogram substantially similar to that shown in FIG. 59.

122. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by any combination of the XRPD peaks set forth in Table 51.

123. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by a 1H NMR spectrum substantially similar to that shown in FIG. 237.

124. The solid form of any one of the previous claims, wherein the solid form of ketanserin L-tartrate Pattern Q is a crystalline polymorph of ketanserin L-tartrate Pattern Q characterized by a melting event at about 148.8 °C.

792